[[{"protocolSection": {"identificationModule": {"nctId": "NCT00875173", "orgStudyIdInfo": {"id": "Oswaldo Cruz"}, "organization": {"fullName": "Oswaldo Cruz Foundation", "class": "OTHER"}, "briefTitle": "Selenium Treatment and Chagasic Cardiopathy (STCC)", "officialTitle": "Selenium Treatment and Chagasic Cardiopathy (STCC): A Prospective Randomized Trial in Patients With Chagas Disease", "acronym": "STCC"}, "statusModule": {"statusVerifiedDate": "2015-11", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-10"}, "primaryCompletionDateStruct": {"date": "2016-12", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2020-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2008-10-20", "studyFirstSubmitQcDate": "2009-04-02", "studyFirstPostDateStruct": {"date": "2009-04-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-11-09", "lastUpdatePostDateStruct": {"date": "2015-11-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Tania Araujo-Jorge", "investigatorTitle": "Full Professor,MD, PhD", "investigatorAffiliation": "Oswaldo Cruz Foundation"}, "leadSponsor": {"name": "Oswaldo Cruz Foundation", "class": "OTHER"}, "collaborators": [{"name": "Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico", "class": "OTHER_GOV"}, {"name": "Ministry of Health, Brazil", "class": "OTHER_GOV"}]}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Selenium", "Chagas disease", "Chagasic cardiopathy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 130, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Selenium", "type": "EXPERIMENTAL", "description": "Sodium selenite 100 micrograms in capsugel by mouth diary for 365 consecutive days", "interventionNames": ["Drug: Selenium"]}, {"label": "Placebo", "type": "ACTIVE_COMPARATOR", "description": "Capsugel for placebo (selenium 100 micrograms capsugel) by mouth diary for 365 consecutive days", "interventionNames": ["Drug: Placebo (for Selenium)"]}], "interventions": [{"type": "DRUG", "name": "Selenium", "description": "selenium as a drug according to Brazilian regulation laws", "armGroupLabels": ["Selenium"], "otherNames": ["Antioxidant therapy"]}, {"type": "DRUG", "name": "Placebo (for Selenium)", "description": "Placebo with similar flavor, smell and colour.", "armGroupLabels": ["Placebo"], "otherNames": ["control"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Ejection fraction by echocardiography", "timeFrame": "Twice a year"}], "secondaryOutcomes": [{"measure": "Electrocardiography", "timeFrame": "twice a year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* altered ECHO (LVEF between 0,35 % and 45 %)\n* age between 20 and 65 years\n\nExclusion Criteria:\n\n* patients \\> 65 years of age\n* smoke habit, patients with non-chagasic cardiopathy, live close to mineral deposit, metals industries and place with radioactive exposition, vegetarian\n* depressive psychological profile\n* pregnant or in lactating period\n* present or presented cancer or diabetes.\n* patients will be excluded if they take anti-convulsive medicines (Clozapine, Valproic Acid)", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Alejandro MH Moreno, MD", "role": "CONTACT", "phone": "55 21 3865 9579", "email": "alejandro.hasslocher@ipec.fiocruz.br"}], "overallOfficials": [{"name": "Tania C Araujo-Jorge, MD/PhD", "affiliation": "Instituto Oswaldo Cruz", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Instituto Nacional de Infectologia/Instituto de Pesquisa Cl\u00ednica Evandro Chagas", "status": "RECRUITING", "city": "Rio de Janeiro", "state": "RJ", "zip": "21040-360", "country": "Brazil", "contacts": [{"name": "Pedro EA Brasil, MD, PhD", "role": "CONTACT", "phone": "213865-9648", "email": "pedro.brasil@ini.fiocruz.br"}, {"name": "TANIA CA JORGE, MD, PhD", "role": "CONTACT", "phone": "212562-1295", "email": "taniaaj@ioc.fiocruz.br"}], "geoPoint": {"lat": -22.90278, "lon": -43.2075}}]}, "referencesModule": {"references": [{"pmid": "34485877", "type": "DERIVED", "citation": "Holanda MT, Mediano MFF, Hasslocher-Moreno AM, Gonzaga BMS, Carvalho ACC, Ferreira RR, Garzoni LR, Pereira-Silva FS, Pimentel LO, Mendes MO, Azevedo MJ, Britto C, Moreira OC, Fernandes AG, Santos CM, Constermani J, Paravidino VB, Maciel ER, Carneiro FM, Xavier SS, Sperandio da Silva GM, Santos PF, Veloso HH, Brasil PEAA, de Sousa AS, Bonecini-de-Almeida MG, da Silva PS, Sangenis LHC, Saraiva RM, Araujo-Jorge TC. Effects of Selenium treatment on cardiac function in Chagas heart disease: Results from the STCC randomized Trial. EClinicalMedicine. 2021 Aug 28;40:101105. doi: 10.1016/j.eclinm.2021.101105. eCollection 2021 Oct."}, {"pmid": "30231899", "type": "DERIVED", "citation": "Holanda MT, Mediano MFF, Hasslocher-Moreno AM, Xavier SS, Saraiva RM, Sousa AS, Maciel ER, Carneiro FM, da Silva PS, Sangenis LHC, Veloso HH, Cardoso CSA, Bonecini-Almeida MDG, Souza AL, Roma EH, Azevedo MJ, Pereira-Silva FS, Pimentel LO, Mendes MO, Garzoni LR, Gonzaga BMS, Carvalho ACC, Brasil PEAA, Sperandio da Silva GM, Araujo-Jorge TC. A protocol update for the Selenium Treatment and Chagasic Cardiomyopathy (STCC) trial. Trials. 2018 Sep 19;19(1):507. doi: 10.1186/s13063-018-2889-8."}, {"pmid": "25284194", "type": "DERIVED", "citation": "Alvarenga Americano do Brasil PE, Pereira de Souza A, Hasslocher-Moreno AM, Xavier SS, Lambert Passos SR, de Fatima Ramos Moreira M, Santini de Oliveira M, Sperandio da Silva GM, Magalhaes Saraiva R, Santos de Aguiar Cardoso C, de Sousa AS, Mediano MF, Bonecini de Almeida Mda G, da Cruz Moreira O, Britto C, de Araujo-Jorge TC. Selenium Treatment and Chagasic Cardiopathy (STCC): study protocol for a double-blind randomized controlled trial. Trials. 2014 Oct 6;15:388. doi: 10.1186/1745-6215-15-388."}], "seeAlsoLinks": [{"label": "Instituto Oswaldo Cruz", "url": "http://www.ioc.fiocruz.br"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D006331", "term": "Heart Diseases"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}, {"id": "D002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9419", "name": "Heart Diseases", "asFound": "Cardiopathy", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D012643", "term": "Selenium"}, {"id": "D000975", "term": "Antioxidants"}], "ancestors": [{"id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D020011", "term": "Protective Agents"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014131", "term": "Trace Elements"}, {"id": "D018977", "term": "Micronutrients"}], "browseLeaves": [{"id": "M15455", "name": "Selenium", "asFound": "Puffs", "relevance": "HIGH"}, {"id": "M4292", "name": "Antioxidants", "asFound": "Fatty Liver", "relevance": "HIGH"}, {"id": "M20198", "name": "Sodium Selenite", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M21009", "name": "Micronutrients", "relevance": "LOW"}, {"id": "M16885", "name": "Trace Elements", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03587766", "orgStudyIdInfo": {"id": "DNDi-FEX-12-CH"}, "secondaryIdInfos": [{"id": "2016-004905-15", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Drugs for Neglected Diseases", "class": "OTHER"}, "briefTitle": "Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease", "officialTitle": "Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease", "acronym": "FEXI12"}, "statusModule": {"statusVerifiedDate": "2020-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-11-13", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-12-19", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-08-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-04-27", "studyFirstSubmitQcDate": "2018-07-03", "studyFirstPostDateStruct": {"date": "2018-07-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-09-21", "lastUpdatePostDateStruct": {"date": "2020-09-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Drugs for Neglected Diseases", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "conditionsModule": {"conditions": ["Chagas' Disease (Chronic) Nos"], "keywords": ["Trypanosoma cruzi Infection", "Chagas' Disease", "Trypanosomiasis, South American", "American Trypanosomiasis", "Kissing bug"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "This study is designed as a double-blind, randomized, prospective, comparative, pharmacokinetic-pharmacodynamic, and proof-of-concept trial design, with three-parallel groups and historical placebo control in patients with chronic indeterminate Chagas Disease.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "maskingDescription": "As the study is double-blinded, the patient, investigators, pharmacist(s) and DNDi study team members involved with the clinical trial implementation will remain blinded to treatment allocation for the duration of the clinical trial.", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 45, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group A", "type": "EXPERIMENTAL", "description": "Fexinidazole (FEXI) 600 mg x 10 days in a single daily dose orally (1 fexinidazole 600 mg tablet and 1 fexinidazole matching placebo oral tablet administered in a single daily dose) (total dose: 6.0 g).", "interventionNames": ["Drug: Fexinidazole", "Drug: Placebo Oral Tablet"]}, {"label": "Group B", "type": "EXPERIMENTAL", "description": "Fexinidazole (FEXI) 1200 mg x 3 days orally (2 fexinidazole 600 mg tablets administered in a single daily dose for 3 days), to be followed by matching placebo oral tablet for 7 days (2 fexinidazole matching placebo oral tablets administered once daily for 7 days) (total dose: 3.6 g).", "interventionNames": ["Drug: Fexinidazole", "Drug: Placebo Oral Tablet"]}, {"label": "Group C", "type": "EXPERIMENTAL", "description": "Fexinidazole (FEXI) 600 mg for 3 days, followed by 1200 mg in a single daily dose orally for 4 days (1 fexinidazole 600 mg tablet AND 1 fexinidazole matching placebo oral tablet administered in a single daily dose for 3 days, to be followed by 2 fexinidazole 600 mg tablets for 4 days), then followed by matching placebo oral tablet for 3 days (2 fexinidazole matching placebo tablets administered once daily for 3 days) (total dose: 6.6 g).", "interventionNames": ["Drug: Fexinidazole", "Drug: Placebo Oral Tablet"]}], "interventions": [{"type": "DRUG", "name": "Fexinidazole", "description": "Drug: fexinidazole (FEXI)", "armGroupLabels": ["Group A", "Group B", "Group C"], "otherNames": ["FEXI"]}, {"type": "DRUG", "name": "Placebo Oral Tablet", "description": "Drug: fexinidazole", "armGroupLabels": ["Group A", "Group B", "Group C"], "otherNames": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Incidence and severity of adverse events.", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Pharmacokinetic : measure of blood concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine AUC0-t values, for all dose levels.", "timeFrame": "D0 (pre-dose), Day 1, Day 2, Day 3, and at steady-state phase (week 2-10)."}, {"measure": "Pharmacokinetic : measure of blood concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine Cmax values, for all dose levels.", "timeFrame": "D0 (pre-dose), Day 1, Day 2, Day 3, and at steady-state phase (week 2-10)."}]}, "eligibilityModule": {"eligibilityCriteria": "Screening Criteria:\n\n* Signed, written informed consent form\n* Age \\>18 to \\< 60 years\n* Weight \\> 50 kg to \\< 90 kg\n* Diagnosis of T. cruzi infection by:\n* Conventional serology (a minimum of two positive tests \\[Conventional ELISA, Recombinant Elisa, Chemiluminescence Immunoassays and/or Indirect Immunofluorescence (IIF)\\]\n* Ability to comply with all protocol specified tests and visits and have a permanent address\n* No signs and/or symptoms of the chronic cardiac and/or digestive form of Chagas Disease (CD) (as per study operating procedures)\n* No personal history of mental disability or suicidal tendencies\n* No acute or chronic health conditions, that in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial drug (such as acute infections, history of HIV infection, liver, and renal disease requiring treatment)\n* No formal contraindication to FEXI (according to the latest available Investigator's Brochure)\n* No history of hypersensitivity, allergic, or serious adverse reactions to any of the \"nitro-imidazoles\" compound, and/or its components\n* No history of CD treatment with BZN, FEXI or Nifurtimox (NFX) at any time in the past\n* No history of alcohol abuse or any other drug addiction (as per Study Manual of Operations)\n* No condition that prevents patient from taking oral medication\n* No concomitant medication with drug known risk of Torsade de Pointe, according AZCERT Scientific Publications and Sudden Arrhythmia Death Syndromes Foundation (SADS Foundation) (https://www.crediblemeds.org/index.php/new-drug-list)\n* No family history of sudden death\n* No family history of sudden infant death syndrome\n\nInclusion Criteria:\n\nFollowing the screening period, patients must also meet all of the following inclusion criteria to be eligible for randomization:\n\n* Confirmed diagnosis of T. cruzi infection by:\n* Serial qualitative PCR (three samples collected over a single day, at least one of which must be positive),\n\nand\n\n* Conventional serology (a minimum of two positive tests must be positive, Conventional ELISA, Recombinant Elisa, Chemiluminescence immunoassays and/or IIF)\n* Women in reproductive age must have a negative serum pregnancy test at screening, must not be breastfeeding, must consistently use a highly effective contraceptive method until end of treatment and estimated FEXI, M1 and M2 clearance (total of 21 days). After this, contraception is no longer required.\n* Normal ECG (Heart rate: 50-100bpm; PR interval \u2264200 msec, QRS complex \u2264120 msec, and QT interval corrected for heart rate (QTc) \u2265350msec and \u2264450 msec interval durations) at screening\n* 24 hour Holter-monitoring with no clinically relevant arrythmias (defined as Ventricular Tachycardia (defined as \\>3 ventricular beats with \\>100bpm); Sustained Accelerated Idio-Ventricular rhythm (defined as \\>30 seconds duration and Heart Rate (HR): 50bpm\\<HR\\<100bpm); frequent Ventricular Premature Beats (10/hour); Atrial Fibrillation/flutter; Mobitz type 2 second degree AV block; High degree and complete AV block; Bradycardia episodes \\<40bpm)\n\nExclusion Criteria:\n\n* Signs and/or symptoms of chronic cardiac and/or digestive form of CD (as per Study Manual of Operations).\n* History of cardiomyopathy, heart failure, or ventricular arrhythmia.\n* History of digestive surgery or mega syndromes.\n* Personal history of mental disability or suicidal tendencies\n* Hospital Anxiety and Depression Scale (HADS - Appendix 1) self-assessment score \\>11 in each of the sub-scales. (Note: If HADS score \\>11, retesting would be allowed before after a minimum period of 15 days and referral to counseling/evaluation.)\n* Any other acute or chronic health conditions that, in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial drug (such as acute infections, history of HIV infection, diabetes, uncontrolled systolic/diastolic blood pressure, liver, and renal diseases requiring medical treatment).\n* Laboratory test values considered clinically significant or out of the allowable range at selection period as follows:\n\n  * Total White Blood Count (WBC) must be within the normal range, with an acceptable margin of +/- 5% (3,800 - 10,500 / mm3).\n  * Platelets must be within the normal range up to 550,000/mm3\n  * Total bilirubin must be within the normal range\n  * Transaminases (ALT and AST) must be within the normal range, with an acceptable margin of 25% above the upper limit of normality (ULN), \\< 1.25 x ULN.\n  * Creatinine must be within an acceptable margin of 10% above the ULN, \\<1.10 x ULN.\n  * Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (\\<,2.5 x ULN)\n  * Gamma-glutamyl Transpeptidase (GGT) must be within the normal range up to 2x ULN.\n  * Fasting glucose (minimum of 8 hours from latest meal) must be within the normal range\n  * Electrolytes (Ca, Mg, K) must be within the normal range\n  * Hepatitis screen must be negative for acute and/or chronic infection (Hepatitis A antibody, Imunoglobulina M (IgM); Hepatitis B surface Ag, Hepatitis B\n\nIf the results of the blood tests (hematology and biochemistry) are out of the ranges defined above, but within the limits of CTCAE (version 4.03) Grade 1, and this laboratory finding is considered as non-clinically significant, a new sample can be collected for a retest. Only one retest will be allowed within the screening period.\n\nIf the result of the retest is within the margins defined above, the Investigator will review the parameter(s) together with all other medical information available (medical history, clinical examinations, vital signs, etc.) and upon his/her medical judgement will decide if the patient is eligible or not for trial randomization.\n\nAny condition that prevents the patient from taking oral medication.\n\n* Patients with any contra-indication (known hypersensitivity) to any nitroimidazoles, e.g. metronidazole\n* Patients with history of allergy (serious or not), allergic skin rash, asthma, intolerance, sensitivity or photosensitivity to any drug\n* Any concomitant use of allopurinol, antimicrobial, anti-parasitic agents, and/or of herbal medicines, food supplements and energetic drinks\n* Any concomitant medication with drug known risk of Torsade de Pointe, according AZCERT Scientific Publications and SADS Foundation (www.crediblemeds.org/index.php/new-drug-list)\n* Any planned surgery likely to interfere with the trial conduction and/or treatment evaluation\n* Unlikely to return for study visits, comply with study treatment and co-operate with the trial-related procedures.\n* Any previous participation in any clinical trial for Chagas Disease treatment evaluation\n* Participation in another trial at the same time or within 3 months prior to selection (according to local regulations).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Joaquim Gasc\u00f3n, MD", "affiliation": "Centro de Salud Internacional, Hospital Cl\u00ednico de Barcelona ISGlobal - Barcelona Institute for Global Health", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hospital Clinic", "city": "Barcelona", "state": "Catalunia", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}]}, "referencesModule": {"references": [{"type": "BACKGROUND", "citation": "WHO | Chagas disease (American trypanosomiasis) [Internet]. WHO. [cited 2013 Aug 22]. Available from: http://www.who.int/mediacentre/factsheets/fs340/en/index.html"}, {"pmid": "19640226", "type": "BACKGROUND", "citation": "Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009 Sep 1;49(5):e52-4. doi: 10.1086/605091."}, {"pmid": "21200426", "type": "BACKGROUND", "citation": "Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazue G, Bray MA, Pecoul B. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923. doi: 10.1371/journal.pntd.0000923."}, {"pmid": "6411009", "type": "BACKGROUND", "citation": "Raether W, Seidenath H. The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica. Ann Trop Med Parasitol. 1983 Feb;77(1):13-26. doi: 10.1080/00034983.1983.11811668."}, {"pmid": "24736467", "type": "BACKGROUND", "citation": "Moraes CB, Giardini MA, Kim H, Franco CH, Araujo-Junior AM, Schenkman S, Chatelain E, Freitas-Junior LH. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep. 2014 Apr 16;4:4703. doi: 10.1038/srep04703."}, {"pmid": "23133682", "type": "BACKGROUND", "citation": "Bahia MT, de Andrade IM, Martins TA, do Nascimento AF, Diniz Lde F, Caldas IS, Talvani A, Trunz BB, Torreele E, Ribeiro I. Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis. 2012;6(11):e1870. doi: 10.1371/journal.pntd.0001870. Epub 2012 Nov 1."}, {"pmid": "25045804", "type": "BACKGROUND", "citation": "Caldas S, Caldas IS, Cecilio AB, Diniz LF, Talvani A, Ribeiro I, Bahia MT. Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock. Parasitology. 2014 Oct;141(12):1628-1637. doi: 10.1017/S0031182014000882."}, {"pmid": "19426663", "type": "BACKGROUND", "citation": "Munoz J, Gomez i Prat J, Gallego M, Gimeno F, Trevino B, Lopez-Chejade P, Ribera O, Molina L, Sanz S, Pinazo MJ, Riera C, Posada EJ, Sanz G, Portus M, Gascon J. Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop. 2009 Jul;111(1):51-5. doi: 10.1016/j.actatropica.2009.02.005. Epub 2009 Mar 5."}, {"pmid": "11992141", "type": "BACKGROUND", "citation": "Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002 Jan;97(1):3-24. doi: 10.1590/s0074-02762002000100001."}, {"pmid": "20399979", "type": "BACKGROUND", "citation": "Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010 Apr 17;375(9723):1388-402. doi: 10.1016/S0140-6736(10)60061-X."}, {"pmid": "16702594", "type": "BACKGROUND", "citation": "Pinto Dias JC. The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med. 2006 May 16;144(10):772-4. doi: 10.7326/0003-4819-144-10-200605160-00012. No abstract available."}, {"pmid": "12209329", "type": "BACKGROUND", "citation": "Castro AM, Luquetti AO, Rassi A, Rassi GG, Chiari E, Galvao LM. Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi. Parasitol Res. 2002 Oct;88(10):894-900. doi: 10.1007/s00436-002-0679-3. Epub 2002 Jun 15."}, {"pmid": "16570199", "type": "BACKGROUND", "citation": "de Castro AM, Luquetti AO, Rassi A, Chiari E, Galvao LM. Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection. Parasitol Res. 2006 Sep;99(4):379-83. doi: 10.1007/s00436-006-0172-5. Epub 2006 Mar 29."}, {"pmid": "7724232", "type": "BACKGROUND", "citation": "Britto C, Cardoso MA, Vanni CM, Hasslocher-Moreno A, Xavier SS, Oelemann W, Santoro A, Pirmez C, Morel CM, Wincker P. Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology. 1995 Apr;110 ( Pt 3):241-7. doi: 10.1017/s0031182000080823."}, {"pmid": "11581230", "type": "BACKGROUND", "citation": "Solari A, Ortiz S, Soto A, Arancibia C, Campillay R, Contreras M, Salinas P, Rojas A, Schenone H. Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR. J Antimicrob Chemother. 2001 Oct;48(4):515-9. doi: 10.1093/jac/48.4.515."}, {"pmid": "14605140", "type": "BACKGROUND", "citation": "Galvao LM, Chiari E, Macedo AM, Luquetti AO, Silva SA, Andrade AL. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J Clin Microbiol. 2003 Nov;41(11):5066-70. doi: 10.1128/JCM.41.11.5066-5070.2003."}, {"pmid": "12917253", "type": "BACKGROUND", "citation": "Schijman AG, Altcheh J, Burgos JM, Biancardi M, Bisio M, Levin MJ, Freilij H. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother. 2003 Sep;52(3):441-9. doi: 10.1093/jac/dkg338. Epub 2003 Aug 13."}, {"pmid": "16968928", "type": "BACKGROUND", "citation": "Flores-Chavez M, Bosseno MF, Bastrenta B, Dalenz JL, Hontebeyrie M, Revollo S, Breniere SF. Polymerase chain reaction detection and serologic follow-up after treatment with benznidazole in Bolivian children infected with a natural mixture of Trypanosoma cruzi I and II. Am J Trop Med Hyg. 2006 Sep;75(3):497-501."}, {"pmid": "19381287", "type": "BACKGROUND", "citation": "Duffy T, Bisio M, Altcheh J, Burgos JM, Diez M, Levin MJ, Favaloro RR, Freilij H, Schijman AG. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis. 2009;3(4):e419. doi: 10.1371/journal.pntd.0000419. Epub 2009 Apr 21."}, {"pmid": "19846646", "type": "BACKGROUND", "citation": "Ramirez JD, Guhl F, Umezawa ES, Morillo CA, Rosas F, Marin-Neto JA, Restrepo S. Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods. J Clin Microbiol. 2009 Dec;47(12):3945-51. doi: 10.1128/JCM.01601-09. Epub 2009 Oct 21."}, {"pmid": "17511688", "type": "BACKGROUND", "citation": "Diez M, Favaloro L, Bertolotti A, Burgos JM, Vigliano C, Lastra MP, Levin MJ, Arnedo A, Nagel C, Schijman AG, Favaloro RR. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant. 2007 Jun;7(6):1633-40. doi: 10.1111/j.1600-6143.2007.01820.x."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Not yet decided how Individual Participant Data (IPD) will be shared, This action is under internal review within DNDi."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02542020", "orgStudyIdInfo": {"id": "32889514.4.0000.5262"}, "organization": {"fullName": "Oswaldo Cruz Foundation", "class": "OTHER"}, "briefTitle": "Prospective Evaluation of HIV Patients Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis", "officialTitle": "Prospective Evaluation of HIV Infected Patients Followed at Evandro Chagas National Institute of Infectious Disease (INI) - Oswaldo Cruz Foundation (FIOCRUZ) Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis", "acronym": "Prospec-HIV"}, "statusModule": {"statusVerifiedDate": "2018-02", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-06"}, "primaryCompletionDateStruct": {"date": "2020-05", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2022-05", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2015-08-27", "studyFirstSubmitQcDate": "2015-09-02", "studyFirstPostDateStruct": {"date": "2015-09-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2019-02-15", "lastUpdatePostDateStruct": {"date": "2019-02-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Oswaldo Cruz Foundation", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Human Immunodeficiency Virus", "Acquired Immune Deficiency Syndrome Virus", "Liver Diseases", "Liver Cirrhosis", "Fibrosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "Blood samples"}, "enrollmentInfo": {"count": 2000, "type": "ESTIMATED"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "Evaluation of stage of fibrosis and grade of steatosis in patients infected by HIV", "description": "Staging of liver fibrosis and quantification of steatosis using non-invasive methods and correlation with risk factors", "timeFrame": "change of fibrosis stage and steatosis grade from baseline at 5 years"}], "secondaryOutcomes": [{"measure": "Prognostic value of non-invasive methods", "description": "Evaluation of the prognostic value of non-invasive methods for prediction of severe outcomes and mortality", "timeFrame": "up to 5 years"}, {"measure": "Prevalence of liver fibrosis", "description": "Estimation of liver fibrosis by non-invasive methods", "timeFrame": "up to 3 years"}, {"measure": "Prevalence of liver steatosis", "description": "Estimation of liver steatosis by non-invasive methods", "timeFrame": "up to 3 years"}, {"measure": "Diagnostic performance of non-invasive methods", "description": "Evaluation of diagnostic accuracy (sensitivity and specificity) of non-invasive methods using the Latent Class Analysis", "timeFrame": "up to 3 years"}, {"measure": "Nutritional status", "description": "Evaluation of the nutritional status by bioelectrical impedance and 24h diet recall", "timeFrame": "From date of inclusion until the date of first documented alteration on nutritional status, assessed up to 5 years"}, {"measure": "Progression of liver fibrosis", "description": "Estimation of liver fibrosis by non-invasive methods", "timeFrame": "From date of inclusion until the date of first documented progression of liver fibrosis, assessed up to 5 years"}, {"measure": "Progression of liver steatosis", "description": "Estimation of liver steatosis by non-invasive methods", "timeFrame": "From date of inclusion until the date of first documented progression of liver steatosis, assessed up to 5 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* HIV infection\n* Age \\>= 18 years\n\nExclusion Criteria:\n\n* Auto-immune hepatitis\n* Primary biliary cirrhosis\n* Primary sclerosing cirrhosis\n* Extra-hepatic cholestasis\n* Acute viral hepatitis\n* Hepatic ischemia\n* Hepatic metastasis", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Patients infected by HIV with or without chronic viral hepatitis", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Hugo Perazzo, PhD", "role": "CONTACT", "phone": "+55 21 3865-9587", "email": "hugo.perazzo@ini.fiocruz.br"}], "overallOfficials": [{"name": "Valdilea G Veloso, PhD", "affiliation": "Oswaldo Cruz Foundation", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Beatriz Grinsztejn, PhD", "affiliation": "Oswaldo Cruz Foundation", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Evandro Chagas National Institute of Infectious Diseases", "status": "RECRUITING", "city": "Rio de Janeiro", "state": "Rio De Janeiro/RJ", "zip": "21040-360", "country": "Brazil", "contacts": [{"name": "Hugo Perazzo, PhD", "role": "CONTACT", "phone": "+5521 3865-9587", "email": "hugo.perazzo@ini.fiocruz.br"}], "geoPoint": {"lat": -22.90278, "lon": -43.2075}}]}, "referencesModule": {"references": [{"pmid": "34873092", "type": "DERIVED", "citation": "Yanavich C, Perazzo H, Li F, Tobin N, Lee D, Zabih S, Morata M, Almeida C, Veloso VG, Grinsztejn B, Aldrovandi GM. A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil. AIDS. 2022 Jan 1;36(1):49-58. doi: 10.1097/QAD.0000000000003084."}, {"pmid": "33529485", "type": "DERIVED", "citation": "Yanavich C, Pacheco AG, Cardoso SW, Nunes EP, Chaves U, Freitas G, Santos R, Morata M, Veloso VG, Grinsztejn B, Perazzo H. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. HIV Med. 2021 Jul;22(6):445-456. doi: 10.1111/hiv.13060. Epub 2021 Feb 2."}, {"pmid": "30394678", "type": "DERIVED", "citation": "Perazzo H, Cardoso SW, Yanavich C, Nunes EP, Morata M, Gorni N, da Silva PS, Cardoso C, Almeida C, Luz P, Veloso VG, Grinsztejn B. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc. 2018 Nov;21(11):e25201. doi: 10.1002/jia2.25201."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D000163", "term": "Acquired Immunodeficiency Syndrome"}, {"id": "D015658", "term": "HIV Infections"}, {"id": "D008107", "term": "Liver Diseases"}, {"id": "D008103", "term": "Liver Cirrhosis"}, {"id": "D007153", "term": "Immunologic Deficiency Syndromes"}, {"id": "D005355", "term": "Fibrosis"}], "ancestors": [{"id": "D014777", "term": "Virus Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D004066", "term": "Digestive System Diseases"}, {"id": "D007154", "term": "Immune System Diseases"}, {"id": "D000086982", "term": "Blood-Borne Infections"}, {"id": "D003141", "term": "Communicable Diseases"}, {"id": "D015229", "term": "Sexually Transmitted Diseases, Viral"}, {"id": "D012749", "term": "Sexually Transmitted Diseases"}, {"id": "D016180", "term": "Lentivirus Infections"}, {"id": "D012192", "term": "Retroviridae Infections"}, {"id": "D012327", "term": "RNA Virus Infections"}, {"id": "D012897", "term": "Slow Virus Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D000091642", "term": "Urogenital Diseases"}], "browseLeaves": [{"id": "M18250", "name": "HIV Infections", "asFound": "Acquired Immune Deficiency Syndrome Virus", "relevance": "HIGH"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M8485", "name": "Fibrosis", "asFound": "Fibrosis", "relevance": "HIGH"}, {"id": "M17522", "name": "Virus Diseases", "relevance": "LOW"}, {"id": "M3522", "name": "Acquired Immunodeficiency Syndrome", "asFound": "Acquired Immune Deficiency Syndrome", "relevance": "HIGH"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M10199", "name": "Immunologic Deficiency Syndromes", "asFound": "Immune Deficiency", "relevance": "HIGH"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M11103", "name": "Liver Cirrhosis", "asFound": "Liver Cirrhosis", "relevance": "HIGH"}, {"id": "M8375", "name": "Fatty Liver", "relevance": "LOW"}, {"id": "M11107", "name": "Liver Diseases", "asFound": "Liver Disease", "relevance": "HIGH"}, {"id": "M8883", "name": "Gastrointestinal Diseases", "relevance": "LOW"}, {"id": "M7255", "name": "Digestive System Diseases", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M2593", "name": "Blood-Borne Infections", "relevance": "LOW"}, {"id": "M15558", "name": "Sexually Transmitted Diseases", "relevance": "LOW"}, {"id": "M17933", "name": "Sexually Transmitted Diseases, Viral", "relevance": "LOW"}, {"id": "M18640", "name": "Lentivirus Infections", "relevance": "LOW"}, {"id": "M15026", "name": "Retroviridae Infections", "relevance": "LOW"}, {"id": "M15149", "name": "RNA Virus Infections", "relevance": "LOW"}, {"id": "M15700", "name": "Slow Virus Diseases", "relevance": "LOW"}, {"id": "M2876", "name": "Genital Diseases", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "T5868", "name": "Visceral Steatosis", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC06", "name": "Digestive System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M11110", "name": "Liver Extracts", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hemat", "name": "Hematinics"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03191162", "orgStudyIdInfo": {"id": "2016-003789-21"}, "organization": {"fullName": "Hospital Universitari Vall d'Hebron Research Institute", "class": "OTHER"}, "briefTitle": "Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.", "officialTitle": "Phase II Clinical Trial for the Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease in Adult Patients. Berenice Project", "acronym": "MULTIBENZ"}, "statusModule": {"statusVerifiedDate": "2023-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-04-21", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-09-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-03-16", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-06-08", "studyFirstSubmitQcDate": "2017-06-16", "studyFirstPostDateStruct": {"date": "2017-06-19", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-12-18", "lastUpdatePostDateStruct": {"date": "2023-12-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Hospital Universitari Vall d'Hebron Research Institute", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Disease", "Trypanosoma Cruzi Infection"], "keywords": ["Benznidazole", "PCR"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 238, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "B300/60", "type": "ACTIVE_COMPARATOR", "description": "Benznidazole 300mg/day p.o. divided in two doses for 60 days", "interventionNames": ["Drug: Benznidazole"]}, {"label": "B150/60", "type": "EXPERIMENTAL", "description": "Benznidazole 150mg/day p.o. divided in two doses for 60 days", "interventionNames": ["Drug: Benznidazole"]}, {"label": "B400/15", "type": "EXPERIMENTAL", "description": "Benznidazole 400mg/day p.o. divided in two doses for 15 days", "interventionNames": ["Drug: Benznidazole"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "description": "To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease", "armGroupLabels": ["B150/60", "B300/60", "B400/15"], "otherNames": ["Abarax"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportion of patients with negative parasitaemia measured by PCR during the first 12 months after starting treatment", "description": "The treatment efficacy is assessed through the proportion of patients with negative parasitaemia measured by PCR during the first 12 months after starting treatment", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Over 18 years old.\n* Diagnosis of Chagas disease through two different serological tests.\n* Positive T. cruzi PCR in peripheral blood.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Previous treatment with Benznidazole or Nifurtimox.\n* Alcohol consumption.\n* Acute or chronic health problems that could interfere in the assessment of the efficacy or safety of the drug (acute infections, HIV infection, liver or renal impairment, etc).\n* Nitroimidazole hipersensitivity.\n* Concomitant or previous treatment with allopurinol or antifungal drugs.\n* Pregnancy.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Israel Molina, PhD", "affiliation": "Hospital Universitario Vall d'Hebron Research Institute", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Instituto Nacional de Parasitolog\u00eda Dr. Mario Fatala Chaben (ANLIS)", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Instituto de Cardiolog\u00eda de Corrientes Juana Francisca Cabral", "city": "Corrientes", "country": "Argentina", "geoPoint": {"lat": -27.4806, "lon": -58.8341}}, {"facility": "Centro de Pesquisas Ren\u00e9 Rachou - Funda\u00e7\u00e3o Oswaldo Cruz. (FIOCRUZ)", "city": "Belo Horizonte", "country": "Brazil", "geoPoint": {"lat": -19.92083, "lon": -43.93778}}, {"facility": "Hospital Universit\u00e1rio Clemente de Faria", "city": "Montes Claros", "country": "Brazil", "geoPoint": {"lat": -16.735, "lon": -43.86167}}, {"facility": "Fundaci\u00f3n Cardioinfantil - Instituto de Cardiolog\u00eda", "city": "Bogot\u00e1", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Centro Atencion y Diagn\u00f3stico de Enfermedades Infecciosas", "city": "Bucaramanga", "country": "Colombia", "geoPoint": {"lat": 7.12539, "lon": -73.1198}}, {"facility": "Infectious Disease Department Vall d'Hebron Hospital", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}]}, "referencesModule": {"references": [{"pmid": "32293523", "type": "DERIVED", "citation": "Molina-Morant D, Fernandez ML, Bosch-Nicolau P, Sulleiro E, Bangher M, Salvador F, Sanchez-Montalva A, Ribeiro ALP, de Paula AMB, Eloi S, Correa-Oliveira R, Villar JC, Sosa-Estani S, Molina I. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial. Trials. 2020 Apr 15;21(1):328. doi: 10.1186/s13063-020-4226-2. Erratum In: Trials. 2023 Nov 14;24(1):726. doi: 10.1186/s13063-023-07659-5."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01377480", "orgStudyIdInfo": {"id": "P05267"}, "secondaryIdInfos": [{"id": "MK-5592-055", "type": "OTHER", "domain": "Merck Protocol Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)", "officialTitle": "Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)", "acronym": "STOP CHAGAS"}, "statusModule": {"statusVerifiedDate": "2018-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-07-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2014-07-22", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-01-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-05-13", "studyFirstSubmitQcDate": "2011-06-20", "studyFirstPostDateStruct": {"date": "2011-06-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-07-13", "resultsFirstSubmitQcDate": "2015-07-13", "resultsFirstPostDateStruct": {"date": "2015-08-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-07-27", "lastUpdatePostDateStruct": {"date": "2018-08-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chagas Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 120, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Posaconazole", "type": "EXPERIMENTAL", "description": "Posaconazole (POS) 400 mg (10 mL) oral suspension twice daily for 60 days", "interventionNames": ["Drug: Posaconazole"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Posaconazole placebo (10 mL) oral suspension twice daily for 60 days", "interventionNames": ["Drug: Placebo for posaconazole"]}, {"label": "Posaconazole + Benznidazole", "type": "EXPERIMENTAL", "description": "Posaconazole 400 mg (10 mL) oral suspension twice daily for 60 days and benznidazole (BNZ) 100 mg oral tablet twice daily (200-mg daily dose) for 60 days", "interventionNames": ["Drug: Posaconazole", "Drug: Benznidazole"]}, {"label": "Benznidazole + Placebo", "type": "ACTIVE_COMPARATOR", "description": "Posaconazole placebo (10 mL) oral suspension twice daily for 60 days and benznidazole 100 mg oral tablet twice daily (200-mg daily dose) for 60 days", "interventionNames": ["Drug: Placebo for posaconazole", "Drug: Benznidazole"]}], "interventions": [{"type": "DRUG", "name": "Posaconazole", "description": "POS 40 mg/mL oral suspension", "armGroupLabels": ["Posaconazole", "Posaconazole + Benznidazole"], "otherNames": ["SCH 056592, MK-5592"]}, {"type": "DRUG", "name": "Placebo for posaconazole", "description": "Placebo oral suspension", "armGroupLabels": ["Benznidazole + Placebo", "Placebo"]}, {"type": "DRUG", "name": "Benznidazole", "description": "BNZ 100 mg oral tablet", "armGroupLabels": ["Benznidazole + Placebo", "Posaconazole + Benznidazole"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction", "description": "Blood samples were collected for qualitative polymerase chain reaction (PCR) assay for Trypanosoma cruzi deoxyribonucleic acid (DNA). Successful response was defined as a negative qualitative PCR value at the Day 180 follow up visit.", "timeFrame": "Day 180"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n- Must have a positive serology result for Trypanosoma cruzi on any 2 of 3 of the following tests: indirect immunofluorescence, indirect hemagglutination, or enzyme-linked immunoabsorbent assay (ELISA)\n\n* Must have a positive qualitative polymerase chain reaction (PCR) for Trypanosoma cruzi\n* Must have a normal 12-lead electrocardiogram (ECG)\n* Must have a normal 2-D echocardiogram\n* Must have no evidence of ventricular tachycardia on 24-hour Holter monitoring\n* Female participants of childbearing age must be using a medically accepted method of birth control before beginning study drug treatment and must agree to continue its use during the study, or must have been surgically sterilized\n* Female participants of childbearing potential must have a negative serum beta-human chorionic gonadotropin (hCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline or within 72 hours before the start of study drug\n\nExclusion Criteria:\n\n* Are breastfeeding, pregnant, or planning to become pregnant\n* Body weight \\<60 kg\n* Have an immunodeficiency or are immunosuppressed\n* History of megacolon with obstipation or megaesophagus with severe swallowing impairment.\n* Have previously received treatment with benznidazole or nifurtimox\n* Known allergy/sensitivity to azoles\n* Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 2.5 times the upper limit of normal at Screening\n* Has serum creatinine \\>2.5 mg/dL or 200 micromoles at Screening\n* Has a history of severe alcohol abuse within two years from Screening\n* Is taking any of the prohibited medication", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "28231946", "type": "RESULT", "citation": "Morillo CA, Waskin H, Sosa-Estani S, Del Carmen Bangher M, Cuneo C, Milesi R, Mallagray M, Apt W, Beloscar J, Gascon J, Molina I, Echeverria LE, Colombo H, Perez-Molina JA, Wyss F, Meeks B, Bonilla LR, Gao P, Wei B, McCarthy M, Yusuf S; STOP-CHAGAS Investigators. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. J Am Coll Cardiol. 2017 Feb 28;69(8):939-947. doi: 10.1016/j.jacc.2016.12.023."}], "availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/study.html?id=P05267&kw=P05267&tab=access"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 393 participants were screened, 123 were eligible for enrollment, and 120 were randomized", "groups": [{"id": "FG000", "title": "Posaconazole", "description": "POS 400 mg (10 mL) oral suspension twice daily for 60 days"}, {"id": "FG001", "title": "Placebo", "description": "POS placebo (10 mL) oral suspension twice daily for 60 days"}, {"id": "FG002", "title": "Posaconazole + Benznidazole", "description": "POS 400 mg (10 mL) oral suspension twice daily for 60 days and BNZ 100 mg oral tablet twice daily (200-mg daily dose) for 60 days"}, {"id": "FG003", "title": "Benznidazole + Placebo", "description": "BNZ 100 mg oral tablet twice daily (200-mg daily dose) for 60 days and POS placebo (10 mL) oral suspension twice daily for 60 days"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Includes 2 participants randomized to POS + BNZ but who only received POS", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "30"}, {"groupId": "FG002", "comment": "2 participants received only POS and were analyzed as part of the posaconazole group", "numSubjects": "28"}, {"groupId": "FG003", "numSubjects": "30"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "29"}, {"groupId": "FG002", "numSubjects": "18"}, {"groupId": "FG003", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "11"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Evidence of drug-induced hepatotoxicity", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Serious adverse event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Posaconazole", "description": "POS 400 mg (10 mL) oral suspension twice daily for 60 days"}, {"id": "BG001", "title": "Placebo", "description": "POS placebo (10 mL) oral suspension twice daily for 60 days"}, {"id": "BG002", "title": "Posaconazole + Benznidazole", "description": "POS 400 mg (10 mL) oral suspension twice daily for 60 days and BNZ 100 mg oral tablet twice daily (200-mg daily dose) for 60 days"}, {"id": "BG003", "title": "Benznidazole + Placebo", "description": "BNZ 100 mg oral tablet twice daily (200-mg daily dose) for 60 days and POS placebo (10 mL) oral suspension twice daily for 60 days"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "30"}, {"groupId": "BG004", "value": "120"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.3", "spread": "8.6"}, {"groupId": "BG001", "value": "42.2", "spread": "7.8"}, {"groupId": "BG002", "value": "40.2", "spread": "8.4"}, {"groupId": "BG003", "value": "40.4", "spread": "7.7"}, {"groupId": "BG004", "value": "40.8", "spread": "8.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "17"}, {"groupId": "BG004", "value": "53"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "13"}, {"groupId": "BG004", "value": "67"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction", "description": "Blood samples were collected for qualitative polymerase chain reaction (PCR) assay for Trypanosoma cruzi deoxyribonucleic acid (DNA). Successful response was defined as a negative qualitative PCR value at the Day 180 follow up visit.", "populationDescription": "The Full Analysis Population included all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Day 180", "groups": [{"id": "OG000", "title": "Posaconazole", "description": "POS 400 mg (10 mL) oral suspension twice daily for 60 days"}, {"id": "OG001", "title": "Placebo", "description": "POS placebo (10 mL) oral suspension twice daily for 60 days"}, {"id": "OG002", "title": "Posaconazole + Benznidazole", "description": "POS 400 mg (10 mL) oral suspension twice daily for 60 days and BNZ 100 mg oral tablet twice daily (200-mg daily dose) for 60 days"}, {"id": "OG003", "title": "Benznidazole + Placebo", "description": "BNZ 100 mg oral tablet twice daily (200-mg daily dose) for 60 days and POS placebo (10 mL) oral suspension twice daily for 60 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "28"}, {"groupId": "OG003", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.6", "lowerLimit": "6.9", "upperLimit": "31.8"}, {"groupId": "OG001", "value": "10.0", "lowerLimit": "3.5", "upperLimit": "25.6"}, {"groupId": "OG002", "value": "82.1", "lowerLimit": "64.4", "upperLimit": "92.1"}, {"groupId": "OG003", "value": "86.7", "lowerLimit": "70.3", "upperLimit": "94.7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "All adverse events: up to Day 90 (30 days post treatment); procedure-related serious adverse events: up to Day 360 (300 days post treatment)", "eventGroups": [{"id": "EG000", "title": "Posaconazole", "description": "POS 400 mg (10 mL) oral suspension twice daily for 60 days", "seriousNumAffected": 1, "seriousNumAtRisk": 32, "otherNumAffected": 12, "otherNumAtRisk": 32}, {"id": "EG001", "title": "Placebo", "description": "POS placebo (10 mL) oral suspension twice daily for 60 days", "seriousNumAffected": 1, "seriousNumAtRisk": 30, "otherNumAffected": 8, "otherNumAtRisk": 30}, {"id": "EG002", "title": "Posaconazole + Benznidazole", "description": "POS 400 mg (10 mL) oral suspension twice daily for 60 days and BNZ 100 mg oral tablet twice daily (200-mg daily dose) for 60 days", "seriousNumAffected": 2, "seriousNumAtRisk": 28, "otherNumAffected": 18, "otherNumAtRisk": 28}, {"id": "EG003", "title": "Benznidazole + Placebo", "description": "BNZ 100 mg oral tablet twice daily (200-mg daily dose) for 60 days and POS placebo (10 mL) oral suspension twice daily for 60 days", "seriousNumAffected": 3, "seriousNumAtRisk": 30, "otherNumAffected": 21, "otherNumAtRisk": 30}], "seriousEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Hepatitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Neuropathy peripheral", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}]}, {"term": "Photodermatosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}]}], "otherEvents": [{"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 7, "numAffected": 5, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 30}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 3, "numAffected": 2, "numAtRisk": 30}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 30}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Transaminase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 14, "numAffected": 8, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 5, "numAffected": 4, "numAtRisk": 30}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 30}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 8, "numAffected": 6, "numAtRisk": 30}]}, {"term": "Rash pruritic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 30}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 30}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts with regard to proprietary information, accuracy, and fair-balance and compliance."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme, Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28", "removedCountries": ["Argentina", "Chile", "Colombia", "Germany", "Guatemala", "Mexico", "Spain"]}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C101425", "term": "Posaconazole"}, {"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D000935", "term": "Antifungal Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D058888", "term": "14-alpha Demethylase Inhibitors"}, {"id": "D065607", "term": "Cytochrome P-450 Enzyme Inhibitors"}, {"id": "D004791", "term": "Enzyme Inhibitors"}, {"id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D065088", "term": "Steroid Synthesis Inhibitors"}, {"id": "D006727", "term": "Hormone Antagonists"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M219015", "name": "Posaconazole", "asFound": "Lumbar spine", "relevance": "HIGH"}, {"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M6252", "name": "Clotrimazole", "relevance": "LOW"}, {"id": "M11796", "name": "Miconazole", "relevance": "LOW"}, {"id": "M4254", "name": "Antifungal Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M30537", "name": "Cytochrome P-450 Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT01842880", "orgStudyIdInfo": {"id": "CEP-41-10-2"}, "organization": {"fullName": "Hospital Sao Rafael", "class": "OTHER"}, "briefTitle": "MicroRNAs as Biomarkers in Patients With Chagas Disease", "officialTitle": "Validation of MicroRNAs as Biomarkers for Determining Patients Prognosis With Chagas Disease"}, "statusModule": {"statusVerifiedDate": "2015-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-01"}, "primaryCompletionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-04-23", "studyFirstSubmitQcDate": "2013-04-25", "studyFirstPostDateStruct": {"date": "2013-04-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-02-19", "lastUpdatePostDateStruct": {"date": "2015-02-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Milena Botelho Pereira Soares", "investigatorTitle": "PhD", "investigatorAffiliation": "Hospital Sao Rafael"}, "leadSponsor": {"name": "Hospital Sao Rafael", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["MicroRNAs", "Chagas disease", "Biomarkers"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "CROSS_SECTIONAL"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "Plasma, Serum, Whole Blood"}, "enrollmentInfo": {"count": 60, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with Chagas disease diagnosis", "description": "Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Correlation of plasmatic levels of MicroRNAs with the percentage of heart fibrosis", "description": "Mensuration of heart fibrosis percentage with Magnetic Resonance Imaging", "timeFrame": "One year"}], "secondaryOutcomes": [{"measure": "Correlation of plasmatic levels of MicroRNAs with the functional cardiovascular capacity", "description": "Mensuration of the functional capacity with treadmill test.", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of MicroRNAs with the left ventricular function", "description": "Mensuration of the left ventricular function with echocardiogram and magnetic resonance imaging", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of MicroRNAs with the serum levels of Pro-BNP.", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of MicroRNAs with the serum levels of TNF-alpha", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of MicroRNAs with the serum levels of IFN-gamma.", "timeFrame": "One year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Chagas disease diagnosis confirmed by 2 different serologies\n* Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.\n\nExclusion Criteria:\n\n* Significant valve disease defined as aortic stenosis with a gradient of VE/Ao \\> 50 mmHg\n* Mitral stenosis with a valve area inferior than 1,5 cm2\n* Severe or moderate aortic and/or mitral regurgitation\n* Chronic use of immunosuppressive agents\n* Dialysis treatment of terminal renal failure\n* Fever on the last 48 hours or evidence of systemic infection in activity according to the definition of sepsis of the ACCP/SCCM (American College os Chest Physicians/Society of Critical Care Medicine)\n* Current abusive use of alcohol or illicit drugs (Based on the DSM IV)\n* Any other comorbidities that impact patient's survival within the next 2 years\n* Liver disease in activity\n* Continuous use of steroids as treatment for COPD\n* Hematologic, neoplastic or bone diseases\n* Homeostasis disturbances\n* Inflammatory diseases or chronic infectious diseases", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Tertiary Hospital", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Milena Botelho Pereira Soares, PhD", "affiliation": "Hospital S\u00e3o Rafael", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Ricardo Ribeiro dos Santos, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_DIRECTOR"}, {"name": "Ticiana Ferreira Larocca, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "M\u00e1rcia Maria Noya Rabelo, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Lu\u00eds Cl\u00e1udio Lemos Correia, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Bruno Solano de Freitas Souza, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Carolina Th\u00e9 Macedo, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Ana Luiza Dias Angelo, PhD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Hospital S\u00e3o Rafael", "city": "Salvador", "state": "Bahia", "zip": "41253-190", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02498782", "orgStudyIdInfo": {"id": "DNDi-CH-FEXI-001"}, "organization": {"fullName": "Drugs for Neglected Diseases", "class": "OTHER"}, "briefTitle": "Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease", "officialTitle": "Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease."}, "statusModule": {"statusVerifiedDate": "2015-07", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-07"}, "primaryCompletionDateStruct": {"date": "2015-09", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2016-02", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2014-08-20", "studyFirstSubmitQcDate": "2015-07-14", "studyFirstPostDateStruct": {"date": "2015-07-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-07-14", "lastUpdatePostDateStruct": {"date": "2015-07-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Drugs for Neglected Diseases", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chagas Disease", "Trypanosomiasis, South American", "South American Trypanosomiasis", "Disease, Chagas"], "keywords": ["Chagas Disease", "Dosage forms", "Regimens"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 140, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fexinidazole, 1800 mg, 2 weeks", "type": "ACTIVE_COMPARATOR", "description": "1800mg (High Dose) 2 weeks (HD - 2 weeks) Group: Fexinidazole, 1800 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 25,2 g)", "interventionNames": ["Drug: Fexinidazole", "Drug: Placebo"]}, {"label": "Fexinidazole, 1800 mg, 4 weeks", "type": "ACTIVE_COMPARATOR", "description": "1800mg (High Dose) 4 weeks (HD - 4 weeks) Group: Fexinidazole, 1800 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 50,4 g)", "interventionNames": ["Drug: Fexinidazole", "Drug: Placebo"]}, {"label": "Fexinidazole, 1800 mg, 8 weeks", "type": "ACTIVE_COMPARATOR", "description": "1800mg (High Dose) 8 weeks (HD - 8 weeks) Group: Fexinidazole, 1800 mg QD, for 8 weeks (total dose: 100,8 g)", "interventionNames": ["Drug: Fexinidazole"]}, {"label": "Fexinidazole, 1200 mg, 2 weeks", "type": "ACTIVE_COMPARATOR", "description": "1200mg (Dose 2 weeks) 2 weeks (LD - 2 weeks) Group: Fexinidazole, 1200 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 16,8 g)", "interventionNames": ["Drug: Fexinidazole", "Drug: Placebo"]}, {"label": "Fexinidazole, 1200 mg, 4 weeks", "type": "ACTIVE_COMPARATOR", "description": "1200mg (Low Dose) 4 weeks (LD - 4 weeks) Group: Fexinidazole, 1200 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 33,6 g)", "interventionNames": ["Drug: Fexinidazole", "Drug: Placebo"]}, {"label": "Fexinidazole, 1200 mg, 8 weeks", "type": "ACTIVE_COMPARATOR", "description": "1200mg (Low Dose) 8 weeks (LD - 8 weeks) Group: Fexinidazole, 1200 mg QD for 8 weeks (total dose: 67,2 g)", "interventionNames": ["Drug: Fexinidazole"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo (8 weeks) Group: Fexinidazole matched placebo tablets QD for 8 weeks.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Fexinidazole", "armGroupLabels": ["Fexinidazole, 1200 mg, 2 weeks", "Fexinidazole, 1200 mg, 4 weeks", "Fexinidazole, 1200 mg, 8 weeks", "Fexinidazole, 1800 mg, 2 weeks", "Fexinidazole, 1800 mg, 4 weeks", "Fexinidazole, 1800 mg, 8 weeks"], "otherNames": ["1Himidazole,1methyl2[4methylthio)phenoxymethyl] 5nitroimidazole"]}, {"type": "DRUG", "name": "Placebo", "armGroupLabels": ["Fexinidazole, 1200 mg, 2 weeks", "Fexinidazole, 1200 mg, 4 weeks", "Fexinidazole, 1800 mg, 2 weeks", "Fexinidazole, 1800 mg, 4 weeks", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Parasitological cure rate (PCR)", "description": "Parasitological cure rate as determined by serial negative qualitative PCR results (3 negative PCR results, from 3 samples to be collected in the same day) at end of treatment (8 weeks) and sustained parasitological clearance until 6 months follow-up.", "timeFrame": "8 weeks and sustained until 6 months"}, {"measure": "Adverse events", "description": "Incidence and severity of adverse events (clinical, laboratory and EKG)", "timeFrame": "7 months"}, {"measure": "Serious Adverse events", "description": "Incidence of Serious Adverse Events and/or adverse events leading to treatment discontinuation", "timeFrame": "7 months"}], "secondaryOutcomes": [{"measure": "Parasite Clearance (qualitative PCR)", "description": "Parasite clearance at weeks 2, 3, 4, 6, 10, and at 4 and 6 months follow-up as measured by qualitative PCR", "timeFrame": "weeks 2, 3, 4, 6, 10, and at 4 and 6 months follow-up"}, {"measure": "Parasite load", "description": "Change in parasite load over time assessed at weeks 2, 3, 4, 6, 10, and at 4 and 6 months follow-up as measured by quantitative PCR", "timeFrame": "weeks 2, 3, 4, 6, 10 and 4 and 6 months"}, {"measure": "Serological response", "description": "Serological response (conventional and non-conventional serologies) (incidence of conversion to negative and changes in titers over time) assessed at week 10 and at 4 and 6 months follow-up.", "timeFrame": "week 10, 4 and 6 months"}, {"measure": "Blood culture for parasite genotyping", "description": "Blood culture and in vitro drug and susceptibility testing of isolated parasite strains at 6 months.", "timeFrame": "6 months"}], "otherOutcomes": [{"measure": "Plasma level concentrations", "description": "Plasma level concentrations of Fexinidazole and its metabolites M1 (sulfoxide) and M2 (sulfone) will be determined at D0 (pre-dose), at randomly selected time after first day of treatment administration (day 1, post-dose), at steady-state phase (week 2-9), and at week 10", "timeFrame": "D0 (pre-dose), at randomly selected time at day 1, post-dose, at steady-state phase (week 2-9), and at week 10"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed diagnosis of T. cruzi infection by Serial qualitative PCR (three samples collected over a single day, at least one of which must be positive) AND Conventional serology (a minimum of two out of three positive tests must be positive \\[Conventional ELISA, Recombinant Elisa or IIF)\n* Women in reproductive age must have a negative serum pregnancy test at screening, must not be breastfeeding, and consistently use a highly effective contraceptive method during the entire trial.\n* Normal EKG (PR \u2264200 msec, QRS \u2264120 msec, and QTc \u2265400msec and \u2264450 msec interval durations) at screening\n\nExclusion Criteria:\n\n* Signs and/or symptoms of chronic cardiac and/or digestive form of CD (as per Study Manual of Operations)\n* History of cardiomyopathy, heart failure or ventricular arrhythmia\n* Any other acute or chronic health conditions that, in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the study drug (such as acute infections, history of HIV infection, diabetes, liver and renal disease requiring medical treatment)\n* Laboratory test values considered clinically significant or out of the allowable range at screening as follows:\n\n  * Total WBC must be within the normal range, with an acceptable margin of +/- 5% (3,800 - 10,500 / mm3).\n  * Platelets must be within the normal range up to 550,000 / mm3\n  * Total bilirubin must be within the normal range Transaminases (ALT and AST) must be within the normal range, with an acceptable margin of 25% above the upper limit of normality (ULN), \\< 1.25 x ULN.\n  * Creatinine must be within an acceptable margin of 10% above the ULN, \\<1.10 x ULN.\n  * Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (\\< 2.5 x ULN)\n  * GGT must be within the normal range up to 2x ULN.\n  * Potassium, Magnesium, Calcium must be within the normal range\n* History of alcohol abuse or any other drug addiction (as specified in the Study Manual of Operations).\n* Any condition that prevents the patient from taking oral medication.\n* Patients with contra-indication (known hypersensitivity) to other nitroimidazoles, e.g. metronidazole.\n* Any concomitant use of antimicrobial or anti-parasitic agents.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Isabela Ribeiro, MD", "role": "CONTACT", "phone": "+552125290400", "email": "iribeiro@dndi.org"}, {"name": "Fabiana BS Rocha, MD", "role": "CONTACT", "phone": "+552125290400", "phoneExt": "0416", "email": "fbarreira@dndi.org"}], "overallOfficials": [{"name": "Faustino Torrico, MD", "affiliation": "Plataforma de Antenci\u00f3n Integral de Pacientes con Enfermedad de Chagas, Cochabamba, Bolivia", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Joaquim Gasc\u00f3n, MD", "affiliation": "Centro de Salud Internacional, Hospital Cl\u00ednico de Barcelona", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Lourdes O Daza, MD", "affiliation": "Plataforma de Antenci\u00f3n Integral de Pacientes con Enfermedad de Chagas, Tarija, Bolivia", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Plataforma Atenci\u00f3n Integral de Pacientes con Enfermedad de Chagas", "status": "RECRUITING", "city": "Cochabamba", "country": "Bolivia", "contacts": [{"name": "Faustino Torrico, MD", "role": "CONTACT", "phone": "59177411905", "email": "foxtorrico@yahoo.com"}, {"name": "Cristina Alonso, MD", "role": "CONTACT", "phone": "59172211312", "email": "calonso@dndi.org"}, {"name": "Faustino Torrico, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -17.3895, "lon": -66.1568}}, {"facility": "Plataforma de Atenci\u00f3n Integral de Pacientes con Enfermedad de Chagas", "status": "RECRUITING", "city": "Tarija", "country": "Bolivia", "contacts": [{"name": "Lourdes O Daza, MD", "role": "CONTACT", "phone": "5916672252", "email": "lourdesortizd@yahoo.es"}, {"name": "Erika Ribeiro, Pharm D", "role": "CONTACT", "phone": "59175969924", "email": "ecorreia@dndi.org"}, {"name": "Lourdes O Daza, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -21.53549, "lon": -64.72956}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D014352", "term": "Trypanosomiasis"}], "ancestors": [{"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "asFound": "Trypanosomiasis", "relevance": "HIGH"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02625974", "orgStudyIdInfo": {"id": "16027"}, "secondaryIdInfos": [{"id": "2022-001504-17", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi", "officialTitle": "Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease"}, "statusModule": {"statusVerifiedDate": "2024-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-01-27", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-07-25", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-08-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-12-07", "studyFirstSubmitQcDate": "2015-12-07", "studyFirstPostDateStruct": {"date": "2015-12-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-07-22", "resultsFirstSubmitQcDate": "2019-10-10", "resultsFirstPostDateStruct": {"date": "2019-10-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-03-21", "lastUpdatePostDateStruct": {"date": "2024-08-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 330, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Nifurtimox 60 days / Arm 1", "type": "EXPERIMENTAL", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)", "interventionNames": ["Drug: Nifurtimox (Lampit, BAYA2502)"]}, {"label": "Nifurtimox 30 days / Arm 2", "type": "EXPERIMENTAL", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)", "interventionNames": ["Drug: Nifurtimox (Lampit, BAYA2502)", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Nifurtimox (Lampit, BAYA2502)", "description": "For pediatric participants with body weight \u2264 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.\n\nFor pediatric participants with body weight \\> 40 kg: 8 - 10 mg/kg/day in three divided doses.\n\n60 days or 30 days of nifurtimox treatment", "armGroupLabels": ["Nifurtimox 30 days / Arm 2", "Nifurtimox 60 days / Arm 1"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo", "armGroupLabels": ["Nifurtimox 30 days / Arm 2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects)", "description": "Cure is defined as sero-reduction (in subjects \u22658 months to \\<18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a \u226520% reduction in optical density \\[OD\\]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G (IgG) concentration measured by two conventional ELISA serology tests.\n\nSubjects who have missing conventional serology results at the 12 month time point were treated as failures (ie, no cure).\n\nFor the primary objective in the study, superiority over placebo was confirmed if the lower limit of the 95% Confidence Interval (CI) for the nifurtimox (60-day regimen) cure rate is greater than 16%, the larger of the upper limits of the 95% CIs for historical placebo control.", "timeFrame": "At 12 months post-treatment"}, {"measure": "Part 2 - Incidence Rate of Seronegative Conversion in Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.", "description": "Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay \\[IHA\\]) in subjects who were randomized and received at least one dose of the 60-day nifurtimox treatment regimen compared to an external control group of historical placebo patients with Chagas' disease. Incidence rate is the number of new cases of seronegative conversion over the study period (i.e., 4 years after end of nifurtimox treatment) divided by the person-time at risk. It was modelled using a Poisson distribution with a 2-sided 95% exact CI.\n\nNumber of participants with events were reported.", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1"}], "secondaryOutcomes": [{"measure": "Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 2", "description": "Measured in sub-population.", "timeFrame": "At Visit 2 (Day 1): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours"}, {"measure": "Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 3", "description": "Measured in sub-population.", "timeFrame": "At Visit 3 (Day 7): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours"}, {"measure": "Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 6", "description": "The evaluation was based on clinical examinations. Measured in sub-population.", "timeFrame": "At Visit 6 (Day 30): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours"}, {"measure": "Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 8", "description": "Measured in sub-population.", "timeFrame": "At Visit 8 (Day 60): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours"}, {"measure": "Part 2 - Incidence Rate of Seronegative Conversion in Subjects Who Received at Least One Dose of the 30-day Nifurtimox Treatment Regimen", "description": "Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay \\[IHA\\]) in subjects who were randomized and received at least one dose of the 30-day nifurtimox treatment regimen. Incidence rate is the number of new cases of seronegative conversion over the study period (i.e., 4 years after end of nifurtimox treatment) divided by the person-time at risk. It was modelled using a Poisson distribution with a 2-sided 95% exact CI.\n\nNumber of participants with events were reported.", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1"}, {"measure": "Part 2 - ECG Signs of Established Chagas-related Cardiomyopathy", "description": "Summary of subjects by evidence of established Chagas-related cardiomyopathy as measured by electrocardiogram (ECG).\n\nEvidence of established Chagas-related cardiomyopathy: Total", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1"}, {"measure": "Part 2 - Serological Response of Established Chagas-related Cardiomyopathy", "description": "Summary of subjects by evidence of established Chagas-related cardiomyopathy as measured by Serological response.\n\nEvidence of established Chagas-related cardiomyopathy: Total", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1"}, {"measure": "Part 1 + Part 2 - Serial Reduction of Optical Density Values Measured by Total Purified Antigen ELISA", "description": "Summary and change from baseline of optical density values measured by total purified antigen ELISA.\n\nOptical density is the measure of absorbance, and is defined as the ratio of the intensity of light falling upon a material and the intensity transmitted.", "timeFrame": "Baseline and Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1"}, {"measure": "Part 1 + Part 2 - Serial Reduction of Optical Density Values Measured by Recombinant ELISA", "description": "Summary and change from baseline of optical density values measured by recombinant ELISA.\n\nOptical density is the measure of absorbance, and is defined as the ratio of the intensity of light falling upon a material and the intensity transmitted.", "timeFrame": "Baseline and Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1"}, {"measure": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1", "description": "The evaluation was based on clinical examinations.", "timeFrame": "At Visit 1 (before treatment started)"}, {"measure": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3", "description": "The evaluation was based on clinical examinations.", "timeFrame": "Up to 7 days (Visit 3)"}, {"measure": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6", "description": "The evaluation was based on clinical examinations.", "timeFrame": "Up to 30 days (Visit 6)"}, {"measure": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8", "description": "The evaluation was based on clinical examinations.", "timeFrame": "Up to 60 days (Visit 8; end of treatment)"}, {"measure": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9", "description": "The evaluation was based on clinical examinations.", "timeFrame": "Up to 90 days (Visit 9 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10", "description": "The evaluation was based on clinical examinations.", "timeFrame": "Up to 240 days (Visit 10 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11", "description": "The evaluation was based on clinical examinations.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects <8 Months of Age)", "timeFrame": "Up to 90 days (Visit 9 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test", "description": "The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results", "description": "The qPCR is molecular technique, considered a tool to diagnose acute and congenital Chagas disease, as well as a marker to measure treatment failure when demonstrating positive (detectable) results", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)", "description": "TEAEs comprised events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug", "timeFrame": "up to 7 days after last application of study drug"}, {"measure": "Part 2 - Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)", "description": "TEAEs comprised events which first occurred or worsened at study start up to end of study in part 2.\n\nIn Part 2, only AEs considered at least possibly related to nifurtimox (administered in part 1) and those caused by protocol-related procedures were reported.", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1"}, {"measure": "Part 1 - Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment", "description": "The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment", "description": "The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment", "description": "The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or high abnormal values at baseline are not included in the number analyzed.\n\nThe number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment", "description": "The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or low abnormal values at baseline are not included in the number analyzed.\n\nThe number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment", "description": "The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment", "description": "The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)", "description": "Urinalysis was performed and the following parameters evaluated: bilirubin, blood (red blood cells, white blood cells), chorionic gonadotropin \u03b2, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators", "description": "Clinical significance of abnormal ECG was based on the judgement of the investigator", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline", "description": "Systolic Blood Pressure", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline", "description": "Diastolic Blood Pressure", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline", "description": "Respiratory Rate", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline", "description": "Heart Rate", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Mean Changes in Vital Signs (Body Temperature) Between the Treatment Groups From Baseline", "description": "Temperature", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)"}], "otherOutcomes": [{"measure": "Part 1: Number of Participants Cured With 60-day Regimen Compared With Historical Active Control (Benznidazole)", "description": "This exploratory efficacy analysis evaluated the cure rate assessed as seroconversion of nifurtimox after 1-year post-treatment follow-up with that of published data for benznidazole (Sosa Estani et al. 1998 and de Andrade et al. 1996) at 4- and 3-year post-treatment follow-up, respectively, used as historical control.", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Relationship of Conventional Serology (Total Purified Antigen ELISA) and qPCR Testing by Visit", "description": "Using frequencies of matches and mismatches to assess agreement\n\nReactive = Reac ELISA Detectable = Detec qPCR Non-reactive = Nonreac ELISA Non-detectable = Nondetec qPCR Non evaluable = Noneval qPCR qPCR Missing = Miss qPCR Missing conventional testing = Miss ELISA", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Relationship of Conventional Serology (Total Purified Antigen ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit", "description": "Using frequencies of matches and mismatches to assess agreement\n\nReactive = Reac ELISA Reactive = Reac F29 Non-reactive = Nonreac ELISA Non-reactive = Nonreac F29", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Relationship of Conventional Serology (Recombinant ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit", "description": "Using frequencies of matches and mismatches to assess agreement\n\nReactive = Reac ELISA Reactive = Reac F29 Non-reactive = Nonreac ELISA Non-reactive= Nonreac F29", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Relationship of Conventional Serology (ELISA) to Indirect Hemagglutination Assay (IHA) Results", "description": "Sero-reduction is defined as a =\\> 20% reduction in optical density \\[OD\\]) using two conventional ELISA serology tests in subjects =\\> 8 months to \\< 18 years of age at randomization; Others: reactive results that are not sero-reduction in subjects =\\> 8 months to \\< 18 years of age at randomization; or reactive results in subjects \\< 8 months of age at randomization.\n\nNon-reactive ELISA = Nonreac ELISA Non-reactive IHA = Nonreac IHA Reactive IHA decrease = Reac IHA dec React IHA nochange = Reac IHA nochange Reactive ELISA: seroreduction = Reac ELISA reduc Reactive ELISA: others = Reac ELISA other", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}, {"measure": "Part 1 - Relationship Between Conventional ELISA Results in Terms of Cure or No Cure and IHA Results in All Patients", "description": "Cure is defined as sero-reduction (in subjects =\\> 8 months to \\< 18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a =\\> 20% reduction in optical density \\[OD\\]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G \\[IgG\\] concentration measured by two conventional ELISA serology tests.\n\nCure = Cure Non reactive/reactive decreasing = Nonreac/reac dec Reactive non-decreasing = Reac nondec No cure = No Cure Missing IHA testing = IHA missing", "timeFrame": "Up to 420 days (Visit 11 post-treatment)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nPart 1:\n\n* Male and female pediatric subjects aged 0 days to younger than 18 years\n* Chagas' disease diagnosed/ confirmed for a) Subjects \\< 8 months of age at randomization must demonstrate direct observation of Trypanosoma cruzi by concentration test; b) Subjects \u2265 8 months to \\< 18 years of age at randomization must demonstrate a positive conventional ELISA result for both recombinant ELISA and total purified antigen ELISA\n\nPart 2:\n\n- Male and female subjects who were randomized and received at least one dose of their assigned 60- or 30-day regimen of nifurtimox treatment\n\nExclusion Criteria:\n\nPart 1:\n\n* Subjects aged 0 to 27 days who, at birth, were pre-term, weighed less than 2500 g, or had a maximum Apgar score \\< 7 at 5 minutes\n* Known evidence of Chagas' disease-related cardiomyopathy/ Chagas' heart disease\n* Known evidence of Chagas' disease-related gastrointestinal dysfunction (e.g. megaoesophagus, megacolon, or both) or Chagas' digestive disease\n* Serious manifestations of acute Chagas' disease, including myocarditis, meningoencephalitis, or pneumonitis\n* Known evidence of Chagas' disease-related damage to the peripheral nervous system or peripheral neuropathy\n* Clinically significant psychiatric disorder (e.g. moderate to severe depression, severe anxiety, or psychosis) or epilepsy\n* Subjects with contraindications/ warnings to nifurtimox administration, or with conditions that may increase the risk of the undesirable effects of nifurtimox\n* Subjects who have had previous treatment with trypanocidal agents or an accepted indication for antiparasitic therapy (e.g. reactivation of Chagas' infection due to immunosuppression by several diseases or treatment with steroids)\n* Subjects living in housing conditions where there is no active or effective vector control to Trypanosoma cruzi reinfection as determined by Ministry of Health guidelines in each country\n\nPart 2:\n\n* Subjects with acute or chronic health conditions or congenital disorders which, in the opinion of the investigator, would make them unsuitable for participation in the clinical study\n* Subjects living in housing conditions where there is no active or effective vector-control to Trypanosoma cruzi reinfection as determined by Ministry of Health guideline of the respective country\n* Subjects with clinical manifestations of Chagas' disease-related gastrointestinal dysfunction or serious manifestations of acute Chagas' disease\n* Immuno-compromised subjects (e.g. with human immunodeficiency virus or treated with immunosuppressive drugs)", "healthyVolunteers": false, "sex": "ALL", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "La Plata", "state": "Buenos Aires", "zip": "1900", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"city": "Buenos Aires", "state": "Ciudad Auton. De Buenos Aires", "zip": "1281", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"city": "Buenos Aires", "state": "Ciudad Auton. De Buenos Aires", "zip": "C1270AAN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"city": "Buenos Aires", "state": "Ciudad Auton. De Buenos Aires", "zip": "C1425AGP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"city": "Buenos Aires", "state": "Ciudad Auton. De Buenos Aires", "zip": "C1425EFD", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"city": "San Salvador de Jujuy", "state": "Jujuy", "zip": "4600", "country": "Argentina", "geoPoint": {"lat": -24.19457, "lon": -65.29712}}, {"city": "Posadas", "state": "Misiones", "country": "Argentina", "geoPoint": {"lat": -27.36708, "lon": -55.89608}}, {"city": "Rosario", "state": "Santa Fe", "zip": "2000", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"city": "Corrientes", "zip": "W3400CBI", "country": "Argentina", "geoPoint": {"lat": -27.4806, "lon": -58.8341}}, {"city": "Formosa", "zip": "P3600HZL", "country": "Argentina", "geoPoint": {"lat": -26.17753, "lon": -58.17814}}, {"city": "La Rioja", "country": "Argentina", "geoPoint": {"lat": -29.41105, "lon": -66.85067}}, {"city": "Mendoza", "zip": "5500", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"city": "Mendoza", "zip": "5535", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"city": "Salta", "zip": "4400", "country": "Argentina", "geoPoint": {"lat": -24.7859, "lon": -65.41166}}, {"city": "Salta", "zip": "A4400ESE", "country": "Argentina", "geoPoint": {"lat": -24.7859, "lon": -65.41166}}, {"city": "San Juan", "zip": "5400", "country": "Argentina", "geoPoint": {"lat": -31.5375, "lon": -68.53639}}, {"city": "Santiago del Estero", "zip": "4202", "country": "Argentina", "geoPoint": {"lat": -27.79511, "lon": -64.26149}}, {"city": "Tucuman", "zip": "4000", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"city": "Cochabamba", "country": "Bolivia", "geoPoint": {"lat": -17.3895, "lon": -66.1568}}, {"city": "Punata", "country": "Bolivia", "geoPoint": {"lat": -17.54234, "lon": -65.83472}}, {"city": "Tarija", "country": "Bolivia", "geoPoint": {"lat": -21.53549, "lon": -64.72956}}, {"city": "Soledad", "state": "Atl\u00e1ntico", "country": "Colombia", "geoPoint": {"lat": 10.91843, "lon": -74.76459}}, {"city": "Yopal", "state": "Casanare", "zip": "0", "country": "Colombia", "geoPoint": {"lat": 5.33775, "lon": -72.39586}}, {"city": "Santa Marta", "state": "Magdalena", "zip": "0", "country": "Colombia", "geoPoint": {"lat": 11.24079, "lon": -74.19904}}, {"city": "Floridablabca", "state": "Santander", "zip": "681011", "country": "Colombia"}]}, "referencesModule": {"references": [{"pmid": "9790423", "type": "RESULT", "citation": "Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg. 1998 Oct;59(4):526-9. doi: 10.4269/ajtmh.1998.59.526."}, {"pmid": "8937280", "type": "RESULT", "citation": "de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996 Nov 23;348(9039):1407-13. doi: 10.1016/s0140-6736(96)04128-1."}, {"pmid": "33412557", "type": "RESULT", "citation": "Altcheh J, Castro L, Dib JC, Grossmann U, Huang E, Moscatelli G, Pinto Rocha JJ, Ramirez TE; CHICO Study Group. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO). PLoS Negl Trop Dis. 2021 Jan 7;15(1):e0008912. doi: 10.1371/journal.pntd.0008912. eCollection 2021 Jan."}], "seeAlsoLinks": [{"label": "Click here to find information about studies related to Bayer Healthcare products conducted in Europe", "url": "http://www.clinicaltrialsregister.eu/"}, {"label": "Click here to find results for studies related to Bayer products.", "url": "https://clinicaltrials.bayer.com/"}, {"label": "Related Info", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217261&amp;parentIdentifier=16027&amp;attachmentIdentifier=341adaa4-a747-4150-98c6-4f09a62e7bcb&amp;fileName=Bayer_16027_PLS_v2.0_2022_08_30.pdf&amp;versionIdentifier="}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Part 1: 330 subjects who were eligible to participate in the study were randomized in a 2:1 ratio to either a 60-Day or 30-Day regimen with nifurtimox tablets. 308 subjects completed treatment in Part 1, and 318 subjects completed Part 1.\n\nPart 2: Of the 318 subjects completed Part 1, 295 subjects were included in Part 2.", "recruitmentDetails": "Part 1 of the study was conducted from 27 JAN 2016 (First subject first visit) to 25 JUL 2018 (Last subject last visit) in Argentina, Bolivia and Colombia.\n\nPart 2 of the study was conducted from 26 SEP 2018 (First subject first visit) to 10 AUG 2021 (Last subject last visit) in Argentina, Bolivia and Colombia.", "groups": [{"id": "FG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "FG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "periods": [{"title": "Part 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "219"}, {"groupId": "FG001", "numSubjects": "111"}]}, {"type": "Received Treatment", "achievements": [{"groupId": "FG000", "numSubjects": "219"}, {"groupId": "FG001", "numSubjects": "111"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "210"}, {"groupId": "FG001", "numSubjects": "108"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "3"}]}]}, {"title": "Part 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "197"}, {"groupId": "FG001", "numSubjects": "98"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "191"}, {"groupId": "FG001", "numSubjects": "91"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Other, including due to the COVID-19 Pandemic", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}, {"id": "BG001", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "219"}, {"groupId": "BG002", "value": "330"}]}], "measures": [{"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "0 to 27 days", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}, {"title": "28 days to younger than 8 months", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "12"}]}, {"title": "8 months to younger than 2 years", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "25"}]}, {"title": "2 years to younger than 18 years", "measurements": [{"groupId": "BG000", "value": "96"}, {"groupId": "BG001", "value": "190"}, {"groupId": "BG002", "value": "286"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "119"}, {"groupId": "BG002", "value": "178"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "152"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "155"}, {"groupId": "BG002", "value": "236"}]}, {"title": "American Indian or Alaska native", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "64"}, {"groupId": "BG002", "value": "94"}]}]}]}, {"title": "Total Purified Antigen enzyme-linked immunosorbent assay (ELISA) test results", "description": "Chagas disease diagnosed by direct observation of T. cruzi by concentration test (subjects \\<8 months of age at randomization) or positive conventional ELISA results for both recombinant ELISA and total purified antigen ELISA (subjects \u22658 months to younger than 18 years of age at randomization) as determined by local laboratory test results were eligible for enrollment.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Reactive", "measurements": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "219"}, {"groupId": "BG002", "value": "329"}]}, {"title": "Non Reactive", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Total Purified Antigen ELISA optical density (OD) values", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "No dimension", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.532", "spread": "0.533"}, {"groupId": "BG001", "value": "1.474", "spread": "0.553"}, {"groupId": "BG002", "value": "1.494", "spread": "0.546"}]}]}]}, {"title": "Recombinant ELISA test results", "description": "Chagas disease diagnosed by direct observation of T. cruzi by concentration test (subjects \\<8 months of age at randomization) or positive conventional ELISA results for both recombinant ELISA and total purified antigen ELISA (subjects \u22658 months to younger than 18 years of age at randomization) as determined by local laboratory test results were eligible for enrollment.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Reactive", "measurements": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "219"}, {"groupId": "BG002", "value": "329"}]}, {"title": "Non Reactive", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Recombinant ELISA OD values", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "No dimension", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.765", "spread": "0.605"}, {"groupId": "BG001", "value": "2.735", "spread": "0.640"}, {"groupId": "BG002", "value": "2.745", "spread": "0.628"}]}]}]}, {"title": "Non conventional ELISA-F29 test results", "description": "The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Reactive", "measurements": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "142"}, {"groupId": "BG002", "value": "214"}]}, {"title": "Non Reactive", "measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "116"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "108"}, {"groupId": "BG001", "value": "217"}, {"groupId": "BG002", "value": "325"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Concentration test for T. cruzi", "description": "Chagas disease diagnosed by direct observation of T. cruzi by concentration test (subjects \\<8 months of age at randomization).", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Positive", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "19"}]}, {"title": "Negative", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Missing", "measurements": [{"groupId": "BG000", "value": "104"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "311"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects)", "description": "Cure is defined as sero-reduction (in subjects \u22658 months to \\<18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a \u226520% reduction in optical density \\[OD\\]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G (IgG) concentration measured by two conventional ELISA serology tests.\n\nSubjects who have missing conventional serology results at the 12 month time point were treated as failures (ie, no cure).\n\nFor the primary objective in the study, superiority over placebo was confirmed if the lower limit of the 95% Confidence Interval (CI) for the nifurtimox (60-day regimen) cure rate is greater than 16%, the larger of the upper limits of the 95% CIs for historical placebo control.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of subjects", "timeFrame": "At 12 months post-treatment", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.9", "lowerLimit": "26.4", "upperLimit": "39.3"}, {"groupId": "OG001", "value": "18.9", "lowerLimit": "11.2", "upperLimit": "26.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "A direct comparison", "paramType": "Difference in cure rate", "paramValue": "14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.7", "ciUpperLimit": "24.2"}]}, {"type": "PRIMARY", "title": "Part 2 - Incidence Rate of Seronegative Conversion in Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.", "description": "Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay \\[IHA\\]) in subjects who were randomized and received at least one dose of the 60-day nifurtimox treatment regimen compared to an external control group of historical placebo patients with Chagas' disease. Incidence rate is the number of new cases of seronegative conversion over the study period (i.e., 4 years after end of nifurtimox treatment) divided by the person-time at risk. It was modelled using a Poisson distribution with a 2-sided 95% exact CI.\n\nNumber of participants with events were reported.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)\n\nTreatment administered in Part 1; no study drug was administered in Part 2"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Incidence rate and 95% CI of seronegative conversion", "paramType": "Risk Ratio (RR)", "paramValue": "2.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.21", "ciUpperLimit": "3.45", "estimateComment": "Person-year = 754"}]}, {"type": "SECONDARY", "title": "Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 2", "description": "Measured in sub-population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "ug/L", "timeFrame": "At Visit 2 (Day 1): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"title": "Predose", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "26.8", "comment": "below the level of detection"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "below the level of detection"}]}]}, {"title": "5 - 10 MIN POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "154.8", "comment": "below the level of detection"}, {"groupId": "OG001", "value": "21.1", "lowerLimit": "NA", "upperLimit": "695.0", "comment": "below the level of detection"}]}]}, {"title": "10 - 120 MIN POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.2", "lowerLimit": "5.8", "upperLimit": "847.5"}, {"groupId": "OG001", "value": "49.0", "lowerLimit": "NA", "upperLimit": "524.3", "comment": "below the level of detection"}]}]}, {"title": "2 - 4 HOURS POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "215.4", "lowerLimit": "77.9", "upperLimit": "516.3"}, {"groupId": "OG001", "value": "300.7", "lowerLimit": "106.9", "upperLimit": "533.5"}]}]}, {"title": "4 - 8 HOURS POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "267.6", "lowerLimit": "40.2", "upperLimit": "508.1"}, {"groupId": "OG001", "value": "289.6", "lowerLimit": "103.2", "upperLimit": "301.0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 3", "description": "Measured in sub-population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "ug/L", "timeFrame": "At Visit 3 (Day 7): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"title": "Predose", "categories": [{"measurements": [{"groupId": "OG000", "value": "47.7", "lowerLimit": "NA", "upperLimit": "407.6", "comment": "below the level of detection"}, {"groupId": "OG001", "value": "38.3", "lowerLimit": "NA", "upperLimit": "472.3", "comment": "below the level of detection"}]}]}, {"title": "5 - 10 MIN POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.6", "lowerLimit": "NA", "upperLimit": "561.6", "comment": "below the level of detection"}, {"groupId": "OG001", "value": "56.0", "lowerLimit": "NA", "upperLimit": "442.8", "comment": "below the level of detection"}]}]}, {"title": "10 - 120 MIN POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "250.6", "lowerLimit": "13.8", "upperLimit": "1035.6"}, {"groupId": "OG001", "value": "232.3", "lowerLimit": "13.9", "upperLimit": "706.3"}]}]}, {"title": "2 - 4 HOURS POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "497.2", "lowerLimit": "57.1", "upperLimit": "1027.4"}, {"groupId": "OG001", "value": "257.7", "lowerLimit": "46.3", "upperLimit": "660.2"}]}]}, {"title": "4 - 8 HOURS POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "427.5", "lowerLimit": "141.2", "upperLimit": "778.2"}, {"groupId": "OG001", "value": "267.0", "lowerLimit": "NA", "upperLimit": "339.6", "comment": "below the level of detection"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 6", "description": "The evaluation was based on clinical examinations. Measured in sub-population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "ug/L", "timeFrame": "At Visit 6 (Day 30): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"title": "Predose", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.8", "lowerLimit": "NA", "upperLimit": "459.3", "comment": "below the level of detection"}, {"groupId": "OG001", "value": "40.8", "lowerLimit": "NA", "upperLimit": "284.3", "comment": "below the level of detection"}]}]}, {"title": "5 - 10 MIN POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.7", "lowerLimit": "NA", "upperLimit": "153.7", "comment": "below the level of detection"}, {"groupId": "OG001", "value": "73.7", "lowerLimit": "NA", "upperLimit": "266.7", "comment": "below the level of detection"}]}]}, {"title": "10 - 120 MIN POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "135.0", "lowerLimit": "NA", "upperLimit": "932.4", "comment": "below the level of detection"}, {"groupId": "OG001", "value": "172.7", "lowerLimit": "14.1", "upperLimit": "387.3"}]}]}, {"title": "2 - 4 HOURS POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "369.5", "lowerLimit": "92.1", "upperLimit": "1277.0"}, {"groupId": "OG001", "value": "103.8", "lowerLimit": "12.3", "upperLimit": "1107.2"}]}]}, {"title": "4 - 8 HOURS POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "249.7", "lowerLimit": "70.9", "upperLimit": "504.3"}, {"groupId": "OG001", "value": "165.2", "lowerLimit": "84.9", "upperLimit": "1089.3"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 8", "description": "Measured in sub-population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "ug/L", "timeFrame": "At Visit 8 (Day 60): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Predose", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "258.7", "comment": "below the level of detection"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "below the level of detection"}]}]}, {"title": "5 - 10 MIN POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.4", "lowerLimit": "15.9", "upperLimit": "255.1"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "below the level of detection"}]}]}, {"title": "10 - 120 MIN POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "139.1", "lowerLimit": "23.6", "upperLimit": "711.4"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "21.5", "comment": "below the level of detection"}]}]}, {"title": "2 - 4 HOURS POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "395.6", "lowerLimit": "166.9", "upperLimit": "883.0"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "below the level of detection"}]}]}, {"title": "4 - 8 HOURS POST", "categories": [{"measurements": [{"groupId": "OG000", "value": "300.6", "lowerLimit": "28.5", "upperLimit": "1217.2"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "below the level of detection"}]}]}]}, {"type": "SECONDARY", "title": "Part 2 - Incidence Rate of Seronegative Conversion in Subjects Who Received at Least One Dose of the 30-day Nifurtimox Treatment Regimen", "description": "Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay \\[IHA\\]) in subjects who were randomized and received at least one dose of the 30-day nifurtimox treatment regimen. Incidence rate is the number of new cases of seronegative conversion over the study period (i.e., 4 years after end of nifurtimox treatment) divided by the person-time at risk. It was modelled using a Poisson distribution with a 2-sided 95% exact CI.\n\nNumber of participants with events were reported.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1", "groups": [{"id": "OG000", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)\n\nTreatment administered in Part 1; no study drug was administered in Part 2"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Incidence rate and 95% CI of seronegative conversion", "paramType": "Risk Ratio (RR)", "paramValue": "2.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.91", "ciUpperLimit": "4.16", "estimateComment": "Person-year = 379"}]}, {"type": "SECONDARY", "title": "Part 2 - ECG Signs of Established Chagas-related Cardiomyopathy", "description": "Summary of subjects by evidence of established Chagas-related cardiomyopathy as measured by electrocardiogram (ECG).\n\nEvidence of established Chagas-related cardiomyopathy: Total", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days: Chagas-related Cardiomyopathy", "description": "ECG signs"}, {"id": "OG001", "title": "Nifurtimox 30 Days: Chagas-related Cardiomyopathy", "description": "ECG signs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "YES", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "NO", "categories": [{"measurements": [{"groupId": "OG000", "value": "189"}, {"groupId": "OG001", "value": "90"}]}]}, {"title": "MISSING", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}]}]}]}, {"type": "SECONDARY", "title": "Part 2 - Serological Response of Established Chagas-related Cardiomyopathy", "description": "Summary of subjects by evidence of established Chagas-related cardiomyopathy as measured by Serological response.\n\nEvidence of established Chagas-related cardiomyopathy: Total", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days: Chagas-related Cardiomyopathy", "description": "Serological response"}, {"id": "OG001", "title": "Nifurtimox 30 Days: Chagas-related Cardiomyopathy", "description": "Serological response"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Non Reactive", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Reactive", "categories": [{"measurements": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "84"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 + Part 2 - Serial Reduction of Optical Density Values Measured by Total Purified Antigen ELISA", "description": "Summary and change from baseline of optical density values measured by total purified antigen ELISA.\n\nOptical density is the measure of absorbance, and is defined as the ratio of the intensity of light falling upon a material and the intensity transmitted.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Optical density", "timeFrame": "Baseline and Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)\n\nTreatment administered in Part 1; no study drug was administered in Part 2"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)\n\nTreatment administered in Part 1; no study drug was administered in Part 2"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Part 1 - Baseline (Visit 1)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.47", "spread": "0.55", "lowerLimit": "0.55", "upperLimit": "2.6"}, {"groupId": "OG001", "value": "1.52", "spread": "0.55", "lowerLimit": "0.55"}]}]}, {"title": "Part 1 - Up to 420 days post-treatment (Visit 11)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.24", "spread": "0.62", "lowerLimit": "0.62", "upperLimit": "2.5"}, {"groupId": "OG001", "value": "1.30", "spread": "0.61", "lowerLimit": "0.61"}]}]}, {"title": "Part 1 - Change from Baseline (Visit 11)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.24", "spread": "0.29", "lowerLimit": "0.29", "upperLimit": "0.3"}, {"groupId": "OG001", "value": "-0.23", "spread": "0.41", "lowerLimit": "0.41"}]}]}, {"title": "Part 2 - Year 2: (FU Visit 1)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.23", "spread": "0.59", "lowerLimit": "0.59"}, {"groupId": "OG001", "value": "1.29", "spread": "0.61", "lowerLimit": "0.61"}]}]}, {"title": "Part 2 - Year 2: Change from Baseline (FU Visit 1)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.25", "spread": "0.41", "lowerLimit": "0.41"}, {"groupId": "OG001", "value": "-0.23", "spread": "0.49", "lowerLimit": "0.49"}]}]}, {"title": "Part 2 - Year 3 (FU Visit 3)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.16", "spread": "0.58", "lowerLimit": "0.58"}, {"groupId": "OG001", "value": "1.23", "spread": "0.58", "lowerLimit": "0.58"}]}]}, {"title": "Part 2 - Year 3: Change from Baseline (FU Visit 3)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "spread": "0.42", "lowerLimit": "0.42"}, {"groupId": "OG001", "value": "-0.30", "spread": "0.50", "lowerLimit": "0.50"}]}]}, {"title": "Part 2 - Year 4 (FU Visit 5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.12", "spread": "0.57", "lowerLimit": "0.57"}, {"groupId": "OG001", "value": "1.23", "spread": "0.59", "lowerLimit": "0.59"}]}]}, {"title": "Part 2 - Year 4: Change from Baseline (FU Visit 5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.35", "spread": "0.40", "lowerLimit": "0.40"}, {"groupId": "OG001", "value": "-0.30", "spread": "0.46", "lowerLimit": "0.46"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 + Part 2 - Serial Reduction of Optical Density Values Measured by Recombinant ELISA", "description": "Summary and change from baseline of optical density values measured by recombinant ELISA.\n\nOptical density is the measure of absorbance, and is defined as the ratio of the intensity of light falling upon a material and the intensity transmitted.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Optical density", "timeFrame": "Baseline and Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)\n\nTreatment administered in Part 1; no study drug was administered in Part 2"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)\n\nTreatment administered in Part 1; no study drug was administered in Part 2"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Part 1 - Baseline (Visit 1)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.74", "spread": "0.63", "lowerLimit": "0.63"}, {"groupId": "OG001", "value": "2.73", "spread": "0.63", "lowerLimit": "0.63"}]}]}, {"title": "Part 1 - Up to 420 days post-treatment (Visit 11)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.27", "spread": "0.98", "lowerLimit": "0.98"}, {"groupId": "OG001", "value": "2.31", "spread": "1.00", "lowerLimit": "1.00"}]}]}, {"title": "Part 1 - Change from Baseline (Visit 11)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "0.74", "lowerLimit": "0.74"}, {"groupId": "OG001", "value": "-0.41", "spread": "0.79", "lowerLimit": "0.79"}]}]}, {"title": "Part 2 - Year 2: (FU Visit 1)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "0.95", "lowerLimit": "0.95"}, {"groupId": "OG001", "value": "2.57", "spread": "0.88", "lowerLimit": "0.88"}]}]}, {"title": "Part 2 - Year 2: Change from Baseline (FU Visit 1)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.23", "spread": "0.87", "lowerLimit": "0.87"}, {"groupId": "OG001", "value": "-0.17", "spread": "0.90", "lowerLimit": "0.90"}]}]}, {"title": "Part 2 - Year 3 (FU Visit 3)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.17", "spread": "0.98", "lowerLimit": "0.98"}, {"groupId": "OG001", "value": "2.25", "spread": "0.91", "lowerLimit": "0.91"}]}]}, {"title": "Part 2 - Year 3: Change from Baseline (FU Visit 3)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.56", "spread": "0.86", "lowerLimit": "0.86"}, {"groupId": "OG001", "value": "-0.45", "spread": "0.87", "lowerLimit": "0.87"}]}]}, {"title": "Part 2 - Year 4 (FU Visit 5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.09", "spread": "1.01", "lowerLimit": "1.01"}, {"groupId": "OG001", "value": "2.22", "spread": "1.00", "lowerLimit": "1.00"}]}]}, {"title": "Part 2 - Year 4: Change from Baseline (FU Visit 5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.64", "spread": "0.89", "lowerLimit": "0.89"}, {"groupId": "OG001", "value": "-0.48", "spread": "0.87", "lowerLimit": "0.87"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1", "description": "The evaluation was based on clinical examinations.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "At Visit 1 (before treatment started)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3", "description": "The evaluation was based on clinical examinations.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 7 days (Visit 3)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Anemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Chagas disease", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hepatomegaly", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Known ECG abnormality", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6", "description": "The evaluation was based on clinical examinations.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 30 days (Visit 6)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "215"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Known ECG abnormality", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Romana sign", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8", "description": "The evaluation was based on clinical examinations.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 60 days (Visit 8; end of treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "217"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"title": "Anemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Chagas disease", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Known ECG abnormality", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphadenopathy", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9", "description": "The evaluation was based on clinical examinations.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 90 days (Visit 9 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "213"}, {"groupId": "OG001", "value": "107"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10", "description": "The evaluation was based on clinical examinations.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 240 days (Visit 10 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "212"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11", "description": "The evaluation was based on clinical examinations.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects <8 Months of Age)", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 90 days (Visit 9 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "7"}]}], "classes": [{"title": "Visit 1|Positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Visit 3|Positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Visit 6|Positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Visit 8|Positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Visit 9|Positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Visit 1|Negative", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Visit 3|Negative", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Visit 6|Negative", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Visit 8|Negative", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Visit 9|Negative", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Visit 1|Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Visit 3|Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Visit 6|Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Visit 8|Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Visit 9|Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test", "description": "The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Reactive", "categories": [{"measurements": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "54"}]}]}, {"title": "Non-reactive", "categories": [{"measurements": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "54"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results", "description": "The qPCR is molecular technique, considered a tool to diagnose acute and congenital Chagas disease, as well as a marker to measure treatment failure when demonstrating positive (detectable) results", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Visit 1 - Non-detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "53"}]}]}, {"title": "Visit 1 - Detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "117"}, {"groupId": "OG001", "value": "57"}]}]}, {"title": "Visit 1 - Non-evaluable", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Visit 1 - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Visit 3 - Non-detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "171"}, {"groupId": "OG001", "value": "86"}]}]}, {"title": "Visit 3 - Detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Visit 3 - Non-evaluable", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Visit 3 - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Visit 6 - Non-detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "105"}]}]}, {"title": "Visit 6 - Detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Visit 6 - Non-evaluable", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Visit 6 - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Visit 8 - Non-detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "105"}]}]}, {"title": "Visit 8 - Detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Visit 8 - Non-evaluable", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Visit 8 - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Visit 10 - Non-detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "206"}, {"groupId": "OG001", "value": "105"}]}]}, {"title": "Visit 10 - Detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Visit 10 - Non-evaluable", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Visit 10 - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Visit 11 - Non-detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "205"}, {"groupId": "OG001", "value": "102"}]}]}, {"title": "Visit 11 - Detectable", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Visit 11 - Non-evaluable", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Visit 11 - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)", "description": "TEAEs comprised events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "up to 7 days after last application of study drug", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Any treatment-emergent adverse event (TEAE)", "categories": [{"measurements": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "66"}]}]}, {"title": "Any Serious TEAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Part 2 - Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)", "description": "TEAEs comprised events which first occurred or worsened at study start up to end of study in part 2.\n\nIn Part 2, only AEs considered at least possibly related to nifurtimox (administered in part 1) and those caused by protocol-related procedures were reported.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)\n\nTreatment administered in Part 1; no study drug was administered in Part 2"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)\n\nTreatment administered in Part 1; no study drug was administered in Part 2"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Any AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Any study drug-related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Any AE related to protocol", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Any SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Any study drug-related SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Any SAE related to protocol", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "AE with outcome death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment", "description": "The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Creatinine (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Albumin (g/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Alkaline Phosphatase (U/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Alanine Aminotransferase (U/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Aspartate Aminotransferase (U/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Bilirubin (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Direct Bilirubin (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Blood Urea Nitrogen (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Urate (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Glucose (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "13"}]}]}, {"title": "Protein (g/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "14"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment", "description": "The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Creatinine (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Albumin (g/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Alkaline Phosphatase (U/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Alanine Aminotransferase (U/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Aspartate Aminotransferase (U/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Bilirubin (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Direct Bilirubin (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Blood Urea Nitrogen (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "Urate (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Glucose (mg/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Protein (g/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "15"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment", "description": "The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or high abnormal values at baseline are not included in the number analyzed.\n\nThe number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Hematocrit (%", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Hemoglobin (g/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Erythrocytes (T/L) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Ery. Mean Corpuscular Volume (fL) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Ery. Mean Corpuscular Hemoglobin (pg) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Ery. Mean Corpuscular HGB Conc. (g/dL) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Leukocytes (GIGA/L) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Neutrophils/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "Neutrophils (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Lymphocytes/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "Lymphocytes (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Monocytes/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "Monocytes (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "Eosinophils/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "26"}]}]}, {"title": "Eosinophils (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "22"}]}]}, {"title": "Basophils/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Basophils (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Platelets (GIGA/L) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "13"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment", "description": "The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or low abnormal values at baseline are not included in the number analyzed.\n\nThe number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Hematocrit (%", "categories": [{"measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "Hemoglobin (g/dL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "Erythrocytes (T/L) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Ery. Mean Corpuscular Volume (fL) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Ery. Mean Corpuscular Hemoglobin (pg) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Ery. Mean Corpuscular HGB Conc. (g/dL) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Leukocytes (GIGA/L) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Neutrophils/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "27"}]}]}, {"title": "Neutrophils (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "25"}]}]}, {"title": "Lymphocytes/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Lymphocytes (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Monocytes/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "28"}]}]}, {"title": "Monocytes (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "22"}]}]}, {"title": "Eosinophils/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Eosinophils (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Basophils/Leukocytes (%)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Basophils (GIGA/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Platelets (GIGA/L) in Blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment", "description": "The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Prothrombin Time (sec) in Plasma", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "23"}]}]}, {"title": "Activated Partial Thromboplastin", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Time in Plasma Prothrombin Intl. Normalized Ratio", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "13"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment", "description": "The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Prothrombin Time (sec) in Plasma", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Activated Partial Thromboplastin", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Time in Plasma Prothrombin Intl. Normalized Ratio", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "5"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)", "description": "Urinalysis was performed and the following parameters evaluated: bilirubin, blood (red blood cells, white blood cells), chorionic gonadotropin \u03b2, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators", "description": "Clinical significance of abnormal ECG was based on the judgement of the investigator", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline", "description": "Systolic Blood Pressure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "VISIT 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.09", "spread": "7.79", "lowerLimit": "7.79"}, {"groupId": "OG001", "value": "0.69", "spread": "7.85", "lowerLimit": "7.85"}]}]}, {"title": "VISIT 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.75", "spread": "7.50", "lowerLimit": "7.50"}, {"groupId": "OG001", "value": "-5.00", "spread": "7.07", "lowerLimit": "7.07"}]}]}, {"title": "VISIT 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.08", "spread": "9.98", "lowerLimit": "9.98"}, {"groupId": "OG001", "value": "-0.50", "spread": "8.45", "lowerLimit": "8.45"}]}]}, {"title": "VISIT 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.74", "spread": "10.70", "lowerLimit": "10.70"}, {"groupId": "OG001", "value": "-1.12", "spread": "9.89", "lowerLimit": "9.89"}]}]}, {"title": "VISIT 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "11.01", "lowerLimit": "11.01"}, {"groupId": "OG001", "value": "0.48", "spread": "11.24", "lowerLimit": "11.24"}]}]}, {"title": "VISIT 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.13", "spread": "11.11", "lowerLimit": "11.11"}, {"groupId": "OG001", "value": "-0.45", "spread": "10.49", "lowerLimit": "10.49"}]}]}, {"title": "VISIT 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "10.46", "lowerLimit": "10.46"}, {"groupId": "OG001", "value": "-1.48", "spread": "10.95", "lowerLimit": "10.95"}]}]}, {"title": "VISIT 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.20", "spread": "11.52", "lowerLimit": "11.52"}, {"groupId": "OG001", "value": "1.57", "spread": "10.70", "lowerLimit": "10.70"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline", "description": "Diastolic Blood Pressure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "VISIT 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "spread": "7.72", "lowerLimit": "7.72"}, {"groupId": "OG001", "value": "0.90", "spread": "7.90", "lowerLimit": "7.90"}]}]}, {"title": "VISIT 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.25", "spread": "2.50", "lowerLimit": "2.50"}, {"groupId": "OG001", "value": "-1.00", "spread": "2.00", "lowerLimit": "2.00"}]}]}, {"title": "VISIT 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.76", "spread": "8.36", "lowerLimit": "8.36"}, {"groupId": "OG001", "value": "0.26", "spread": "8.05", "lowerLimit": "8.05"}]}]}, {"title": "VISIT 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.26", "spread": "10.87", "lowerLimit": "10.87"}, {"groupId": "OG001", "value": "-0.14", "spread": "10.21", "lowerLimit": "10.21"}]}]}, {"title": "VISIT 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "spread": "9.91", "lowerLimit": "9.91"}, {"groupId": "OG001", "value": "0.93", "spread": "10.17", "lowerLimit": "10.17"}]}]}, {"title": "VISIT 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.68", "spread": "8.81", "lowerLimit": "8.81"}, {"groupId": "OG001", "value": "-0.21", "spread": "10.03", "lowerLimit": "10.03"}]}]}, {"title": "VISIT 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.99", "spread": "9.90", "lowerLimit": "9.90"}, {"groupId": "OG001", "value": "0.85", "spread": "9.53", "lowerLimit": "9.53"}]}]}, {"title": "VISIT 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.30", "spread": "11.06", "lowerLimit": "11.06"}, {"groupId": "OG001", "value": "3.25", "spread": "10.95", "lowerLimit": "10.95"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline", "description": "Respiratory Rate", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "BREATHS/MIN", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "VISIT 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "4.10", "lowerLimit": "4.10"}, {"groupId": "OG001", "value": "0.47", "spread": "2.91", "lowerLimit": "2.91"}]}]}, {"title": "VISIT 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.50", "spread": "3.42", "lowerLimit": "3.42"}, {"groupId": "OG001", "value": "-1.00", "spread": "1.15", "lowerLimit": "1.15"}]}]}, {"title": "VISIT 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "3.15", "lowerLimit": "3.15"}, {"groupId": "OG001", "value": "-0.14", "spread": "3.91", "lowerLimit": "3.91"}]}]}, {"title": "VISIT 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.57", "spread": "4.16", "lowerLimit": "4.16"}, {"groupId": "OG001", "value": "-0.06", "spread": "3.87", "lowerLimit": "3.87"}]}]}, {"title": "VISIT 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.77", "spread": "4.04", "lowerLimit": "4.04"}, {"groupId": "OG001", "value": "0.04", "spread": "4.58", "lowerLimit": "4.58"}]}]}, {"title": "VISIT 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.01", "spread": "4.06", "lowerLimit": "4.06"}, {"groupId": "OG001", "value": "-0.50", "spread": "3.76", "lowerLimit": "3.76"}]}]}, {"title": "VISIT 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.36", "spread": "4.50", "lowerLimit": "4.50"}, {"groupId": "OG001", "value": "-0.24", "spread": "3.60", "lowerLimit": "3.60"}]}]}, {"title": "VISIT 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.93", "spread": "5.10", "lowerLimit": "5.10"}, {"groupId": "OG001", "value": "-0.74", "spread": "4.61", "lowerLimit": "4.61"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline", "description": "Heart Rate", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "BEATS/MIN", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "VISIT 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.08", "spread": "10.19", "lowerLimit": "10.19"}, {"groupId": "OG001", "value": "0.26", "spread": "11.37", "lowerLimit": "11.37"}]}]}, {"title": "VISIT 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.75", "spread": "2.22", "lowerLimit": "2.22"}, {"groupId": "OG001", "value": "-0.75", "spread": "2.99", "lowerLimit": "2.99"}]}]}, {"title": "VISIT 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "spread": "10.11", "lowerLimit": "10.11"}, {"groupId": "OG001", "value": "-0.51", "spread": "11.46", "lowerLimit": "11.46"}]}]}, {"title": "VISIT 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.78", "spread": "11.49", "lowerLimit": "11.49"}, {"groupId": "OG001", "value": "-0.75", "spread": "11.92", "lowerLimit": "11.92"}]}]}, {"title": "VISIT 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.27", "spread": "11.65", "lowerLimit": "11.65"}, {"groupId": "OG001", "value": "-1.34", "spread": "11.03", "lowerLimit": "11.03"}]}]}, {"title": "VISIT 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.26", "spread": "11.97", "lowerLimit": "11.97"}, {"groupId": "OG001", "value": "-1.63", "spread": "10.56", "lowerLimit": "10.56"}]}]}, {"title": "VISIT 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.28", "spread": "11.87", "lowerLimit": "11.87"}, {"groupId": "OG001", "value": "-3.28", "spread": "11.61", "lowerLimit": "11.61"}]}]}, {"title": "VISIT 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.57", "spread": "12.57", "lowerLimit": "12.57"}, {"groupId": "OG001", "value": "-4.66", "spread": "14.73", "lowerLimit": "14.73"}]}]}]}, {"type": "SECONDARY", "title": "Part 1 - Mean Changes in Vital Signs (Body Temperature) Between the Treatment Groups From Baseline", "description": "Temperature", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u00b0C", "timeFrame": "Baseline and up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}, {"id": "OG001", "title": "Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2", "description": "Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "VISIT 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.39", "lowerLimit": "0.39"}, {"groupId": "OG001", "value": "0.04", "spread": "0.36", "lowerLimit": "0.36"}]}]}, {"title": "VISIT 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.35", "spread": "0.45", "lowerLimit": "0.45"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.39", "lowerLimit": "0.39"}]}]}, {"title": "VISIT 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "spread": "0.36", "lowerLimit": "0.36"}, {"groupId": "OG001", "value": "0.04", "spread": "0.43", "lowerLimit": "0.43"}]}]}, {"title": "VISIT 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.44", "lowerLimit": "0.44"}, {"groupId": "OG001", "value": "0", "spread": "0.44", "lowerLimit": "0.44"}]}]}, {"title": "VISIT 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.45", "lowerLimit": "0.45"}, {"groupId": "OG001", "value": "0.05", "spread": "0.42", "lowerLimit": "0.42"}]}]}, {"title": "VISIT 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.44", "lowerLimit": "0.44"}, {"groupId": "OG001", "value": "0.02", "spread": "0.47", "lowerLimit": "0.47"}]}]}, {"title": "VISIT 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "spread": "0.49", "lowerLimit": "0.49"}, {"groupId": "OG001", "value": "-0.01", "spread": "0.52", "lowerLimit": "0.52"}]}]}, {"title": "VISIT 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.14", "spread": "0.51", "lowerLimit": "0.51"}, {"groupId": "OG001", "value": "-0.10", "spread": "0.50", "lowerLimit": "0.50"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Part 1: Number of Participants Cured With 60-day Regimen Compared With Historical Active Control (Benznidazole)", "description": "This exploratory efficacy analysis evaluated the cure rate assessed as seroconversion of nifurtimox after 1-year post-treatment follow-up with that of published data for benznidazole (Sosa Estani et al. 1998 and de Andrade et al. 1996) at 4- and 3-year post-treatment follow-up, respectively, used as historical control.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days / Arm 1", "description": "Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Part 1 - Relationship of Conventional Serology (Total Purified Antigen ELISA) and qPCR Testing by Visit", "description": "Using frequencies of matches and mismatches to assess agreement\n\nReactive = Reac ELISA Detectable = Detec qPCR Non-reactive = Nonreac ELISA Non-detectable = Nondetec qPCR Non evaluable = Noneval qPCR qPCR Missing = Miss qPCR Missing conventional testing = Miss ELISA", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days Reactive Detectable", "description": "Nifurtimox 60 days with Reac ELISA and Detec qPCR"}, {"id": "OG001", "title": "Nifurtimox 60 Days Reactive Non-detectable", "description": "Nifurtimox 60 days with Reac ELISA and Nondetec qPCR"}, {"id": "OG002", "title": "Nifurtimox 60 Days Non-reactive Detectable", "description": "Nifurtimox 60 days with Nonreac ELISA and Detec qPCR"}, {"id": "OG003", "title": "Nifurtimox 60 Days Non-reactive Non-detectable", "description": "Nifurtimox 60 days with Nonreac ELISA and Nondetec qPCR"}, {"id": "OG004", "title": "Nifurtimox 60 Days Reactive Non Evaluable", "description": "Nifurtimox 60 days with Reac ELISA and Non evaluable qPCR"}, {"id": "OG005", "title": "Nifurtimox 60 Days Reactive qPCR Missing", "description": "Nifurtimox 60 days with Reac ELISA and missing qPCR"}, {"id": "OG006", "title": "Nifurtimox 30 Days Reactive Detectable", "description": "Nifurtimox 30 days with Reac ELISA and Detec qPCR"}, {"id": "OG007", "title": "Nifurtimox 30 Days Reactive Non-detectable", "description": "Nifurtimox 30 days with Reac ELISA and Nondetec qPCR"}, {"id": "OG008", "title": "Nifurtimox 30 Days Non-reactive Detectable", "description": "Nifurtimox 30 days with Nonreac ELISA and Detec qPCR"}, {"id": "OG009", "title": "Nifurtimox 30 Days Non-reactive Non-detectable", "description": "Nifurtimox 30 days with Nonreac ELISA and Nondetec qPCR"}, {"id": "OG010", "title": "Nifurtimox 30 Days Reactive Non Evaluable", "description": "Nifurtimox 30 days with Reac ELISA and Non evaluable qPCR"}, {"id": "OG011", "title": "Nifurtimox 30 Days Missing Conventional Testing Non-detectable", "description": "Nifurtimox 30 days with Miss ELISA and Nondetec qPCR"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "219"}, {"groupId": "OG002", "value": "219"}, {"groupId": "OG003", "value": "219"}, {"groupId": "OG004", "value": "219"}, {"groupId": "OG005", "value": "219"}, {"groupId": "OG006", "value": "111"}, {"groupId": "OG007", "value": "111"}, {"groupId": "OG008", "value": "111"}, {"groupId": "OG009", "value": "111"}, {"groupId": "OG010", "value": "111"}, {"groupId": "OG011", "value": "111"}]}], "classes": [{"title": "Visit 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "117"}, {"groupId": "OG001", "value": "99"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "57"}, {"groupId": "OG007", "value": "52"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "1"}, {"groupId": "OG010", "value": "1"}, {"groupId": "OG011", "value": "0"}]}]}, {"title": "Visit 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "210"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "1"}, {"groupId": "OG007", "value": "103"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "1"}, {"groupId": "OG010", "value": "2"}, {"groupId": "OG011", "value": "1"}]}]}, {"title": "Visit 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "195"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "11"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "2"}, {"groupId": "OG007", "value": "99"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "6"}, {"groupId": "OG010", "value": "2"}, {"groupId": "OG011", "value": "0"}]}]}, {"title": "Visit 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "194"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "11"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "1"}, {"groupId": "OG006", "value": "5"}, {"groupId": "OG007", "value": "96"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "6"}, {"groupId": "OG010", "value": "1"}, {"groupId": "OG011", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Part 1 - Relationship of Conventional Serology (Total Purified Antigen ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit", "description": "Using frequencies of matches and mismatches to assess agreement\n\nReactive = Reac ELISA Reactive = Reac F29 Non-reactive = Nonreac ELISA Non-reactive = Nonreac F29", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days Reactive and Reactive", "description": "Nifurtimox 60 days with Reac ELISA and Reac F29"}, {"id": "OG001", "title": "Nifurtimox 60 Days Reactive and Non-reactive", "description": "Nifurtimox 60 days with Reac ELISA and Nonreac F29"}, {"id": "OG002", "title": "Nifurtimox 60 Days Non-reactive and Reactive", "description": "Nifurtimox 60 days with Nonreac ELISA and Reac F29"}, {"id": "OG003", "title": "Nifurtimox 60 Days Non-reactive and Non-reactive", "description": "Nifurtimox 60 days with Nonreac ELISA and Nonreac F29"}, {"id": "OG004", "title": "Nifurtimox 30 Days Reactive and Reactive", "description": "Nifurtimox 30 days with Reac ELISA and Reac F29"}, {"id": "OG005", "title": "Nifurtimox 30 Days Reactive and Non-reactive", "description": "Nifurtimox 30 days with Reac ELISA and Nonreac F29"}, {"id": "OG006", "title": "Nifurtimox 30 Days Non-reactive and Reactive", "description": "Nifurtimox 30 days with Nonreac ELISA and Reac F29g"}, {"id": "OG007", "title": "Nifurtimox 30 Days Non-reactive and Non-reactive", "description": "Nifurtimox 30 days Nonreac ELISA and Nonreac F29"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "219"}, {"groupId": "OG002", "value": "219"}, {"groupId": "OG003", "value": "219"}, {"groupId": "OG004", "value": "111"}, {"groupId": "OG005", "value": "111"}, {"groupId": "OG006", "value": "111"}, {"groupId": "OG007", "value": "111"}]}], "classes": [{"title": "Visit 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "77"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "72"}, {"groupId": "OG005", "value": "38"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "1"}]}]}, {"title": "Visit 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "64"}, {"groupId": "OG005", "value": "43"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "1"}]}]}, {"title": "Visit 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "67"}, {"groupId": "OG005", "value": "42"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "1"}]}]}, {"title": "Visit 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "63"}, {"groupId": "OG004", "value": "63"}, {"groupId": "OG005", "value": "43"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "1"}]}]}, {"title": "Visit 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "92"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "9"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "42"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "6"}]}]}, {"title": "Visit 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "8"}, {"groupId": "OG004", "value": "54"}, {"groupId": "OG005", "value": "48"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "6"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Part 1 - Relationship of Conventional Serology (Recombinant ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit", "description": "Using frequencies of matches and mismatches to assess agreement\n\nReactive = Reac ELISA Reactive = Reac F29 Non-reactive = Nonreac ELISA Non-reactive= Nonreac F29", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Nifurtimox 60 Days Reactive and Reactive", "description": "Nifurtimox 60 days Reac ELISA and Reac F29"}, {"id": "OG001", "title": "Nifurtimox 60 Days Reactive and Non-reactive", "description": "Nifurtimox 60 days with Reac ELISA and Nonreac F29"}, {"id": "OG002", "title": "Nifurtimox 60 Days Non-reactive and Reactive", "description": "Nifurtimox 60 days with Nonreac ELISA and Reac F29"}, {"id": "OG003", "title": "Nifurtimox 60 Days Non-reactive and Non-reactive", "description": "Nifurtimox 60 days Nonreac ELISA and Nonreac F29"}, {"id": "OG004", "title": "Nifurtimox 30 Days Reactive and Reactive", "description": "Nifurtimox 30 days with Reactive ConvReac ELISA and Reac F29"}, {"id": "OG005", "title": "Nifurtimox 30 Days Non-reactive and Reactive", "description": "Nifurtimox 30 days with Nonreac ELISA and Reac F29"}, {"id": "OG006", "title": "Nifurtimox 30 Days Non-reactive and Non-reactive", "description": "Nifurtimox 30 days with Nonreac ELISA and Nonreac F29"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "219"}, {"groupId": "OG002", "value": "219"}, {"groupId": "OG003", "value": "219"}, {"groupId": "OG004", "value": "111"}, {"groupId": "OG005", "value": "111"}, {"groupId": "OG006", "value": "111"}]}], "classes": [{"title": "Visit 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "77"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "72"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "1"}]}]}, {"title": "Visit 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "64"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "1"}]}]}, {"title": "Visit 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "67"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "1"}]}]}, {"title": "Visit 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "63"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "1"}]}]}, {"title": "Visit 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "59"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "5"}]}]}, {"title": "Visit 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "53"}, {"groupId": "OG005", "value": "1"}, {"groupId": "OG006", "value": "6"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Part 1 - Relationship of Conventional Serology (ELISA) to Indirect Hemagglutination Assay (IHA) Results", "description": "Sero-reduction is defined as a =\\> 20% reduction in optical density \\[OD\\]) using two conventional ELISA serology tests in subjects =\\> 8 months to \\< 18 years of age at randomization; Others: reactive results that are not sero-reduction in subjects =\\> 8 months to \\< 18 years of age at randomization; or reactive results in subjects \\< 8 months of age at randomization.\n\nNon-reactive ELISA = Nonreac ELISA Non-reactive IHA = Nonreac IHA Reactive IHA decrease = Reac IHA dec React IHA nochange = Reac IHA nochange Reactive ELISA: seroreduction = Reac ELISA reduc Reactive ELISA: others = Reac ELISA other", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Non-reactive ELISA and Non-reactive IHA", "description": "Nonreac ELISA and Nonreac IHA"}, {"id": "OG001", "title": "Non-reactive ELISA and Reactive IHA Decrease", "description": "Nonreac ELISA and Reac IHA dec"}, {"id": "OG002", "title": "Non-react ELISA and React IHA Nochange", "description": "Nonreac ELISA and Reac IHA nochange"}, {"id": "OG003", "title": "Reactive ELISA: Sero-reduction and Non-react IHA", "description": "Reac ELISA and Nonreac IHA"}, {"id": "OG004", "title": "Reactive ELISA: Sero Reduction and Reactive IHA Decrease", "description": "Reac ELISA reduc and Reac IHA dec"}, {"id": "OG005", "title": "Reactive ELISA: Sero-reduction and Reactive IHA Nochange", "description": "Reac ELISA reduc and Reac IHA nochange"}, {"id": "OG006", "title": "Reactive ELISA: Others and Non-reactive IHA", "description": "Reac ELISA other and Nonreac IHA"}, {"id": "OG007", "title": "Reactive ELISA: Others and React IHA Decrease", "description": "Reac ELISA other and Reac IHA dec"}, {"id": "OG008", "title": "Reactive ELISA: Others and React IHA Nochange", "description": "Reac ELISA other and Reac IHA nochange"}, {"id": "OG009", "title": "Reactive ELISA: Others and Missing IHA", "description": "Reac ELISA other and IHA missing"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}, {"groupId": "OG001", "value": "318"}, {"groupId": "OG002", "value": "318"}, {"groupId": "OG003", "value": "318"}, {"groupId": "OG004", "value": "318"}, {"groupId": "OG005", "value": "330"}, {"groupId": "OG006", "value": "318"}, {"groupId": "OG007", "value": "318"}, {"groupId": "OG008", "value": "318"}, {"groupId": "OG009", "value": "318"}]}], "classes": [{"title": "Nifurtimox 60 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "40"}, {"groupId": "OG005", "value": "20"}, {"groupId": "OG006", "value": "1"}, {"groupId": "OG007", "value": "47"}, {"groupId": "OG008", "value": "89"}, {"groupId": "OG009", "value": "1"}]}]}, {"title": "Nifurtimox 30 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "4"}, {"groupId": "OG006", "value": "1"}, {"groupId": "OG007", "value": "30"}, {"groupId": "OG008", "value": "58"}, {"groupId": "OG009", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Part 1 - Relationship Between Conventional ELISA Results in Terms of Cure or No Cure and IHA Results in All Patients", "description": "Cure is defined as sero-reduction (in subjects =\\> 8 months to \\< 18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a =\\> 20% reduction in optical density \\[OD\\]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G \\[IgG\\] concentration measured by two conventional ELISA serology tests.\n\nCure = Cure Non reactive/reactive decreasing = Nonreac/reac dec Reactive non-decreasing = Reac nondec No cure = No Cure Missing IHA testing = IHA missing", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 420 days (Visit 11 post-treatment)", "groups": [{"id": "OG000", "title": "Cure and Non Reactive/Reactive Decreasing", "description": "ELISA Cure and IHA Nonreac/reac dec"}, {"id": "OG001", "title": "Cure and Reactive Non-decreasing", "description": "ELISA Cure and IHA Reac nondec"}, {"id": "OG002", "title": "No Cure and Non Reactive/Reactive Decreasing", "description": "ELISA No Cure and IHA results: Nonreac/reac dec"}, {"id": "OG003", "title": "No Cure and Reactive Non-decreasing", "description": "ELISA No Cure and IHA Reac nondec"}, {"id": "OG004", "title": "No Cure and Missing IHA Testing", "description": "ELISA No Cure and IHA missing"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}, {"groupId": "OG001", "value": "318"}, {"groupId": "OG002", "value": "318"}, {"groupId": "OG003", "value": "318"}, {"groupId": "OG004", "value": "318"}]}], "classes": [{"title": "Nifurtimox 60 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "48"}, {"groupId": "OG003", "value": "89"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "Nifurtimox 30 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "58"}, {"groupId": "OG004", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Part 1: From first application of study drug up to and including 7 days after last application of study drug Part 2: first occurred or worsened at start of study part 2 up to 3 years.", "eventGroups": [{"id": "EG000", "title": "Nifurtimox 60-day Regimen", "description": "Nifurtimox daily dose 8-10 mg/kg (adolescents, 40-60 kg) or 10-20 mg/kg (infants/children, below 40 kg) for 60 days", "deathsNumAffected": 0, "deathsNumAtRisk": 219, "seriousNumAffected": 6, "seriousNumAtRisk": 219, "otherNumAffected": 128, "otherNumAtRisk": 219}, {"id": "EG001", "title": "Nifurtimox 30-day Regimen", "description": "Nifurtimox daily dose 8-10 mg/kg (adolescents, 40-60 kg) or 10-20 mg/kg (infants/children, below 40 kg) for 30 days followed by placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 111, "seriousNumAffected": 3, "seriousNumAtRisk": 111, "otherNumAffected": 51, "otherNumAtRisk": 111}], "seriousEvents": [{"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Chronic tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Ear infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}]}, {"term": "Pelvic inflammatory disease", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}]}, {"term": "Burns second degree", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Snake bite", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Febrile convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Completed suicide", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Apnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}]}, {"term": "Abortion induced", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}]}], "otherEvents": [{"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 19, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 11, "numAffected": 9, "numAtRisk": 111}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 15, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 111}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 16, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 111}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 19, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 15, "numAffected": 14, "numAtRisk": 111}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 57, "numAffected": 33, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 111}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 20, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 111}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 12, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 111}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 22, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 13, "numAffected": 11, "numAtRisk": 111}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 13, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 13, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 25, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 111}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v21/v24", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 44, "numAffected": 30, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 23, "numAffected": 16, "numAtRisk": 111}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Abnormal findings on neurological examination by physical examination after Screening will be documented as AEs."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Therapeutic Area Head", "organization": "Bayer AG", "email": "clinical-trials-contact@bayer.com", "phone": "1-888-8422937"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-11-03", "uploadDate": "2022-08-08T04:56", "filename": "Prot_002.pdf", "size": 3365930}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-01-26", "uploadDate": "2022-08-08T04:56", "filename": "SAP_003.pdf", "size": 912081}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D009547", "term": "Nifurtimox"}], "ancestors": [{"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M12486", "name": "Nifurtimox", "asFound": "DSM-IV", "relevance": "HIGH"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT04984265", "orgStudyIdInfo": {"id": "4920/19/139"}, "organization": {"fullName": "University of Sao Paulo General Hospital", "class": "OTHER"}, "briefTitle": "SBRT in Chagas Disease Ventricular Tachycardia", "officialTitle": "Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia in Chagas Disease Patients"}, "statusModule": {"statusVerifiedDate": "2024-07", "overallStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-07-14", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-07-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-07-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2021-07-21", "studyFirstSubmitQcDate": "2021-07-21", "studyFirstPostDateStruct": {"date": "2021-07-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-07-15", "lastUpdatePostDateStruct": {"date": "2024-07-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Mauricio Ibrahim Scanavacca", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "University of Sao Paulo General Hospital"}, "leadSponsor": {"name": "University of Sao Paulo General Hospital", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Ventricular Tachycardia", "Chagas Disease", "Cardiac Arrhythmia"], "keywords": ["Cardiac Radioablation", "Chagas Disease", "Refractory Ventricular Tachycardia", "Stereotactic Body Radiation Therapy", "SBRT"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 10, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Stereotactic Body rRadiotherapy (SBRT)", "type": "EXPERIMENTAL", "description": "SBRT targeting the area of the circuit of Ventricular Tachycardia", "interventionNames": ["Radiation: Stereotactic Body Radiation Therapy"]}], "interventions": [{"type": "RADIATION", "name": "Stereotactic Body Radiation Therapy", "description": "SBRT targeting the area of the circuit of Ventricular Tachycardia", "armGroupLabels": ["Stereotactic Body rRadiotherapy (SBRT)"], "otherNames": ["SBRT"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Safety of SBRT for the treatment of Ventricular Tachycardia", "description": "Incidence of cardiac and extra-cardiac adverse effects related to SBRT", "timeFrame": "12 months"}, {"measure": "Efficacy of SBRT for the treatment of Ventricular Tachycardia", "description": "Rate of VT recurrence after a blanking period of 6 weeks following SBRT", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Time to VT Recurrence", "description": "Time to VT recurrence after a blanking period of 6 weeks following SBRT", "timeFrame": "12 months"}, {"measure": "VT Burden", "description": "Number of ICD therapies following SBRT compared to 12 months before", "timeFrame": "12 months"}, {"measure": "Mortality", "description": "Rate of mortality following SBRT", "timeFrame": "12 months"}, {"measure": "Cardiac Mortality", "description": "Rate of mortality due to cardiac causes following SBRT", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Diagnosis of Chagas heart disease including positive serology\n2. Recurrent sustained ventricular tachycardia requiring therapy due to symptoms, ICD shocks, or requiring hospitalization.\n3. Age\\>18 years.\n4. Able to give written, informed consent. If the patient requires continuous sedation/anesthesia for arrhythmia control consent can be provided by the next of kin.\n5. Medically fit to undergo radiation planning and treatment sessions.\n6. Failed antiarrhythmic medications due to VT recurrence, drug intolerance, or contraindication.\n7. Failed prior catheter ablation due to arrhythmia recurrence or ineligible for endocardial or epicardial catheter ablation (LV thrombus, epicardial adhesion, megacolon, prior open chest surgery)\n\nExclusion Criteria:\n\n1. Cardiogenic shock not due to VT with no possibility of heart transplant or ventricular assist device.\n2. Inability for patient to be adequately immobilized for radiation planning and treatment.\n3. Repeat catheter ablation is felt to be a reasonable option.\n4. Previous radiation to the chest.\n5. Pregnancy or refusal to use contraception.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mauricio I Scanavacca, MD, PhD", "affiliation": "University of S\u00e3o Paulo General Hospital", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "University of Sao Paulo General Hospital", "city": "Sao Paulo", "state": "SP", "zip": "01246-000", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D001145", "term": "Arrhythmias, Cardiac"}, {"id": "D013610", "term": "Tachycardia"}, {"id": "D017180", "term": "Tachycardia, Ventricular"}], "ancestors": [{"id": "D006331", "term": "Heart Diseases"}, {"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D000075224", "term": "Cardiac Conduction System Disease"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M16384", "name": "Tachycardia", "asFound": "Tachycardia", "relevance": "HIGH"}, {"id": "M4453", "name": "Arrhythmias, Cardiac", "asFound": "Cardiac Arrhythmia", "relevance": "HIGH"}, {"id": "M19488", "name": "Tachycardia, Ventricular", "asFound": "Ventricular Tachycardia", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M1472", "name": "Cardiac Conduction System Disease", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04024163", "orgStudyIdInfo": {"id": "LPRI747-301"}, "organization": {"fullName": "Insud Pharma", "class": "INDUSTRY"}, "briefTitle": "Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease", "officialTitle": "Prospective, Single-arm, Multicentre Study, Using a Historical Control, to Evaluate the Efficacy/Safety and Population Pharmacokinetics of Benznidazole in Children With Chronic Indeterminate Chagas Disease"}, "statusModule": {"statusVerifiedDate": "2023-08", "overallStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-09-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2027-08-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2028-03-30", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-07-14", "studyFirstSubmitQcDate": "2019-07-16", "studyFirstPostDateStruct": {"date": "2019-07-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-08-08", "lastUpdatePostDateStruct": {"date": "2023-08-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Insud Pharma", "class": "INDUSTRY"}, "collaborators": [{"name": "Chemo Research", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "conditionsModule": {"conditions": ["Chagas Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "Historical control-based comparison, single-arm assignment, multicentre study", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 178, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benznidazole", "type": "EXPERIMENTAL", "description": "Benznidazole 100 mg Tablets or Benznidazole 12.5 mg Tablets by mouth, every 12 hours for 60 days", "interventionNames": ["Drug: Benznidazole"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "description": "Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg", "armGroupLabels": ["Benznidazole"], "otherNames": ["National Drug Code (NDC) 0642-7464-10", "National Drug Code (NDC) 0642-7464-12"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Serological Cure by Conventional ELISA", "description": "Percentage of patients with negative conventional ELISA results as a measure of serological cure at the end of the 72-month follow up", "timeFrame": "72-month follow up"}], "secondaryOutcomes": [{"measure": "Serological Cure by Conventional ELISA at different timepoints", "description": "Percentage of patients with negative conventional ELISA results as a measure of serological cure", "timeFrame": "Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up"}, {"measure": "Serological Cure by two conventional serology tests at 72 month", "description": "Percentage of patients with two negative conventional serology results as a measure of serological cure", "timeFrame": "72 months of follow-up"}, {"measure": "Serological Cure by two conventional serology tests at 48 months", "description": "Percentage of patients with two negative conventional serology results as a measure of serological cure", "timeFrame": "48 months of follow-up"}, {"measure": "Serological Cure by three serology tests at different timepoints", "description": "Percentage of patients with three negative serology results as a measure of serological cure", "timeFrame": "Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up"}, {"measure": "Serological Cure by Non-Conventional ELISA at different timepoints", "description": "Percentage of patients with negative non-conventional ELISA (F29) results as a measure of serological cure", "timeFrame": "Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up"}, {"measure": "Cure by qPCR at different timepoints", "description": "Consistently negative quantitative polymerase chain reaction (qPCR) results as a surrogate measure of cure", "timeFrame": "Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up"}, {"measure": "Serological titres reduction at different timepoints", "description": "Reduction of conventional and nonconventional serological titres over the period of follow-up", "timeFrame": "Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up"}, {"measure": "Progression of clinical disease at different timepoints", "description": "Percentage of patients with progression to clinical disease over the period of follow-up", "timeFrame": "Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up"}, {"measure": "Progression of clinical disease and serological cure by one assay at different timepoints", "description": "Percentage of patients with no evidence of established cardiomyopathy over the period of follow-up and seroconversion to negative by one assay", "timeFrame": "48 and 72 months of follow-up"}, {"measure": "Progression of clinical disease and serological cure by two assays at different timepoints", "description": "Percentage of patients with no evidence of established cardiomyopathy over the period of follow-up and seroconversion to negative by two assay", "timeFrame": "48 and 72 months of follow-up"}], "otherOutcomes": [{"measure": "Safety and Tolerability", "description": "Rate and severity of adverse events (AEs)", "timeFrame": "Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up"}, {"measure": "Population Pharmacokinetic - blood concentration", "description": "Benznidazole blood concentrations", "timeFrame": "pre-dose, day 7 and day 30"}, {"measure": "Population Pharmacokinetic - area under the curve (AUC)", "description": "Benznidazole area under the curve (AUC)", "timeFrame": "pre-dose, day 7 and day 30"}, {"measure": "Population Pharmacokinetic - volume of distribution", "description": "Benznidazole volume of distribution", "timeFrame": "pre-dose, day 7 and day 30"}, {"measure": "Intensive Pharmacokinetic - blood concentrations", "description": "Benznidazole blood concentrations", "timeFrame": "Day 1 or day 7"}, {"measure": "Intensive Pharmacokinetic - area under the curve (AUC)", "description": "Benznidazole area under the curve (AUC)", "timeFrame": "Day 1 or day 7"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age between 2 years and 18 years (age limits inclusive)\n* Diagnosis of Trypanosoma cruzi (T. cruzi) infection by conventional serology based on positive ELISA and at least 1 other positive conventional serology test (recombinant ELISA or IIF)\n* Written informed consent by parent/legal representative and informed assent from patients if \\>7 years old when applicable (as requirements may vary by country and by site)\n* Females of childbearing potential (ie, female patients who have experienced menarche) and male patients must agree to use highly effective contraception if sexually active from the time of signing of the informed consent/assent form until \u22655 days after the last dose of study treatment\n\nExclusion Criteria:\n\n* Pregnant or intending to become pregnant during treatment and within 5 days after the last dose of study treatment\n* Patient presenting any other acute or chronic health conditions, which in the opinion of the Principal Investigator (PI), may interfere with the pharmacokinetic (PK), efficacy, and/or safety evaluation of the study treatment\n* Signs and/or symptoms of acute Chagas Disease\n* Known history of hypersensitivity or serious adverse reactions to nitroimidazoles\n* History of Chagas Disease treatment with Benznidazole (BZN) or nifurtimox\n* Immunocompromised (clinical history compatible with human immunodeficiency virus (HIV) infection, primary immunodeficiency, or prolonged treatment with corticosteroids or other immunosuppressive drugs)\n* Abnormal laboratory test values (as per protocol-specified ranges) at Screening for the following parameters: total white blood cell (WBC) count, platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and creatinine\n* Abnormal ECG (as per protocol-specified ranges) and/or any Chagas disease associated findings\n* Any condition that prevents the patient from taking oral medication\n* Patient is known to or suspected of not being able to comply with the study protocol and the use of the investigational medicinal product (IMP)\n* Evidence or history of alcohol or drug abuse (within the last 12 months)\n* Any planned procedure that may interfere with highly effective contraception during treatment and within 5 days after the last dose of study treatment\n* Employee of the Investigator or trial centre, or family member of the employees or the Investigator\n* Any condition that, in the opinion of the Investigator, may jeopardise the trial conduct according to the protocol", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "2 Years", "maximumAge": "18 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Hospital de Ninos \"Dr. Ricardo Gutierrez\"", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Hospital \"Luis Carlos Lagomaggiore\"", "city": "Mendoza", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Hospital Pediatrico \"Dr. Humberto Notti\"", "city": "Mendoza", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Hospital P\u00fablico Descentralizado Dr. Guillermo Rawson", "city": "San Juan", "country": "Argentina", "geoPoint": {"lat": -31.5375, "lon": -68.53639}}, {"facility": "Centro de Enfermedad de Chagas y Patolog\u00edas Regionales", "city": "Santiago Del Estero", "country": "Argentina", "geoPoint": {"lat": -27.79511, "lon": -64.26149}}, {"facility": "Antigua Hospital Viedma", "city": "Cochabamba", "country": "Bolivia", "geoPoint": {"lat": -17.3895, "lon": -66.1568}}, {"facility": "CEADES - Plataforma de Chagas Sucre", "city": "Sucre", "country": "Bolivia", "geoPoint": {"lat": -19.03332, "lon": -65.26274}}, {"facility": "Fundaci\u00f3n Salud para el Tr\u00f3pico", "city": "Santa Marta", "country": "Colombia", "geoPoint": {"lat": 11.24079, "lon": -74.19904}}, {"facility": "Centro de Atenci\u00f3n e Investigaci\u00f3n M\u00e9dica (CAIMED)", "city": "Yopal", "country": "Colombia", "geoPoint": {"lat": 5.33775, "lon": -72.39586}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01340963", "orgStudyIdInfo": {"id": "012345/96"}, "organization": {"fullName": "Universidade Gama Filho", "class": "OTHER"}, "briefTitle": "The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort", "officialTitle": "Prognostic Value of the Spectral Turbulence Analysis of the Signal-averaged Electrocardiogram in Chagas Heart Disease", "acronym": "SEARCH-Rio"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1995-06"}, "primaryCompletionDateStruct": {"date": "2001-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-04-21", "studyFirstSubmitQcDate": "2011-04-22", "studyFirstPostDateStruct": {"date": "2011-04-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-12-09", "lastUpdatePostDateStruct": {"date": "2013-12-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Paulo Roberto Benchimol Barbosa", "investigatorTitle": "Head Researcher", "investigatorAffiliation": "Universidade Gama Filho"}, "leadSponsor": {"name": "Universidade Gama Filho", "class": "OTHER"}, "collaborators": [{"name": "Rio de Janeiro State University", "class": "OTHER"}, {"name": "The University of Texas Health Science Center, Houston", "class": "OTHER"}, {"name": "Instituto Nacional de Cardiologia de Laranjeiras", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chagas Cardiomyopathy", "Cardiac Arrhythmia", "Stroke", "Left Ventricular Function Systolic Dysfunction", "Cardiac Death"], "keywords": ["Chagas heart disease", "ventricular tachycardia", "atrial fibrillation", "stroke", "cardiac death", "signal averaged electrocardiogram"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 100, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Class I", "description": "Structurally normal heart, no bundle branch block"}, {"label": "Class II", "description": "Mild symptoms, bundle brunch block or hemi-block on resting surface electrocardiogram, normal cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction as relaxation deficit (type I), none or mild global left ventricular systolic dysfunction"}, {"label": "Class III", "description": "Overtly symptomatic, enlarged cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction, global systolic dysfunction, ventricular tachycardia, atrio-ventricular block (any degree)"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Cardiac death [Time Frame: up to 10 years ]", "description": "Defined as intractable heart failure, arrhythmic, coronary occlusion, or sudden death.\n\nAssessment twice an year by active and direct contact to subjects or relatives and review of medical records.", "timeFrame": "up tp 10 years"}], "secondaryOutcomes": [{"measure": "Ventricular tachycardia", "description": "New onset ventricular tachycardia defined as symptomatic (palpitations, dizziness or syncope), \\>=3 consecutive beats, bundle branch block configuration, ventricular rate \\>100bpm, atrial-ventricular dissociation.\n\nAssessed with 24h-ambulatory electrocardiogram monitoring requested at discretion of non-investigational primary evaluation and confirmed by review of medical records.", "timeFrame": "up to ten years"}, {"measure": "Stroke, either fatal or nonfatal", "description": "Evidence of clinically definite stroke (focal neurological deficits persisting for more than 24 hours) confirmed or not by non-investigational CT.\n\nAssessment twice an year by active and direct contact to patents or relatives and review of medical records.", "timeFrame": "up to 10 years"}, {"measure": "Persistent atrial fibrillation", "description": "Irregular non-sinus interbeat interval, lasting more that 24h, confirmed by either non-investigational 24h ambulatory electrocardiogram monitoring or resting 12-lead surface electrocardiogram two to four times a year.\n\nAssessment by review of medical records.", "timeFrame": "up to 10 years"}, {"measure": "Cardiac function and dimensions", "description": "Non-investigational M-mode/2-D echocardiographic evaluation at the discretion of primary care assistance.\n\nAssessment by review of medical records.", "timeFrame": "up to 10 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Clinically stable outpatients with at least 10 years of regular outpatients follow-up and positive epidemiological history and serological confirmation of Chagas disease with ate least two immunological tests\n\nExclusion Criteria:\n\n* Any degree of atrioventricular block or non-sinus rhythm\n* Previous documented acute coronary events (due to documented obstructive epicardial coronary vessels)\n* Chronic obstructive pulmonary disease\n* Rheumatic valvular heart disease\n* Alcohol addiction\n* Thyroid dysfunction\n* Abnormal serum electrolytes and biochemical abnormalities", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "One hundred clinically stable subjects with at least 10 years of regular outpatients follow-up and positive epidemiological history and serological confirmation of Chagas disease with ate least two immunological tests.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Paulo R Benchimol-Barbosa, MD, DSc", "affiliation": "Rio de Janeiro State University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Texas at Houston", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Hospital Universit\u00e1rio Pedro Ernesto", "city": "Rio de Janeiro", "state": "RJ", "zip": "20551-900", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "Universidade Gama Filho", "city": "Rio de Janeiro", "state": "RJ", "zip": "20740-900", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "Instituto Nacional de Cardiologia", "city": "Rio de Janeiro", "state": "RJ", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}]}, "referencesModule": {"references": [{"pmid": "19428130", "type": "BACKGROUND", "citation": "Benchimol-Barbosa PR, Nasario-Junior O, Nadal J. The effect of configuration parameters of time-frequency maps in the detection of intra-QRS electrical transients of the signal-averaged electrocardiogram: impact in clinical diagnostic performance. Int J Cardiol. 2010 Nov 5;145(1):59-61. doi: 10.1016/j.ijcard.2009.04.013. Epub 2009 May 9."}, {"pmid": "17692944", "type": "BACKGROUND", "citation": "Benchimol-Barbosa PR, Muniz RT. Ventricular late potential duration correlates to the time of onset of electrical transients during ventricular activation in subjects post-acute myocardial infarction. Int J Cardiol. 2008 Sep 26;129(2):285-7. doi: 10.1016/j.ijcard.2007.05.057. Epub 2007 Aug 10."}, {"pmid": "19762096", "type": "BACKGROUND", "citation": "Benchimol-Barbosa PR. Trends on acute Chagas' disease transmitted by oral route in Brazil: steady increase in new cases and a concealed residual fluctuation. Int J Cardiol. 2010 Dec 3;145(3):494-6. doi: 10.1016/j.ijcard.2009.08.030. Epub 2009 Sep 16. No abstract available."}, {"pmid": "19287904", "type": "RESULT", "citation": "Benchimol-Barbosa PR, Barbosa-Filho J. Mechanical cardiac remodeling and new-onset atrial fibrillation in long-term follow-up of subjects with chronic Chagas' disease. Braz J Med Biol Res. 2009 Mar;42(3):251-62. doi: 10.1590/s0100-879x2009000300006."}, {"pmid": "18199497", "type": "RESULT", "citation": "Benchimol-Barbosa PR. Predictors of mortality in Chagas' disease: the impact of atrial fibrillation and oral transmission on infected population. Int J Cardiol. 2009 Apr 3;133(2):275-7. doi: 10.1016/j.ijcard.2007.11.053. Epub 2008 Jan 15."}, {"pmid": "18053595", "type": "RESULT", "citation": "Benchimol-Barbosa PR. Cardiac remodeling and predictors for cardiac death in long-term follow-up of subjects with chronic Chagas' heart disease: a mathematical model for progression of myocardial damage. Int J Cardiol. 2009 Jan 24;131(3):435-8. doi: 10.1016/j.ijcard.2007.07.151. Epub 2007 Nov 28."}, {"pmid": "17689724", "type": "RESULT", "citation": "Benchimol-Barbosa PR, Barbosa-Filho J. Atrial mechanical remodeling and new onset atrial fibrillation in chronic Chagas' heart disease. Int J Cardiol. 2008 Jul 21;127(3):e113-5. doi: 10.1016/j.ijcard.2007.04.103. Epub 2007 Aug 8."}, {"pmid": "19477538", "type": "RESULT", "citation": "Benchimol-Barbosa PR. Nonlinear mathematical model for predicting long term cardiac remodeling in Chagas' heart disease: introducing the concepts of 'limiting cardiac function' and 'cardiac function deterioration period'. Int J Cardiol. 2010 Nov 19;145(2):219-221. doi: 10.1016/j.ijcard.2009.05.010. Epub 2009 May 27."}, {"type": "RESULT", "citation": "Benchimol-Barbosa PR, Kantharia BK, Carvalhaes CG. Nonlinear Dynamics in Long-Term Left Ventricular Remodeling in Chagas Heart Disease and Adverse Outcomes: SEARCH-Rio Substudy. Circulation Research. 2012;111:A351"}, {"type": "RESULT", "citation": "Benchimol-Barbosa PR, Tura BR, Barbosa E, Barbosa-Filho J, Kantharia BK. A Novel Risk Score Based on Noninvasive ECG Monitoring Aiming at Predicting Ventricular Tachycardia and Cardiac Death in Chronic Chagas Disease. Circulation. 2010; 122: A19759."}, {"pmid": "17273653", "type": "RESULT", "citation": "Benchimol Barbosa PR. Noninvasive prognostic markers for cardiac death and ventricular arrhythmia in long-term follow-up of subjects with chronic Chagas' disease. Braz J Med Biol Res. 2007 Feb;40(2):167-78."}, {"type": "RESULT", "citation": "Benchimol-Barbosa PR, Duque GS, Barbosa-Filho J. Long term cardiac remodelling in chronic Chagas' heart disease. Eur Heart J; 2008. 29(suppl 1): 441-441. doi:10.1093/eurheartj/ehn375"}, {"type": "RESULT", "citation": "Benchimol-Barbosa PR, Duque GS, Barbosa EC, Bomfim AS, Dantas-Carletti MS, Barbosa-Filho J. High spectral turbulence in signal-averaged electrocardiogram is an independent predictor for cardiac death in long-term follow-up of subjects with chronic Chagas disease. Eur Heart J; 2009. 30(suppl 1): 697-697. doi:10.1093/eurheartj/ehp415"}, {"type": "RESULT", "citation": "Benchimol-Barbosa PR, Tura BR, Barbosa EC, Barbosa-Filho J, Kantharia BK. A novel risk score for predicting cardiac death in chronic chagas heart disease based on spectral turbulence analysis of the signal-averaged ECG. Eur Heart J; 2010. 31(suppl 1): 163-163. doi:10.1093/eurheartj/ehq287"}, {"type": "RESULT", "citation": "Benchimol-Barbosa PR, Tura BR, Barbosa-Filho J, Kantharia BK. Increasing 24h incidence of isolated PVC is associated with growing complexity and incidence of cardiac tachyarrhythmia in Chagas heart disease. Eur Heart J; 2010. 31(suppl 1): 480-480. doi:10.1093/eurheartj/ehq288"}, {"type": "RESULT", "citation": "Benchimol-Barbosa PR. Clinical characteristics of spontaneous ventricular tachycardia episodes associated with unfavorable prognosis in chronic Chagas disease. Eur Heart J; 2010. 31(suppl 1): 480-480. doi:10.1093/eurheartj/ehq288"}, {"type": "RESULT", "citation": "PR Benchimol-Barbosa. Ventricular tachyarrhythmic events triggers in chronic Chagas disease. Eur Heart J; 2010. 31(suppl 1): 481-481. doi:10.1093/eurheartj/ehq288"}, {"pmid": "24270912", "type": "RESULT", "citation": "Benchimol-Barbosa PR, Tura BR, Barbosa EC, Kantharia BK. Utility of a novel risk score for prediction of ventricular tachycardia and cardiac death in chronic Chagas disease - the SEARCH-RIO study. Braz J Med Biol Res. 2013 Nov;46(11):974-984. doi: 10.1590/1414-431X20133141. Epub 2013 Oct 22."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D002598", "term": "Chagas Cardiomyopathy"}, {"id": "D009202", "term": "Cardiomyopathies"}, {"id": "D001145", "term": "Arrhythmias, Cardiac"}, {"id": "D003643", "term": "Death"}], "ancestors": [{"id": "D006331", "term": "Heart Diseases"}, {"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D014355", "term": "Chagas Disease"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M6845", "name": "Death", "asFound": "Cardiac Death", "relevance": "HIGH"}, {"id": "M22306", "name": "Stroke", "relevance": "LOW"}, {"id": "M4586", "name": "Atrial Fibrillation", "relevance": "LOW"}, {"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M16384", "name": "Tachycardia", "relevance": "LOW"}, {"id": "M4453", "name": "Arrhythmias, Cardiac", "asFound": "Cardiac Arrhythmia", "relevance": "HIGH"}, {"id": "M19488", "name": "Tachycardia, Ventricular", "relevance": "LOW"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M5845", "name": "Chagas Cardiomyopathy", "asFound": "Chagas Cardiomyopathy", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04090489", "orgStudyIdInfo": {"id": "Holter Chagas Children"}, "organization": {"fullName": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}, "briefTitle": "Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children", "officialTitle": "Post Treatment Evaluation of Terapeutic Response Biomarkers. Cardiological Studies in Children Treated for Chagas Disease"}, "statusModule": {"statusVerifiedDate": "2020-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-01-22", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-11-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-03-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-09-10", "studyFirstSubmitQcDate": "2019-09-12", "studyFirstPostDateStruct": {"date": "2019-09-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-04-23", "lastUpdatePostDateStruct": {"date": "2020-04-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dr Jaime Altcheh", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires"}, "leadSponsor": {"name": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Disease", "Chagas Cardiomyopathy"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 120, "type": "ACTUAL"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "To evaluate the efficacy of CD treatment in preventing the development of cardiac alterations in treated children.", "description": "To compare number of patients with pathological cardiac findings, measured by Holter and ECG, in two different groups: patients with treated Chagas disease (either with Nifurtimox or Benznidazole) and healthy (without Chagas disease) patients of the same population (control group).", "timeFrame": "10 years"}], "secondaryOutcomes": [{"measure": "Post treatment evaluation of treatment response biomarkers", "description": "To compare serology titles in patients treated for Chagas disease (either with Nifurtimox or Benznidazole) with PCR titles in the same group of patients and evaluate if PCR can be an early marker of therapeutic response compared to serology.", "timeFrame": "5 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Chagas diseases children treated with benznidazole / or nifurtimox\n* Patients with at least 6 years of after-treatment follow-up.\n* Diagnosis of Chagas disease: in infants younger than 8 months by direct observation of T.cruzi using parasitological concentration method (microhematocrit test); in infants older than 9 months 2 reactive serological test (ELISA, Indirect Hemagglutination ).\n\nExclusion Criteria:\n\n* Patients with chronic diseases (renal, hepatic, neurological) that at the discretion of the researcher could affect the interpretation of the results.\n* Subjects with congenital heart disease.", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "50 Years", "stdAges": ["CHILD", "ADULT"], "studyPopulation": "A cohort of CD treated children with at least 6 years post-treatment parasitological (T. cruzi qPCR), serological and cardiological follow-up. Treatment: benznidazole (Bz) or nifurtimox (Nftx), standard dose, for 60 days.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Parasitology Division, Children's Hospital \"R Gutierrez\" of Buenos Aires", "city": "Buenos Aires", "zip": "1425", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D002598", "term": "Chagas Cardiomyopathy"}, {"id": "D009202", "term": "Cardiomyopathies"}], "ancestors": [{"id": "D006331", "term": "Heart Diseases"}, {"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M5845", "name": "Chagas Cardiomyopathy", "asFound": "Chagas Cardiomyopathy", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00511589", "orgStudyIdInfo": {"id": "upeclin/HC/FMB-Unesp-pre01"}, "organization": {"fullName": "UPECLIN HC FM Botucatu Unesp", "class": "OTHER"}, "briefTitle": "Chagas Disease Diagnostic - Inconclusive Serology", "officialTitle": "PCR in Blood Cultures of Individuals With Positive and Inconclusive Serology for Chagas' Disease"}, "statusModule": {"statusVerifiedDate": "2007-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "studyFirstSubmitDate": "2007-08-03", "studyFirstSubmitQcDate": "2007-08-03", "studyFirstPostDateStruct": {"date": "2007-08-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-03-23", "lastUpdatePostDateStruct": {"date": "2011-03-24", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"leadSponsor": {"name": "UPECLIN HC FM Botucatu Unesp", "class": "OTHER"}}, "conditionsModule": {"conditions": ["Parasitemia", "Protozoan Infections"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"interventionModel": "PARALLEL", "maskingInfo": {"masking": "NONE"}}}, "armsInterventionsModule": {"interventions": [{"type": "OTHER", "name": "chagas disease diagnostic"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* individuals with positive or inconclusive results in conventional serological tests: ELISA, HAI and IFI for Chagas disease", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mariele Cristina M Picka, MSc", "affiliation": "UPECLIN HC FM Botucatu Unesp", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Univerdidade Estadual Paulista", "city": "Botucatu", "state": "S\u00e3o Paulo", "zip": "18600-000", "country": "Brazil", "geoPoint": {"lat": -22.88583, "lon": -48.445}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D018512", "term": "Parasitemia"}, {"id": "D011528", "term": "Protozoan Infections"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}, {"id": "D018805", "term": "Sepsis"}, {"id": "D018746", "term": "Systemic Inflammatory Response Syndrome"}, {"id": "D007249", "term": "Inflammation"}, {"id": "D010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M14388", "name": "Protozoan Infections", "asFound": "Protozoan Infections", "relevance": "HIGH"}, {"id": "M20615", "name": "Parasitemia", "asFound": "Parasitemia", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "M20864", "name": "Sepsis", "relevance": "LOW"}, {"id": "M16869", "name": "Toxemia", "relevance": "LOW"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M20818", "name": "Systemic Inflammatory Response Syndrome", "relevance": "LOW"}, {"id": "M10293", "name": "Inflammation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01650792", "orgStudyIdInfo": {"id": "R01NS064905", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01NS064905"}, "secondaryIdInfos": [{"id": "R01NS064905", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01NS064905"}], "organization": {"fullName": "Federal University of Bahia", "class": "OTHER"}, "briefTitle": "Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS)", "officialTitle": "CHADSS: Chagas Disease Scan Study", "acronym": "CLINICS"}, "statusModule": {"statusVerifiedDate": "2023-03", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-06", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2024-06", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2012-07-24", "studyFirstSubmitQcDate": "2012-07-25", "studyFirstPostDateStruct": {"date": "2012-07-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2023-03-02", "lastUpdatePostDateStruct": {"date": "2023-03-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Jamary Oliveira-Filho", "investigatorTitle": "Associate Professor", "investigatorAffiliation": "Federal University of Bahia"}, "leadSponsor": {"name": "Federal University of Bahia", "class": "OTHER"}, "collaborators": [{"name": "National Institutes of Health (NIH)", "class": "NIH"}, {"name": "National Institute of Neurological Disorders and Stroke (NINDS)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease With Heart Failure"], "keywords": ["Chagas disease", "Heart failure", "Stroke", "Dementia"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 500, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aspirin", "type": "ACTIVE_COMPARATOR", "description": "Aspirin 300mg per day for 7 days in patients with HITS on transcranial Doppler monitorization", "interventionNames": ["Drug: Aspirin"]}, {"label": "Best medical treatment", "type": "NO_INTERVENTION", "description": "Best medical treatment including drugs for heart failure and hypertension will be given to both groups."}], "interventions": [{"type": "DRUG", "name": "Aspirin", "armGroupLabels": ["Aspirin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Brain magnetic resonance imaging lesions", "description": "Primary hypothesis is that silent brain infarcts, brain atrophy and white matter disease will be more common in patients with Chagas disease heart failure when compared to other etiologies of heart failure.", "timeFrame": "Baseline cross-sectional data"}, {"measure": "Biomarkers", "description": "Primary hypothesis is that serum biomarkers orosomucoid, neprilysin, interleukin-6 and matrix metalloproteinase-9 will be increased in Chagas disease heart failure when compared to other etiologies of heart failure", "timeFrame": "Baseline cross-sectional data"}, {"measure": "Proportion of high intensity transient signals on transcranial Doppler monitorization", "description": "Primary hypothesis is that the proportion of patients with high intensity transient signals (HITS) on one-hour transcranial Doppler monitorization after one-week treatment with 300mg aspirin and best medical treatment will be less when compared with best medical treatment without aspirin", "timeFrame": "One week"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of heart failure according to Framingham criteria\n* Informed consent\n* Age 18 years or above\n\nExclusion Criteria:\n\n* Patients with a history of an untreated malignancy (except local skin cancers)\n* Ischemic stroke (determined using the Questionnaire for Verifying Stroke-Free Status (QVSFS)\n* Patients on renal dialysis or with end-stage hepatic dysfunction\n* Acute infection/inflammation (Temperature \\> 101.5 F, and/or WBC\\> 15, 000)\n* Inability to obtain informed consent from patient or next of kin\n* Anticoagulant use (warfarin or heparin)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Jamary Oliveira-Filho, MD, PhD", "role": "CONTACT", "phone": "+557191620954", "email": "jamaryof@ufba.br"}], "overallOfficials": [{"name": "Jamary Oliveira-Filho, MD, PhD", "affiliation": "Associate Professor, Federal University of Bahia", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hospital Universitario Professor Edgard Santos", "status": "RECRUITING", "city": "Salvador", "state": "Bahia", "zip": "40110060", "country": "Brazil", "contacts": [{"name": "Jamary Oliveira-Filho, MD, PhD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -12.97111, "lon": -38.51083}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D006333", "term": "Heart Failure"}], "ancestors": [{"id": "D006331", "term": "Heart Diseases"}, {"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M6904", "name": "Dementia", "relevance": "LOW"}, {"id": "M22306", "name": "Stroke", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D001241", "term": "Aspirin"}], "ancestors": [{"id": "D000894", "term": "Anti-Inflammatory Agents, Non-Steroidal"}, {"id": "D018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000700", "term": "Analgesics"}, {"id": "D018689", "term": "Sensory System Agents"}, {"id": "D018373", "term": "Peripheral Nervous System Agents"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D000893", "term": "Anti-Inflammatory Agents"}, {"id": "D018501", "term": "Antirheumatic Agents"}, {"id": "D005343", "term": "Fibrinolytic Agents"}, {"id": "D050299", "term": "Fibrin Modulating Agents"}, {"id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D016861", "term": "Cyclooxygenase Inhibitors"}, {"id": "D004791", "term": "Enzyme Inhibitors"}, {"id": "D058633", "term": "Antipyretics"}], "browseLeaves": [{"id": "M4548", "name": "Aspirin", "asFound": "Effectiveness", "relevance": "HIGH"}, {"id": "M4218", "name": "Anti-Inflammatory Agents, Non-Steroidal", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M8473", "name": "Fibrinolytic Agents", "relevance": "LOW"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M19209", "name": "Cyclooxygenase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M29176", "name": "Antipyretics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Antipy", "name": "Antipyretics"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "FiAg", "name": "Fibrinolytic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03784391", "orgStudyIdInfo": {"id": "20302"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina", "officialTitle": "Effectiveness of Nifurtimox in Patients With Chagas' Disease Based on Data From Patient Medical Records in Argentina: a Retrospective Medical Chart Review Study"}, "statusModule": {"statusVerifiedDate": "2021-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-12-14", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-04-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-04-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-12-20", "studyFirstSubmitQcDate": "2018-12-20", "studyFirstPostDateStruct": {"date": "2018-12-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-04-06", "lastUpdatePostDateStruct": {"date": "2021-04-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas' Disease"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 3000, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment", "description": "Patients diagnosed with acute and chronic Chagas' disease, respectively, who were treated with nifurtimox", "interventionNames": ["Drug: Lampit (Nifurtimox, BAYA2502)"]}, {"label": "Reference", "description": "Patients diagnosed with acute and chronic Chagas' disease, respectively, who did not receive antitrypanosomal treatment"}], "interventions": [{"type": "DRUG", "name": "Lampit (Nifurtimox, BAYA2502)", "description": "Nifurtimox is a drug already approved in some South American countries since more than 45 years", "armGroupLabels": ["Treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Parasitological cure of adult patients with chronic Chagas' disease", "description": "Change in the laboratory test result for Chagas' disease to negative after treatment with nifurtimox and without antitrypanosomal treatment compared to baseline.\n\nAdults are defined as patients who were 18 years or older at the time of initial diagnosis of acute or chronic Chagas' disease", "timeFrame": "Retrospective analysis from late 1960s to about 1980"}], "secondaryOutcomes": [{"measure": "Parasitological cure of pediatric patients with acute and chronic Chagas' disease", "description": "Change in the laboratory test result for Chagas' disease to negative after treatment with nifurtimox and without antitrypanosomal treatment compared to baseline.\n\nPediatric population will comprise patients aged 0 to below 18 years at the time of initial diagnosis of acute or chronic Chagas' disease", "timeFrame": "Retrospective analysis from late 1960s to about 1980"}, {"measure": "Occurrence of cardiac manifestations in patients with chronic Chagas' disease", "description": "Change from a lower to a more advanced Kuschnir group or cardiac death (change of clinical group) and appearance of new abnormalities on ECG compared to baseline.", "timeFrame": "Retrospective analysis from late 1960s to about 1980"}, {"measure": "Treatment of Cardiomyopathy and/or Heart Failure", "timeFrame": "Retrospective analysis from late 1960s to about 1980"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female patients aged \u22650 years at time of diagnosis with Chagas' disease\n* Diagnosis of Chagas' disease confirmed by parasitological and/or serological method(s) before start of antitrypanosomal treatment or during the course of this antitrypanosomal treatment cycle for the first episode recorded.\n\nExclusion Criteria:\n\n* Treatment with antitrypanosomal agent(s) other than nifurtimox, including experimental investigational products for Chagas' disease or antitrypanosomal combination treatment\n* Patients with known evidence of organ manifestation of chronic Chagas' disease, e.g.Chagas' disease-related cardiomyopathy/heart disease, Chagas' disease-related digestive disease at time of primary diagnosis.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "0 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "The study population will comprise adult and pediatric patients diagnosed with Chagas' disease, respectively, who were treated with nifurtimox (nifurtimox groups). An untreated reference group comprising adult patients diagnosed with chronic Chagas' disease, who did not receive antitrypanosomal treatment will be considered.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Many locations", "city": "Multiple Locations", "country": "Argentina"}]}, "referencesModule": {"references": [{"pmid": "34606501", "type": "DERIVED", "citation": "Vizcaya D, Grossmann U, Kleinjung F, Zhang R, Suzart-Woischnik K, Seu S, Ramirez T, Colmegna L, Ledesma O. Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina. PLoS Negl Trop Dis. 2021 Oct 4;15(10):e0009801. doi: 10.1371/journal.pntd.0009801. eCollection 2021 Oct."}], "seeAlsoLinks": [{"label": "Click here to find results for studies related to Bayer products", "url": "http://clinicaltrials.bayer.com"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D009547", "term": "Nifurtimox"}], "ancestors": [{"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M12486", "name": "Nifurtimox", "asFound": "DSM-IV", "relevance": "HIGH"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01842867", "orgStudyIdInfo": {"id": "CEP-41-10-1"}, "organization": {"fullName": "Hospital Sao Rafael", "class": "OTHER"}, "briefTitle": "Syndecan-4 as a Biomarker in Patients With Chagas Disease", "officialTitle": "Validation of Syndecan-4 as a Biomarker for Determining Patients Prognosis With Chagas Disease."}, "statusModule": {"statusVerifiedDate": "2015-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-01"}, "primaryCompletionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-04-18", "studyFirstSubmitQcDate": "2013-04-29", "studyFirstPostDateStruct": {"date": "2013-04-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-10-09", "lastUpdatePostDateStruct": {"date": "2015-10-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Milena Botelho Pereira Soares", "investigatorTitle": "PhD", "investigatorAffiliation": "Hospital Sao Rafael"}, "leadSponsor": {"name": "Hospital Sao Rafael", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Syndecan-4", "Chagas disease", "Biomarkers"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "CROSS_SECTIONAL"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "Plasma, Serum, Whole Blood"}, "enrollmentInfo": {"count": 60, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with Chagas disease diagnosis", "description": "Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Correlation of plasmatic levels of syndecan-4 with the percentage of heart fibrosis", "description": "Mensuration of heart fibrosis percentage with Magnetic Resonance Imaging", "timeFrame": "One year"}], "secondaryOutcomes": [{"measure": "Correlation of plasmatic levels of syndecan-4 with the functional cardiovascular capacity", "description": "Mensuration of the functional capacity with treadmill test.", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of Syndecan-4 with the left ventricular function", "description": "Mensuration of the left ventricular function with echocardiogram and magnetic resonance imaging", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of Syndecan-4 with the serum levels of Pro-BNP.", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of Syndecan-4 with the serum levels of TNF-alpha", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of Syndecan-4 with the serum levels of IFN-gamma.", "timeFrame": "One year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Chagas disease diagnosis confirmed by 2 different serologies\n* Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.\n\nExclusion Criteria:\n\n* Significant valve disease defined as aortic stenosis with a gradient of VE/Ao \\> 50 mmHg\n* Mitral stenosis with a valve area inferior than 1,5 cm2\n* Superior or moderated aortic and/or mitral regurgitation\n* Chronic use of immunosuppressive agents\n* Dialysis treatment of terminal renal failure\n* Fever on the last 48 hours or evidence of systemic infection in activity according to the definition of sepsis of the ACCP/SCCM (American College os Chest Physicians/Society of Critical Care Medicine)\n* Current abusive use of alcohol or illicit drugs (Based on the DSM IV)\n* Any other comorbidities that impact patient's survival within the next 2 years\n* Liver disease in activity\n* Continuous use of steroids as treatment for COPD\n* Hematologic, neoplastic or bone diseases\n* Homeostasis disturbances\n* Inflammatory diseases or chronic infectious diseases", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Tertiary Hospital", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Milena Botelho Pereira Soares, PhD", "affiliation": "Hospital S\u00e3o Rafael", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Ricardo Ribeiro dos Santos, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_DIRECTOR"}, {"name": "Ticiana Ferreira Larocca, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "M\u00e1rcia Maria Noya Rabelo, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Lu\u00eds Cl\u00e1udio Lemos Correia, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Bruno Solano de Freitas Souza, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Carolina Th\u00e9 Macedo, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Hospital S\u00e3o Rafael", "city": "Salvador", "state": "Bahia", "zip": "41253-190", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04274101", "orgStudyIdInfo": {"id": "Nifurtimox vs. Benznidazole"}, "organization": {"fullName": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}, "briefTitle": "Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment", "officialTitle": "Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment, Retrospective Cohort"}, "statusModule": {"statusVerifiedDate": "2023-02", "overallStatus": "UNKNOWN", "lastKnownStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-06-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-08-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2025-02-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2020-02-14", "studyFirstSubmitQcDate": "2020-02-14", "studyFirstPostDateStruct": {"date": "2020-02-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-02-28", "lastUpdatePostDateStruct": {"date": "2023-03-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dr Jaime Altcheh", "investigatorTitle": "PHD MD", "investigatorAffiliation": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires"}, "leadSponsor": {"name": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Disease"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 900, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Nifurtimox", "description": "Patients treated with Nifurtimox from 1984 to 2017", "interventionNames": ["Other: Clinical Manifestations", "Diagnostic Test: Serologic response", "Diagnostic Test: Direct method", "Behavioral: Adverse events"]}, {"label": "Benznidazole", "description": "Patients treated with Benznidazole from 1984 to 2017", "interventionNames": ["Other: Clinical Manifestations", "Diagnostic Test: Serologic response", "Diagnostic Test: Direct method", "Behavioral: Adverse events"]}], "interventions": [{"type": "OTHER", "name": "Clinical Manifestations", "description": "Clinical manifestations in patients treated with Nifurtimox and Benznidazole", "armGroupLabels": ["Benznidazole", "Nifurtimox"]}, {"type": "DIAGNOSTIC_TEST", "name": "Serologic response", "description": "Serologic response in patients treated with Nifurtimox and Benznidazole", "armGroupLabels": ["Benznidazole", "Nifurtimox"]}, {"type": "DIAGNOSTIC_TEST", "name": "Direct method", "description": "Direct method tests in patients treated with Nifurtimox and Benznidazole", "armGroupLabels": ["Benznidazole", "Nifurtimox"]}, {"type": "BEHAVIORAL", "name": "Adverse events", "description": "Adverse events in patients treated with Nifurtimox and Benznidazole", "armGroupLabels": ["Benznidazole", "Nifurtimox"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Nifurtimox versus Benznidazole serologic, parasitemia and clinical response for treatment in patients", "description": "To compare Nifurtimox versus Benznidazole treatment efficacy, by measuring serologic response, parasitemia and clinical manifestations in infected patients", "timeFrame": "Patients treated from 1984 to 2017"}], "secondaryOutcomes": [{"measure": "Nifurtimox versus Benznidazole security and tolerance", "description": "To compare Nifurtimox versus Benznidazole security profiles, by measuring adverse events in infected patients and comparing both groups (number of adverse reactions, type and severity of reactions)", "timeFrame": "Patients treated from 1984 to 2017"}, {"measure": "To compare Chagas disease characteristics associated with treatment", "description": "To describe source of infection, age of acquisition of parasite, diagnosis time frame and clinical manifestations that may be associated with treatment response and compare both groups", "timeFrame": "Patients treated from 1984 to 2017"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n- Patients between 0 and 18 years of age with confirmed Chagas disease (defined as patients under 8 months with positive parasitemia or older with 2 positive different techniques for serology) that received treatment with Nifurtimox or Benznidazole.\n\nExclusion Criteria:\n\n- Patients that abandoned follow-up", "healthyVolunteers": false, "sex": "ALL", "maximumAge": "18 Years", "stdAges": ["CHILD", "ADULT"], "studyPopulation": "All pediatric patients with criteria to receive treatment (Chagas infection confirmed) that received treatment and completed follow-up at Parasitology and Chagas department of Children's Hospital Ricardo Gutierrez, Argentina.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Parasitology and Chagas Service, Buenos Aires Children\u00b4s Hospital Ricardo Gutierrez", "city": "Buenos Aires", "zip": "1425", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}, "referencesModule": {"references": [{"pmid": "35416710", "type": "DERIVED", "citation": "Falk N, Berenstein AJ, Moscatelli G, Moroni S, Gonzalez N, Ballering G, Freilij H, Altcheh J. Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults. Antimicrob Agents Chemother. 2022 May 17;66(5):e0202121. doi: 10.1128/aac.02021-21. Epub 2022 Apr 13."}, {"pmid": "33168612", "type": "DERIVED", "citation": "Berenstein AJ, Falk N, Moscatelli G, Moroni S, Gonzalez N, Garcia-Bournissen F, Ballering G, Freilij H, Altcheh J. Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults. Antimicrob Agents Chemother. 2021 Jan 20;65(2):e01135-20. doi: 10.1128/AAC.01135-20. Print 2021 Jan 20."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "relevance": "LOW"}, {"id": "M12486", "name": "Nifurtimox", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04239144", "orgStudyIdInfo": {"id": "49701215.2.0000.0068"}, "organization": {"fullName": "University of Sao Paulo General Hospital", "class": "OTHER"}, "briefTitle": "Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease", "officialTitle": "Role of Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease - Pilot Study Randomized Controlled Trial"}, "statusModule": {"statusVerifiedDate": "2023-05", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-11-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-03-09", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-03-09", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-01-23", "studyFirstSubmitQcDate": "2020-01-20", "studyFirstPostDateStruct": {"date": "2020-01-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-05-05", "lastUpdatePostDateStruct": {"date": "2023-05-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Paulo Manuel P\u00eago Fernandes", "investigatorTitle": "Professor", "investigatorAffiliation": "University of Sao Paulo General Hospital"}, "leadSponsor": {"name": "University of Sao Paulo General Hospital", "class": "OTHER"}, "collaborators": [{"name": "Biosense Webster, Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Cardiomyopathy", "Ventricular Arrythmia"], "keywords": ["Ventricular Tachycardia,", "Chagas Disease", "Catheter Ablation", "Bilateral Sympathectomy", "Cardiac Sympathetic Denervation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "In this pilot study, the investigators will select 45 patients with Chagas cardiomyopathy with ICD who presented at least four ICD therapies in the prior six months. These patients will be randomly assigned to three groups, 15 patients in medical therapy group, 15 in catheter ablation and 15 in bilateral sympathectomy. The objective of this study is to evaluate the efficacy of the bilateral sympathectomy in the reduction of ventricular tachycardia in patients with Chagas cardiomyopathy.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 45, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Medical therapy group", "type": "NO_INTERVENTION", "description": "Arm 1 - 15 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming."}, {"label": "Catheter ablation", "type": "ACTIVE_COMPARATOR", "description": "Intervention Arm 2 -15 patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible).", "interventionNames": ["Procedure: Catheter ablation"]}, {"label": "Bilateral sympathectomy", "type": "EXPERIMENTAL", "description": "Interventional Arm 3 - 15 patients allocated to this group will undergo bilateral sympathectomy, which will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers.", "interventionNames": ["Procedure: Bilateral sympathectomy"]}], "interventions": [{"type": "PROCEDURE", "name": "Bilateral sympathectomy", "description": "Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.", "armGroupLabels": ["Bilateral sympathectomy"], "otherNames": ["Cardiac Sympathetic Denervation"]}, {"type": "PROCEDURE", "name": "Catheter ablation", "description": "Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.", "armGroupLabels": ["Catheter ablation"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time to Ventricular Tachycardia Recurrence", "description": "Compare the time to the first documented Ventricular Tachycardia episode between groups", "timeFrame": "12 months"}, {"measure": "Burden of Ventricular Tachycardia Recurrence", "description": "Compare the number of Ventricular Tachycardia episodes between groups in 12 months", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Ventricular Tachycardia Recurrence Following Sympathectomy Compared to Catheter Ablation.", "description": "Time to first VT episode after sympathectomy compared to Catheter ablation", "timeFrame": "12 months"}, {"measure": "Mortality and Transplant Rate", "description": "To compare between groups the number of patients who died or received a cardiac transplant at the end of the follow-up", "timeFrame": "12 months"}, {"measure": "Ventricular Ectopic Beats Density", "description": "To evaluate the density of ventricular premature beats in the 24-hour Holter in the follow-up, for each group.", "timeFrame": "12 months"}, {"measure": "Length of Hospital Stay", "description": "Compare the number of in-hospital days according to the type of intervention.", "timeFrame": "12 months"}, {"measure": "Rate of Complications Following Intervention", "description": "Compare the rate of clinical complications according to the type of intervention.", "timeFrame": "12 months"}, {"measure": "Impact on Left Ventricular Ejection Fraction", "description": "To evaluate the variations of the Left Ventricular Ejection Fraction in each group.", "timeFrame": "12 months"}, {"measure": "Autonomic Measures", "description": "To compare the RR variability measures in the 24h-Holter between groups", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with Chagas Disease Cardiomyopathy having an ICD\n* At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records;\n* Use of amiodarone and beta blockers in an optimized fashion;\n* Life expectancy of more than one year\n* Conditions for following the plan of clinical follow-up of the study.\n\nExclusion criteria:\n\n* Presence of an absolute contraindication to receive any of the possible treatments of the study;\n* Pregnant Woman;\n* Less than 18 years-old;\n* Renal insufficiency with creatinine \\>2.5 mg/dL (221 umol/L);\n* Mobile thrombus in the left ventricle;\n* Left Ventricle Ejection fraction \\< 10%;\n* Unstable angina;\n* Severe aortic stenosis\n* Primary severe mitral insufficiency;\n* New York Heart Association (NYHA) functional class IV;\n* Previous cardiac surgery or scheduled.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Paulo M Pego Fernandes, PhD", "role": "CONTACT", "phone": "+551126615921", "email": "paulo.fernandes@incor.usp.br"}, {"name": "Rodrigo M Kulchetscki, MD", "role": "CONTACT", "phone": "+551198246-8680\u202c", "email": "r.kulchetscki@gmail.com"}], "overallOfficials": [{"name": "Paulo M Pego Fernandes, MD, PhD", "affiliation": "Instituto do Cora\u00e7\u00e3o Faculdade de Medicina da USP - (INCOR-FMUSP)", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Rodrigo M Kulchetscki, MD", "affiliation": "Instituto do Cora\u00e7\u00e3o Faculdade de Medicina da USP - (INCOR-FMUSP)", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Maur\u00edcio I Scanavacca, MD, PhD", "affiliation": "Instituto do Cora\u00e7\u00e3o Faculdade de Medicina da USP - (INCOR-FMUSP)", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Heart Institute of Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo", "status": "RECRUITING", "city": "Sao Paulo", "zip": "05403-900", "country": "Brazil", "contacts": [{"name": "Rodrigo M Kulchetscki, MD", "role": "CONTACT", "phone": "+5511982468680", "email": "r.kulchetscki@gmail.com"}, {"name": "Gabriela Faria, Assistant", "role": "CONTACT", "phone": "+551126615921", "email": "gabriela.faria@incor.usp.br"}, {"name": "Rodrigo M Kulchetscki, MD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Cristiano F Pisani, MD, PhD", "role": "SUB_INVESTIGATOR"}, {"name": "Muhieddine O Chokr, MD, PhD", "role": "SUB_INVESTIGATOR"}, {"name": "Lucas G Moura, MD", "role": "SUB_INVESTIGATOR"}, {"name": "Gabriela Faria, DNP", "role": "SUB_INVESTIGATOR"}, {"name": "Sergio F Siqueira, ENG", "role": "SUB_INVESTIGATOR"}, {"name": "Martino Martinelli Filho, MD, PhD", "role": "SUB_INVESTIGATOR"}, {"name": "Paulo Manoel Pego Fernandes, MD, PhD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Mauricio I Scanavacca, MD, PhD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -23.5475, "lon": -46.63611}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Deidentified data will be shared with other investigators upon request.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF"], "timeFrame": "2 years", "accessCriteria": "Upon request."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D002598", "term": "Chagas Cardiomyopathy"}, {"id": "D009202", "term": "Cardiomyopathies"}, {"id": "D001145", "term": "Arrhythmias, Cardiac"}], "ancestors": [{"id": "D006331", "term": "Heart Diseases"}, {"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M16384", "name": "Tachycardia", "relevance": "LOW"}, {"id": "M4453", "name": "Arrhythmias, Cardiac", "asFound": "Arrhythmia", "relevance": "HIGH"}, {"id": "M19488", "name": "Tachycardia, Ventricular", "relevance": "LOW"}, {"id": "M5845", "name": "Chagas Cardiomyopathy", "asFound": "Chagas Cardiomyopathy", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC01", "name": "Infections"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M3976", "name": "Amiodarone", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05519046", "orgStudyIdInfo": {"id": "57563722.3.0000.0068"}, "organization": {"fullName": "InCor Heart Institute", "class": "OTHER"}, "briefTitle": "Cardiac Contractility Modulation in Chagas Heart Disease", "officialTitle": "Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas", "acronym": "FIX-Chagas"}, "statusModule": {"statusVerifiedDate": "2022-08", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-05-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2023-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2022-08-10", "studyFirstSubmitQcDate": "2022-08-26", "studyFirstPostDateStruct": {"date": "2022-08-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-08-26", "lastUpdatePostDateStruct": {"date": "2022-08-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Martino Martinelli Filho", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "InCor Heart Institute"}, "leadSponsor": {"name": "InCor Heart Institute", "class": "OTHER"}, "collaborators": [{"name": "Impulse Dynamics", "class": "INDUSTRY"}, {"name": "I2medi Comercial Medica LTDA", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Cardiomyopathy", "Heart Failure", "Systolic Dysfunction", "Right Bundle Branch Block and Left Anterior Fascicular Block", "Right Bundle Branch Block and Left Posterior Fascicular Block"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 60, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Cardiac Contractility Modulation Group - CCM Group", "type": "EXPERIMENTAL", "description": "CCM implantation.", "interventionNames": ["Device: Cardiac Contractility Modulation (CCM)"]}, {"label": "Cardiac Resynchronization Therapy Group - CRT Group", "type": "ACTIVE_COMPARATOR", "description": "CRT implantation", "interventionNames": ["Device: CRT"]}], "interventions": [{"type": "DEVICE", "name": "Cardiac Contractility Modulation (CCM)", "description": "Cardiac Contractility Modulation (CCM) implantation", "armGroupLabels": ["Cardiac Contractility Modulation Group - CCM Group"]}, {"type": "DEVICE", "name": "CRT", "description": "Cardiac Resynchronization Therapy", "armGroupLabels": ["Cardiac Resynchronization Therapy Group - CRT Group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "QoL Score", "description": "KCCQS - Kansas City cardiomyopathy quality score", "timeFrame": "At baseline"}, {"measure": "QoL Score", "description": "KCCQS - Kansas City cardiomyopathy quality score", "timeFrame": "At 6 months"}, {"measure": "GLS", "description": "Global longitudinal strain at rest/effort - (tissue tracking)", "timeFrame": "At baseline"}, {"measure": "GLS", "description": "Global longitudinal strain at rest/effort - (tissue tracking)", "timeFrame": "At 6 months"}], "secondaryOutcomes": [{"measure": "6MWT", "description": "6-minute walk test", "timeFrame": "At baseline"}, {"measure": "6MWT", "description": "6-minute walk test", "timeFrame": "At 6 months"}, {"measure": "NYHAFC", "description": "HF functional class assessed as established by the NYHA", "timeFrame": "At baseline"}, {"measure": "NYHAFC", "description": "HF functional class assessed as established by the NYHA", "timeFrame": "At 6 months"}, {"measure": "LVEF", "description": "Left ventricle ejection fraction", "timeFrame": "At baseline"}, {"measure": "LVEF", "description": "Left ventricle ejection fraction", "timeFrame": "At 6 months"}, {"measure": "Heart Failure Hospitalization (HFH) checklist", "description": "Heart Failure Hospitalization", "timeFrame": "Through study completion, an average of 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Signing of an informed consent form (ICF) before randomization and any study procedure,\n* Both genders, age \\>18 years and \\<75 years,\n* Recent positive (last two years) and documented serology for Chagas disease, in at least two different tests (indirect hemagglutination, indirect immunofluorescence, or ELISA),\n* NYHA II-III heart failure functional class,\n* LVEF\\< 35%,\n* Non left bundle branch block\n* Intraventricular desynchrony (Yu index)\n* Global longitudinal strain \\>11 %.\n\nExclusion Criteria:\n\n* Participation in another study, presently or terminated \\<1 year ago, except for a totally unrelated observational study,\n* Other concomitant cardiovascular diseases, including uncontrolled diabetes mellitus (systemic arterial hypertension without permitted target organ compromise),\n* Kidney dysfunction (serum creatinine \\>1.5mg/dL or eGFR \\<30mL/min/1.73m2) or liver dysfunction, with diagnosis of cirrhosis or portal hypertension or elevated serum enzymes (AST or ALT) \\> 3x the upper limit of normality,\n* Moderate or severe chronic obstructive pulmonary disease,\n* Peripheral polyneuropathy,\n* Hyperthyroidism,\n* Current alcoholism or not abandoned for \\>2 years,\n* Diagnosed with psychopathy or psychosis or addiction to illicit drugs,\n* Life expectancy \\<1 year, due to the disease itself or comorbidities (including NYHA class IV),\n* Pregnancy or breastfeeding,\n* Potential to become pregnant during the study (non-menopausal patients who have not undergone a radical and safe contraceptive process),\n* Previously withdrawn from this study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Martino Martinelli Filho, PhD", "role": "CONTACT", "phone": "+551126615515", "email": "martino@incor.usp.br"}, {"name": "Sergio F Siqueira, MsC", "role": "CONTACT", "phone": "+551126615514", "email": "sergio.siqueira@hc.fm.usp.br"}], "locations": [{"facility": "InCor - HCFMUSP", "status": "RECRUITING", "city": "S\u00e3o Paulo", "state": "Sao Paulo", "zip": "05403-900", "country": "Brazil", "contacts": [{"name": "Martino MM Martinelli Filho, PHD", "role": "CONTACT", "phone": "55 11 2661 5517", "phoneExt": "5517", "email": "martino.filho@incor.usp.br"}, {"name": "Sergio F Siqueira, Master", "role": "CONTACT", "phone": "55 11 2661 5514", "phoneExt": "5514", "email": "siqueira@incor.usp.br"}], "geoPoint": {"lat": -23.5475, "lon": -46.63611}}]}, "referencesModule": {"references": [{"pmid": "4982469", "type": "RESULT", "citation": "Dias JC, Kloetzel K. The prognostic value of the electrocardiographic features of chronic Chagas' disease. Rev Inst Med Trop Sao Paulo. 1968 May-Jun;10(3):158-62. No abstract available."}, {"pmid": "3997291", "type": "RESULT", "citation": "Espinosa R, Carrasco HA, Belandria F, Fuenmayor AM, Molina C, Gonzalez R, Martinez O. Life expectancy analysis in patients with Chagas' disease: prognosis after one decade (1973-1983). Int J Cardiol. 1985 May;8(1):45-56. doi: 10.1016/0167-5273(85)90262-1."}, {"pmid": "8175216", "type": "RESULT", "citation": "Carrasco HA, Parada H, Guerrero L, Duque M, Duran D, Molina C. Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas' disease. Int J Cardiol. 1994 Jan;43(1):27-38. doi: 10.1016/0167-5273(94)90087-6."}, {"pmid": "7987526", "type": "RESULT", "citation": "Martinelli Filho M, Sosa E, Nishioka S, Scanavacca M, Bellotti G, Pileggi F. Clinical and electrophysiologic features of syncope in chronic chagasic heart disease. J Cardiovasc Electrophysiol. 1994 Jul;5(7):563-70. doi: 10.1111/j.1540-8167.1994.tb01297.x."}, {"pmid": "7994859", "type": "RESULT", "citation": "Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation. 1994 Dec;90(6):3098-102. doi: 10.1161/01.cir.90.6.3098."}, {"pmid": "8187110", "type": "RESULT", "citation": "Bestetti RB, Dalbo CM, Freitas OC, Teno LA, Castilho OT, Oliveira JS. Noninvasive predictors of mortality for patients with Chagas' heart disease: a multivariate stepwise logistic regression study. Cardiology. 1994;84(4-5):261-7. doi: 10.1159/000176409."}, {"pmid": "7547025", "type": "RESULT", "citation": "de Paola AA, Gomes JA, Terzian AB, Miyamoto MH, Martinez Fo EE. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br Heart J. 1995 Sep;74(3):293-5. doi: 10.1136/hrt.74.3.293."}, {"pmid": "8904674", "type": "RESULT", "citation": "Bestetti RB, Dalbo CM, Arruda CA, Correia Filho D, Freitas OC. Predictors of sudden cardiac death for patients with Chagas' disease: a hospital-derived cohort study. Cardiology. 1996 Nov-Dec;87(6):481-7. doi: 10.1159/000177142."}, {"pmid": "2365530", "type": "RESULT", "citation": "Carrasco HA, Guerrero L, Parada H, Molina C, Vegas E, Chuecos R. Ventricular arrhythmias and left ventricular myocardial function in chronic chagasic patients. Int J Cardiol. 1990 Jul;28(1):35-41. doi: 10.1016/0167-5273(90)90006-q."}, {"pmid": "10677747", "type": "RESULT", "citation": "Lopes ER. Sudden death in patients with Chagas disease. Mem Inst Oswaldo Cruz. 1999;94 Suppl 1:321-4. doi: 10.1590/s0074-02761999000700061. No abstract available."}, {"pmid": "11175486", "type": "RESULT", "citation": "Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol. 2001 Jan;76(1):75-96. doi: 10.1590/s0066-782x2001000100008. No abstract available. English, Portuguese."}, {"pmid": "10707756", "type": "RESULT", "citation": "Bestetti R. Stroke in a hospital-derived cohort of patients with chronic Chagas' disease. Acta Cardiol. 2000 Feb;55(1):33-8. doi: 10.2143/AC.55.1.2005715."}, {"pmid": "15845889", "type": "RESULT", "citation": "Carod-Artal FJ, Vargas AP, Horan TA, Nunes LG. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke. 2005 May;36(5):965-70. doi: 10.1161/01.STR.0000163104.92943.50. Epub 2005 Apr 21."}, {"pmid": "19142374", "type": "RESULT", "citation": "Sousa AS, Xavier SS, Freitas GR, Hasslocher-Moreno A. Prevention strategies of cardioembolic ischemic stroke in Chagas' disease. Arq Bras Cardiol. 2008 Nov;91(5):306-10. doi: 10.1590/s0066-782x2008001700004. English, Portuguese."}, {"pmid": "4994717", "type": "RESULT", "citation": "Oliveira JS, Barbieri Neto J. [Chagasic cardiopathy. Rupture of the apical aneurysm]. Arq Bras Cardiol. 1970 Oct;23(5):335-8. No abstract available. Portuguese."}, {"pmid": "8728813", "type": "RESULT", "citation": "Pinto Dias JC. [Natural history of Chagas disease]. Arq Bras Cardiol. 1995 Oct;65(4):359-66. No abstract available. Portuguese."}, {"pmid": "20399979", "type": "RESULT", "citation": "Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010 Apr 17;375(9723):1388-402. doi: 10.1016/S0140-6736(10)60061-X."}, {"pmid": "2486527", "type": "RESULT", "citation": "Dias JC. The indeterminate form of human chronic Chagas' disease A clinical epidemiological review. Rev Soc Bras Med Trop. 1989 Jul-Sep;22(3):147-56. doi: 10.1590/s0037-86821989000300007."}, {"pmid": "8650479", "type": "RESULT", "citation": "Barretto AC, Ianni BM. The undetermined form of Chagas' heart disease: concept and forensic implications. Sao Paulo Med J. 1995 Mar-Apr;113(2):797-801. doi: 10.1590/s1516-31801995000200010."}, {"pmid": "17339569", "type": "RESULT", "citation": "Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation. 2007 Mar 6;115(9):1109-23. doi: 10.1161/CIRCULATIONAHA.106.624296."}, {"pmid": "17891282", "type": "RESULT", "citation": "Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007 Oct 30;102 Suppl 1:75-85. doi: 10.1590/s0074-02762007005000093. Erratum In: Mem Inst Oswaldo Cruz. 2007 Dec;102(8):2 p following 1009."}, {"pmid": "18545843", "type": "RESULT", "citation": "Dias JC, Prata A, Correia D. Problems and perspectives for Chagas disease control: in search of a realistic analysis. Rev Soc Bras Med Trop. 2008 Mar-Apr;41(2):193-6. doi: 10.1590/s0037-86822008000200012."}, {"pmid": "19753454", "type": "RESULT", "citation": "Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:17-30. doi: 10.1590/s0074-02762009000900005."}, {"pmid": "19131444", "type": "RESULT", "citation": "Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart. 2009 Apr;95(7):524-34. doi: 10.1136/hrt.2008.159624. Epub 2009 Jan 8."}, {"pmid": "16928995", "type": "RESULT", "citation": "Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, Rassi GG, Hasslocher-Moreno A, Sousa AS, Scanavacca MI. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006 Aug 24;355(8):799-808. doi: 10.1056/NEJMoa053241."}, {"pmid": "16202650", "type": "RESULT", "citation": "Brunckhorst CB, Shemer I, Mika Y, Ben-Haim SA, Burkhoff D. Cardiac contractility modulation by non-excitatory currents: studies in isolated cardiac muscle. Eur J Heart Fail. 2006 Jan;8(1):7-15. doi: 10.1016/j.ejheart.2005.05.011. Epub 2005 Oct 3."}, {"pmid": "23621145", "type": "RESULT", "citation": "Kahwash R, Burkhoff D, Abraham WT. Cardiac contractility modulation in patients with advanced heart failure. Expert Rev Cardiovasc Ther. 2013 May;11(5):635-45. doi: 10.1586/erc.13.48."}, {"pmid": "27394714", "type": "RESULT", "citation": "Abi-Samra F, Gutterman D. Cardiac contractility modulation: a novel approach for the treatment of heart failure. Heart Fail Rev. 2016 Nov;21(6):645-660. doi: 10.1007/s10741-016-9571-6."}, {"pmid": "31772622", "type": "RESULT", "citation": "Mando R, Goel A, Habash F, Saad M, Ayoub K, Vallurupalli S, Maskoun W. Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Cardiovasc Ther. 2019 Jun 17;2019:9769724. doi: 10.1155/2019/9769724. eCollection 2019."}, {"pmid": "29754812", "type": "RESULT", "citation": "Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D, Hasenfuss G. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018 Oct;6(10):874-883. doi: 10.1016/j.jchf.2018.04.010. Epub 2018 May 10. Erratum In: JACC Heart Fail. 2023 Jan;11(1):132. doi: 10.1016/j.jchf.2022.11.003."}, {"pmid": "7055867", "type": "RESULT", "citation": "Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. Circulation. 1982 Mar;65(3):457-64. doi: 10.1161/01.cir.65.3.457."}, {"pmid": "19168514", "type": "RESULT", "citation": "Parissis JT, Nikolaou M, Farmakis D, Paraskevaidis IA, Bistola V, Venetsanou K, Katsaras D, Filippatos G, Kremastinos DT. Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure. Eur J Heart Fail. 2009 Feb;11(2):163-9. doi: 10.1093/eurjhf/hfn032."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D002598", "term": "Chagas Cardiomyopathy"}, {"id": "D006331", "term": "Heart Diseases"}, {"id": "D009202", "term": "Cardiomyopathies"}, {"id": "D002037", "term": "Bundle-Branch Block"}, {"id": "D006327", "term": "Heart Block"}], "ancestors": [{"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D001145", "term": "Arrhythmias, Cardiac"}, {"id": "D000075224", "term": "Cardiac Conduction System Disease"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D014355", "term": "Chagas Disease"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "relevance": "LOW"}, {"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M5309", "name": "Bundle-Branch Block", "asFound": "Bundle Branch Block", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M5845", "name": "Chagas Cardiomyopathy", "asFound": "Chagas Cardiomyopathy", "relevance": "HIGH"}, {"id": "M9415", "name": "Heart Block", "asFound": "Bundle Branch Block", "relevance": "HIGH"}, {"id": "M4453", "name": "Arrhythmias, Cardiac", "relevance": "LOW"}, {"id": "M1472", "name": "Cardiac Conduction System Disease", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC01", "name": "Infections"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01162967", "orgStudyIdInfo": {"id": "CHAGASAZOL01"}, "organization": {"fullName": "Hospital Universitari Vall d'Hebron Research Institute", "class": "OTHER"}, "briefTitle": "Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole", "officialTitle": "PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE", "acronym": "CHAGASAZOL"}, "statusModule": {"statusVerifiedDate": "2013-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-09"}, "primaryCompletionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-05-20", "studyFirstSubmitQcDate": "2010-07-14", "studyFirstPostDateStruct": {"date": "2010-07-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-09-09", "lastUpdatePostDateStruct": {"date": "2013-09-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Hospital Universitari Vall d'Hebron Research Institute", "class": "OTHER"}, "collaborators": [{"name": "Hospital Vall d'Hebron", "class": "OTHER"}, {"name": "Tropical Medicine and International Health Unit Drassanes. Barcelona", "class": "UNKNOWN"}, {"name": "International Health Unit Metropolitana Nord. Santa Coloma.", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 78, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benznidazole", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Benznidazole"]}, {"label": "Posaconazole, low dose", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Posaconazole"]}, {"label": "Posaconazole, high dose", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Posaconazole"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "description": "Standard dosage", "armGroupLabels": ["Benznidazole"]}, {"type": "DRUG", "name": "Posaconazole", "armGroupLabels": ["Posaconazole, high dose", "Posaconazole, low dose"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Parasitological cure measured by a real time PCR in blood sample", "description": "PCR negative at the end of follow up", "timeFrame": "12 months after starting treatment"}], "secondaryOutcomes": [{"measure": "Parasitological cure measured by real time PCR in blood sample", "description": "substained parasitological response", "timeFrame": "End of treatment, weeks 8, 16, 24 and 40 after treatment"}, {"measure": "Safety and tolerability of both drugs", "timeFrame": "First 2 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Consenting patients with serological evidence of Chagas infection and positive PCR real time\n\nExclusion Criteria:\n\n-", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Molina Israel, MD", "affiliation": "Infectious Disease Department Vall d'Hebron Hospital", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Pahisssa Albert, MD Ph", "affiliation": "Infectious Disease Department Vall d'Hebron Hospital", "role": "STUDY_CHAIR"}, {"name": "Gomez Jordi, MD", "affiliation": "International Health Unit Drassanes", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Valerio Lluis, MD", "affiliation": "International Health Unit Metropolitana Nord", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "International Health Unit Metropolitana Nord", "city": "Santa Coloma", "state": "Barcelona", "country": "Spain"}, {"facility": "Infectious Disease Department Vall d'Hebron Hospital", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "International Health Unit Drassanes", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}]}, "referencesModule": {"references": [{"pmid": "24827034", "type": "DERIVED", "citation": "Molina I, Gomez i Prat J, Salvador F, Trevino B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valerio L, Blanco-Grau A, Sanchez-Montalva A, Vidal X, Pahissa A. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med. 2014 May 15;370(20):1899-908. doi: 10.1056/NEJMoa1313122."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C101425", "term": "Posaconazole"}, {"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D000935", "term": "Antifungal Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D058888", "term": "14-alpha Demethylase Inhibitors"}, {"id": "D065607", "term": "Cytochrome P-450 Enzyme Inhibitors"}, {"id": "D004791", "term": "Enzyme Inhibitors"}, {"id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D065088", "term": "Steroid Synthesis Inhibitors"}, {"id": "D006727", "term": "Hormone Antagonists"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M219015", "name": "Posaconazole", "asFound": "Lumbar spine", "relevance": "HIGH"}, {"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M6252", "name": "Clotrimazole", "relevance": "LOW"}, {"id": "M11796", "name": "Miconazole", "relevance": "LOW"}, {"id": "M4254", "name": "Antifungal Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M30537", "name": "Cytochrome P-450 Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00005455", "orgStudyIdInfo": {"id": "4488"}, "secondaryIdInfos": [{"id": "Z01HL005264", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/Z01HL005264"}], "organization": {"fullName": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}, "briefTitle": "Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States"}, "statusModule": {"statusVerifiedDate": "2001-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1993-01"}, "completionDateStruct": {"date": "1993-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2000-05-25", "studyFirstSubmitQcDate": "2000-05-25", "studyFirstPostDateStruct": {"date": "2000-05-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-07-14", "lastUpdatePostDateStruct": {"date": "2016-07-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"leadSponsor": {"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}}, "conditionsModule": {"conditions": ["Heart Diseases", "Myocardial Diseases", "Chagas Disease"]}, "designModule": {"studyType": "OBSERVATIONAL"}, "eligibilityModule": {"eligibilityCriteria": "No eligibility criteria", "healthyVolunteers": false, "sex": "MALE", "maximumAge": "100 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D006331", "term": "Heart Diseases"}, {"id": "D009202", "term": "Cardiomyopathies"}], "ancestors": [{"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M12154", "name": "Cardiomyopathies", "asFound": "Myocardial Disease", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03524768", "orgStudyIdInfo": {"id": "CHAGASKASALTIBIRI\u00c7\u00c1"}, "organization": {"fullName": "National Institute of Cardiology, Laranjeiras, Brazil", "class": "OTHER_GOV"}, "briefTitle": "Microvascular Endothelial Function in a Cohort of Patients With the Cardiac Form of Chronic Chagas Disease.", "officialTitle": "Microvascular Endothelial Function in a Cohort of Patients With the Cardiac Form of Chronic Chagas Disease."}, "statusModule": {"statusVerifiedDate": "2020-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-08-20", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-08-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-08-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-04-21", "studyFirstSubmitQcDate": "2018-05-12", "studyFirstPostDateStruct": {"date": "2018-05-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-08-19", "lastUpdatePostDateStruct": {"date": "2020-08-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Eduardo Tibirica, MD, PhD", "investigatorTitle": "Senior Researcher, MD, PhD", "investigatorAffiliation": "National Institute of Cardiology, Laranjeiras, Brazil"}, "leadSponsor": {"name": "National Institute of Cardiology, Laranjeiras, Brazil", "class": "OTHER_GOV"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Cardiomyopathy"], "keywords": ["endothelial function, microvascular", "laser speckle contrast imaging", "capillaroscopy, skin"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 70, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "patients presenting with Chagas cardiomyopathy", "description": "Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy", "interventionNames": ["Diagnostic Test: skin laser speckle contrast imaging and video-capillaroscopy"]}, {"label": "control group", "description": "Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy", "interventionNames": ["Diagnostic Test: skin laser speckle contrast imaging and video-capillaroscopy"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "skin laser speckle contrast imaging and video-capillaroscopy", "description": "Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment", "armGroupLabels": ["control group", "patients presenting with Chagas cardiomyopathy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Endothelium-dependent skin microvascular function", "description": "systemic microvascular vasodilation induced by endothelium-dependent agents", "timeFrame": "2 hours"}], "secondaryOutcomes": [{"measure": "Endothelium-dependent skin capillary density", "description": "capillary opening induced by post-occlusive reactive hyperemia", "timeFrame": "1 hour"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* patients presenting with Chagas cardiomyopathy\n\nExclusion Criteria:\n\n* diabetes", "healthyVolunteers": true, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "The present study aims to evaluate the microvascular endothelial function of a single centre cohort of patients presenting with the cardiac form of Chagas disease in the National Institute of Cardiology, Ministry of Health, Rio de Janeiro,, Brazil", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "National Institute of Cardiology, Ministry of Health, Brazil", "city": "Rio de Janeiro", "zip": "22240-006", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D002598", "term": "Chagas Cardiomyopathy"}, {"id": "D009202", "term": "Cardiomyopathies"}], "ancestors": [{"id": "D006331", "term": "Heart Diseases"}, {"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M5845", "name": "Chagas Cardiomyopathy", "asFound": "Chagas Cardiomyopathy", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00123916", "orgStudyIdInfo": {"id": "BEN01"}, "secondaryIdInfos": [{"id": "CONEP-11394", "type": "OTHER", "domain": "Comiss\u00e3o Nacional de \u00c9tica em Pesquisa (CONEP)"}], "organization": {"fullName": "Population Health Research Institute", "class": "OTHER"}, "briefTitle": "BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease", "officialTitle": "Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial", "acronym": "BENEFIT"}, "statusModule": {"statusVerifiedDate": "2020-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-11"}, "primaryCompletionDateStruct": {"date": "2015-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-07-21", "studyFirstSubmitQcDate": "2005-07-22", "studyFirstPostDateStruct": {"date": "2005-07-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2020-02-27", "lastUpdatePostDateStruct": {"date": "2020-03-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Salim Yusuf's office", "investigatorTitle": "Principal Co-Investigator", "investigatorAffiliation": "Population Health Research Institute"}, "leadSponsor": {"name": "Population Health Research Institute", "class": "OTHER"}, "collaborators": [{"name": "Canadian Institutes of Health Research (CIHR)", "class": "OTHER_GOV"}, {"name": "World Health Organization", "class": "OTHER"}, {"name": "Instituto Dante Pazzanese de Cardiologia", "class": "OTHER"}, {"name": "University of Sao Paulo", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chagas Disease", "Trypanosomiasis", "Heart Disease"], "keywords": ["Chagas Disease", "Trypanosomiasis", "Benznidazole", "Chronic Heart disease", "Trypanosoma Cruzi"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 2854, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benznidazole", "type": "EXPERIMENTAL", "description": "40 - 80 days (according to body weight) treatment with benznidazol", "interventionNames": ["Drug: Benznidazole"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "40 - 80 days (according to body weight) treatment with matching placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "description": "Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)", "armGroupLabels": ["Benznidazole"], "otherNames": ["Rochagan/LaFepe"]}, {"type": "DRUG", "name": "Placebo", "description": "a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)", "armGroupLabels": ["Placebo"], "otherNames": ["Rochagan/LaFepe"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Composite of First of cardiovascular events: Death, Resuscitated Cardiac Arrest, Sustained VentricularTachycardia, New/worsening Heart Failure, New Pacemaker/ICD, Stroke/TIA or other Embolic Events, Cardiac Transplant.", "description": "Composite cardiovascular outcome,", "timeFrame": "through study completion, an average of 5 years"}], "secondaryOutcomes": [{"measure": "New development of any of the following echo changes, segmental wall motion abnormalities, ventricular aneurysm, reduction in LV ejection fraction >5%, increase in LVDD> 5 mm compared to baseline.", "timeFrame": "through study completion, an average of 5 years"}, {"measure": "New 12 lead ECG alterations (complete bundle branch block, fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc).", "timeFrame": "through study completion, an average of 5 years"}, {"measure": "Progression of NYHA functional class by at least one category", "timeFrame": "through study completion, an average of 5 years"}, {"measure": "New 12 lead electrocardiogram (ECG) alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc.)", "timeFrame": "through study completion, an average of 5 years"}, {"measure": "Progression of New York Heart Association (NYHA) functional class by at least one category", "timeFrame": "through study completion, an average of 5 years"}, {"measure": "Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment", "timeFrame": "through study completion, an average of 5 years"}, {"measure": "Determination of the efficacy of benznidazole in patients with Chronic Chagas heart disease based on a 50% reduction in both qualitative and quantitative PCR.", "description": "Polymerase Chain Reaction study on patient's blood samples and report negativization at the end of treatment, 2Y and final visit.", "timeFrame": "through study completion, an average of 5 years"}, {"measure": "Safety and tolerability of benznidazole", "timeFrame": "through study completion, an average of 5 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Consenting patients (between 18 and 75 years of age) with serological evidence of Chagas infection (any combination of 2 positive tests) and that have one or more of the following:\n* Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left anterior or posterior fascicular block; ventricular premature beat; first degree atrioventricular \\[AV\\] block; Mobitz type I AV block; sinus bradycardia; primary ST-T changes; abnormal Q waves; low voltage QRS; or atrial fibrillation);\n* Abnormal ECG (Mobitz type II, advanced or third degree AV block);\n* Increased cardiothoracic ratio (\\> 0.50);\n* Complex ventricular arrythmias on 24 hour ambulatory ECG monitoring;\n* Evidence of regional wall motion abnormality or reduced global left ventricular systolic function or increased left ventricular and diastolic diameter on 2D-Echo.\n\nExclusion Criteria:\n\nPatients will be excluded if having:\n\n* NYHA heart failure class IV or decompensated heart failure\n* Evidence of concomitant coronary artery disease (CAD) or other etiology of dilated cardiomyopathy\n* Previous treatment with antitrypanosomal agents or an accepted indication for antiparasitic therapy\n* Inability to comply with follow-up visits\n* History of severe alcohol abuse within 2 years\n* Known chronic renal or hepatic insufficiency or hepatic insufficiency\n* Pregnancy or breast feeding\n* Megaesophagus with swallowing impairment\n* Other severe disease significantly curtailing life expectancy", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Carlos Morillo, MD", "affiliation": "Population Health Research Institute - McMaster University", "role": "STUDY_CHAIR"}, {"name": "Jose Antonio Marin-Neto, MD, PhD", "affiliation": "University of Sao Paulo", "role": "STUDY_CHAIR"}, {"name": "Salim Yusuf, MD, DPh", "affiliation": "Population Health Research Institute - McMaster University", "role": "STUDY_CHAIR"}, {"name": "Sergio Sosa-Estani, MD, PhD", "affiliation": "Argentina National Coordinator - CenDIE, Argentina", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Fernando Rosas, M.D.", "affiliation": "Fundacion Clinica Shaio, Bogota, Colombia", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "BENEFIT Ivestigational Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "state": "Apital Federal", "zip": "3556", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "BENEFIT Investigational Site", "city": "Bel\u00e9n De Escobar", "state": "Buenos Aires", "zip": "1753", "country": "Argentina", "geoPoint": {"lat": -34.34833, "lon": -58.79265}}, {"facility": "BENEFIT Investigational Site", "city": "Isidro Casanova", "state": "Buenos Aires", "zip": "1282", "country": "Argentina", "geoPoint": {"lat": -34.7008, "lon": -58.59074}}, {"facility": "BENEFIT Investigational Site", "city": "San Juan", "state": "Buenos Aires", "zip": "1625", "country": "Argentina", "geoPoint": {"lat": -31.5375, "lon": -68.53639}}, {"facility": "BENEFIT Investigational Site", "city": "Santiago del Estero", "state": "Buenos Aires", "zip": "4200", "country": "Argentina", "geoPoint": {"lat": -27.79511, "lon": -64.26149}}, {"facility": "BENEFIT Investigational Site", "city": "Santiago del Estero", "state": "Buenos Aires", "zip": "5400", "country": "Argentina", "geoPoint": {"lat": -27.79511, "lon": -64.26149}}, {"facility": "BENEFIT Investigational Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "state": "Capital Federal", "zip": "1063", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "BENEFIT Investigational Site", "city": "San Fernando del Valle de Catamarca", "state": "Catamarca", "country": "Argentina", "geoPoint": {"lat": -28.46957, "lon": -65.78524}}, {"facility": "BENEFIT Investigational Site", "city": "Charata", "state": "Chaco", "zip": "H3730AVI", "country": "Argentina", "geoPoint": {"lat": -27.21438, "lon": -61.18795}}, {"facility": "BENEFIT Investigational Site", "city": "Paran\u00e1", "state": "Entre Rios", "zip": "3100", "country": "Argentina", "geoPoint": {"lat": -31.73197, "lon": -60.5238}}, {"facility": "BENEFIT Investigational Site", "city": "Buenos Aires", "state": "General Rodr\u00edguez Partido", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "BENEFIT Investigational Site", "city": "San Salvador de Jujuy", "state": "Jujuy", "zip": "4600", "country": "Argentina", "geoPoint": {"lat": -24.19457, "lon": -65.29712}}, {"facility": "BENEFIT Investigational Site", "city": "Corrientes", "state": "Rosario, Santa Fe", "zip": "3400", "country": "Argentina", "geoPoint": {"lat": -27.4806, "lon": -58.8341}}, {"facility": "BENEFIT Investigational Site", "city": "Rosario", "state": "Santa Fe", "zip": "2000", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "BENEFIT Investigational Site", "city": "A\u00f1atuya", "state": "Santiago Del Estero", "zip": "3760", "country": "Argentina", "geoPoint": {"lat": -28.46064, "lon": -62.83472}}, {"facility": "BENEFIT Investigational Site", "city": "Santiago Del Estero", "state": "Sgo. Del Estero", "zip": "4200", "country": "Argentina", "geoPoint": {"lat": -27.79511, "lon": -64.26149}}, {"facility": "BENEFIT Investigational Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "BENEFIT Investigational Site", "city": "Salta", "zip": "A4406CLA", "country": "Argentina", "geoPoint": {"lat": -24.7859, "lon": -65.41166}}, {"facility": "BENEFIT Investigational Site", "city": "Tupiza", "state": "Potosi", "country": "Bolivia", "geoPoint": {"lat": -21.44345, "lon": -65.71875}}, {"facility": "BENEFIT Investigational Site", "city": "Salvador", "state": "Bahaia", "zip": "40050-410", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}, {"facility": "BENEFIT Investigational Site", "city": "Salvador", "state": "Bahaia", "zip": "40110-909", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}, {"facility": "BENEFIT Investigational Site", "city": "Salvador", "state": "Bahaia", "zip": "40425-060", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}, {"facility": "BENEFIT Investigational Site", "city": "Carmo", "state": "Belo Horizonte", "zip": "30130-690", "country": "Brazil", "geoPoint": {"lat": -21.93361, "lon": -42.60861}}, {"facility": "BENEFIT Investigational Site", "city": "Bras\u00edlia", "state": "Brazilian Federal District", "zip": "70658-700", "country": "Brazil", "geoPoint": {"lat": -15.77972, "lon": -47.92972}}, {"facility": "BENEFIT Investigational Site", "city": "Goi\u00e2nia", "state": "GO", "zip": "74110-010", "country": "Brazil", "geoPoint": {"lat": -16.67861, "lon": -49.25389}}, {"facility": "BENEFIT Investigational Site", "city": "Goi\u00e2nia", "state": "GO", "zip": "74110-020", "country": "Brazil", "geoPoint": {"lat": -16.67861, "lon": -49.25389}}, {"facility": "BENEFIT Investigational Site", "city": "Goi\u00e2nia", "state": "GO", "zip": "74605-050", "country": "Brazil", "geoPoint": {"lat": -16.67861, "lon": -49.25389}}, {"facility": "BENEFIT Investigational Site", "city": "Uberlandia", "state": "MG", "zip": "38025-440", "country": "Brazil", "geoPoint": {"lat": -18.91861, "lon": -48.27722}}, {"facility": "BENEFIT Investigational Site", "city": "Uberl\u00e2ndia", "state": "MG", "zip": "38400-299", "country": "Brazil", "geoPoint": {"lat": -18.91861, "lon": -48.27722}}, {"facility": "BENEFIT Investigational Site", "city": "Uberaba", "state": "Minas Gerais", "zip": "38010-160", "country": "Brazil", "geoPoint": {"lat": -19.74833, "lon": -47.93194}}, {"facility": "BENEFIT Investigational Site", "city": "Curitiba", "state": "Parana", "zip": "80060-900", "country": "Brazil", "geoPoint": {"lat": -25.42778, "lon": -49.27306}}, {"facility": "BENEFIT Investigational Site", "city": "Recife", "state": "Pernambuco", "zip": "50100-130", "country": "Brazil", "geoPoint": {"lat": -8.05389, "lon": -34.88111}}, {"facility": "BENEFIT Investigational Site", "city": "Pelotas", "state": "Rio Grande Do Sul", "zip": "96015-290", "country": "Brazil", "geoPoint": {"lat": -31.77194, "lon": -52.3425}}, {"facility": "BENEFIT Investigational Site", "city": "Campinas", "state": "S\u00e3o Paulo", "zip": "13059-740", "country": "Brazil", "geoPoint": {"lat": -22.90556, "lon": -47.06083}}, {"facility": "BENEFIT Investigational Site", "city": "Ribeir\u00e3o Preto", "state": "S\u00e3o Paulo", "zip": "14048-900", "country": "Brazil", "geoPoint": {"lat": -21.1775, "lon": -47.81028}}, {"facility": "BENEFIT Investigational Site", "city": "S\u00e3o Jos\u00e9 do Rio Preto", "state": "S\u00e3o Paulo", "zip": "15015-210", "country": "Brazil", "geoPoint": {"lat": -20.81972, "lon": -49.37944}}, {"facility": "BENEFIT Investigational Site", "city": "S\u00e3o Jos\u00e9 do Rio Preto", "state": "S\u00e3o Paulo", "zip": "15090-000", "country": "Brazil", "geoPoint": {"lat": -20.81972, "lon": -49.37944}}, {"facility": "BENEFIT Investigational Site", "city": "Votuporanga", "state": "S\u00e3o Paulo", "zip": "15500-003", "country": "Brazil", "geoPoint": {"lat": -20.42278, "lon": -49.97278}}, {"facility": "BENEFIT Investigational Site", "city": "Rio de Janeiro", "zip": "21040-360", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "BENEFIT Investigational Site", "city": "Rio de Janeiro", "zip": "21941-913", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "BENEFIT Investigational Site", "city": "S\u00e3o Paulo", "zip": "01417 010", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "BENEFIT Investigational Site", "city": "S\u00e3o Paulo", "zip": "04012-909", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "BENEFIT Investigational Site", "city": "S\u00e3o Paulo", "zip": "05403-000", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "BENEFIT Investigational Site", "city": "S\u00e3o Paulo", "zip": "05403-901", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "BENEFIT Investigational Site", "city": "Bogota", "state": "Bogot\u00e1", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "BENEFIT Investigational Site", "city": "San Gil", "state": "Santander", "country": "Colombia", "geoPoint": {"lat": 6.55952, "lon": -73.13637}}, {"facility": "BENEFIT Ivestigational Site", "city": "San Salvador", "country": "El Salvador", "geoPoint": {"lat": 13.68935, "lon": -89.18718}}]}, "referencesModule": {"references": [{"pmid": "18585495", "type": "BACKGROUND", "citation": "Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S; BENEFIT Investigators. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J. 2008 Jul;156(1):37-43. doi: 10.1016/j.ahj.2008.04.001."}, {"pmid": "26323937", "type": "DERIVED", "citation": "Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, Villena E, Quiroz R, Bonilla R, Britto C, Guhl F, Velazquez E, Bonilla L, Meeks B, Rao-Melacini P, Pogue J, Mattos A, Lazdins J, Rassi A, Connolly SJ, Yusuf S; BENEFIT Investigators. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med. 2015 Oct;373(14):1295-306. doi: 10.1056/NEJMoa1507574. Epub 2015 Sep 1."}, {"pmid": "19753491", "type": "DERIVED", "citation": "Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, Morillo CA, Sosa-Estani S, Yusuf S; BENEFIT Investigators. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:319-24. doi: 10.1590/s0074-02762009000900042. Erratum In: Mem Inst Oswaldo Cruz. 2009 Sep;104(6):937. Morillo, Carlos A [added]; Sosa-Estani, Sergio [added]; Yusuf, Salim [added]; BENEFIT Investigators [added]."}], "seeAlsoLinks": [{"label": "Population Health Research Institute", "url": "http://www.phri.ca"}, {"label": "Instituto Dante Pazzanese de Cardiologia", "url": "http://www.idpc.org.br/pesquisa/"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28", "removedCountries": ["Canada"]}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D006331", "term": "Heart Diseases"}], "ancestors": [{"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "asFound": "Trypanosomiasis", "relevance": "HIGH"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Pedigree", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04897516", "orgStudyIdInfo": {"id": "NuestroBen"}, "organization": {"fullName": "Laboratorio Elea Phoenix S.A.", "class": "INDUSTRY"}, "briefTitle": "Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease", "officialTitle": "Phase III Randomized,Multicenter Non-inferiority Study to Evaluate the Efficacy and Safety of Shorter Benznidazole Regimens Compared to the Standard Regimen to Treat Adult Patients With Chronic Chagas Disease", "acronym": "NuestroBen"}, "statusModule": {"statusVerifiedDate": "2023-09", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-07-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-06-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-12-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2021-05-18", "studyFirstSubmitQcDate": "2021-05-18", "studyFirstPostDateStruct": {"date": "2021-05-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-11-27", "lastUpdatePostDateStruct": {"date": "2023-11-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Laboratorio Elea Phoenix S.A.", "class": "INDUSTRY"}, "collaborators": [{"name": "Drugs for Neglected Diseases", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Chagas disease", "Benznidazole", "Trypanosoma Cruzi", "Standar treatment", "Short treatment"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Phase III, open-label, prospective, controlled, multicenter, non-inferiority study to compare the efficacy of the Drug: 1. Short regimen of benznidazole :Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.\n\n2. Drug: Short regimen of benznidazole : Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks. And 3. Drug: Standard treatment with benznidazole : Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 300, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Short regimen of benznidazole 2 weeks", "type": "EXPERIMENTAL", "description": "Experimental: Short regimen of benznidazole Participants will receive an investigational treatment of benznidazole for 2 weeks.\n\nBenznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.", "interventionNames": ["Drug: Short regimen of benznidazole"]}, {"label": "Short regimen of benznidazole 4 weeks", "type": "EXPERIMENTAL", "description": "Experimental: Short regimen of benznidazole Participants will receive an investigational treatment of benznidazole for 4 weeks.\n\nBenznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks.", "interventionNames": ["Drug: Short treatment with benznidazole"]}, {"label": "Standard treatment with benznidazole", "type": "ACTIVE_COMPARATOR", "description": "Active Comparator: Standard treatment with benznidazole Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks", "interventionNames": ["Drug: Standard treatment with benznidazole"]}], "interventions": [{"type": "DRUG", "name": "Short regimen of benznidazole", "description": "Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.", "armGroupLabels": ["Short regimen of benznidazole 2 weeks"], "otherNames": ["Benznidazole 2 weeks"]}, {"type": "DRUG", "name": "Short treatment with benznidazole", "description": "Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks.", "armGroupLabels": ["Short regimen of benznidazole 4 weeks"], "otherNames": ["Benznidazole 4 weeks"]}, {"type": "DRUG", "name": "Standard treatment with benznidazole", "description": "Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks", "armGroupLabels": ["Standard treatment with benznidazole"], "otherNames": ["Benznidazole 8 weeks"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportion of patients with sustained negativation of parasitemia according to the results of qualitative PCR tests", "description": "Sustained parasitological response will be determined by negative serial qualitative PCR results (two negative PCR results from three DNA extractions from a sample) from the end of treatment with the elimination of sustained parasitaemia until the end of 12 months' follow-up from the end of treatment.", "timeFrame": "From the end of treatment, and up to 12 months of follow-up from the end of treatment."}], "secondaryOutcomes": [{"measure": "Proportion of patients with negative parasitemia at 1, 4, 6 and 8 months follow-up form the end of treatment", "description": "Proportion of patients with negative parasitemia at 1, 4, 6 and 8 months follow-up form the end of treatment", "timeFrame": "1, 4, 6 and 8 months from the end of treatment"}, {"measure": "Incidence and severity of adverse events", "description": "Incidence and severity of adverse events", "timeFrame": "From the end of treatment, and up to 12 months of follow-up from the end of treatment"}, {"measure": "Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption", "description": "Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption", "timeFrame": "From the end of treatment, and up to 12 months of follow-up from the end of treatment."}, {"measure": "Descriptions of patients adherence to treatment in each study arm.", "description": "describing the number of completed treatment in patients vs uncompleted treatment in patients", "timeFrame": "2, 4 and 8 weeks"}], "otherOutcomes": [{"measure": "Incidence and severity of adverse events", "description": "Incidence and severity of adverse events", "timeFrame": "From the end of treatment, and up to 12 months of follow-up from the end of treatment."}, {"measure": "Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption", "description": "Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption", "timeFrame": "From the end of treatment, and up to 12 months of follow-up from the end of treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria (Subjects must meet ALL the inclusion requirements listed below to enter the study):\n\n* Signed informed consent form;\n* Between \u226518 and \u226460 years of age;\n* Weight \u2265 50 kg to \u2264 95 kg;\n* Confirmation of the diagnosis of T. cruzi infection by conventional serology (a minimum of two tests must be reactive);\n* Serial qualitative PCR (one blood sample divided in three DNA extractions, at least one of which must be positive);\n* Women of childbearing potential must have a negative pregnancy result at the time of inclusion, must not be breast-feeding, and must use a highly effective method of contraception during study treatment and until 30 days after the last dose of study treatment or demonstrate permanent sterilization;\n* Ability to comply with all exams and specific protocol visits;\n* Having a permanent address;\n* ECG criteria: (Heart rate: 50 -100 bpm or isolate sinus bradycardia from 41 to 59 beats/min; QRS \u2264120 msec, and QTc \u2265 350 msec and \u2264 450 msec) at screening) or following findings belonging to non-severe chagasic cardiomyopathy: uncomplete right bundle branch block, Left anterior fascicular block, First-degree atrioventricular block, Low voltage. The abnormalities included are not exclusionary;\n* Normal or minimal structural changes in echocardiogram (left ventricular diastolic diameter (LVDD) \\<= 55 mm, diastolic dysfunction, absence of Microaneurysm or tip aneurysm, absence of hypo or generalized akinesia, absence of Systolic dysfunction (low fractional shortening and ejection fraction), and/or absence of mural thrombus);\n* Not presenting signs or symptoms of moderate- severe chronic cardiac and/or digestive forms of Chagas disease (criteria detailed in Study Manual and specific SOP);\n* No prior history of mental disorders or suicidal tendencies;\n* Not suffering from known acute or chronic illnesses at the moment of selection for the study that, in the Investigator's discretion, may interfere with the evaluation of the efficacy or safety of the investigational product (such as acute infections, immunosuppressive conditions, or liver or kidney diseases that have required treatment);\n* Not having received a formal indication not to take BZN (contraindication, according to the Summary of Product Characteristics - SmPC);\n* No prior history of hypersensitivity, allergy, or serious adverse reactions to any of the nitroimidazole compounds (including BNZ) and/or its components/excipients;\n* Have not previously undergone antiparasitic treatment for T. cruzi infection;\n* No prior history of drug abuse or alcoholism;\n* Not suffering from any disease or condition that prevents subjects from consuming oral medication.\n\nExclusion criteria (The presence of any of the items below will exclude subjects from inclusion in the study):\n\n* Subject pregnant or intending to become pregnant during treatment and within 30 days of the last dose of study treatment;\n* Signs or symptoms of the established (moderate- severe) chronic cardiac and/or digestive form of Chagas disease, or any ECG/ echocardiographic findings not included at Inclusion criteria;\n* History of cardiomyopathy, heart failure, or severe ventricular arrhythmia;\n* History of digestive surgery potentially related to Chagas Disease or megacolon / mega-esophagus;\n* Acute or chronic disease that, in the Investigator's discretion, may interfere with the evaluation of the efficacy or safety of the investigational product (such as acute infection, history of immunosuppressive conditions, or liver or kidney disease that has required treatment);\n* Laboratory test values that are considered clinically significant or outside the allowable values, per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 1;\n* Disease or clinical condition that prevents subjects from consuming oral medication;\n* Subjects with a contraindication (known hypersensitivity) to any of the nitroimidazole compounds, e.g. metronidazole;\n* Subjects with a history of allergy (serious or not), allergic rash, asthma, intolerance, sensitivity or photosensitivity;\n* Concomitant use and/or consumption of allopurinol, antimicrobial and antiparasitic agents, herbal medicines, dietary supplements and energy drinks;\n* Scheduled surgery that may interfere with the conduct of the trial and/or with the treatment evaluation;\n* Inability to attend study visits, comply with treatment, and cooperate with study procedures;\n* Previous participation in a trial for the evaluation of the treatment of T. cruzi infection;\n* Simultaneous participation in another trial or within 3 months prior to screening for this trial (in accordance with national regulations).\n* Subjects suffering from a serious medical or psychiatric illness that increases the risk associated with study participation or that interferes with the interpretation of study results should not be included.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Carola Lombas, MD", "role": "CONTACT", "phone": "(54) 11 44898300", "email": "carola.lombas@elea.com"}, {"name": "Tayn\u00e1 Marques, MSc", "role": "CONTACT", "phone": "(55) 21 9978 40503", "email": "tmarques@dndi.org"}], "overallOfficials": [{"name": "Mar\u00eda Jes\u00fas Pinazo, MD", "affiliation": "Drugs for Neglected Diseases", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Instituto Nacional de Parasitolog\u00eda \"Dr. Mario Fatala Chaben\"", "status": "NOT_YET_RECRUITING", "city": "Buenos Aires", "zip": "C1097", "country": "Argentina", "contacts": [{"name": "Marisa Fernandez, MD", "role": "CONTACT", "email": "marisa.fernandez@gmail.com"}], "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Fundaci\u00f3n Hu\u00e9sped", "status": "RECRUITING", "city": "Buenos Aires", "zip": "C1202ABB", "country": "Argentina", "contacts": [{"name": "Patricia Patterson, MD", "role": "CONTACT", "email": "patricia.patterson@huesped.org.ar"}], "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Hospital Francisco Javier Mu\u00f1iz", "status": "RECRUITING", "city": "Buenos Aires", "zip": "C1282A", "country": "Argentina", "contacts": [{"name": "Susana Lloveras, MD", "role": "CONTACT", "email": "sclloveras@gmail.com"}], "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Hospital Donaci\u00f3n Francisco Santojanni", "status": "NOT_YET_RECRUITING", "city": "Buenos Aires", "zip": "C1408INH", "country": "Argentina", "contacts": [{"name": "Pablo Scapellato, MD", "role": "CONTACT", "email": "pscapel@intramed.net"}], "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Instituto de Cardiolog\u00eda de Corrientes \"Juana Francisca Cabral\"", "status": "RECRUITING", "city": "Corrientes", "zip": "W3400", "country": "Argentina", "contacts": [{"name": "Mar\u00eda del Carmen Bangher, MD", "role": "CONTACT", "email": "mbangher@yahoo.com.ar"}], "geoPoint": {"lat": -27.4806, "lon": -58.8341}}, {"facility": "Centro de Chagas y Patolog\u00eda Regional, Hospital Independencia", "status": "RECRUITING", "city": "Santiago Del Estero", "zip": "G4200", "country": "Argentina", "contacts": [{"name": "Javier Rosmiro, MD", "role": "CONTACT", "email": "rosmirojfernandez@hotmail.com"}], "geoPoint": {"lat": -27.79511, "lon": -64.26149}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Data from the study will be made available upon request. Requests are evaluated by DNDi's scientific advisory committee. Interested researchers can contact DNDi for data access requests via email at ctdata@dndi.org. Researchers can also request data by completing the form available at https://www.dndi.org/category/clinical-trials/. In this data request form, researchers must confirm that they will share data and results with DNDi and will publish any results open access.", "infoTypes": ["STUDY_PROTOCOL", "SAP"], "timeFrame": "Beginning 6 months after publication of study results", "accessCriteria": "Beginning 6 months after publication of study results"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01566617", "orgStudyIdInfo": {"id": "Chagas2303"}, "secondaryIdInfos": [{"id": "0034.0.009.000-11", "type": "OTHER", "domain": "Research Ethics Committee of the Evandro Chagas Clinical Research Institute (IPEC)"}], "organization": {"fullName": "Evandro Chagas Institute of Clinical Research", "class": "OTHER"}, "briefTitle": "Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease", "officialTitle": "Impact of The Pharmaceutical Care on the Quality of Life of Patients With Chagas Disease and Heart Failure: Randomized Clinical Trial", "acronym": "ChagasCare"}, "statusModule": {"statusVerifiedDate": "2016-01", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-10"}, "primaryCompletionDateStruct": {"date": "2017-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2017-03", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2012-03-23", "studyFirstSubmitQcDate": "2012-03-28", "studyFirstPostDateStruct": {"date": "2012-03-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-01-20", "lastUpdatePostDateStruct": {"date": "2016-01-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Gilberto Marcelo Sperandio da Silva", "investigatorTitle": "PhD", "investigatorAffiliation": "Evandro Chagas Institute of Clinical Research"}, "leadSponsor": {"name": "Evandro Chagas Institute of Clinical Research", "class": "OTHER"}, "collaborators": [{"name": "Alejandro Marcel Hasslocher Moreno, MD MSc PhD student", "class": "UNKNOWN"}, {"name": "Andrea Costa, MD PhD", "class": "UNKNOWN"}, {"name": "Andrea Silvestre de Sousa, MD PhD", "class": "UNKNOWN"}, {"name": "Luiz Henrique C. Sangenis, MD MSc PhD student", "class": "UNKNOWN"}, {"name": "Marcelo Teixeira de Holanda, MD MSc PhD student", "class": "UNKNOWN"}, {"name": "Mayara da Costa Chambela - MSc student", "class": "UNKNOWN"}, {"name": "Pedro Emmanuel Alvarenga Americano do Brasil, MD PhD", "class": "UNKNOWN"}, {"name": "Roberto Magalh\u00e3es Saraiva, MD PhD", "class": "UNKNOWN"}, {"name": "Sergio Salles Xavier, MD PhD", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Heart Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER"]}}, "enrollmentInfo": {"count": 88, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Standard Care", "type": "OTHER", "description": "(1) group who will receive standard care", "interventionNames": ["Other: Standard care"]}, {"label": "Standard Care and Pharmaceutical Care", "type": "OTHER", "description": "(2) group who will receive standard care and pharmaceutical care", "interventionNames": ["Other: Standard care and Pharmaceutical care"]}], "interventions": [{"type": "OTHER", "name": "Standard care and Pharmaceutical care", "description": "Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.", "armGroupLabels": ["Standard Care and Pharmaceutical Care"]}, {"type": "OTHER", "name": "Standard care", "description": "These patients will only receive standard care, with out follow-up by the pharmacist", "armGroupLabels": ["Standard Care"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Quality of life.", "description": "The primary outcome of this trial is the evaluation of quality of life, measured by the 36-item short-form and the Minnesota Living with Heart Failure Questionnaire. Evaluation of patient quality of life during follow up of two parallel groups: (1) group who will receive standard care and pharmaceutical care; and (2) group who will receive only standard care.", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Incidence and types of drug-related problems", "description": "To evaluate the drug-related problems based on the classi\ufb01cation of the Brazilian Pharmaceutical Care Consensus. Evaluation of drug-related problems during follow up of two parallel groups: (1) group who will receive standard care and pharmaceutical care; and (2) group who will receive only standard care.", "timeFrame": "12 months"}, {"measure": "Physical functional capacity.", "description": "All patients will have their physical functional capacity measured by the 6 minute-walk test (The patients will split in two parallel groups: (1) group who will receive standard care and pharmaceutical care; and (2) group who will receive only standard care). The test will be performed at the beginning of protocol and after 12 months of follow-up.", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* The proposed clinical trial will be conducted in volunteers with Chagas disease complicated by heart failure.\n* Subjects will include adults, men and women, racial or ethnic minorities.\n* Diagnosed by two distinct Chagas serology tests (indirect immunofluorescence and enzyme linked immunosorbent assay\n\nExclusion Criteria:\n\n* Patients with any of comorbidities that significantly affect the cardiac performance, such as coronary artery disease, moderate or severe heart valvular disease, left ventricular (LV) hypertrophy, congenital heart disease, or that limit their survival, such as malignant tumors and HIV, will be excluded from the study.\n* Patients will be also be excluded in case of failure to give informed consent, inability to perform 6 minute- walk test, significant cognitive impairment, or pregnancy.\n* Individuals who are participating in others intervention trials will also be excluded.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "76 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Mayara C Chambela, pharmaceutics", "role": "CONTACT", "phone": "552138659648", "email": "Mayarachambela@gmail.com"}, {"name": "Gilberto M Silva", "role": "CONTACT", "phone": "552138659648", "email": "gilbertomarcelo@gmail.com"}], "overallOfficials": [{"name": "Gilberto M Silva, pharmaceutical", "affiliation": "Evandro Chagas Clinical Research Institute", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Evandro Chagas Clinical Research Institute", "status": "RECRUITING", "city": "Rio de Janeiro", "zip": "21040360", "country": "Brazil", "contacts": [{"name": "Gilberto M Sperandio da Silva, pharmaceutist", "role": "CONTACT", "phone": "552138659648", "email": "gilbertomarcelo@gmail.com"}, {"name": "Gilberto M Sperandio da Silva, pharmaceutist", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -22.90278, "lon": -43.2075}}]}, "referencesModule": {"references": [{"pmid": "23270509", "type": "DERIVED", "citation": "Sperandio da Silva GM, Chambela MC, Sousa AS, Sangenis LH, Xavier SS, Costa AR, Brasil PE, Hasslocher-Moreno AM, Saraiva RM. Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial. Trials. 2012 Dec 27;13:244. doi: 10.1186/1745-6215-13-244."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D006331", "term": "Heart Diseases"}], "ancestors": [{"id": "D002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "relevance": "LOW"}, {"id": "T6034", "name": "Quality of Life", "asFound": "Quality of Life", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04984616", "orgStudyIdInfo": {"id": "U1111-1267-3513"}, "organization": {"fullName": "University of Chile", "class": "OTHER"}, "briefTitle": "Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease", "officialTitle": "Effect of Statins (Atorvastatin) on Inflammation and Cardiac Function in Patients with Chronic Chagas Disease: Pathophysiological Studies in a Multicenter Proof-of-concept", "acronym": "ATOCHA"}, "statusModule": {"statusVerifiedDate": "2023-05", "overallStatus": "TERMINATED", "whyStopped": "The recruitment rate in all centers was extremely low. The number of participants failed to reach a statistically significant minimum.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-10-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-03-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-04-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2021-06-29", "studyFirstSubmitQcDate": "2021-07-21", "studyFirstPostDateStruct": {"date": "2021-07-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-09-06", "lastUpdatePostDateStruct": {"date": "2024-09-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Juan D. Maya", "investigatorTitle": "Full Professor", "investigatorAffiliation": "University of Chile"}, "leadSponsor": {"name": "Juan D. Maya", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "conditionsModule": {"conditions": ["Chronic Chagas Disease"], "keywords": ["Chagas Disease", "Atorvastatin", "Inflammation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 300, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "ATORVASTATIN 40", "type": "EXPERIMENTAL", "description": "40 mg Atorvastatin/day for 120 days P.O.", "interventionNames": ["Drug: 40 mg Atorvastatin/day for 120 days P.O."]}, {"label": "ATORVASTATIN 80", "type": "EXPERIMENTAL", "description": "80 mg Atorvastatin/day for 120 days P.O.", "interventionNames": ["Drug: Atorvastatin 80"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo/day for 120 days P.O.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "40 mg Atorvastatin/day for 120 days P.O.", "description": "Oral administration of Atorvastatin 40 mg/daily for 120 days", "armGroupLabels": ["ATORVASTATIN 40"]}, {"type": "DRUG", "name": "Atorvastatin 80", "description": "Oral administration of Atorvastatin 80 mg/daily for 120 days", "armGroupLabels": ["ATORVASTATIN 80"]}, {"type": "DRUG", "name": "Placebo", "description": "Oral administration of Placebo daily for 120 days", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of patients that present a change in the phase of the chronic cardiomyopathy", "description": "To evaluate whether the effect of atorvastatin in combination with antiparasitic therapy (NFX or BZD), more effective than antiparasitic therapy alone in preventing the onset of cardiac disorders as determined by non-progression in the phase from the A-phase according to the I Latin American Guidelines for the diagnosis and treatment of Chagas cardiomyopathy (Andrade et al, Arq Bras Cardiol 2011;97 Suppl 3:1-48.).", "timeFrame": "Twelve months"}], "secondaryOutcomes": [{"measure": "plasma levels of cytokines (pg/mL)", "description": "Plasma levels of the tumor necrosis factor -\u03b1, interferon -\u03b3, IL-10, IL-1B, IL-4, and IL-17A cytokines will be determined by a multiplex analysis", "timeFrame": "Twelve months"}, {"measure": "Plasma levels of endothelial adhesion molecules (pg/mL)", "description": "Plasma levels of the soluble forms of Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and E-selectin, as determined by a multiplex analysis", "timeFrame": "Twelve months"}, {"measure": "Proportion of patients with change in heart rate measured by electrocardiographic examination", "description": "Percentage of patients in the treatment arms that present changes in cardiac rate as compared with the placebo arm", "timeFrame": "Twelve months"}, {"measure": "Proportion of patients with changes in the QT interval duration (milliseconds)", "description": "Percentage of patients in the treatment arms that present changes in repolarization, as determined by the QT interval duration in the electrocardiogram, when compared with the placebo arm", "timeFrame": "Twelve months"}, {"measure": "Proportion of patients with abnormalities in ventricular electrical conduction determined by the duration of the QRS interval (milliseconds)", "description": "Percentage of patients in the treatment arms that present changes in ventricular conduction, as determined by QRS interval duration in the electrocardiogram, when compared with the placebo arm", "timeFrame": "Twelve months"}, {"measure": "Proportion of patients with alterations in ventricular function as measured by changes in the ejection fraction percentage estimated by echocardiography", "description": "Percentage of patients in the treatment arms that present changes in ventricular function, as determined by ejection fraction calculated using echocardiography analysis, when compared with the placebo arm.", "timeFrame": "Twelve months"}, {"measure": "Plasma levels of Cardiac function biomarkers (pg/mL)", "description": "Cardiac functional damage evidenced by a change in the plasma levels of brain natriuretic peptide (BNP) and cardiac troponin T (cTnT)", "timeFrame": "Twelve months"}, {"measure": "Parasite load in a blood sample (number of parasites/mL)", "description": "To determine the parasitic load in blood by quantitative polymerase chain reaction assay (qPCR)", "timeFrame": "Twelve months"}, {"measure": "Incidence of severe adverse events", "description": "To evaluate the incidence of treatment discontinuation due to severe Adverse Events", "timeFrame": "Twelve months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adults older than 18 and younger than 50 years,\n* with a weight higher than 40 kg\n* Positive conventional confirmatory serology for T. cruzi infection from the NAtional Public Health institute (ISPCH), and\n* A positive qPCR\n* Have normal laboratory test values for the following parameters: total white blood cell count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl transferase (GGT) \\> 2 times the upper limit of normal (X ULN);\n* Women of reproductive age must have a negative serum pregnancy test, must not be breastfeeding, and must consistently use a highly effective contraceptive method throughout the treatment phase\n* Ability to comply with all protocol-specified follow-up tests and visits and have a permanent address;\n* Signed written informed consent form\n\nExclusion Criteria:\n\n* Signs and symptoms of the digestive form of Chagas Disease;\n* Chronic cardiac Chagas Disease stage II or higher;\n* Acute or chronic health conditions such as acute infections, history of HIV infection, diabetes, liver and kidney disease;\n* Hypothyroidism\n* Family history of muscle disorders\n* Pre-existing heart disease unrelated to Chagas disease;\n* Formal contraindication to receive nifurtimox or benznidazole,\n* Known history of hypersensitivity, allergy or severe adverse reactions to atorvastatin, benznidazole or nifurtimox;\n* History of previous treatment for Chagas Disease;\n* History of prior treatment with atorvastatin, lovastatin, rosuvastatin, simvastatin or any other statin;\n* Any concomitant use of antimicrobial agents;\n* History of alcohol or drug abuse;\n* Any condition that precludes oral medication;\n* Concomitant or intended use of CYP3A4 modifiers;\n* Medical history of familial short QT syndrome or concomitant therapy with medications that may shorten the QT interval.\n* Abnormal laboratory test values for the following parameters: total white blood cell count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl transferase (GGT) \\> 2 times the upper limit of normal (X ULN);\n* Being pregnant or breastfeeding\n* Refusing to use a highly effective contraceptive method during the treatment phase.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Juan D. Maya, Ph.D.", "affiliation": "Full Professor", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hospital Felix Bulnes", "city": "Quinta Normal", "state": "Regi\u00f3n Metropolitana", "zip": "8520398", "country": "Chile", "geoPoint": {"lat": -33.44186, "lon": -70.67899}}, {"facility": "Hospital San Juan de Dios", "city": "Santiago", "state": "Regi\u00f3n Metropolitana", "zip": "8350533", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Hospital San Martin", "city": "Quillota", "state": "Valparaiso", "zip": "2260494", "country": "Chile", "geoPoint": {"lat": -32.88341, "lon": -71.24882}}, {"facility": "Hospital Gustavo Fricke", "city": "Vi\u00f1a del Mar", "state": "Valpara\u00edso", "zip": "2570017", "country": "Chile", "geoPoint": {"lat": -33.02457, "lon": -71.55183}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "The study protocol and the Clinical Study Report will be available as supporting information alongside all publications derived from this study.\n\nBy incorporating the Individual Participant Data on a repository after an embargo period of one year after the last patient is recruited"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D007249", "term": "Inflammation"}], "ancestors": [{"id": "D010335", "term": "Pathologic Processes"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M10293", "name": "Inflammation", "asFound": "Inflammation", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069059", "term": "Atorvastatin"}], "ancestors": [{"id": "D000924", "term": "Anticholesteremic Agents"}, {"id": "D000960", "term": "Hypolipidemic Agents"}, {"id": "D000963", "term": "Antimetabolites"}, {"id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D057847", "term": "Lipid Regulating Agents"}, {"id": "D019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"id": "D004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M351", "name": "Atorvastatin", "asFound": "Addition", "relevance": "HIGH"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01755403", "orgStudyIdInfo": {"id": "CINEBENZ"}, "organization": {"fullName": "Barcelona Centre for International Health Research", "class": "OTHER"}, "briefTitle": "Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease", "officialTitle": "Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship.", "acronym": "CINEBENZ"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-12"}, "primaryCompletionDateStruct": {"date": "2013-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-12-19", "studyFirstSubmitQcDate": "2012-12-19", "studyFirstPostDateStruct": {"date": "2012-12-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-25", "lastUpdatePostDateStruct": {"date": "2015-05-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Barcelona Centre for International Health Research", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 52, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benznidazole", "type": "OTHER", "interventionNames": ["Drug: Benznidazole"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "armGroupLabels": ["Benznidazole"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Population pharmacokinetic parameters of Benznidazole", "description": "Population pharmacokinetic model development", "timeFrame": "2 months (treatment period)"}], "secondaryOutcomes": [{"measure": "Adverse reactions", "description": "Number of participants with adverse events. Severity of adverse events. Relationship between adverse event and drug concentration.", "timeFrame": "2 months (treatment period)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients with Chronic Chagas Disease diagnosed by 2 different and positive serological tests.\n* Patients with Chronic Chagas Disease who are going to start treatment with Benznidazole.\n* Any gender.\n* All the participants must agree to participate in the study and must sign the informed consent.\n\nExclusion Criteria:\n\n* Patients younger than 18.\n* Patients with previous hypersensitivity to Benznidazole.\n* Immunocompromised patients as AIDS, cancer, chemotherapy, longterm corticoids need, primary immunodeficiency, or any other.\n* Hepatic dysfunction\n* Renal dysfunction: serum creatinin higher than 3 mg/dl.\n* Pregnancy or lactation.\n* Low adhesion to treatment or check-up.\n* Impossibility of follow-up.\n* Severe adverse reaction to Benznidazole.\n* Any other situation that could be risky for the patient.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Joaquim Gasc\u00f3n, PhD", "affiliation": "Barcelona Centre for International Health Research (CRESIB)", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "International Health Department, Hospital Clinic, Barcelona", "city": "Barcelona", "state": "Catalu\u00f1a", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}]}, "referencesModule": {"references": [{"pmid": "29351667", "type": "DERIVED", "citation": "Aldasoro E, Posada E, Requena-Mendez A, Calvo-Cano A, Serret N, Casellas A, Sanz S, Soy D, Pinazo MJ, Gascon J. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. J Antimicrob Chemother. 2018 Apr 1;73(4):1060-1067. doi: 10.1093/jac/dkx516."}, {"pmid": "25824212", "type": "DERIVED", "citation": "Soy D, Aldasoro E, Guerrero L, Posada E, Serret N, Mejia T, Urbina JA, Gascon J. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother. 2015;59(6):3342-9. doi: 10.1128/AAC.05018-14. Epub 2015 Mar 30."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02606864", "orgStudyIdInfo": {"id": "16005"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients", "officialTitle": "Non-blinded, Randomized, Single Center, Single Dose, Cross-over Study to Assess the Effect of a High Calorie/High Fat Meal on the Pharmacokinetics of Four 30 mg Nifurtimox Tablets Taken Orally by Adult Male and Female Patients Suffering From Chronic Chagas' Disease"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-12"}, "primaryCompletionDateStruct": {"date": "2016-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-11-16", "studyFirstSubmitQcDate": "2015-11-16", "studyFirstPostDateStruct": {"date": "2015-11-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-11", "lastUpdatePostDateStruct": {"date": "2016-11-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 36, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BAYa2502 without food", "type": "EXPERIMENTAL", "description": "Oral intake of a single 120 mg nifurtimox dose under fasted conditions", "interventionNames": ["Drug: Nifurtimox (BAYa2502)"]}, {"label": "BAYa2502 with food", "type": "EXPERIMENTAL", "description": "Oral intake of a single 120 mg nifurtimox dose under fed conditions after ingestion of a high calorie and high fat breakfast", "interventionNames": ["Drug: Nifurtimox (BAYa2502)"]}], "interventions": [{"type": "DRUG", "name": "Nifurtimox (BAYa2502)", "description": "Oral Intake of 4 x 30 mg nifurtimox tablets", "armGroupLabels": ["BAYa2502 with food", "BAYa2502 without food"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Area under the drug-concentration vs. time curve of nifurtimox from time 0 to the last data point[AUC(0-tlast)]", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24 hours"}, {"measure": "Plasma concentration nifurtimox characterized by Cmax", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24 hours"}, {"measure": "Plasma concentration of nifurtimox characterized by tmax", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24 hours"}, {"measure": "Plasma concentration of nifurtimox characterized by AUC", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24 hours"}], "secondaryOutcomes": [{"measure": "Number of participants with adverse events as a measure of safety and tolerability", "timeFrame": "Up to 8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Study participants of reproductive potential must agree to utilize two reliable and acceptable methods of contraception simultaneously when sexually active. One of these methods must include a barrier method.\n\nSubjects who are not of reproductive potential include: vasectomized males or non-vasectomized males with documented azospermia prior to screening, as well as females who are surgically sterilized with bilateral tubal ligation or who have undergone hysterectomy. Women who are menopausal are also considered not of reproductive potential if there has been no menses \\> 12 months prior to screening and supported by a pre-screening follicle stimulating hormone (FSH) \\> 40 mIU/ml if available.\n\nExamples of reliable and acceptable methods of birth control include, but are not limited to: diaphragm with spermicide, condoms with spermicide or oral contraception with condom use in the male partner. This applies from the signing of the informed consent up until 12 weeks after the last dose of the study medication.\n\n* Male/female subject diagnosed with chronic Chagas' disease: Previous diagnosis of acute or chronic Chagas' disease by a health clinic prior to screening for the study. The diagnosis of chronic Chagas' disease may be made by clinical findings, supported by antibody titers if available. If there is a known history of acute disease, it is preferable to have documentation of parasites on the blood smear if available\n* Age: 18 to 45 years (inclusive) at the first screening visit\n* Body mass index (BMI): above/equal 18 and below/equal 29.9 kg / m\u00b2\n\nExclusion Criteria:\n\n* Incompletely cured pre-existing diseases (except chronic Chagas) for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal\n* Acute Chagas'disease (During the acute phase, the parasite on a blood smear may be seen under a microscope. Different antibodies are present, depending on the course of the disease)\n* Known hypersensitivity to the study drugs (active substances or excipients of the preparations)\n* Unstable or uncontrolled medical condition such as hypertension or diabetes, decompensated heart failure, gastrointestinal (GI) conditions that would interfere with the absorption of the study drug (e.g. GI ulceration, peptic ulceration, GI bleeding, gastroesophageal reflux, or other GI disease affecting gastroesophageal junction), conditions that could potentially have an impact on drug metabolism or elimination (renal, hepatic such as known hepatic or biliary abnormalities), or any clinically relevant active infections in the opinion of the investigator within 4 weeks before the screening visit, e.g. clinically relevant history or presence of significant respiratory (e.g. interstitial lung disease), hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, metabolic (e.g. diabetes), and dermatological or connective tissue disease\n* Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them within 4 weeks before the first study drug administration, e.g. an investigational drug, any drug altering GI motility and/or gastric pH (e.g. antacids, anticholinergic, para-sympatholytics), any drug known to induce liver enzymes (e.g. dexamethasone, barbiturates, St. John's Wort \\[hypericum perforatum\\]), any drug known to inhibit liver enzymes (e.g. ketoconazole, macrolides)\n* Clinically relevant findings in the ECG such as a second- or third-degree atrioventricular block, prolongation of the QRS complex over 120 msec or of the QT-interval over 450 msec using Bazett's Formula (QTcB) or Fridericia's Formula (QTcF). (clinically stable subjects with Chagas'- related heart disease and pacemaker in place for \\>1 year and evaluated by a cardiologist \u22646 months before the first dose of study drug will not be excluded.)\n* Systolic blood pressure below 100 or above 140 mmHg (after resting in supine position for a minimum of 3 min)\n* Diastolic blood pressure below 50 or above 90 mmHg (after resting in supine position for a minimum of 3 min)\n* Pulse rate below 45 or above 95 beats / min (after resting in supine position for a minimum of 3 min)\n* Findings that would exclude the subject in the physician's judgment e.g. enlarged liver, irregular heartbeat, undiagnosed acute illness, melanoma", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Buenos Aires", "state": "Ciudad Auton. de Buenos Aires", "zip": "C1425BAB", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D009547", "term": "Nifurtimox"}], "ancestors": [{"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M12486", "name": "Nifurtimox", "asFound": "DSM-IV", "relevance": "HIGH"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03981523", "orgStudyIdInfo": {"id": "743474"}, "secondaryIdInfos": [{"id": "U01AI129783", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U01AI129783"}], "organization": {"fullName": "University of Texas, El Paso", "class": "OTHER"}, "briefTitle": "New Therapies and Biomarkers for Chagas Infection", "officialTitle": "New Chemotherapy Regimens and Biomarkers for Chagas Disease", "acronym": "TESEO"}, "statusModule": {"statusVerifiedDate": "2024-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-12-18", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-05-29", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-05-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-04-08", "studyFirstSubmitQcDate": "2019-06-06", "studyFirstPostDateStruct": {"date": "2019-06-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-07-16", "lastUpdatePostDateStruct": {"date": "2024-07-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Igor C Almeida, D.Sc.", "investigatorTitle": "Professor", "investigatorAffiliation": "University of Texas, El Paso"}, "leadSponsor": {"name": "University of Texas, El Paso", "class": "OTHER"}, "collaborators": [{"name": "Fundaci\u00f3n Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES)", "class": "UNKNOWN"}, {"name": "Barcelona Institute for Global Health", "class": "OTHER"}, {"name": "Institute of Parasitology and Biomedicine Lopez Neyra", "class": "UNKNOWN"}, {"name": "U.S. Food and Drug Administration (FDA)", "class": "UNKNOWN"}, {"name": "Drugs for Neglected Diseases", "class": "OTHER"}, {"name": "Mundo Sano Foundation", "class": "UNKNOWN"}, {"name": "National Institute of Allergy and Infectious Diseases (NIAID)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "conditionsModule": {"conditions": ["Trypanosoma Cruzi Infection", "Chagas Disease"], "keywords": ["Chagas disease", "Trypanosoma cruzi", "Chemotherapy", "Benznidazole", "Nifurtimox", "Biomarkers", "Bolivia", "Antiparasitic Agents", "Parasitic Diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Three of 6 parallel groups will receive one of three different oral benznidazole (BZN) dosing regimens and the other three will receive one of the three different nifurtimox (NFX) regimens.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 450, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BZN-60", "type": "EXPERIMENTAL", "description": "150 mg twice a day for 60 days.", "interventionNames": ["Drug: Benznidazole"]}, {"label": "BZN-30", "type": "EXPERIMENTAL", "description": "150 mg once a day for 30 days.", "interventionNames": ["Drug: Benznidazole"]}, {"label": "BZN-90", "type": "EXPERIMENTAL", "description": "150 mg once a day for 90 days.", "interventionNames": ["Drug: Benznidazole"]}, {"label": "NFX-60", "type": "EXPERIMENTAL", "description": "240 mg twice a day for 60 days.", "interventionNames": ["Drug: Nifurtimox"]}, {"label": "NFX-30", "type": "EXPERIMENTAL", "description": "240 mg twice a day for 30 days.", "interventionNames": ["Drug: Nifurtimox"]}, {"label": "NFX-90", "type": "EXPERIMENTAL", "description": "240 mg once a day for 90 days.", "interventionNames": ["Drug: Nifurtimox"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "description": "50 mg and 100 mg tablet taken orally", "armGroupLabels": ["BZN-30", "BZN-60", "BZN-90"], "otherNames": ["P01CA02", "Abarax", "Radanil", "Rochagan"]}, {"type": "DRUG", "name": "Nifurtimox", "description": "120 mg tablet taken orally", "armGroupLabels": ["NFX-30", "NFX-60", "NFX-90"], "otherNames": ["Lampit", "P01CC01", "QP51AC01"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Sustained Parasitological Clearance by qPCR at End of Follow-Up (36 months)", "description": "The primary efficacy endpoint or measure is a binary 'cured' (success), 'not-cured' (failure) variable based on a total of eight qPCR timepoints from end-of-treatment (EOT) up to 36 months of follow-up. Each of the timepoints includes a total of three sequential qPCR examinations on blood samples collected during one visit. Therefore, for a patient to be considered \"cured\", a total of 24 negative qPCR results should be documented.\n\nBlood samples to be collected at EOT (30, 60, or 90 days), and at 4, 6, 12, 18, 24, 30 and 36 months of follow-up (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months).", "timeFrame": "up to 36 months"}], "secondaryOutcomes": [{"measure": "Changes Over Time in the blood parasitic load by qPCR", "description": "Evaluate changes over time in blood parasitic load as measured by qPCR. The unit for the qPCR is parasite equivalents/milliliter of blood (Par. Eq./mL). The limit of detection (LOD) and limit of quantification (LOQ) for the qPCR assay is 0.69 and 1.5 Par. Eq./mL blood, respectively.\n\nKaplan-Meier survival curves will be drawn to depict the time-to-reappearance of blood parasitic load for patients who have cleared blood parasitic load at EOT (as such this is a time-to-relapse for 'success' patients) across treatment groups. A discrete-time survival model will be used to analyze this event time data.\n\nChange in parasite load over time assessed at days 14-17, 59-62, and EOT (30, 60, or 90 days), according to the treatment arm, and months 4, 6, 12, 18, 24, 30, and 36 of follow-up (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months), as measured by qPCR.", "timeFrame": "Days 14-17, 59-62; EOT-30, EOT-60, and EOT-90; and months 4, 6, 12, 18, 24, 30, and 36 during follow-up (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months)."}, {"measure": "Changes Over Time in the Conventional Serology using parasite antigenic mixture", "description": "Evaluate changes over time in serological titers and incidence of negative seroconversion through conventional serology. Chagas disease serology commercial kit using a parasite antigenic mixture (lysate) will be used to perform this analysis. Serum samples from all timepoints in the study for each patient will be analyzed in the same ELISA plate to avoid bias due to interassay variations.\n\nGeneralized linear mixed-effects models will be used to evaluate the conventional serological response over time. The dependent variable in both models will be a binary conventional serology parameter. The treatment arm will be included in the model as a fixed effect. The significance of the treatment covariate will be tested at the 0.05 two-sided significance level with Likelihood Ratio Test.", "timeFrame": "Day -28; EOT-30, EOT-60, and EOT-90; and months 4, 6, 12, 18, 24, 30, and 36 (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months) during follow-up."}, {"measure": "Changes Over Time in the Conventional Serology using recombinant parasite antigens", "description": "Evaluate changes over time in serological titers and incidence of negative seroconversion through conventional serology. Chagas disease serology commercial kit using recombinant parasite antigens will be used to perform this analysis. Serum samples from all timepoints in the study for each patient will be analyzed in the same ELISA plate to avoid bias due to interassay variations.\n\nGeneralized linear mixed-effects models will be used to evaluate the conventional serological response over time. The dependent variable in both models will be a binary conventional serology parameter. The treatment arm will be included in the model as a fixed effect. The significance of the treatment covariate will be tested at the 0.05 two-sided significance level with Likelihood Ratio Test.", "timeFrame": "Day -28; EOT-30, EOT-60, and EOT-90; and months 4, 6, 12, 18, 24, 30, and 36 (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months) during follow-up."}, {"measure": "Changes Over Time in the Non-Conventional Serology Biomarker \"Lytic Anti-\u03b1-Gal Antibodies\"", "description": "Evaluate changes over time in the non-conventional serology biomarker (BMK) \"Lytic Anti-\u03b1-Gal Antibodies\" and incidence of negative seroconversion for it, as measured by chemiluminescent (CL)-ELISA using T. cruzi tGPI-mucins as antigens. CL-ELISA unit is the Titer (T). T is the ratio of the relative luminescence units (RLU) of the tested serum to the cutoff value (CV). The CV is calculated by defining the upper prediction limit (as standard deviation, SD), multiplied by a factor according to the number of negative controls (NC) and a confidence interval of 99.5%. For each test plate in which six NC are included, the CV is defined as the NC mean plus 4.355 times the SD. A serum sample is positive when T = or \\>1.000; negative when T = or \\< 0.900; and inconclusive when T \\> 0.900, \\< 1.000.\n\nGeneralized linear mixed-effects models (GLMM) will define how this BMK affects binary outcomes of parasite clearance. The BMK variable will be included in the model, with repeated measures.", "timeFrame": "Days 0, 14-17, 59-62; EOT-30, EOT-60, and EOT-90; and at months 4, 6, 12, 18, 24, 30, and 36 during follow-up (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months)."}, {"measure": "Changes Over Time in the Non-Conventional Serology Biomarker \"Anti-KMP11 Antibodies\"", "description": "This BMK is measured by Enzyme-Linked Immunosorbent Assay (ELISA), whose unit is Optical Density (OD) at 492 nm. Cutoff: A negative result will be considered when OD values = or \\<0.200, and positive when OD values \\>0.300, at 1/200 serum dilution; indeterminate results will be OD values comprised between 0.200 and 0.300.\n\nTherapeutic efficacy will imply a continuous and substantial drop in the reactivity after treatment. A substantial decrease has to be at least 40% compared with the reactivity at T0 (before treatment). A slight increase (= or \\<20%) in the reactivity against the BMK shortly after treatment versus OD at T0 will be allowed.\n\nGeneralized linear mixed-effects models (GLMM) will define how this BMK affects binary outcomes of parasite clearance. The BMK variable will be included in the model, with repeated measures.", "timeFrame": "Days 0, 14-17, 59-62; EOT-30, EOT-60, and EOT-90; and at months 4, 6, 12, 18, 24, 30, and 36 during follow-up (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months)."}, {"measure": "Changes in the Non-Conventional Serology Biomarker \"Anti-HSP70 Antibodies\"", "description": "This BMK is measured by Enzyme-Linked Immunosorbent Assay (ELISA), whose unit is Optical Density (OD) at 492 nm. Cutoff: A negative result will be considered when OD values = or \\<0.300, and positive when OD values \\>0.450, at 1/200 serum dilution; indeterminate results will be OD values comprised between 0.300 and 0.450.\n\nTherapeutic efficacy will imply a continuous and substantial drop in the reactivity after treatment. A substantial decrease has to be at least 30% compared with the reactivity at T0 (before treatment). A slight increase (= or \\< 20%) in the reactivity against the BMK shortly after treatment versus OD at T0 will be allowed.", "timeFrame": "Days 0, 14-17, 59-62; EOT-30, EOT-60, and EOT-90; and at months 4, 6, 12, 18, 24, 30, and 36 during follow-up (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months)."}, {"measure": "Changes Over Time in the Non-Conventional Serology Biomarker \"Anti-PFR2 Antibodies\"", "description": "This BMK is measured by Enzyme-Linked Immunosorbent Assay (ELISA), whose unit is Optical Density (OD) at 492 nm. Cutoff: A negative result will be considered when OD values = or \\<0.250 at 1/400 dilution, and positive when OD values \\>0.350, at 1/400 serum dilution; indeterminate results will be OD values comprised between 0.250 and 0.350.\n\nTherapeutic efficacy will imply a continuous and substantial drop in the reactivity after treatment. A substantial decrease has to be at least 40% compared with the reactivity at T0 (before treatment). A slight increase (= or \\<20%) in the reactivity against the BMK shortly after treatment versus OD at T0 will be allowed.\n\nGeneralized linear mixed-effects models (GLMM) will define how this BMK affects binary outcomes of parasite clearance. The BMK variable will be included in the model, with repeated measures.", "timeFrame": "Days 0, 14-17, 59-62; EOT-30, EOT-60, and EOT-90; and at months 4, 6, 12, 18, 24, 30, and 36 during follow-up (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months)."}, {"measure": "Changes Over Time in the Non-Conventional Serology Biomarker \"Anti-Peptide 3973 Antibodies\"", "description": "This BMK is measured by Enzyme-Linked Immunosorbent Assay (ELISA), whose unit is Optical Density (OD) at 492 nm. Cutoff: A negative result will be considered when OD values = or \\<0.250, and positive when OD values \\>0.350, at 1/400 serum dilution; indeterminate results will be OD values comprised between 0.250 and 0.350.\n\nTherapeutic efficacy will imply a continuous and substantial drop in the reactivity after treatment. A substantial decrease has to be at least 40% compared with the reactivity at T0 (before treatment). A slight increase (= or \\<20%) in the reactivity against the BMK shortly after treatment versus OD at T0 will be allowed.\n\nGeneralized linear mixed-effects models (GLMM) will define how this BMK affects binary outcomes of parasite clearance. The BMK variable will be included in the model, with repeated measures.", "timeFrame": "Days 0, 14-17, 59-62; EOT-30, EOT-600, and EOT-90; and at months 4, 6, 12, 18, 24, 30, and 36 during follow-up (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months)."}, {"measure": "Changes Over Time in the Non-Conventional Serology Biomarker \"Trypomastigote Excreted/Secreted Antigens (TESA)\"", "description": "Evaluate changes over time in the non-conventional serology biomarker (BMK) \"Trypomastigote Excreted/Secreted Antigens (TESA)\" and incidence of negative seroconversion for it, as measured by the aptamer assay.\n\nThe unit of the aptamer assay is relative fluorescence unit (RFU). A Signal to Cutoff (S/CO) ratio is calculated for each clinical specimen by dividing the RFU value of the test sample by the cutoff (CO). The CO is the highest RFU value obtained from the endemic control specimens included in each run. The S/CO of a positive control included in the same run must meet pre-established acceptance criteria to be valid. A specimen with an S/CO \\> 1.0 is interpreted as positive for the presence of the BMK (=infected). A specimen with an S/CO \\< 1 is interpreted as negative (=non-infected).\n\nGeneralized linear mixed-effects models (GLMM) will define how this BMK affects binary outcomes of parasite clearance. The BMK variable will be included in the model, with repeated measures.", "timeFrame": "Days 0, 14-17, 59-62; EOT-30, EOT-60, and EOT-90; and at months 4, 6, 12, 18, 24, 30, and 36 during follow-up (with a window period of +/- 7 days from 4 to 12 months and +/- 14 days from 18 to 36 months)."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults, 18-50 years.\n2. Weight: 88-198 pounds (40-90 Kg).\n3. Individuals diagnosed as being infected with T. cruzi by conventional serology (two positive tests with different antigens) with at least one positive qualitative RT-PCR assay out of three during the screening.\n4. Patient classified as being in the indeterminate form (without clinical manifestations) or early cardiac form (Kushnir 1) of chronic Chagas disease.\n5. Signed informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Clinical signs of dilated cardiomyopathy (dyspnea, legs' edema, syncope, pulmonary crackles). Patients with an EKG showing the following characteristics: sinus tachycardia or atrial fibrillation, ventricular arrhythmias, left atrial enlargement, left bundle-branch block (LBBB) accompanied by right axis deviation (RAD), and/or patients with Calculation of Fridericia's corrected QT interval (QTcF) \\> 450ms, a formula for calculating the QT interval on an electrocardiogram (ECG).\n2. History of Chagas disease treatment with BZN or NFX or any triazole drug(s) in the last five years.\n3. Clinical signs and/or symptoms of digestive form of Chagas disease, which is characterized by the presence of two or more of the following criteria \\*:\n\n   1. Excessive exertion in at least 25% of bowel movements\n   2. Hard stools in at least 25% of stools (type 1-2 of Bristol)\n   3. Feeling of incomplete evacuation in at least 25% of bowel movements\n   4. Feeling of obstruction or anorectal block in at least 25% of bowel movements\n   5. Manual maneuvers to facilitate defecation in at least 25% of bowel movements\n   6. Less than 3 complete spontaneous stools per week\n\n      * Criteria must be met for at least the last three months and symptoms must have been started for at least six months before diagnosis.\n4. Hypersensitivity to the active substances (BZN or NFX) or to the excipient.\n5. Previous diagnosis of porphyria.\n6. Any other acute or chronic health conditions that in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the study drug.\n7. Formal contraindication to BZN or NFX.\n8. Any concomitant or anticipated use of drugs that are contraindicated with the use of BZN or NFX.\n9. Individuals currently known to abuse alcohol and/or drugs. Furthermore, if throughout the course of the study the team becomes aware that a participant is using drugs/alcohol that participant will be excluded from the treatment but will continue with the follow-up visits. The study manual outlines how abuse and dependence will be measured for this study.\n10. Pregnancy. Females of childbearing potential will be required to complete a pregnancy test prior to enrollment and throughout the course of treatment.\n11. Women in reproductive age must have a negative serum pregnancy test at screening, must not be breastfeeding, and consistently use and/or have partner consistently use a highly effective contraceptive method during the entire treatment phase of the trial.\n12. Transaminases (alanine aminotransferase-ALT and aspartate aminotransferase- AST). AST must be within the normal range, within an acceptable margin of 25% above the upper limit of normality for both, according to the insert of the biochemical kit being used in this study.\n13. Creatinine must be within an acceptable range, within an acceptable margin of 10% above the upper limit of normality, according to the insert of the biochemical kit being used. The normal ranges of transaminases (ALT and AST) and creatinine are defined by the inserts of the commercial biochemical kits selected to be used in the present study. All treatment centers (Chagas Platforms in Cochabamba, Sucre, and Tarija) are going to use the same biochemical kits. The participating clinical laboratories at the Platforms (in Cochabamba, Sucre, and Tarija) will use the Common Terminology Criteria for Adverse Events (CTCAE, v.5.0; ttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf).\n14. Total bilirubin must be within the normal range, within an acceptable margin of 15% above the upper limit of normality for both sexes, according to the insert of the biochemical kit being used in this study.\n15. For other standard exclusion criteria, a detailed explanation for each criterion is provided in the Manual of Operations and Procedures (MOP).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Igor C Almeida, D.Sc.", "affiliation": "The University of Texas at El Paso (UTEP)", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Faustino Torrico, M.D., Ph.D", "affiliation": "Fundaci\u00f3n Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES)", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Joaquim Gascon, M.D., Ph.D", "affiliation": "Barcelona Institute for Global Health", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Platform for the Comprehensive Care of Patients with Chagas Disease", "city": "Cochabamba", "state": "Cercado", "country": "Bolivia", "geoPoint": {"lat": -17.3895, "lon": -66.1568}}, {"facility": "Platform for the Comprehensive Care of Patients with Chagas Disease", "city": "Tarija", "state": "Cercado", "country": "Bolivia", "geoPoint": {"lat": -21.53549, "lon": -64.72956}}, {"facility": "Platform for the Comprehensive Care of Patients with Chagas Disease", "city": "Sucre", "country": "Bolivia", "geoPoint": {"lat": -19.03332, "lon": -65.26274}}]}, "referencesModule": {"references": [{"pmid": "18000201", "type": "BACKGROUND", "citation": "Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA. 2007 Nov 14;298(18):2171-81. doi: 10.1001/jama.298.18.2171."}, {"pmid": "24716790", "type": "BACKGROUND", "citation": "Bustamante JM, Tarleton RL. Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol. 2014 May;7(3):317-25. doi: 10.1586/17512433.2014.909282. Epub 2014 Apr 9."}, {"pmid": "20398860", "type": "BACKGROUND", "citation": "Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 2010 May;9(5):533-42. doi: 10.1016/S1474-4422(10)70042-9."}, {"pmid": "24579882", "type": "BACKGROUND", "citation": "Gascon J, Vilasanjuan R, Lucas A. The need for global collaboration to tackle hidden public health crisis of Chagas disease. Expert Rev Anti Infect Ther. 2014 Apr;12(4):393-5. doi: 10.1586/14787210.2014.896194. Epub 2014 Mar 3."}, {"pmid": "20932171", "type": "BACKGROUND", "citation": "Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis. 2010 Nov 15;51(10):e69-75. doi: 10.1086/656917. Epub 2010 Oct 8."}, {"pmid": "10194457", "type": "BACKGROUND", "citation": "Kierszenbaum F. Chagas' disease and the autoimmunity hypothesis. Clin Microbiol Rev. 1999 Apr;12(2):210-23. doi: 10.1128/CMR.12.2.210."}, {"pmid": "23395248", "type": "BACKGROUND", "citation": "Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013 Apr;13(4):342-8. doi: 10.1016/S1473-3099(13)70002-1. Epub 2013 Feb 8."}, {"pmid": "24621252", "type": "BACKGROUND", "citation": "Pinazo MJ, Thomas MC, Bua J, Perrone A, Schijman AG, Viotti RJ, Ramsey JM, Ribeiro I, Sosa-Estani S, Lopez MC, Gascon J. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther. 2014 Apr;12(4):479-96. doi: 10.1586/14787210.2014.899150."}, {"pmid": "23583863", "type": "BACKGROUND", "citation": "Perez-Molina JA, Sojo-Dorado J, Norman F, Monge-Maillo B, Diaz-Menendez M, Albajar-Vinas P, Lopez-Velez R. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Trop. 2013 Aug;127(2):101-4. doi: 10.1016/j.actatropica.2013.04.003. Epub 2013 Apr 11."}, {"pmid": "20399979", "type": "BACKGROUND", "citation": "Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010 Apr 17;375(9723):1388-402. doi: 10.1016/S0140-6736(10)60061-X."}, {"pmid": "21907431", "type": "BACKGROUND", "citation": "Regueiro A, Garcia-Alvarez A, Sitges M, Ortiz-Perez JT, De Caralt MT, Pinazo MJ, Posada E, Heras M, Gascon J, Sanz G. Myocardial involvement in Chagas disease: insights from cardiac magnetic resonance. Int J Cardiol. 2013 Apr 30;165(1):107-12. doi: 10.1016/j.ijcard.2011.07.089. Epub 2011 Sep 9."}, {"pmid": "25824212", "type": "BACKGROUND", "citation": "Soy D, Aldasoro E, Guerrero L, Posada E, Serret N, Mejia T, Urbina JA, Gascon J. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother. 2015;59(6):3342-9. doi: 10.1128/AAC.05018-14. Epub 2015 Mar 30."}, {"pmid": "11334941", "type": "BACKGROUND", "citation": "Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol. 2001 May 1;31(5-6):550-4. doi: 10.1016/s0020-7519(01)00158-8."}, {"pmid": "18162039", "type": "BACKGROUND", "citation": "Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE. The challenges of Chagas Disease-- grim outlook or glimmer of hope. PLoS Med. 2007 Dec;4(12):e332. doi: 10.1371/journal.pmed.0040332."}, {"pmid": "14580960", "type": "BACKGROUND", "citation": "Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 2003 Nov;19(11):495-501. doi: 10.1016/j.pt.2003.09.001. No abstract available."}, {"pmid": "19254164", "type": "BACKGROUND", "citation": "Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther. 2009 Mar;7(2):157-63. doi: 10.1586/14787210.7.2.157."}, {"pmid": "24247135", "type": "BACKGROUND", "citation": "Viotti R, Alarcon de Noya B, Araujo-Jorge T, Grijalva MJ, Guhl F, Lopez MC, Ramsey JM, Ribeiro I, Schijman AG, Sosa-Estani S, Torrico F, Gascon J; Latin American Network for Chagas Disease, NHEPACHA. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother. 2014;58(2):635-9. doi: 10.1128/AAC.01662-13. Epub 2013 Nov 18."}, {"pmid": "10395865", "type": "BACKGROUND", "citation": "Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis. 1999 Aug;180(2):480-6. doi: 10.1086/314889."}, {"type": "BACKGROUND", "citation": "Schelldorfer, J., Meier, L., and Buhlmann, P. (2014). GLMMLasso: An algorithm for high-dimensional generalized linear mixed models using l1-penalization. J Comput Graph Stat 23, 460-477."}, {"pmid": "34972765", "type": "DERIVED", "citation": "Alonso-Vega C, Urbina JA, Sanz S, Pinazo MJ, Pinto JJ, Gonzalez VR, Rojas G, Ortiz L, Garcia W, Lozano D, Soy D, Maldonado RA, Nagarkatti R, Debrabant A, Schijman A, Thomas MC, Lopez MC, Michael K, Ribeiro I, Gascon J, Torrico F, Almeida IC. New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia. BMJ Open. 2021 Dec 31;11(12):e052897. doi: 10.1136/bmjopen-2021-052897."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2021-06-09", "uploadDate": "2021-06-28T12:37", "filename": "ICF_000.pdf", "size": 277348}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D007239", "term": "Infections"}, {"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M10283", "name": "Infections", "asFound": "Infection", "relevance": "HIGH"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}, {"id": "D009547", "term": "Nifurtimox"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M12486", "name": "Nifurtimox", "asFound": "DSM-IV", "relevance": "HIGH"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01678599", "orgStudyIdInfo": {"id": "MSF/DNDi-CD-PCR-01"}, "organization": {"fullName": "Drugs for Neglected Diseases", "class": "OTHER"}, "briefTitle": "Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease", "officialTitle": "Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia", "acronym": "PCR"}, "statusModule": {"statusVerifiedDate": "2018-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-04"}, "primaryCompletionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-03-01", "studyFirstSubmitQcDate": "2012-08-30", "studyFirstPostDateStruct": {"date": "2012-09-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-06-20", "lastUpdatePostDateStruct": {"date": "2018-06-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Drugs for Neglected Diseases", "class": "OTHER"}, "collaborators": [{"name": "Medecins Sans Frontieres, Netherlands", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Chagas Disease", "PCR", "diagnosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 220, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benznidazol", "type": "OTHER", "description": "This is a single arm, open label study; therefore, all subjects enrolled will receive benznidazol.", "interventionNames": ["Drug: Benznidazole"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "description": "All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients \\> 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.", "armGroupLabels": ["Benznidazol"], "otherNames": ["LAFEPE Benznidazol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The primary endpoints are: - A positive or negative PCR at baseline (BL) among serology positive patients.", "timeFrame": "Bloods will be at baseline and EOT (last day of treatment +10 + 5 days), 6 months and 12 months follow-up visits."}, {"measure": "- Identification of the optimal relationship between sensitivity and feasibility at baseline.", "description": "For BL and EOT visits, blood samples will be as follows: one initial blood of 10 mL (Sample 1), followed by 1 sample of 5mL collected immediately following (Sample 2); plus one blood sample of 10mL collected 1 week later (Sample 3).\n\nOnce the optimal strategy has been defined for EOT visit (see section 10.7), this will be the strategy of blood collection to be used at the 6 and 12 months follow-up visits", "timeFrame": "Bloods will be at baseline and EOT (last day of treatment +10 + 5 days), 6 months and 12 months follow-up visits."}], "secondaryOutcomes": [{"measure": "- Identification of the optimal relationship between sensitivity and Identification of the optimal relationship between sensitivity and feasibility at End Of Treatment (EOT)", "timeFrame": "Bloods will be at baseline and EOT (last day of treatment +10 + 5 days), 6 months and 12 months follow-up visits."}, {"measure": "- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at EOT - to be estimated using 1) the current sampling schedule (CS), the most sensitive one and the optimal one.", "timeFrame": "Bloods will be at baseline and EOT (last day of treatment +10 + 5 days), 6 months and 12 months follow-up visits."}, {"measure": "- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at 6 and 12 months follow-up - to be estimated using 1) the current sampling schedule (CS) and the optimal one (based on EOT data).", "timeFrame": "Bloods will be at baseline and EOT (last day of treatment +10 + 5 days), 6 months and 12 months follow-up visits."}, {"measure": "- Relative reduction [(parasite count at baseline - parasite count at EOT, 6 and 12 months)/parasite count at baseline] of parasitemia - to be evaluated through parasite load at EOT, 6 and 12 months through quantitative PCR.", "timeFrame": "Bloods will be at baseline and EOT (last day of treatment +10 + 5 days), 6 months and 12 months follow-up visits."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age between \\> 18 - 60 years\n* Diagnosis of T. cruzi infection by Chagas serology. Two out of three serological tests must be positive \\[conventional ELISA, recombinant ELISA, or HAI)\n* Written informed consent form\n\nExclusion Criteria:\n\n* Women in reproductive age who have a positive pregnancy test at screening, or who are breastfeeding Note: Women in reproductive age must accept to use a contraceptive method during the entire treatment phase of the trial\n* Current presentation of serious health condition such as: active pulmonary tuberculosis and clinical signs of liver or renal failure.\n* Chagasic cardiomyopathy stage II, III and IV (according to the NYHA classification)\n* Subjects requiring pacemaker implantation or other serious cardiac conduction defects\n* History of CD treatment with benznidazole or nifurtimox at any time in the past\n* Inability to comply with follow-up and/or not having a permanent address\n* History of alcohol abuse or any other drug addiction", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Lourdes Loza, Biochemist", "affiliation": "Medicin Sans Fronti\u00e8rs", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Medicin Sans Fronti\u00e8rs (MSF)", "city": "Aiquile", "country": "Bolivia", "geoPoint": {"lat": -18.20408, "lon": -65.18068}}]}, "referencesModule": {"references": [{"pmid": "19381287", "type": "BACKGROUND", "citation": "Duffy T, Bisio M, Altcheh J, Burgos JM, Diez M, Levin MJ, Favaloro RR, Freilij H, Schijman AG. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis. 2009;3(4):e419. doi: 10.1371/journal.pntd.0000419. Epub 2009 Apr 21."}, {"pmid": "30509941", "type": "DERIVED", "citation": "Parrado R, Ramirez JC, de la Barra A, Alonso-Vega C, Juiz N, Ortiz L, Illanes D, Torrico F, Gascon J, Alves F, Flevaud L, Garcia L, Schijman AG, Ribeiro I. Usefulness of Serial Blood Sampling and PCR Replicates for Treatment Monitoring of Patients with Chronic Chagas Disease. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01191-18. doi: 10.1128/AAC.01191-18. Print 2019 Feb."}], "seeAlsoLinks": [{"label": "Drugs for Neglected Diseases initiative", "url": "http://dndi.org"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01927224", "orgStudyIdInfo": {"id": "16004"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients", "officialTitle": "Open Label, Randomized, Single Dose Cross-over Study to Assess Bioequivalence Between Single 120 mg Nifurtimox Tablet and Four 30 mg Nifurtimox Tablets Administered Orally, Following High Calorie/High Fat Meal to Adult Male and Female Patients Suffering From Chronic Chagas' Disease and to Determine the Pharmacokinetics of Nifurtimox Tablets Administered Orally, in a Form of Aqueous Slurry"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-11"}, "primaryCompletionDateStruct": {"date": "2014-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-08-20", "studyFirstSubmitQcDate": "2013-08-20", "studyFirstPostDateStruct": {"date": "2013-08-22", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-10-14", "lastUpdatePostDateStruct": {"date": "2015-10-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 37, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Nifurtimox (Group 1)", "type": "EXPERIMENTAL", "description": "Descriptive pharmacokinetic group", "interventionNames": ["Drug: Nifurtimox (BAYa2502) (4 x 30 mg tablet)", "Drug: Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)"]}, {"label": "Nifurtimox (Group 2)", "type": "EXPERIMENTAL", "description": "The assessment of bioequivalence of the two formulation (30mg vs.120mg)", "interventionNames": ["Drug: Nifurtimox (BAYa2502) (4 x 30 mg tablet)", "Drug: Nifurtimox (BAYa2502) (120 mg tablet)"]}], "interventions": [{"type": "DRUG", "name": "Nifurtimox (BAYa2502) (4 x 30 mg tablet)", "description": "120 mg single dose as four 30 mg tablets after a high fat, high calorie meal", "armGroupLabels": ["Nifurtimox (Group 1)", "Nifurtimox (Group 2)"]}, {"type": "DRUG", "name": "Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)", "description": "120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal", "armGroupLabels": ["Nifurtimox (Group 1)"]}, {"type": "DRUG", "name": "Nifurtimox (BAYa2502) (120 mg tablet)", "description": "120 mg single dose as one 120 mg tablet after a high fat, high calorie meal", "armGroupLabels": ["Nifurtimox (Group 2)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Area under the drug-concentration vs. time curve of nifurtimox from time 0 to the last data point [AUC(0-tn)]", "timeFrame": "0-24 hours"}, {"measure": "Maximum drug concentration of nifurtimox in plasma (Cmax)", "timeFrame": "Up to 24 hours"}], "secondaryOutcomes": [{"measure": "Number of participants with adverse events as a measure of safety and tolerability", "timeFrame": "Up to 8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Upon consent, women of childbearing potential must use 2 forms of highly effective contraception for the duration of the study and for 12 weeks after the last drug administration. The definition of highly effective contraception will be left at the discretion of the investigator and will be in line with ICH Topic M 3 (R2): Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals\n* Male subjects who are sterile, not sexually active or agree to use 2 forms of highly effective contraception during the study and for 12 weeks after receiving the study drug. The definition of highly effective contraception will be left at the discretion of the investigator and will be in line with ICH ICH Topic M 3 (R2): Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals\n* Male/female subject diagnosed with chronic Chagas' disease: Previous diagnosis of acute or chronic Chagas' disease by a health clinic prior to screening for the study. The diagnosis of chronic Chagas' disease may be made by clinical findings, supported by antibody titers if available. If there is a known history of acute disease, it is preferable to have documentation of parasites on the blood smear if available\n* Age: 18 to 45 years (inclusive) at the first screening visit\n* Body mass index (BMI): above/equal 18 and below/equal 29.9 kg / m\u00b2\n\nExclusion Criteria:\n\n* Incompletely cured pre-existing diseases (except chronic Chagas) for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal\n* Acute Chagas'disease (During the acute phase, the parasite on a blood smear may be seen under a microscope. Different antibodies are present, depending on the course of the disease)\n* Known hypersensitivity to the study drugs (active substances or excipients of the preparations)\n* Unstable or uncontrolled medical condition such as hypertension or diabetes; decompensated heart failure, gastrointestinal (GI) conditions that would interfere with the absorption of the study drug (e.g. GI ulceration, peptic ulceration, GI bleeding, gastroesophageal reflux, or other GI disease affecting gastroesophageal junction), conditions that could potentially have an impact on drug metabolism ar elimination (renal, hepatic such as known hepatic or biliary abnormalities), or any clinically relevant active infections in the opinion of the investigator within 4 weeks before the screening visit e.g. clinically relevant history or presence of significant respiratory (e.g., interstitial lung disease), hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, metabolic (e.g., diabetes), and dermatological or connective tissue disease\n* Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them within 4 weeks before the first study drug administration, e.g. an investigational drug, any drug altering gastrointestinal motility and /or gastric pH (e.g. antacids, anticholinergic, para-sympatholytics), any drug known to induce liver enzymes (e.g. dexamethasone, barbiturates, St. John's Wort \\[hypericum perforatum\\]), any drug known to inhibit liver enzymes (e.g. ketoconazole, macrolides)\n* Clinically relevant findings in the electrocardiogram (ECG) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QTc-interval over 450 msec\n* Systolic blood pressure below 100 or above 140 mmHg (after at least 15 min supine)\n* Diastolic blood pressure below 50 or above 90 mmHg (after at least 15 min supine)\n* Heart rate below 45 or above 95 beats / min (after at least 15 min supine)\n* Findings that would exclude the subject in the physician's judgment e.g. enlarged liver, irregular heartbeat, undiagnosed acute illness, melanoma", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Buenos Aires", "state": "Ciudad Auton. de Buenos Aires", "zip": "C1425BAB", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D009547", "term": "Nifurtimox"}], "ancestors": [{"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M12486", "name": "Nifurtimox", "asFound": "DSM-IV", "relevance": "HIGH"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02386358", "orgStudyIdInfo": {"id": "TRAENA"}, "organization": {"fullName": "Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben", "class": "OTHER_GOV"}, "briefTitle": "Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial", "officialTitle": "Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial", "acronym": "TRAENA"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1999-03"}, "primaryCompletionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-01-19", "studyFirstSubmitQcDate": "2015-03-05", "studyFirstPostDateStruct": {"date": "2015-03-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-03-05", "lastUpdatePostDateStruct": {"date": "2015-03-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Adelina Rosa Riarte", "investigatorTitle": "Adelina Rosa Riarte MD", "investigatorAffiliation": "Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben"}, "leadSponsor": {"name": "Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben", "class": "OTHER_GOV"}, "collaborators": [{"name": "National Council of Scientific and Technical Research, Argentina", "class": "OTHER_GOV"}, {"name": "Pan American Health Organization", "class": "OTHER"}, {"name": "Becas Carrillo O\u00f1ativia, Ministerio de Salud, Argentina", "class": "UNKNOWN"}, {"name": "Drugs for Neglected Diseases", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Chronic Chagas Disease", "Randomized Clinical Trial double blind", "Benznidazole vs Placebo", "Adult patients"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 910, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benznidazole", "type": "ACTIVE_COMPARATOR", "description": "Benznidazole pills of 100 mg, dose 5 mg/Kg/day, twice a day during 60 days", "interventionNames": ["Drug: Benznidazole"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo pills 100 mg, dose 5mg/Kg/day, twice a day, during 60 days", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "description": "Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-", "armGroupLabels": ["Benznidazole"], "otherNames": ["Radanil (Roche Laboratory)"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo at a dose 5 m/Kg/day until 60 days", "armGroupLabels": ["Placebo"], "otherNames": ["Placebo pills"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Cardiovascular Mortality", "description": "Sudden death, unexpectedly in time and in its presentation,preceded by the abrupt loss of consciousness within a maximum of one hour of the onset of symptoms,when it happened during sleep or unexpectedly in a patient was stable until then. Related Death, when presented in a patient with signs of progressive heart failure.Ischemic or Hemorrhagic Stroke", "timeFrame": "Time to event: from date of randomization until the date of first documented progression or date of death from any cause up to 10 years of follow-up"}, {"measure": "Development of heart failure", "description": "Dyspnea is evaluated according to the classification of the New York Heart Association (NYHA),gallop rhythm, jugular venous distension, crackles in the lungs, edema or pleural effusion,hepatomegaly", "timeFrame": "Time to event: from date of randomization until the date of first documented progression of heart failure up to 10 years of follow-up"}, {"measure": "Severe arrhythmias with hemodynamic compromise or pacemaker implant or Implantable cardiac defibrillator", "description": "Sustained ventricular tachycardia, atrioventricular block, trifascicular block, Atrial fibrillation", "timeFrame": "Time to event: from date of randomization until the date of first documented progression up to 10 years of follow-up"}], "secondaryOutcomes": [{"measure": "Electrocardiographic endpoints. New development of permanent changes in the electrocardiographic", "description": "* Stable sinus bradycardia (\\<50 beats / min)\n* Auriculoventricular blocks of 2nd and 3rd degree\n* Left anterior hemi-block\n* Complete right bundle branch block\n* Atrial flutter or fibrillation\n* Sustained ventricular tachycardia", "timeFrame": "Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up"}, {"measure": "Changes in clinical stage in chronic Chagas disease", "description": "Clinical progression", "timeFrame": "Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up"}, {"measure": "Enlargement of the left ventricle (LV) detected by echocardiography.", "description": "Clinical Progression", "timeFrame": "Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up"}, {"measure": "New Heart Failure", "description": "Clinical Progression", "timeFrame": "Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up"}, {"measure": "Stroke", "description": "Clinical progression", "timeFrame": "Time to event: from date of randomization until the date of first documented as defined in the secondary outcome up to 10 years of follow-up"}, {"measure": "Serological negativization", "description": "by ELISA F29 vs. conventional serology as a late indicator of efficacy or therapeutic failure.", "timeFrame": "time to event: from the date of randomization to the date of the first documented serological negativization that persists until 10 years of follow-up"}, {"measure": "Development and validation of RT-PCR", "description": "Demonstration of RT-PCR as an early indicator of efficacy or therapeutic failure.", "timeFrame": "time to event: from the date of randomization to the date of the first documented no detectable RT-PCR that persists until 10 years of follow-up"}, {"measure": "Changes of the secondary objectives during RCT development. New single endpoints", "description": "1. Any change in clinical stage 0 to II due to left ventricular enlargement demonstrated by echocardiogram, or I to III stage due to development of heart failure.\n2. Complete left branch block\n\n   * 3. Atrial fibrillation\n   * 4. Repetitive ventricular extrasystoles: doublets, triplets, bigemina, trigeminus, ventricular tachycardia", "timeFrame": "Since October 2011 during 18 months"}, {"measure": "Combined clinical endpoints:", "description": "* Right bundle branch block associated with left anterior hemi-block.\n* Parietal motility disorders of left ventricle by echocardiography (akinesia, hypokinesia, and dyskinesia) associated with impaired left ventricular systolic function.\n* Parietal motility disorders of left ventricle by echocardiogram (Akinesia, Hypokinesia, dyskinesia) and /or impaired LV systolic function associated with new electrocardiographic changes (complete left branch block, right bundle branch block, left anterior hemi-block, ventricular extrasystoles.\n* Occurrence of left ventricle aneurysm point by echocardiogram associated to ventricular arrhythmia (section 2.4.1.4.).\n* Occurrence of left ventricle aneurysm point by echocardiogram associated with depression of LV systolic function by echocardiography.", "timeFrame": "Since October 2011 during 18 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients living in urban areas\n* Reactive to at least 2 for serological test performed in Fatala Chaben Institute (ELISA and IFI) ,\n* Patients who agreed to be part of this protocol through informed consent form signed\n\nExclusion Criteria:\n\n* Patients with chronic Chagas disease who have received prior treatment with benznidazole\n* Other cardiomyopathies : idiopathic , alcoholic , peripartum myocarditis, secondary to coronary artery disease, valve disease, hypertension, restrictive, hypertrophic or congenital\n* Chronic renal disease\n* Bleeding disorders\n* History of liver disease or current liver disease ,\n* Any other severe clinical disease that decreases their life expectancy\n* History of severe allergies\n* Pregnant patients\n* Patients who have not signed the informed consent.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Adellina R Riarte, MD", "affiliation": "Chief of Clinical, Pathology and Treatment Department", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Instituto Nacional de Parasitolog\u00eda Dr Mario Fatala Chaben", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "state": "Buenos Aires", "zip": "1063", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}, "referencesModule": {"references": [{"pmid": "9790423", "type": "RESULT", "citation": "Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg. 1998 Oct;59(4):526-9. doi: 10.4269/ajtmh.1998.59.526."}, {"pmid": "8937280", "type": "RESULT", "citation": "de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996 Nov 23;348(9039):1407-13. doi: 10.1016/s0140-6736(96)04128-1."}, {"pmid": "8273735", "type": "RESULT", "citation": "Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994 Jan;127(1):151-62. doi: 10.1016/0002-8703(94)90521-5."}, {"pmid": "16702588", "type": "RESULT", "citation": "Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006 May 16;144(10):724-34. doi: 10.7326/0003-4819-144-10-200605160-00006."}, {"pmid": "8948328", "type": "RESULT", "citation": "Porcel BM, Bontempi EJ, Henriksson J, Rydaker M, Aslund L, Segura EL, Pettersson U, Ruiz AM. Trypanosoma rangeli and Trypanosoma cruzi: molecular characterization of genes encoding putative calcium-binding proteins, highly conserved in trypanosomatids. Exp Parasitol. 1996 Dec;84(3):387-99. doi: 10.1006/expr.1996.0127."}, {"pmid": "3835868", "type": "RESULT", "citation": "Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. [Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy]. Arq Bras Cardiol. 1985 Oct;45(4):249-56. No abstract available. Spanish."}, {"pmid": "16235350", "type": "RESULT", "citation": "Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004102. doi: 10.1002/14651858.CD004102.pub2."}, {"pmid": "24867876", "type": "RESULT", "citation": "Villar JC, Perez JG, Cortes OL, Riarte A, Pepper M, Marin-Neto JA, Guyatt GH. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2014 May 27;2014(5):CD003463. doi: 10.1002/14651858.CD003463.pub2."}, {"pmid": "21264349", "type": "RESULT", "citation": "Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, Mejia Jaramillo AM, Cura C, Auter F, Veron V, Qvarnstrom Y, Deborggraeve S, Hijar G, Zulantay I, Lucero RH, Velazquez E, Tellez T, Sanchez Leon Z, Galvao L, Nolder D, Monje Rumi M, Levi JE, Ramirez JD, Zorrilla P, Flores M, Jercic MI, Crisante G, Anez N, De Castro AM, Gonzalez CI, Acosta Viana K, Yachelini P, Torrico F, Robello C, Diosque P, Triana Chavez O, Aznar C, Russomando G, Buscher P, Assal A, Guhl F, Sosa Estani S, DaSilva A, Britto C, Luquetti A, Ladzins J. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis. 2011 Jan 11;5(1):e931. doi: 10.1371/journal.pntd.0000931."}], "seeAlsoLinks": [{"label": "National Administration of Health Laboratories and Institutes \"Dr Carlos G. Malbr\u00e1n\"/ National Institute of Parasitology", "url": "http://www.anlis.gov.ar/inp"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02544139", "orgStudyIdInfo": {"id": "DSC0227"}, "organization": {"fullName": "InBios International, Inc.", "class": "INDUSTRY"}, "briefTitle": "Specificity Study of Diagnostic for Chagas Disease", "officialTitle": "Determination of Estimated Specificity of Chagas Detect Plus Rapid Tests"}, "statusModule": {"statusVerifiedDate": "2017-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-09-04", "studyFirstSubmitQcDate": "2015-09-04", "studyFirstPostDateStruct": {"date": "2015-09-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-08-15", "lastUpdatePostDateStruct": {"date": "2017-08-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "InBios International, Inc.", "class": "INDUSTRY"}}, "conditionsModule": {"conditions": ["Infectious Diseases"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "serum"}, "enrollmentInfo": {"count": 200, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "OTHER", "name": "Chagas Detect Plus"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "number of subjects with negative result", "timeFrame": "one day"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female subjects 18 to 70 years of age\n2. Subjects must be able to answer questions concerning:\n\n   1. Clinical symptoms\n   2. Blood transfusions\n   3. Organ transplants\n   4. Travel or residence in Chagas endemic areas\n\nExclusion Criteria:\n\n1. Any subject who knows that they have positive serology for Chagas disease\n2. Subjects who are unable to understand verbal of written or oral language of the consent, or require a legal authorized representative for consent.", "healthyVolunteers": true, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "The study will enroll male and female subjects between 18 and 70 years of age without known risk factors for Chagas. Typically Chagas disease is a chronic, asymptomatic disease.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Johns Hopkins Bloomberg School of Public Health", "city": "Baltimore", "state": "Maryland", "zip": "21205", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D003141", "term": "Communicable Diseases"}, {"id": "D007239", "term": "Infections"}], "ancestors": [{"id": "D020969", "term": "Disease Attributes"}, {"id": "D010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M10283", "name": "Infections", "asFound": "Infectious Disease", "relevance": "HIGH"}, {"id": "M6368", "name": "Communicable Diseases", "asFound": "Infectious Disease", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04084379", "orgStudyIdInfo": {"id": "ETMIplus ChC/SiC"}, "organization": {"fullName": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}, "briefTitle": "Implementation Strategy of Bio-molecular Techniques for Early Diagnose of Congenital Syphilis and Chagas Diseases", "officialTitle": "Implementation Strategy of Bio-molecular Techniques for Early Diagnose of Congenital Syphilis and Chagas Diseases in Context of ETMIplus Program, OPS/OMS. Multicentric Study"}, "statusModule": {"statusVerifiedDate": "2023-02", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-07-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-12-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2024-09-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-09-05", "studyFirstSubmitQcDate": "2019-09-06", "studyFirstPostDateStruct": {"date": "2019-09-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-02-28", "lastUpdatePostDateStruct": {"date": "2023-03-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dr Jaime Altcheh", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires"}, "leadSponsor": {"name": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Disease", "Syphilis"], "keywords": ["congenital chagas disease", "congenital syphilis", "Chagas PCR diagnose", "Syphilis PCR diagnose", "Children"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 560, "type": "ESTIMATED"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "Implementation of Bio-molecular Techniques (PCR) for Early Diagnose of Congenital Syphilis and Chagas Diseases", "description": "Evaluate PCR sensitivity, specificity, PPV and NPP in diagnose of congenital syphilis and congenital Chagas diseases and compare it with current methods. The investigators will measure PCR titles during one year in each patient, and then compare results with serologies, in order to assess if PCR positivization and negativization occurs earlier than current methods. This may allow physicians to shorten time required for follow-up in these patients.", "timeFrame": "2 years"}], "secondaryOutcomes": [{"measure": "Implementation of Bio-molecular Techniques (PCR) as terapeutic response biomarker for Congenital Syphilis and Chagas Disease", "description": "Investigators will evaluate the utility of PCR as an early biomarker of terapeutic response and compare it to serology for T.pallidum and T. cruzi during and after treatment. This could prevent unnecessary prolonged treatments, and could also allow early diagnose for treatment failures.", "timeFrame": "2 years"}, {"measure": "Identification of different genotypes of T.pallidum in samples to create a database of T.pallidum genotypes", "description": "Identification of different genotypes of T.pallidum in samples taken from active skin lessions and blood samples, in order to create a data base of T.pallidum genotypes causing congenital syphilis and acquired syphilis", "timeFrame": "2 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Child under 1 year of age, born from mother positive for syphilis not treated or inadequately treated during pregnancy\n* Patients with acquired syphilis\n* Child under 1 year of age, born from mother with positive serology test for Chagas\n\nExclusion Criteria:\n\n* Patients who had received treatment for syphilis or Chagas previously\n* Patients who are not able to complete scheduled visits\n* Other diseases that could difficult implementation of this protocol or results interpretation.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "1 Day", "maximumAge": "18 Years", "stdAges": ["CHILD", "ADULT"], "studyPopulation": "Population of this study are children born from mother positive for syphilis or Chagas diseases, with congenital infection suspected and children with acquired syphilis.\n\nThey will be recruited at five centers from different geographical areas of Argentina", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Parasitology Division, Children's Hospital \"R Gutierrez\" of Buenos Aires", "status": "RECRUITING", "city": "Buenos Aires", "zip": "1425", "country": "Argentina", "contacts": [{"name": "Altcheh, Dr", "role": "CONTACT", "phone": "54-11-4964-3093", "email": "jaltcheh@gmail.com"}, {"name": "Jaime Altcheh, Dr", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D013587", "term": "Syphilis"}, {"id": "D014355", "term": "Chagas Disease"}, {"id": "D013590", "term": "Syphilis, Congenital"}], "ancestors": [{"id": "D014211", "term": "Treponemal Infections"}, {"id": "D013145", "term": "Spirochaetales Infections"}, {"id": "D016905", "term": "Gram-Negative Bacterial Infections"}, {"id": "D001424", "term": "Bacterial Infections"}, {"id": "D001423", "term": "Bacterial Infections and Mycoses"}, {"id": "D007239", "term": "Infections"}, {"id": "D015231", "term": "Sexually Transmitted Diseases, Bacterial"}, {"id": "D012749", "term": "Sexually Transmitted Diseases"}, {"id": "D003141", "term": "Communicable Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D000079426", "term": "Vector Borne Diseases"}, {"id": "D007232", "term": "Infant, Newborn, Diseases"}], "browseLeaves": [{"id": "M16364", "name": "Syphilis", "asFound": "Syphilis", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M16367", "name": "Syphilis, Congenital", "asFound": "Congenital Syphilis", "relevance": "HIGH"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M16964", "name": "Treponemal Infections", "relevance": "LOW"}, {"id": "M4722", "name": "Bacterial Infections", "relevance": "LOW"}, {"id": "M19249", "name": "Gram-Negative Bacterial Infections", "relevance": "LOW"}, {"id": "M12136", "name": "Mycoses", "relevance": "LOW"}, {"id": "M4721", "name": "Bacterial Infections and Mycoses", "relevance": "LOW"}, {"id": "M15558", "name": "Sexually Transmitted Diseases", "relevance": "LOW"}, {"id": "M17935", "name": "Sexually Transmitted Diseases, Bacterial", "relevance": "LOW"}, {"id": "M2876", "name": "Genital Diseases", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "M10276", "name": "Infant, Newborn, Diseases", "relevance": "LOW"}, {"id": "T5701", "name": "Treponema Infection", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06339710", "orgStudyIdInfo": {"id": "U1111-1288-5508"}, "organization": {"fullName": "Evandro Chagas Institute of Clinical Research", "class": "OTHER"}, "briefTitle": "Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients", "officialTitle": "Double Blind, Phase III Randomized,Safety and Efficacy Non-inferiority Trial to Evaluate Two Short Benznidazole Regimens for the Treatment of Adults in the Chronic Phase of Chagas Disease in Its Indeterminate and Mild Cardiac Forms in Bolivia and Colombia", "acronym": "Benlatino"}, "statusModule": {"statusVerifiedDate": "2024-07", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-11-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2026-01-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-10-30", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-02-15", "studyFirstSubmitQcDate": "2024-03-27", "studyFirstPostDateStruct": {"date": "2024-04-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-07-11", "lastUpdatePostDateStruct": {"date": "2024-07-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Israel Molina", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Evandro Chagas Institute of Clinical Research"}, "leadSponsor": {"name": "Evandro Chagas Institute of Clinical Research", "class": "OTHER"}, "collaborators": [{"name": "Andrea Silvestre de Sousa", "class": "UNKNOWN"}]}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chronic Chagas Disease"], "keywords": ["Chagas disease", "Short treatment", "Benznidazole"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 672, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Short treatment 1", "type": "EXPERIMENTAL", "description": "benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or", "interventionNames": ["Drug: benznidazole 300 mg daily 8 weeks"]}, {"label": "Short Treatment 2", "type": "EXPERIMENTAL", "description": "benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks", "interventionNames": ["Drug: benznidazole 300 mg daily 8 weeks"]}, {"label": "Standard treatment", "type": "ACTIVE_COMPARATOR", "description": "benznidazole 300 mg daily for 8 weeks", "interventionNames": ["Drug: benznidazole 300 mg daily 8 weeks"]}], "interventions": [{"type": "DRUG", "name": "benznidazole 300 mg daily 8 weeks", "description": "672 participants will be randomly assigned to receive the standard-dose of benznidazole (300 mg daily for 8 weeks) or the short experimental regimens (benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks)", "armGroupLabels": ["Short Treatment 2", "Short treatment 1", "Standard treatment"], "otherNames": ["benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks", "benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportion of participants with sustained negative Polymerase Chain Reaction (PCR) during the 24 months of follow-up after treatment.", "description": "The treatment efficacy of each treatment arm is assessed through the proportion of patients with negative parasitaemia measured by PCR during the first 24 months after starting treatment", "timeFrame": "during the 24-month follow-up"}], "secondaryOutcomes": [{"measure": "Incidence of Adverse Events (AE) leading to treatment discontinuation during treatment period", "description": "The safety profile will me measured with the proportion of patients with treatment discontinuation atributed to the drug toxicity in each treatment arm", "timeFrame": "during treatment period (up to 8 weeks)"}, {"measure": "Proportion of participants with positive PCR at different time points", "description": "Parasitic kinetics will be evaluated by detecting parasitic DNA measured by qualitative PCR in peripheral blood in 1, 4, 6, 8, 12, 18 and 24 months after the end of treatment in each of the different therapeutic regimens.", "timeFrame": "At the different time points: 1, 4, 6, 8, 12, 18 and 24 months after the end of treatment"}], "otherOutcomes": [{"measure": "Incidence and severity of clinically relevant events attributed to Chagas disease", "description": "To assess the incidence of events will be taking into account a composite outcome of clinically relevant events: number of hospitalizations, progression to cardiac form or deaths related to Chagas disease.", "timeFrame": "during the 24-month follow-up"}, {"measure": "To measure the quality of life (QoL) of participants", "description": "Quality of life will be assessed through longitudinal changes on the score of quality of life using the instrument: The World Health Organization Quality of Life Brief Version (WHOQoL-BREF)", "timeFrame": "during the 24-month follow-up"}, {"measure": "To measure the quality of life (QoL) of participants", "description": "Quality of life will be assessed through longitudinal changes on the score of quality of life using the instrument EuroQol 5 Dimensions (EQ5-D)", "timeFrame": "during the 24-month follow-up"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:o Adults aged \u2265 18 years;\n\n* CD diagnosis through the positivity of two serological tests that use different antigens (recombinant and native antigens, according to World Health Organization (WHO) recommendations) (28).\n* Informed consent form read and signed by the participant.\n* Weight \u2265 50 kg to \u2264 95 kg.\n\nExclusion Criteria:\n\n* o Currently pregnant, breastfeeding or expressing gestational desire for the next 2 months.\n\n  * Previously received treatment with Benznidazole (BZN) or NIfurtimox (NFX) - (either completely or incompletely);\n  * Any concomitant use or documented history of using allopurinol or antifungals (ketoconazole, itraconazole and posaconazole);\n  * History of hypersensitivity, allergic or serious adverse event (SAE) to any \"nitroimidazole\", and/or its components;\n  * Acute or chronic health problems that, in the informed opinion of the investigator, may interfere with the evaluation of the efficacy and/or safety of the drug. Examples are acute infections, Human Immunodeficiency Virus (HIV) infections, liver disease with liver failure and kidney disease requiring support treatment;\n  * Signs and/or symptoms of severe cardiac form of CD ;\n  * History of cardiomyopathy, heart failure or severe ventricular arrhythmia of any etiology;\n  * Alcoholic participants or those with a history of alcohol abuse (considered as intake of \\>4 drinks on any single day AND \\>14 drinks per week for men and \\>3 drinks on any single day AND \\>7 drinks per week for women);\n  * Have basic laboratory parameters outside the normal range or parameters that are considered clinically relevant by the physician responsible for the participant;\n  * Participation in another clinical trial over the past 12 months.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Debbie Vermeij, MsC", "role": "CONTACT", "phone": "+5521998298318", "email": "debbievermeij@cuidachagas.org"}, {"name": "Andrea S de Sousa, PHD", "role": "CONTACT", "phone": "55 21 99918-2147", "email": "andreasilvestre@cuidachagas.org"}], "locations": [{"facility": "Israel Molina", "city": "Minas Gerais", "state": "Belo Horizonte", "country": "Brazil", "contacts": [{"name": "Monique MG Gurgel, Master", "role": "CONTACT", "phone": "+55 21 997248094", "email": "moniquegurgel@cuidachagas.org"}], "geoPoint": {"lat": -8.96667, "lon": -72.78333}}, {"facility": "Monique Gurgel de Oliveira", "city": "Rio de Janeiro", "state": "RJ", "zip": "24350211", "country": "Brazil", "contacts": [{"name": "Israel Molina, PHD", "role": "CONTACT", "phone": "+34 679 33 76 05", "email": "israel.molina@fiocruz.br"}, {"name": "Monique G de Oliveira, MsC", "role": "CONTACT", "phone": "+55 21997248094", "email": "moniquegurgel@cuidachagas.org"}, {"name": "Israel Molina, PHD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Ana Gabriela Herrera, PHD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Maria Ximena E Lazcano, PHD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Mario Mario Oliveira", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Juan Carlos Villar", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Andrea S de Sousa, PHD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -22.90278, "lon": -43.2075}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2023-02-14", "uploadDate": "2024-03-19T19:03", "filename": "Prot_000.pdf", "size": 1319333}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2023-02-14", "uploadDate": "2024-03-19T18:18", "filename": "ICF_001.pdf", "size": 392791}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03704181", "orgStudyIdInfo": {"id": "4436/16/102"}, "organization": {"fullName": "University of Sao Paulo General Hospital", "class": "OTHER"}, "briefTitle": "Colchicine for Patients With Chagas\u00b4 Disease( B1 Stage)", "officialTitle": "Effect of Colchicine on Inflammation and Myocardial Fibrosis Assessed by Magnetic Resonance Imaging in Patients With Chagas' Heart Disease", "acronym": "COACH"}, "statusModule": {"statusVerifiedDate": "2018-09", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-10-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-12-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2021-01-05", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2018-09-27", "studyFirstSubmitQcDate": "2018-10-10", "studyFirstPostDateStruct": {"date": "2018-10-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-03-08", "lastUpdatePostDateStruct": {"date": "2019-03-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Sao Paulo General Hospital", "class": "OTHER"}, "collaborators": [{"name": "Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo", "class": "OTHER_GOV"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Disease", "Colchicine Resistance"], "keywords": ["fibrosis", "Inflammation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 60, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "colchicine", "type": "EXPERIMENTAL", "description": "colchicine 0,5 milligram tablet by mouth every 12 hours, for 1 year", "interventionNames": ["Drug: Colchicine 0.5 MG twice day for one year"]}, {"label": "placebo", "type": "ACTIVE_COMPARATOR", "description": "placebo tablet by mouth every 12 hours, for 1 year\n\npill manufactured to mimic coclchicine 0,5 mg tablet", "interventionNames": ["Drug: Placebo Oral Tablet"]}], "interventions": [{"type": "DRUG", "name": "Colchicine 0.5 MG twice day for one year", "description": "placebo twice day for one year", "armGroupLabels": ["colchicine"], "otherNames": ["placebo oral tablet"]}, {"type": "DRUG", "name": "Placebo Oral Tablet", "description": "placebo twice day for one year", "armGroupLabels": ["placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Effect of colchicine on myocardial inflammation assessed by magnetic resonance imaging", "description": "myocardial edema quantified in grams or percent of LV mass, myocardial hyperaemia quantified in grams or percent of LV mass", "timeFrame": "1 year"}, {"measure": "Effect of colchicine on myocardial fibrosis assessed by magnetic resonance imaging", "description": "myocardial fibrosis quantified in grams or percent of LV mass", "timeFrame": "1 year"}], "secondaryOutcomes": [{"measure": "Effect of colchicine on inflammatory markers such as interleukin-1, interleukin-6, interleukin-8, interleukin-10", "description": "interleukin-1, interleukin-6, interleukin-8, interleukin-10, ELISA (pg/mL)", "timeFrame": "1 year"}, {"measure": "Effect of colchicine on inflammatory marker such as TNF-\u03b1", "description": "TNF-\u03b1 ELISA (pg/mL)", "timeFrame": "1 year"}, {"measure": "Effect of colchicine on inflammatory marker such as interferon-gama", "description": "Interferon -gama ELISA (pg/mL)", "timeFrame": "1 year"}, {"measure": "Effect of colchicine on T Cruzi polymerase chain reaction", "description": "7500 PCR-Real time System (Life Technologies)", "timeFrame": "1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Clinical and serological diagnosis of Chagas\u00b4disease ( Stage B1)\n* Must be able to swallow tablets\n\nExclusion Criteria:\n\n* myocardial infarction or coronary artery disease,\n* diabetes mellitus,\n* valvular disease,\n* creatinine clearance \\<30 ml / kg / min\n* contraindication to perform cardiac magnetic resonance imaging\n* use of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone blockers\n* previous use of benzonidazole", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Fabio Fernandes, MD, PHD", "role": "CONTACT", "phone": "+55 11 2661 5057", "email": "fabio.fernandes@incor.usp.br"}, {"name": "Paula Buck, PHD", "role": "CONTACT", "phone": "+55 11 2661 5346", "email": "carpaula@incor.usp.br"}], "overallOfficials": [{"name": "Fabio Fernandes, Md, PHD", "affiliation": "Heart Institute, University of S\u00e3o Paulo", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Fabio Fernandes", "status": "RECRUITING", "city": "S\u00e3o Paulo", "zip": "05403000", "country": "Brazil", "contacts": [{"name": "Fabio Fernandes, MD", "role": "CONTACT", "phone": "+55 11 997681946", "email": "fabio.fernandes@incor.usp.br"}], "geoPoint": {"lat": -23.5475, "lon": -46.63611}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M10293", "name": "Inflammation", "relevance": "LOW"}, {"id": "M8485", "name": "Fibrosis", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC01", "name": "Infections"}]}, "interventionBrowseModule": {"meshes": [{"id": "D003078", "term": "Colchicine"}], "ancestors": [{"id": "D006074", "term": "Gout Suppressants"}, {"id": "D018501", "term": "Antirheumatic Agents"}, {"id": "D050257", "term": "Tubulin Modulators"}, {"id": "D050256", "term": "Antimitotic Agents"}, {"id": "D050258", "term": "Mitosis Modulators"}, {"id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000970", "term": "Antineoplastic Agents"}], "browseLeaves": [{"id": "M6307", "name": "Colchicine", "asFound": "Sarcoma", "relevance": "HIGH"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M26197", "name": "Tubulin Modulators", "relevance": "LOW"}, {"id": "M26196", "name": "Antimitotic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ANeo", "name": "Antineoplastic Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03334838", "orgStudyIdInfo": {"id": "16006"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study", "officialTitle": "Open-label, Randomized, Single-dose, Cross-over Study to Evaluate the Influence of Dietary Habits on the Pharmacokinetics, Safety, and Tolerability of a 120 mg Dose and to Assess the Relative Bioavailability of a 240 mg Dose of Nifurtimox Tablets Administered to Adult Male and Female Patients With Chagas' Disease"}, "statusModule": {"statusVerifiedDate": "2020-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-06-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-11-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-01-29", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-11-03", "studyFirstSubmitQcDate": "2017-11-03", "studyFirstPostDateStruct": {"date": "2017-11-07", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-12-29", "lastUpdatePostDateStruct": {"date": "2020-12-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas' Disease"], "keywords": ["Food effect", "Dose proportionality"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 36, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "GRP 1 - Assess relative bioavailability (4-way crossover)", "type": "EXPERIMENTAL", "description": "GROUP 1 (Treatments A, B, C, D) All treatments in Group 1 consisted of a dose of 120 mg nifurtimox (4 x 30 mg tablets).\n\nIn Treatment A, dose administration was in a fasted state.\n\nFor the other treatments, dose administration was in a fed state:\n\nTreatment B after a low-fat breakfast; Treatment C after a breakfast consisting of dairy products (yogurt+milk); and Treatment D after a high-calorie and high-fat breakfast.", "interventionNames": ["Drug: Nifurtimox (Lampit, BAYA2502)"]}, {"label": "GRP 2 - Assess relative bioavailability (2-way crossover)", "type": "EXPERIMENTAL", "description": "All subjects in Group 2 received a single dose of nifurtimox in each of the Treatments D and E.\n\nIn Treatment D, subjects received 120 mg nifurtimox (4 x 30 mg tablets), and in Treatment E, subjects received 240 mg nifurtimox (8 x 30 mg tablets). Both treatments were administered in a fed state, after a high-calorie and high-fat breakfast.", "interventionNames": ["Drug: Nifurtimox (Lampit, BAYA2502)"]}], "interventions": [{"type": "DRUG", "name": "Nifurtimox (Lampit, BAYA2502)", "description": "Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.", "armGroupLabels": ["GRP 1 - Assess relative bioavailability (4-way crossover)", "GRP 2 - Assess relative bioavailability (2-way crossover)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AUC(0-tlast) of nifurtimox (evaluation of food effect)", "description": "Area under the drug-concentration vs. time curve of nifurtimox from time 0 to the last data point\\[AUC(0-tlast)\\]", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}, {"measure": "Cmax of nifurtimox (evaluation of food effect)", "description": "Peak concentrations (Cmax) of the plasma concentration vs time profiles", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}], "secondaryOutcomes": [{"measure": "Number of participants with treatment-emergent adverse events (TEAEs)", "description": "Clinical Laboratory Test, physical examinations, vital signs and 12 electrocardiograms ( ECG's) for safety and tolerability", "timeFrame": "Up to 8 weeks"}, {"measure": "AUC(0-tlast)/D of nifurtimox (evaluation of food effect)", "description": "AUC(0-tlast)/D: AUC(0-tlast) divided by dose", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}, {"measure": "Cmax/D of nifurtimox (evaluation of food effect)", "description": "Cmax/D: Cmax divided by dose", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent must be provided before any study-specific tests or procedures are performed.\n* Male/female patient diagnosed with chronic Chagas' disease:\n\nPrevious diagnosis of acute or chronic Chagas' disease by a health clinic prior to screening for the study. The diagnosis of chronic Chagas' disease may be made by clinical findings, supported by antibody titers if available. If there is a known history of acute disease, it is preferable to have documentation of parasites on the blood smear, if available.\n\n* Women and men of reproductive potential must agree to use adequate contraception when sexually active. This applies for the time period between signing of the informed consent form and 12 weeks after the last administration of study drug. The definition of adequate contraception will be based on the judgment of the investigator and on local requirements. Acceptable methods of contraception include, but are not limited to: (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based contraception. Subjects must agree to utilize two reliable and acceptable methods of contraception simultaneously.\n* Women of childbearing potential with confirmed last menstrual period by anamnesis and negative serum pregnancy test (beta-human chorionic gonadotropin \\[\u03b2hCG\\]) at screening and negative urine pregnancy test (\u03b2hCG) at pre-dose of each treatment.\n* Women of non-childbearing potential, such as surgically sterile women with either written documentation of surgical sterility or negative serum pregnancy test (\u03b2hCG) at screening and negative urine pregnancy test (\u03b2hCG) at pre-dose of each treatment.\n* Male subjects who agree not to act as sperm donors for 12 weeks after last administration of study drug.\n* Age: 18 to 45 years (inclusive) at screening.\n* Body mass index (BMI): \u226518 and \\<29.9 kg/m\u00b2.\n\nExclusion Criteria:\n\n* Incompletely cured pre-existing diseases (except chronic Chagas' disease without active GI condition) for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study drugs will not be normal.\n* Acute Chagas' disease. (During the acute phase, the parasite on a blood smear may be seen under a microscope. Different antibodies are present, depending on the course of the disease).\n* Known hypersensitivity to the study drug (active substance or excipients of the preparations)\n* Unstable or uncontrolled medical condition such as hypertension or diabetes, decompensated heart failure, GI conditions that would interfere with the absorption of the study drug (e.g. GI ulceration, peptic ulceration, GI bleeding, gastroesophageal reflux, or other GI disease affecting gastroesophageal junction), conditions that could potentially have an impact on drug metabolism or elimination (renal, hepatic such as known hepatic or biliary abnormalities), or any clinically relevant active infections in the opinion of the investigator within 4 weeks before the screening visit, e.g. clinically relevant history or presence of significant respiratory (e.g. interstitial lung disease), hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, metabolic (e.g. diabetes), and dermatological or connective tissue disease.\n* Use of systemic or topical medicines or substances which oppose the study objectives (including clinical treatment with nifurtimox and benznidazole) or which might influence them within 4 weeks before the first study drug administration, e.g. an investigational drug, any drug altering GI motility and/or gastric pH (e.g. antacids, anticholinergic, para-sympatholytics), any drug known to induce liver enzymes (e.g. dexamethasone, barbiturates, St. John's Wort \\[hypericum perforatum\\]), any drug known to inhibit liver enzymes (e.g. ketoconazole, macrolides).\n* Clinically relevant findings in the ECG such as a second- or third-degree atrioventricular block, prolongation of the QRS complex over 120 msec or of the QT interval over 450 msec using Bazett's formula (QTcB). (Clinically stable subjects with Chagas'-related heart disease and pacemaker in place for \\>1 year and evaluated by a cardiologist \u22646 months before the first dose of study drug will not be excluded.)\n* Systolic blood pressure \\<100 or \\>140 mmHg (after resting in supine position for a minimum of 3 minutes).\n* Diastolic blood pressure \\<50 or \\>90 mmHg (after resting in supine position for a minimum of 3 minutes).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "FP Clinical Pharma", "city": "Buenos Aires", "state": "Ciudad Auton. De Buenos Aires", "zip": "C1431CEF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}, "referencesModule": {"references": [{"pmid": "34265407", "type": "DERIVED", "citation": "Stass H, Just S, Weimann B, Ince I, Willmann S, Feleder E, Freitas C, Yerino G, Munster U. Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets - Implications for quality control and application. Eur J Pharm Sci. 2021 Nov 1;166:105940. doi: 10.1016/j.ejps.2021.105940. Epub 2021 Jul 12."}], "seeAlsoLinks": [{"label": "Click here to find results for studies related to Bayer products", "url": "https://clinicaltrials.bayer.com/"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D009547", "term": "Nifurtimox"}], "ancestors": [{"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M13561", "name": "Phenylephrine", "relevance": "LOW"}, {"id": "M13031", "name": "Oxymetazoline", "relevance": "LOW"}, {"id": "M12486", "name": "Nifurtimox", "asFound": "DSM-IV", "relevance": "HIGH"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CaAg", "name": "Cardiotonic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03350295", "orgStudyIdInfo": {"id": "16007"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg", "officialTitle": "Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Tablets, Administered to Adult Male and Female Patients With Chagas' Disease"}, "statusModule": {"statusVerifiedDate": "2019-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-06-14", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-09-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-12-14", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-11-09", "studyFirstSubmitQcDate": "2017-11-19", "studyFirstPostDateStruct": {"date": "2017-11-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-12-11", "lastUpdatePostDateStruct": {"date": "2019-12-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Relative bioavailability", "In vitro dissolution"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": "Group 1 ( Treatment A,B,C - 3 way cross-over), Group 2 ( Treatment D, E - 2 way cross over)", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 48, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "GRP1 - Assess relative bioavailability(3-way cross-over)", "type": "EXPERIMENTAL", "description": "GROUP 1 (Treatments A, B, C) All 3 treatments in Group 1 consist of a dose of 120 mg nifurtimox (4 x 30 mg tablets). Participants received the 3 treatments in one of six treatment sequences under fed condition.\n\nTreatment A, dose administration with fast in vitro dissolution characteristics Treatment B, dose administration with medium in vitro dissolution characteristics Treatment C, dose administration with slow in vitro dissolution characteristics", "interventionNames": ["Drug: Nifurtimox (Lampit, BAYA2502)"]}, {"label": "GRP2 - Assess relative bioavailability (2-way cross-over)", "type": "EXPERIMENTAL", "description": "GROUP 2 (Treatments D and E) Participants received the 2 treatments in one of two treatment sequences under fed condition.\n\nTreatment D, a single dose 30 mg nifurtimox dose with medium in vitro dissolution characteristics Treatment E, a single dose of 120 mg nifurtimox", "interventionNames": ["Drug: Nifurtimox (Lampit, BAYA2502)"]}], "interventions": [{"type": "DRUG", "name": "Nifurtimox (Lampit, BAYA2502)", "description": "Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E", "armGroupLabels": ["GRP1 - Assess relative bioavailability(3-way cross-over)", "GRP2 - Assess relative bioavailability (2-way cross-over)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AUC(0-tlast) of nifurtimox", "description": "AUC(0-tlast):Area under the drug-concentration vs. time curve of nifurtimox from time 0 to the last data point", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}, {"measure": "Cmax of nifurtimox", "description": "Cmax: Maximum observed drug concentration in measured matrix after single dose administration", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}, {"measure": "AUC of nifurtimox", "description": "AUC: Area under the concentration versus time curve from zero to infinity after single (first) dose", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}], "secondaryOutcomes": [{"measure": "Number of participants with adverse events", "timeFrame": "up to 8 weeks"}, {"measure": "AUC divided by dose: AUC/D", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}, {"measure": "AUC(0-tlast) divided by dose: AUC(0-tlast)/D", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}, {"measure": "Cmax divided by dose: Cmax/D", "timeFrame": "0, 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,15 hour"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n* Women and men of reproductive potential must agree to use adequate contraception when sexually active. This applies for the time period between signing of the informed consent form and 12 weeks after the last administration of study drug. The definition of adequate contraception will be based on the judgment of the investigator and on local requirements. Acceptable methods of contraception include, but are not limited to: (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based contraception. Subjects must agree to utilize two reliable and acceptable methods of contraception simultaneously.\n* Women of childbearing potential with confirmed last menstrual period by anamnesis and negative serum pregnancy test (beta-human chorionic gonadotropin \\[\u03b2hCG\\]) at screening and negative urine pregnancy test (\u03b2hCG) at pre-dose of each treatment.\n* Women of non-childbearing potential, such as surgically sterile women with either written documentation of surgical sterility or negative serum pregnancy test (\u03b2hCG) at screening and negative urine pregnancy test (\u03b2hCG) at pre-dose of each treatment.\n* Male subjects who agree not to act as sperm donors for 12 weeks after last administration of study drug.\n* Age: 18 to 45 years (inclusive) at screening.\n* Body mass index (BMI): \u226518 and \\<29.9 kg/m\u00b2.\n* Written informed consent must be provided before any study-specific tests or procedures are performed.\n* Male/female patient diagnosed with chronic Chagas' disease:\n* Previous diagnosis of acute or chronic Chagas' disease by a health clinic prior to screening for the study. The diagnosis of chronic Chagas' disease may be made by clinical findings, supported by antibody titers if available. If there is a known history of acute disease, it is preferable to have documentation of parasites on the blood smear, if available.\n\nExclusion Criteria\n\n* Incompletely cured pre-existing diseases (except chronic Chagas' disease without active GI condition) for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study drugs will not be normal.\n* Acute Chagas' disease. (During the acute phase, the parasite on a blood smear may be seen under a microscope. Different antibodies are present, depending on the course of the disease).\n* Known hypersensitivity to the study drug (active substance or excipients of the preparations)\n* Unstable or uncontrolled medical condition such as hypertension or diabetes, decompensated heart failure, GI conditions that would interfere with the absorption of the study drug (e.g. GI ulceration, peptic ulceration, GI bleeding, gastroesophageal reflux, or other GI disease affecting gastroesophageal junction), conditions that could potentially have an impact on drug metabolism or elimination (renal, hepatic such as known hepatic or biliary abnormalities), or any clinically relevant active infections in the opinion of the investigator within 4 weeks before the screening visit, e.g. clinically relevant history or presence of significant respiratory (e.g. interstitial lung disease), hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, metabolic (e.g. diabetes), and dermatological or connective tissue disease.\n* Use of systemic or topical medicines or substances which oppose the study objectives (including clinical treatment with nifurtimox and benznidazole) or which might influence them within 4 weeks before the first study drug administration, e.g. an investigational drug, any drug altering GI motility and/or gastric pH (e.g. antacids, anticholinergic, para-sympatholytics), any drug known to induce liver enzymes (e.g. dexamethasone, barbiturates, St. John's Wort \\[hypericum perforatum\\]), any drug known to inhibit liver enzymes (e.g. ketoconazole, macrolides).\n* Clinically relevant findings in the ECG such as a second- or third-degree atrioventricular block, prolongation of the QRS complex over 120 msec or of the QT interval over 450 msec using Bazett's formula (QTcB). (Clinically stable subjects with Chagas'-related heart disease and pacemaker in place for \\>1 year and evaluated by a cardiologist \u22646 months before the first dose of study drug will not be excluded.)\n* Systolic blood pressure \\<100 or \\>140 mmHg (after resting in supine position for a minimum of 3 minutes).\n* Diastolic blood pressure \\<50 or \\>90 mmHg (after resting in supine position for a minimum of 3 minutes).\n* Findings that would exclude the subject in the investigator's judgment, e.g. enlarged liver, irregular heartbeat, undiagnosed acute illness, and melanoma.\n* Positive pregnancy test.\n* Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV 1+2).\n* Positive urine drug screening..", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "FP Clinical Pharma", "city": "Buenos Aires", "state": "Ciudad Auton. De Buenos Aires", "zip": "C1425BAB", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}, "referencesModule": {"references": [{"pmid": "34265407", "type": "DERIVED", "citation": "Stass H, Just S, Weimann B, Ince I, Willmann S, Feleder E, Freitas C, Yerino G, Munster U. Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets - Implications for quality control and application. Eur J Pharm Sci. 2021 Nov 1;166:105940. doi: 10.1016/j.ejps.2021.105940. Epub 2021 Jul 12."}], "seeAlsoLinks": [{"label": "Click here to find results for studies related to Bayer products", "url": "https://clinicaltrials.bayer.com/"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D009547", "term": "Nifurtimox"}], "ancestors": [{"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M12486", "name": "Nifurtimox", "asFound": "DSM-IV", "relevance": "HIGH"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02327052", "orgStudyIdInfo": {"id": "PCL01-04"}, "organization": {"fullName": "Hospital Sao Rafael", "class": "OTHER"}, "briefTitle": "Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease", "officialTitle": "Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Subjects With Chagas Disease"}, "statusModule": {"statusVerifiedDate": "2021-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-01"}, "primaryCompletionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-12-18", "studyFirstSubmitQcDate": "2014-12-29", "studyFirstPostDateStruct": {"date": "2014-12-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-09", "resultsFirstSubmitQcDate": "2021-03-01", "resultsFirstPostDateStruct": {"date": "2021-03-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-03-01", "lastUpdatePostDateStruct": {"date": "2021-03-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Milena Botelho Pereira Soares", "investigatorTitle": "Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Subjects with Chagas Disease", "investigatorAffiliation": "Hospital Sao Rafael"}, "leadSponsor": {"name": "Hospital Sao Rafael", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Chagas disease", "longitudinal global strain", "speckle tracking"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "OTHER", "timePerspective": "CROSS_SECTIONAL"}, "enrollmentInfo": {"count": 58, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Chagas disease", "description": "The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests.", "interventionNames": ["Other: No intervention was performed."]}], "interventions": [{"type": "OTHER", "name": "No intervention was performed.", "description": "No intervention was performed.", "armGroupLabels": ["Chagas disease"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Correlation Between Longitudinal Global Strain and the Percentage of Myocardial Fibrosis on Magnetic Resonance", "description": "Longitudinal global strain were assesseb by standard transthoracic echocardiographic examinations were recorded in all subjects using the Vivid 7 digital ultrasound system (GE Vingmed Ultrasound AS, Horten, Norway) and myocardial fibrosis by cardiac magnetic resonance exams were performed on all subjects using the General Electric Sigma HDx 1.5-T system (Fairfield, CT, USA).\n\n.", "timeFrame": "Both outcome measures will be assessed at one month of follow up."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Chagas disease, established based on microbiological confirmation by two positive serologic tests (indirect hemagglutination and indirect immunofluorescence)\n* Between 18 and 70 years of age.\n\nExclusion Criteria:\n\n* Previous myocardial infarction or history of coronary artery disease\n* Primary valve disease\n* Dialysis treatment of terminal renal failure\n* Liver disease in activity\n* Hematologic, neoplastic or bone diseases\n* And MRI contraindications.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Adult subjects in the Chagas disease outpatient clinics at our institution from January 2011 to December 2013 were invited to participate in this study.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Milena Soares, PhD", "affiliation": "Hospital S\u00e3o Rafael", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hospital S\u00e3o Rafael", "city": "Salvador", "state": "Bahia", "zip": "41253-190", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Chagas Disease", "description": "The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests, from a convenience sample."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "58"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "58"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Chagas Disease", "description": "See below Baseline Measures"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "58"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "58"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58", "spread": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "34"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "24"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Brazil", "categories": [{"measurements": [{"groupId": "BG000", "value": "58"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Correlation Between Longitudinal Global Strain and the Percentage of Myocardial Fibrosis on Magnetic Resonance", "description": "Longitudinal global strain were assesseb by standard transthoracic echocardiographic examinations were recorded in all subjects using the Vivid 7 digital ultrasound system (GE Vingmed Ultrasound AS, Horten, Norway) and myocardial fibrosis by cardiac magnetic resonance exams were performed on all subjects using the General Electric Sigma HDx 1.5-T system (Fairfield, CT, USA).\n\n.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of fibrosis", "timeFrame": "Both outcome measures will be assessed at one month of follow up.", "groups": [{"id": "OG000", "title": "Chagas Disease", "description": "The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.8", "spread": "5.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "No intervention was performed and we conducted a cross-sectional study, therefore adverse events were not monitored", "description": "No intervention was performed and we conducted a cross-sectional study, therefore adverse events were not monitored", "eventGroups": [{"id": "EG000", "title": "Chagas Disease", "description": "No intervention was performed and we conducted a cross-sectional study, therefore there were no adverse events.", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Milena Botelho Pereira Soares", "organization": "Hospital S\u00e3o Rafael", "email": "milenabpsoares@gmail.com", "phone": "+557132816455"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M8485", "name": "Fibrosis", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT06632600", "orgStudyIdInfo": {"id": "CLXE408B12201"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.", "officialTitle": "A Randomized, Participant- and Investigator-blinded, Controlled, Parallel Group Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LXE408 in Participants With Chronic Chagas Disease Without Severe Organ Dysfunction."}, "statusModule": {"statusVerifiedDate": "2024-12", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-04-21", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2027-04-07", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2027-10-08", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-10-07", "studyFirstSubmitQcDate": "2024-10-07", "studyFirstPostDateStruct": {"date": "2024-10-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-12-18", "lastUpdatePostDateStruct": {"date": "2024-12-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["LXE408", "Chronic Chagas disease", "Chronic indeterminate Chagas disease", "Chronic Chagas disease without severe organ dysfunction", "CICD", "Chronic CD", "Trypanosoma cruzi"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "The benznidazole arm is open-label.\n\nFor the LXE and placebo arms:\n\nParticipants, investigator, staff, and persons performing the assessments will remain blinded to the identity of the treatment from the time of randomization until final (12 month) database lock for blinded arms. The sponsor clinical trial team (CTT) will be blinded until the primary endpoint analysis (when all participants complete 6 month visit) and may become unblinded as needed at any other interim analysis.", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 130, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "LXE408 28 days", "type": "EXPERIMENTAL", "description": "LXE408 administered by oral route", "interventionNames": ["Drug: LXE408"]}, {"label": "LXE408 14 days and Placebo 14 days", "type": "EXPERIMENTAL", "description": "LXE408 administered by oral route, followed by Placebo administered by oral route", "interventionNames": ["Drug: LXE408", "Drug: Placebo"]}, {"label": "Placebo 28 days", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered by oral route", "interventionNames": ["Drug: Placebo"]}, {"label": "Benznidazole 60 days", "type": "ACTIVE_COMPARATOR", "description": "Benznidazole administered by oral route", "interventionNames": ["Drug: Benznidazole"]}], "interventions": [{"type": "DRUG", "name": "LXE408", "description": "LXE408 administered by oral route", "armGroupLabels": ["LXE408 14 days and Placebo 14 days", "LXE408 28 days"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo administered by oral route", "armGroupLabels": ["LXE408 14 days and Placebo 14 days", "Placebo 28 days"]}, {"type": "DRUG", "name": "Benznidazole", "description": "Benznidazole administered by oral route (administered as standard of care)", "armGroupLabels": ["Benznidazole 60 days"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 28 days versus placebo.", "description": "The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.", "timeFrame": "At Months 2, 4, and 6"}], "secondaryOutcomes": [{"measure": "Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 -14 days versus placebo", "description": "The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.", "timeFrame": "At Months 2, 4, and 6"}, {"measure": "Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months-LXE408 - 28 days and 14 days versus benznidazone", "description": "The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.", "timeFrame": "At Months 2, 4, and 6"}, {"measure": "Presence or absence of parasitological clearance", "description": "The parasitological load will be measured using polymerase chain reaction (PCR). The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Parasitological clearance is achieved if participant is negative at all 3 visits.", "timeFrame": "At Day 7, 14 and 28"}, {"measure": "Presence or absence of sustained parasitological clearance over 12 months by PCR testing", "description": "The parasitological load will be measured using polymerase chain reaction (PCR). The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all visits.", "timeFrame": "Up to 12 Months"}, {"measure": "Time to parasitological clearance based on serial PCR testing", "description": "Time to parasitological clearance based on PCR by treatment will be estimated using the Kaplan-Meier approach.", "timeFrame": "Up to 12 Months"}, {"measure": "Presence or absence of seroreversion using conventional serology", "description": "Seroreversion as measured by conventional serology will be evaluated at 6 and 12-month study visits. Seroreversion is determined by the proportion of participants achieving serology changes from positive at baseline to negative at each time point.", "timeFrame": "At Month 6 and Month 12"}, {"measure": "Occurrence and severity of treatment emergent adverse events during the study", "description": "Incidence and severity of AEs by treatment group, including changes in the vital signs, echocardiogram, electrocardiogram and laboratory results qualifying and reported as AEs.", "timeFrame": "Up to 12 Months"}, {"measure": "Occurrence of adverse events resulting in treatment discontinuation", "description": "Incidence of AEs that result in treatment discontinuation.", "timeFrame": "Up to 12 Months"}, {"measure": "Occurrence of all-cause mortality through end of study visit", "description": "Incidence of death through the end of study visit.", "timeFrame": "Up to 12 Months"}, {"measure": "Maximum plasma concentration (Cmax) of LXE408", "description": "Cmax is defined as the maximum (peak) observed concentration following a dose.", "timeFrame": "At Day 1, 7, 14, 28"}, {"measure": "Time to maximum plasma concentration (Tmax) of LXE408", "description": "Tmax is defined as the time to reach maximum (peak) concentration following a dose.", "timeFrame": "At Day 1, 7, 14, 28"}, {"measure": "Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8)", "description": "AUC0-8 will be calculated by non-compartmental methods based on LXE408 plasma concentration data.", "timeFrame": "At Day 1, 7, 14, 28"}, {"measure": "Pre-dose concentration", "description": "Pre-dose concentration is the observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval.", "timeFrame": "At Day 14 and Day 28"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female participants aged \u2265 18 years to \u2264 60 years old\n* Confirmed diagnosis of T. cruzi infection\n* History that participant has been determined to be in chronic phase of CD\n* Written informed consent must be obtained before any assessment is performed, and participants should express understanding of the consent form and the study\n* Participants must be considered by the investigator eligible for and able to comply with local prescribing information for benznidazole\n* Ability and willingness to communicate well with the investigator/study site and comply with requirements of the study\n\nExclusion Criteria:\n\n* Signs (on physical examination) and/or symptoms of CD in the acute phase as determined by the investigator at screening\n* History of CD treatment with benznidazole or nifurtimox at any time in the past\n* History of and/or current (at screening) symptoms or signs (physical examination findings) of moderate or severe CD-related gastrointestinal disease\n* Participants who weigh \\< 50 kg or \\>90kg at screening\n* At sites conducting the MRI assessments, participants may participate in the overall study, but will be excluded from the MRI assessment if they have contraindications to MRI imaging\n* Any clinically significant disease during screening that, in the opinion of the investigator, would put the safety of the participant at risk through participating, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study, or would compromise participant compliance or preclude completion of the study\n* Documented history or current findings at screening of clinically significant cardiovascular conditions such as, but not limited to: unstable ischemic heart disease; NYHA Class III/IV heart failure (due to Chagas disease or other conditions); arrhythmias\n* Known or suspected ongoing, chronic or recurrent viral, bacterial or fungal infectious diseases including but not limited to: Tuberculosis, leishmaniasis, severe malaria, atypical mycobacterial infection, listeriosis, aspergillosis, or endemic mycoses, and/or documented positivity for human immunodeficiency virus (HIV) infection\n* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years prior to screening (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed)\n* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant during the study period\n\n  * Pancreatic injury or pancreatitis: If any single parameter of amylase or lipase exceeds 1.5x ULN at screening Participants with known recurrent pancreatitis (more than 1 episode in lifetime, from any cause) are excluded\n  * Liver disease or liver injury as indicated by abnormal liver function tests (LFTs):\n\nAny single parameter of ALT, AST, GGT, alkaline phosphatase must not exceed 1.5x ULN at screening Serum bilirubin must not exceed the ULN at screening elevated serum bilirubin is not excluded if there is a documented history of Gilbert's Syndrome\n\n\u2022 History of renal disease as indicated by creatinine level above 1.5x ULN or microalbuminuria or hematuria at screening; Evidence of urinary obstruction, or difficulty in voiding at screening; evidence of congenital renal abnormalities with known effect on renal function; calculated eGFR \\<60 mL/min (\\<0.835 mL/s) using the CKD-EPI formula for adults\n\n* Participants with screening hematology parameters outside of the thresholds\n* Current use of medications prohibited by the protocol at screening and/or baseline visits, or expected use of any prohibited medication during the study treatment period\n* Use of other investigational drugs at the time of study drug dosing\n* History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study or to benznidazole\n* History of drug abuse or unhealthy alcohol use within the 12 months prior to dosing\n* Pregnant or nursing (lactating/breast-feeding) women\n* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 5 days after stopping of investigational drug and benznidazole\n* Participants who, in the opinion of the investigator, will not be able to comply with study procedures or visits, adhere to dosing schedule, or other otherwise be in compliance with study requirements\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Novartis Pharmaceuticals", "role": "CONTACT", "phone": "1-888-669-6682", "email": "novartis.email@novartis.com"}, {"name": "Novartis Pharmaceuticals", "role": "CONTACT", "phone": "+41613241111"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.", "url": "https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Novartis.aspx"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02517632", "orgStudyIdInfo": {"id": "CAAE:38038914.6.0000.5262"}, "organization": {"fullName": "Evandro Chagas National Institute of Infectious Disease", "class": "OTHER"}, "briefTitle": "Physical Exercise Program in Chronic Chagas Heart Disease", "officialTitle": "Impact of a Physical Exercise Program in Cardiopulmonary RehAbilitation In Patients With Chronic Chagas Heart Disease: a Randomized Controlled Trial (PEACH Trial)", "acronym": "PEACH"}, "statusModule": {"statusVerifiedDate": "2017-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-08-05", "studyFirstSubmitQcDate": "2015-08-06", "studyFirstPostDateStruct": {"date": "2015-08-07", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-07-25", "lastUpdatePostDateStruct": {"date": "2017-07-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Fernanda de Souza Nogueira Sardinha Mendes", "investigatorTitle": "Researcher", "investigatorAffiliation": "Evandro Chagas National Institute of Infectious Disease"}, "leadSponsor": {"name": "Evandro Chagas National Institute of Infectious Disease", "class": "OTHER"}, "collaborators": [{"name": "National Institute of Cardiology, Laranjeiras, Brazil", "class": "OTHER_GOV"}]}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease", "Chagas Cardiomyopathy"], "keywords": ["Physical activity", "Cardiac rehabilitation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "The intervention group performed exercise sessions, pharmaceutical and nutritional counceling. The control group had only pharmaceutical and nutritional counceling.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Exercise group", "type": "EXPERIMENTAL", "description": "This arm will be submitted to a exercise session and counseling from pharmaceutical and nutritional professionals.", "interventionNames": ["Behavioral: Exercise, nutritional and pharmaceutical counceling"]}, {"label": "Control group", "type": "OTHER", "description": "This arm will have only the counseling from pharmaceutical and nutritional professionals.", "interventionNames": ["Behavioral: Nutritional and pharmaceutical counceling"]}], "interventions": [{"type": "BEHAVIORAL", "name": "Exercise, nutritional and pharmaceutical counceling", "description": "The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.", "armGroupLabels": ["Exercise group"]}, {"type": "BEHAVIORAL", "name": "Nutritional and pharmaceutical counceling", "description": "The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.", "armGroupLabels": ["Control group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Functional capacity measured by peak exercise oxygen consumption", "description": "This measure is taken during a maximal progressive cardiopulmonary exercise test.", "timeFrame": "Changes from baselint at three and six months"}], "secondaryOutcomes": [{"measure": "Muscle respiratory strength", "description": "Maximal inspiratory pressure and maximal expiratory pressure (cmH2O)", "timeFrame": "Changes from baselint at three and six months"}, {"measure": "Body composition (body fat percentage)", "description": "Measurement of skinfold thickness were taken at the chest, midaxillary, triceps, subscapular, abdomen, suprailiac and thigh sites on the right side of the body while standing in a relaxed position. The sum of these seven skinfold thicknesses was used to estimate body composition by Jackson \\& Pollock equation.", "timeFrame": "Changes from baselint at three and six months"}, {"measure": "Cardiac function (maily ejection fraction)", "description": "Meaured by echocardiography", "timeFrame": "Changes from baselint at three and six months"}, {"measure": "Laboratorial biomarkers composite", "description": "Total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol,triacylglycerol, glucose, glycated hemoglobin, inflammatory cytokines, Brain Natriuretic Peptide and components of oxidative stress.", "timeFrame": "Changes from baselint at three and six months"}, {"measure": "Quality of life", "description": "Minnesota Living with Heart Failure questionnaire (MLHFQ). Score ranging from 0 - 105.", "timeFrame": "Changes from baselint at three and six months"}, {"measure": "24 hours Holter", "description": "Cardiac rhythm through continuous dynamic ECG", "timeFrame": "Changes from baselint at three and six months"}, {"measure": "Nutritional assessment", "description": "By semiquantitative food frequency questionnaire and 24-hour food intake recall.", "timeFrame": "Changes from baselint at three and six months"}, {"measure": "Pharmaceutical assessment", "description": "Semi-structured questionnaires, Morisky\u00b4s test, Naranjo Algorithm.", "timeFrame": "Changes from baselint at three and six months"}, {"measure": "Microvascular reactivity", "description": "Measured by laser speckle flowmetry", "timeFrame": "Changes from baselint at three and six months"}, {"measure": "Body mass index", "description": "Measured by the body weight (kg) divided by squared height (in meters).", "timeFrame": "Changes from baselint at three and six months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic cardiomyopathy, with left ventricular ejection fraction \\<45% or compensated heart failure (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical treatment and (5) age above 18 years.\n\nExclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4) evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise practice or hemodynamic stress tests (6) unavailability to attend three times a week for a minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Fernanda Mendes, M.D.", "affiliation": "Evandro Chagas National Institute of Infectious Disease", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation.", "city": "Rio de Janeiro", "zip": "21040-360", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}]}, "referencesModule": {"references": [{"pmid": "27590681", "type": "DERIVED", "citation": "Mendes Fde S, Sousa AS, Souza FC, Pinto VL, Silva PS, Saraiva RM, Xavier SS, Veloso HH, Holanda MT, Costa AR, Carneiro FM, Silva GM, Borges JP, Tibirica E, Pinheiro RO, Lara FA, Hasslocher-Moreno AM, Brasil PE, Mediano MF. Effect of physical exercise training in patients with Chagas heart disease: study protocol for a randomized controlled trial (PEACH study). Trials. 2016 Sep 2;17(1):433. doi: 10.1186/s13063-016-1553-4."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D002598", "term": "Chagas Cardiomyopathy"}, {"id": "D006331", "term": "Heart Diseases"}, {"id": "D009202", "term": "Cardiomyopathies"}], "ancestors": [{"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M5845", "name": "Chagas Cardiomyopathy", "asFound": "Chagas Cardiomyopathy", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02099903", "orgStudyIdInfo": {"id": "18400613.1.0000.0068"}, "organization": {"fullName": "InCor Heart Institute", "class": "OTHER"}, "briefTitle": "Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease", "officialTitle": "Transcatheter Renal Denervation in Patients With Systolic Heart Failure Due to Chagas' Disease - a Safety and Efficacy Study."}, "statusModule": {"statusVerifiedDate": "2014-03", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-03"}, "primaryCompletionDateStruct": {"date": "2014-12", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2015-08", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2014-03-19", "studyFirstSubmitQcDate": "2014-03-26", "studyFirstPostDateStruct": {"date": "2014-03-31", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-03-26", "lastUpdatePostDateStruct": {"date": "2014-03-31", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Pedro A. Lemos", "investigatorTitle": "Professor of Medicine", "investigatorAffiliation": "InCor Heart Institute"}, "leadSponsor": {"name": "InCor Heart Institute", "class": "OTHER"}, "collaborators": [{"name": "Johnson & Johnson", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Heart Failure", "Heart Failure, Systolic", "Chagas Disease", "Chagas Cardiomyopathy"], "keywords": ["Heart Failure", "Heart Failure, Systolic", "Chagas Disease", "Chagas Cardiomyopathy", "Renal Denervation", "Irrigated Radiofrequency Catheter"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Medical therapy for heart failure", "type": "NO_INTERVENTION", "description": "Standard optimized medical therapy for heart failure."}, {"label": "Renal denervation + medical therapy.", "type": "EXPERIMENTAL", "description": "Transcatheter Renal Denervation with irrigated radiofrequency catheter + standard medical therapy.", "interventionNames": ["Device: transcatheter renal denervation"]}], "interventions": [{"type": "DEVICE", "name": "transcatheter renal denervation", "description": "Renal sympathetic denervation with an irrigated radiofrequency catheter.", "armGroupLabels": ["Renal denervation + medical therapy."], "otherNames": ["Celsius Thermocool (Biosense Webster, California, USA)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Composite: death, myocardial infarction, cerebrovascular event, need of intervention on renal arteries and renal function impairment (decrease in estimated GFR > 30% from baseline).", "timeFrame": "30 days."}], "secondaryOutcomes": [{"measure": "Left Ventricular Ejection Fraction (LVEF) by echocardiography.", "timeFrame": "9 months."}, {"measure": "New York Heart Association (NYHA) functional class.", "timeFrame": "9 months."}, {"measure": "6-minute walk test", "timeFrame": "9 months."}, {"measure": "Peak Oxygen consumption (VO2) by ergoespirometry.", "timeFrame": "9 months."}], "otherOutcomes": [{"measure": "Change in serum B-type natriuretic peptide (BNP).", "timeFrame": "9 months."}, {"measure": "Quality of life assessed by Minnesota and EuroQOL five dimensions (EQ-5D)questionnaires.", "timeFrame": "9 months."}, {"measure": "Peripheral sympathetic activity measured by microneurography.", "timeFrame": "9 months."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients \u2265 18 to \u2264 70 years of age with chronic systolic heart failure, Chagas disease etiology.\n2. Two positive serology results for Chagas by two distinct methods.\n3. NYHA (New York Heart Association) class II or III.\n4. Patients treated with maximum tolerated doses of standard pharmacotherapy for heart failure.\n5. LVEF (Left Ventricular Ejection Fraction) \u2264 40% (Simpson Method).\n\nExclusion Criteria:\n\n1. Patients with NYHA class I or IV.\n2. Sustained ventricular tachycardia (\\>30 sec) or with hemodynamic compromise.\n3. Presence of permanent pacemaker or implantable defibrillator.\n4. Systolic blood pressure \\< 90 mmHg.\n5. Heart beat \\< 60 bpm at rest.\n6. Advanced renal insufficiency (estimated glomerular filtration rate (GFR) \\< 30 ml/min/1.73 square meters).\n7. Patients with planned cardiac surgery or percutaneous revascularization.\n8. Other reasons which would preclude the patient from participating in the study (comorbidities, life expectancy less than 1 year).\n9. Unsuitable anatomy of renal arteries, renal stenosis or previous treatment with balloon or stent.\n10. Refusal of the patient.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Heart Institute - InCor. University of Sao Paulo Medical School", "status": "RECRUITING", "city": "Sao Paulo", "zip": "05403-000", "country": "Brazil", "contacts": [{"name": "Patricia Pereira", "role": "CONTACT", "phone": "+55 11 2661-5368", "email": "patricia.pereira@incor.usp.br"}, {"name": "Pedro Lemos, MD PhD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -23.5475, "lon": -46.63611}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D002598", "term": "Chagas Cardiomyopathy"}, {"id": "D006333", "term": "Heart Failure"}, {"id": "D009202", "term": "Cardiomyopathies"}, {"id": "D054143", "term": "Heart Failure, Systolic"}, {"id": "D054160", "term": "Systolic Murmurs"}], "ancestors": [{"id": "D006331", "term": "Heart Diseases"}, {"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D006337", "term": "Heart Murmurs"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M12307", "name": "Neoplasm Metastasis", "relevance": "LOW"}, {"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "asFound": "Systolic", "relevance": "HIGH"}, {"id": "M5845", "name": "Chagas Cardiomyopathy", "asFound": "Chagas Cardiomyopathy", "relevance": "HIGH"}, {"id": "M27579", "name": "Heart Failure, Systolic", "asFound": "Heart Failure, Systolic", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M9425", "name": "Heart Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC04", "name": "Neoplasms"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC01", "name": "Infections"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00699387", "orgStudyIdInfo": {"id": "CHAGAS-CHILDREN-POPPK"}, "organization": {"fullName": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}, "briefTitle": "Population Pharmacokinetics of Benznidazole in Children With Chagas Disease", "officialTitle": "Population Pharmacokinetics Study of Benznidazole in Children With Chagas Disease"}, "statusModule": {"statusVerifiedDate": "2011-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-04"}, "primaryCompletionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-06-16", "studyFirstSubmitQcDate": "2008-06-17", "studyFirstPostDateStruct": {"date": "2008-06-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-07-29", "lastUpdatePostDateStruct": {"date": "2011-08-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Dr Jaime Altcheh", "oldOrganization": "Servicio de Parasitolog\u00eda, Hospital de Ni\u00f1os \"R Guti\u00e9rrez\" de Buenos Aires"}, "leadSponsor": {"name": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}, "collaborators": [{"name": "Thrasher Research Fund", "class": "OTHER"}, {"name": "The Hospital for Sick Children", "class": "OTHER"}, {"name": "Fundacion Bunge y Born (Argentina)", "class": "UNKNOWN"}, {"name": "Universidad Nacional de La Plata", "class": "OTHER"}, {"name": "Consejo de Investigacion en Salud Gobierno de Buenos Aires", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Chagas disease", "Pediatrics", "benznidazole", "population pharmacokinetics", "neglected diseases", "parasitology", "pediatric clinical pharmacology"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 37, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benznidazole", "type": "EXPERIMENTAL", "description": "Treatment of pediatric Chagas disease with benznidazole", "interventionNames": ["Drug: Benznidazole"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "description": "benznidazole (RADANIL\u00ae, Roche) 5-8 mg/kg/d bid PO for 60 days", "armGroupLabels": ["Benznidazole"], "otherNames": ["Children with Chagas Disease Treated with Benznidazole", "Ni\u00f1os con Chagas en Tratamiento con Benznidazol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Description of Population pharmacokinetics parameters of benznidazole (i.e. median population clearance, absorption and volume of distribution, and their respective inter-individual variabilities)", "timeFrame": "2 months (treatment period)"}], "secondaryOutcomes": [{"measure": "Adverse events", "timeFrame": "2 months (treatment period)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Children 2 - 12 years old of both sexes, with a diagnosis of Chagas' disease and eligible for treatment with benznidazole, as per current treatment protocols.\n* Chagas disease diagnostic criteria: At least 2 positive serological tests for Trypanosoma cruzi infection (ELISA, hemoagglutination, particle agglutination tests).\n* Informed consent signed by the parents, and consent or assent of the patients (according to age and consenting capacity).\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity to benznidazole or any of the drug excipients\n* Immunocompromised patients\n* Altered hepatic function (increase in AST/ALT x3 or bilirubin x3) or altered renal function (increase in creatinine x3)\n* Pregnancy", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "2 Years", "maximumAge": "12 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jaime Altcheh, MD", "affiliation": "Parasitology Service, Children's Hospital \"R. Gutierrez\" of Buenos Aires", "role": "STUDY_DIRECTOR"}, {"name": "Facundo Garcia Bournissen, MD", "affiliation": "Division of Clinical Pharmacology & Toxicology, Hospital for Sick Children, University of Toronto", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Norberto Giglio, MD", "affiliation": "Epidemiology Service, Children's Hospital \"R. Gutierrez\" of Buenos Aires", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Gideon Koren, MD", "affiliation": "Division of Clinical Pharmacology &Toxicology, Hospital for Sick Children, University of Toronto", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Oscar Della Vedova", "affiliation": "Universidad Nacional de La Plata", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Guido Mastrantonio", "affiliation": "Facultad de Ciencias Exactas, Universidad Nacional de La Plata", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Parasitology Division, Children's Hospital \"R Gutierrez\" of Buenos Aires", "city": "Buenos Aires", "zip": "1425", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}, "referencesModule": {"references": [{"pmid": "24853169", "type": "DERIVED", "citation": "Altcheh J, Moscatelli G, Mastrantonio G, Moroni S, Giglio N, Marson ME, Ballering G, Bisio M, Koren G, Garcia-Bournissen F. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis. 2014 May 22;8(5):e2907. doi: 10.1371/journal.pntd.0002907. eCollection 2014 May."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M28967", "name": "Neglected Diseases", "relevance": "LOW"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01547533", "orgStudyIdInfo": {"id": "LACT-BENZNIDAZOLE"}, "organization": {"fullName": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}, "briefTitle": "Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease", "officialTitle": "Study of Benznidazole Transfer Into Breastmilk in Lactating Women Treated for Chagas Disease", "acronym": "LACTBENZ"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-08"}, "primaryCompletionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-03-01", "studyFirstSubmitQcDate": "2012-03-07", "studyFirstPostDateStruct": {"date": "2012-03-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-03-17", "lastUpdatePostDateStruct": {"date": "2015-03-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Facundo Garcia-Bournissen", "investigatorTitle": "Associate Researcher", "investigatorAffiliation": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires"}, "leadSponsor": {"name": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chagas Disease", "Lactation"], "keywords": ["Chagas disease", "lactation", "breastmilk", "postpartum period", "infants", "pediatric clinical pharmacology", "developmental clinical pharmacology", "parasitology", "trypanosoma cruzi"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "breastmilk; plasma"}, "enrollmentInfo": {"count": 10, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lactating Women with Chagas disease", "description": "Women with Chagas disease who fulfill clinical criteria for treatment with benznidazole, and who are also lactating"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Benznidazole concentration in breastmilk and in plasma", "description": "Randomly obtained breastmilk samples will be obtained to both evaluate the breastmilk / plasma concentration ratio of the drug, and to develop a population pharmacokinetics model of drug trasfer into breastmilk, if possible.\n\nBreastmilk concentrations will be used to calculate potential infant exposure through breastmilk to the medication (benznidazole) taken by the mother", "timeFrame": "at randomly selected time points during the 30 days of treatment"}], "secondaryOutcomes": [{"measure": "incidence of adverse drug reactions in women treated with benznidazole during lactation", "description": "Women receiving treatment with benznidazole while lactating, enrolled in the study will be followed according to current clinical guidelines, and monitored during the 60 days of the treatment (as per Chagas disease treatment guidelines), and monthly for 3 months after treatment completion.", "timeFrame": "throughout the 30 days of treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Lactating women with Chagas disease, not treated before\n* Use of contraception\n\nExclusion Criteria:\n\n* History of allergy to benznidazole or its excipients\n* Pregnancy\n* Significant heart involvement (due to Chagas disease)\n* Significant systemic diseases that could affect the interpretation of the results in the opinion of the principal investigator", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"], "studyPopulation": "population of young women with Chagas disease referred to our center for evaluation and treatment", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Facundo Garcia Bournissen, MD PhD", "affiliation": "Buenos Aires Children\u00b4s Hospital Ricardo Gutierrez ; CONICET", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Parasitology and Chagas Service, Buenos Aires Children\u00b4s Hospital Ricardo Gutierrez", "city": "Buenos Aires", "zip": "1425", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}, "referencesModule": {"references": [{"pmid": "25210104", "type": "DERIVED", "citation": "Garcia-Bournissen F, Moroni S, Marson ME, Moscatelli G, Mastrantonio G, Bisio M, Cornou L, Ballering G, Altcheh J. Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease. Arch Dis Child. 2015 Jan;100(1):90-4. doi: 10.1136/archdischild-2014-306358. Epub 2014 Sep 10."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02295215", "orgStudyIdInfo": {"id": "NCT01900000"}, "organization": {"fullName": "University of Sao Paulo General Hospital", "class": "OTHER"}, "briefTitle": "Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction", "officialTitle": "Effects of Physical Training on Sensitivity Baroreflex Patients Without Chagas' Heart Ventricular Systolic Dysfunction", "acronym": "CH0660/10"}, "statusModule": {"statusVerifiedDate": "2013-06", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-06"}, "primaryCompletionDateStruct": {"date": "2015-12", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2015-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2014-08-25", "studyFirstSubmitQcDate": "2014-11-14", "studyFirstPostDateStruct": {"date": "2014-11-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-11-14", "lastUpdatePostDateStruct": {"date": "2014-11-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Sao Paulo General Hospital", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["chagas disease", "exercise", "baroreflex sensitivity"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 24, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sedentary Group", "type": "NO_INTERVENTION", "description": "The patients will not do exercise training"}, {"label": "Trained Group", "type": "EXPERIMENTAL", "description": "The patients will do exercise training for sixteen weeks.", "interventionNames": ["Other: Exercise"]}], "interventions": [{"type": "OTHER", "name": "Exercise", "description": "Exercise Training for 4 months", "armGroupLabels": ["Trained Group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Sympathetic nerve activityAutonomic control", "description": "Exercise training will improve baroreflex sensitivity and reduce sympathetic nerve activity.", "timeFrame": "4 months"}], "secondaryOutcomes": [{"measure": "Peak oxygen consumption", "description": "Exercise training will improve peak oxygen consumption", "timeFrame": "4 months"}, {"measure": "Skeletal muscle strength", "description": "Exercise training will increase skeletal muscle strength", "timeFrame": "4 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Chagas' disease patients, diagnosed with at least two positive serological reactions to Chagas' disease,\n* Ejection fraction \u226555%\n\nExclusion Criteria:\n\n* Participation in a regular exercise program in the last 3 months preceding the survey\n* Use of oral anticoagulant\n* Use of a pacemaker or implantable cardioverter\n* Hemodynamic instability\n* Myocardial revascularization infarction or unstable angina in the last 3 months of the start of the protocol\n* Diabetes mellitus\n* Hypertension\n* Pulmonary Disease\n* Valvular lesions\n* Atrial Fibrillation\n* Angina of effort", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "25 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Carlos E Negr\u00e3o", "role": "CONTACT", "phone": "5511 26615699", "email": "cndnegrao@incor.usp.br"}, {"name": "Adriana S Oliveira", "role": "CONTACT", "phone": "5511 26615057", "email": "adriana.sarmento@usp.br"}], "overallOfficials": [{"name": "Adriana O Sarmento", "affiliation": "University of Sao Paulo General Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Heart Institute - HC-FMUSP", "status": "RECRUITING", "city": "Sao Paulo", "state": "SP", "zip": "05403-900", "country": "Brazil", "contacts": [{"name": "Adriana S Oliveira", "role": "CONTACT", "phone": "5511 26615057", "email": "adriana.sarmento@usp.br"}], "geoPoint": {"lat": -23.5475, "lon": -46.63611}}]}, "referencesModule": {"references": [{"pmid": "32875456", "type": "DERIVED", "citation": "Sarmento AO, Antunes-Correa LM, Alves MJNN, Bacurau AVN, Fonseca KCB, Pessoa FG, Lobo DML, Moreira LDP, Trombetta IC, Rondon MUPB, Rondon E, Vieira MLC, Ramires FJA, do Brasileiro-Santos MS, Brum PC, Mady C, Negrao CE, Thomas S, Ianni BM. Effect of exercise training on cardiovascular autonomic and muscular function in subclinical Chagas cardiomyopathy: a randomized controlled trial. Clin Auton Res. 2021 Apr;31(2):239-251. doi: 10.1007/s10286-020-00721-1. Epub 2020 Sep 1."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M20824", "name": "Ventricular Dysfunction", "relevance": "LOW"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC01", "name": "Infections"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03189056", "orgStudyIdInfo": {"id": "Chagas_urology"}, "organization": {"fullName": "Institut de Recherche pour le Developpement", "class": "OTHER_GOV"}, "briefTitle": "Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation", "officialTitle": "Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation"}, "statusModule": {"statusVerifiedDate": "2018-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-07-14", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-10-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-10-20", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-06-09", "studyFirstSubmitQcDate": "2017-06-13", "studyFirstPostDateStruct": {"date": "2017-06-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-03-26", "lastUpdatePostDateStruct": {"date": "2018-03-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Elsa BEY", "investigatorTitle": "Resident in urological surgery", "investigatorAffiliation": "Institut de Recherche pour le Developpement"}, "leadSponsor": {"name": "Institut de Recherche pour le Developpement", "class": "OTHER_GOV"}, "collaborators": [{"name": "Instituto de Investigaci\u00f3n Hospital Universitario La Paz", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Chagas' Disease (Chronic) With Other Organ Involvement"], "keywords": ["chronic Chagas disease", "bladder", "lower urinary tract", "urodynamic"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "ECOLOGIC_OR_COMMUNITY", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 152, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Single cohort", "description": "single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography\n\nIf symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure.", "interventionNames": ["Diagnostic Test: Chagas serology", "Biological: Creatinina", "Procedure: Urodynamic exploration"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "Chagas serology", "description": "IFI + ELISA method if no biological confirmation of chagas disease is in our possession", "armGroupLabels": ["Single cohort"]}, {"type": "BIOLOGICAL", "name": "Creatinina", "description": "Plasmatic single mesure after consultation 1, to evaluate renal function", "armGroupLabels": ["Single cohort"]}, {"type": "PROCEDURE", "name": "Urodynamic exploration", "description": "With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled", "armGroupLabels": ["Single cohort"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Symptomatic patients", "description": "ICIQ SF\\>0 IPSS\\>7 or past acute urinary retention IIEF5\\<11", "timeFrame": "at consultation : 1 day (transversal study, the participant will not be followed)"}], "secondaryOutcomes": [{"measure": "Megabladder", "description": "Bladder capacity \\>600cc and \\<4 daily micturition", "timeFrame": "at consultation : 1 day (transversal study, the participant will not be followed)"}, {"measure": "Mega ureter", "description": "Ultrasonographic dilatation of renal pelvis\\>20mm or of ureter \\>7mm", "timeFrame": "at consultation : 1 day (transversal study, the participant will not be followed)"}, {"measure": "Hyperactive bladder", "description": "\\>8 daily micturition + urgency on dairy subsection detrusor hyperactivity on cystomanometry", "timeFrame": "micturition calendar over 2 days (transversal study, the participant will not be followed)"}, {"measure": "Detrusor underactivity", "description": "Qmax\\<15 mL/s and post void residual\\>150cc per-micturition pressure \\<40 cm H2O", "timeFrame": "at consultation : 1 day (transversal study, the participant will not be followed)"}, {"measure": "Renal insufficiency", "description": "CDK EPI\\<60 mL/mn", "timeFrame": "at consultation : 1 day (transversal study, the participant will not be followed)"}, {"measure": "Urinary recurrent infections", "description": "past history \\> 3 py\u00e9lonephritis or \\>5 cystitis/year in the past 5 years, if associated with dilatated ureter/renal pelvis or significant post void residual", "timeFrame": "reported infections duing the last 5 years (transversal study, the participant will not be followed)"}, {"measure": "Urinary sphincter insufficiency", "description": "P max\\<30 cm H20 and stress urinary incontinence", "timeFrame": "at consultation : 1 day (transversal study, the participant will not be followed)"}, {"measure": "Erectile dysfunction in males", "description": "IIEF5 \\<16", "timeFrame": "at consultation : 1 day (transversal study, the participant will not be followed)"}, {"measure": "Hypofertility", "description": "oral assess by difficulty to obtain pregnancy \\>1 year", "timeFrame": "at consultation : 1 day (transversal study, the participant will not be followed)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female between 18 and 50 years of age\n* Presenting a chronic form of Chagas disease : cardiopathy or enteropathy\n* Previously treated or not treated\n* Signed informed consent\n\nExclusion Criteria:\n\n* Diabetes\n* Neurologic pathology\n* Past history of extensive pelvic surgery\n* Vaginal prolaps \\> grade 3 of Baden \\& Walker (female)\n* Past history of vertebral fracture \\> L2", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"], "studyPopulation": "All patients presenting a chronic form of chagas disease diagnosed by the SELADIS institute (serology), by cardiology, gastro-enterology or infectious disease consultation in La Paz may be include, after the informed consent have been signed.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Elsa BEY, Resident", "affiliation": "IRD", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "SELADIS Institute, Universidad Mayor de San Andr\u00e8s", "city": "La Paz", "country": "Bolivia", "geoPoint": {"lat": -16.5, "lon": -68.15}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Jelicks, Linda A., et Herbert B. Tanowitz. \" Advances in Imaging of Animal Models of Chagas Disease \". Advances in Parasitology 75 (2011): 193-208. doi:10.1016/B978-0-12-385863-4.00009-5.", "url": "https://doi.org/10.1016/B978-0-12-385863-4.00009-5"}, {"label": "Ny, Lars et al. \" A Magnetic Resonance Imaging Study of Intestinal Dilation in Trypanosoma Cruzi-Infected Mice Deficient in Nitric Oxide Synthase \". The American Jour", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701742/"}, {"label": "Ardito et al. \" Chronic Renal Impairment in Patients with Chagas Cardiomyopathy with Chronic Systolic Heart Failure: Prevalence and Prognostic Significance \". Inte", "url": "http://dx.doi.org/10.1016/j.ijcard.2011.07.060"}, {"label": "Koeberle, F. \" ENTEROMEGALY AND CARDIOMEGALY IN CHAGAS DISEASE \". Gut 4 (d\u00e9cembre 1963): 399-405.", "url": "https://www.ncbi.nlm.nih.gov/pubmed/14084752"}, {"label": "Mirkin et al. \" Experimental Chagas' Disease: Electrophysiology and Cell Composition of the Neuromyopathic Inflammatory Lesions in Mice Infected with a Myotropic and a Pantropic Strain of", "url": "https://www.ncbi.nlm.nih.gov/pubmed/9030871"}, {"label": "Cabrine-Santos et al. \" Genitourinary Changes in Hamsters Infected and Reinfected with Trypanosoma Cruzi \". Mem\u00f3rias Do Insti", "url": "https://www.ncbi.nlm.nih.gov/pubmed/12937767"}, {"label": "Scremin, L. H., C. E. Corbett, M. D. Laurenti, E. V. Nunes, J. J. Gama-Rodrigues, et M. Okumura. \" Megabladder in Experimental Chagas Disease: Pathological Features of the Bladder Wall \". Revista Do Hospital Das Cl\u00ednicas 54, n\u1d52 2 (avril 1999): 43-46.", "url": "https://www.ncbi.nlm.nih.gov/pubmed/10513065"}, {"label": "Suaid et al. \" Modulation of Urethral Alpha-Sympathetic by Parasympathetic before and Following Bethanechol Chloride Injection \". International Braz J Urol: Official J", "url": "https://www.ncbi.nlm.nih.gov/pubmed/15745502"}, {"label": "DeFaria, C. R., J. M. De Rezende, et A. Rassi. \" \\[Peripheral denervation in the various clinical forms of Chagas' disease\\] \". Arquivos De Neuro-Psiquiatria 46, n\u1d52 3 (septembre 1988): 225-37.", "url": "https://www.ncbi.nlm.nih.gov/pubmed/2851967"}, {"label": "Carraro, A. A., R. A. Lopes, R. D. Ribeiro, et T. L. Lamano Carvalho. \" The Male Reproductive Organs in the Chronic Phase of Experimental Chagas' Disease \". Angewandte Parasitologie 33, n\u1d52 1 (f\u00e9vrier 1992): 3-9.", "url": "https://www.ncbi.nlm.nih.gov/pubmed/1590593"}, {"label": "Rocha, J. N., H. J. Suaid, A. C. P. Martins, A. J. Cologna, S. Tucci Jr., et M. A. Gon\u00e7alves. \" URODYNAMIC ASSESSEMENT IN PATIENTS WITH CHAGAS DISEASE \". Acta Cirurgica Brasileira 16 (2001): 7-8. doi:10.1590/S0102-86502001000500003.", "url": "http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0102-86502001000500003&lng=en&nrm=iso&tlng=pt"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "asFound": "Chronic", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00453700", "orgStudyIdInfo": {"id": "06H-561004"}, "organization": {"fullName": "Olive View-UCLA Education & Research Institute", "class": "OTHER"}, "briefTitle": "Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram", "officialTitle": "Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram"}, "statusModule": {"statusVerifiedDate": "2007-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2009-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-03-28", "studyFirstSubmitQcDate": "2007-03-28", "studyFirstPostDateStruct": {"date": "2007-03-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2019-03-11", "lastUpdatePostDateStruct": {"date": "2019-03-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Sheba Meymandi", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "University of California, Los Angeles"}, "leadSponsor": {"name": "Olive View-UCLA Education & Research Institute", "class": "OTHER"}, "collaborators": [{"name": "Centers for Disease Control and Prevention", "class": "FED"}]}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["chagas", "trypanosoma cruzi"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 327, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "serological testing", "description": "In Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles, serological testing for Trypanosoma cruzi was performed at enrollment.", "interventionNames": ["Procedure: Trypanosoma cruzi serology"]}], "interventions": [{"type": "PROCEDURE", "name": "Trypanosoma cruzi serology", "armGroupLabels": ["serological testing"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Prevalence of positive trypanosoma cruzi serologies", "timeFrame": "At enrollment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* One of the following EKG abnormalities:\n\n  * Complete or incomplete right bundle branch block (RBBB)\n  * Left anterior fascicular block (LAFB)\n  * Left bundle branch block (LBBB)\n* Residence at any point in past in an endemic area (any country in Central or South America or Mexico) for at least 12 months.\n* Age \\>18 and \\<60.\n\nExclusion Criteria:\n\n* Ejection fraction \\<40%\n* Symptomatic heart failure\n* Documented coronary artery disease", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"], "studyPopulation": "All Latin American immigrant patients with newly diagnosed nonischemic cardiomyopathy at one U.S. medical center were asked to participate in this study.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sheba K Meymandi, M.D.", "affiliation": "OV-UCLA Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "OV-UCLA Medical Center", "city": "Sylmar", "state": "California", "zip": "91342", "country": "United States", "geoPoint": {"lat": 34.30778, "lon": -118.44925}}]}}, "annotationSection": {"annotationModule": {"unpostedAnnotation": {"unpostedResponsibleParty": "Sheba Meymandi, Principal Investigator, University of California, Los Angeles", "unpostedEvents": [{"type": "RELEASE", "date": "2021-02-22"}, {"type": "RESET", "date": "2021-03-16"}]}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2021-02-22", "submissionInfos": [{"releaseDate": "2021-02-22", "resetDate": "2021-03-16"}]}}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M12", "name": "Congenital Abnormalities", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02369978", "orgStudyIdInfo": {"id": "124156935014"}, "organization": {"fullName": "Universidad Aut\u00f3noma de Bucaramanga", "class": "OTHER"}, "briefTitle": "CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)", "officialTitle": "Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis)", "acronym": "CHICAMOCHA-3"}, "statusModule": {"statusVerifiedDate": "2017-07", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-08", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-08", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2019-02", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2015-02-17", "studyFirstSubmitQcDate": "2015-02-23", "studyFirstPostDateStruct": {"date": "2015-02-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-07-18", "lastUpdatePostDateStruct": {"date": "2017-07-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Juan Carlos Villar, MD, PhD", "investigatorTitle": "Professor, Department of Medicine", "investigatorAffiliation": "Universidad Aut\u00f3noma de Bucaramanga"}, "leadSponsor": {"name": "Universidad Aut\u00f3noma de Bucaramanga", "class": "OTHER"}, "collaborators": [{"name": "Fundaci\u00f3n Cardioinfantil Instituto de Cardiolog\u00eda", "class": "OTHER"}, {"name": "Instituto Nacional de Salud, Colombia", "class": "OTHER_GOV"}, {"name": "Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben", "class": "OTHER_GOV"}]}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Trypanocidal therapy", "Benznidazole", "Nifurtimox", "Polymerase chain reaction", "Randomized trial"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 500, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Nifurtimox (NFX)", "type": "EXPERIMENTAL", "description": "60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)", "interventionNames": ["Drug: Nifurtimox"]}, {"label": "Benznidazole (BZN)", "type": "ACTIVE_COMPARATOR", "description": "60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)", "interventionNames": ["Drug: Benznidazole"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "120 days of treatment with matching placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Nifurtimox", "description": "Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D", "armGroupLabels": ["Nifurtimox (NFX)"], "otherNames": ["Lampit (Bayer)"]}, {"type": "DRUG", "name": "Benznidazole", "description": "Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D", "armGroupLabels": ["Benznidazole (BZN)"], "otherNames": ["Radanil (Roche), Rochagan (Roche), Abarax (ELEA)"]}, {"type": "DRUG", "name": "Placebo", "description": "Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D", "armGroupLabels": ["Placebo"], "otherNames": ["Control group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Quantitative Polymerase Chain Reaction (qPCR) for Trypanosoma cruzi", "description": "Proportion of participants with at least one out of three positive tests (performed at least one week apart from each other)", "timeFrame": "12 - 18 months after starting therapy"}], "secondaryOutcomes": [{"measure": "T. cruzi positive serology status", "description": "Proportion of participants with positive T. cruyzi serology status", "timeFrame": "12 months after starting therapy"}, {"measure": "Mean change in T. cruzi antibody titers", "description": "Mean change (before-after) in antibody readings as measured with ELISA serology", "timeFrame": "12 months after starting therapy"}], "otherOutcomes": [{"measure": "Reported adverse reactions", "description": "Proportion of participants with at least one of the following a) Reporting hospitalization or inability to work b) Stopping study treatment because of adverse reactions /intolerance c) having abnormal levels of at least two biochemical or blood markers", "timeFrame": "60 days after starting therapy"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Positive serology status to Trypanosoma cruzi\n* No clinical signs of dilated cardiomyopathy\n\nExclusion Criteria:\n\n* Unacceptable risk of re-infection, based on the investigators judgment\n* Previous treatment with NFX or BZN\n* History of peripheral neuropathy\n* Health condition limiting the mobility, cognitive function or life expectancy within two years of the enrollment visit\n* Pregnancy / Unwilling to use reliable contraceptive methods during childbearing age", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Juan C Villar, MD, PhD", "role": "CONTACT", "phone": "+5776436111", "phoneExt": "514", "email": "jvillar@unab.edu.co"}, {"name": "Bernardo I Useche, PhD", "role": "CONTACT", "phone": "+5776436111", "phoneExt": "539", "email": "buseche@unab.edu.co"}], "overallOfficials": [{"name": "Juan C Villar, MD, PhD", "affiliation": "Universidad Aut\u00f3noma de Bucaramanga", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Fundaci\u00f3n Oftalmol\u00f3gica de Santander - Cl\u00ednica Ardila Lulle (FOSCAL)", "status": "RECRUITING", "city": "Bucaramanga", "state": "Santander", "country": "Colombia", "contacts": [{"name": "Gustavo A Parra, MD", "role": "CONTACT", "email": "guparra@unab.edu.co"}, {"name": "Skarlet M V\u00e1squez, RN, MSc", "role": "CONTACT", "email": "svasquez196@unab.edu.co"}], "geoPoint": {"lat": 7.12539, "lon": -73.1198}}]}, "referencesModule": {"references": [{"pmid": "24867876", "type": "BACKGROUND", "citation": "Villar JC, Perez JG, Cortes OL, Riarte A, Pepper M, Marin-Neto JA, Guyatt GH. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2014 May 27;2014(5):CD003463. doi: 10.1002/14651858.CD003463.pub2."}, {"pmid": "31307503", "type": "DERIVED", "citation": "Villar JC, Herrera VM, Perez Carreno JG, Vaquiro Herrera E, Castellanos Dominguez YZ, Vasquez SM, Cucunuba ZM, Prado NG, Hernandez Y. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial. Trials. 2019 Jul 15;20(1):431. doi: 10.1186/s13063-019-3423-3. Erratum In: Trials. 2019 Aug 20;20(1):516. doi: 10.1186/s13063-019-3630-y."}]}}, "annotationSection": {"annotationModule": {"unpostedAnnotation": {"unpostedResponsibleParty": "Juan Carlos Villar, MD, PhD, Professor, Department of Medicine, Universidad Aut\u00f3noma de Bucaramanga", "unpostedEvents": [{"type": "RELEASE", "date": "2023-04-05"}, {"type": "RESET", "date": "2024-01-11"}]}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2023-04-05", "submissionInfos": [{"releaseDate": "2023-04-05", "resetDate": "2024-01-11"}]}}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D014352", "term": "Trypanosomiasis"}], "ancestors": [{"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "asFound": "Trypanosomiasis", "relevance": "HIGH"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}, {"id": "D009547", "term": "Nifurtimox"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M12486", "name": "Nifurtimox", "asFound": "DSM-IV", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03708133", "orgStudyIdInfo": {"id": "19500"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation", "officialTitle": "Open-label, Randomized, Single-dose, Cross-over Study to Assess Bioequivalence Between a Single 120 mg Nifurtimox Tablet and a Newly Developed 120 mg Nifurtimox Tablet, Administered Orally Under Fed Conditions to Adult Male and Female Patients With Chronic Chagas' Disease"}, "statusModule": {"statusVerifiedDate": "2020-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-12-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-04-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-06-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-10-12", "studyFirstSubmitQcDate": "2018-10-12", "studyFirstPostDateStruct": {"date": "2018-10-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-06-09", "lastUpdatePostDateStruct": {"date": "2020-06-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "conditionsModule": {"conditions": ["Bioequivalence"], "keywords": ["New formulation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 24, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Test Treatment + Reference Treatment", "type": "EXPERIMENTAL", "description": "Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:\n\n1. Test treatment\n2. Reference treatment", "interventionNames": ["Drug: Nifurtimox (Lampit, BAYA2502)_Test", "Drug: Nifurtimox (Lampit, BAYA2502)_Reference"]}, {"label": "Reference Treatment + Test Treatment", "type": "EXPERIMENTAL", "description": "Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:\n\n1. Reference treatment\n2. Test treatment", "interventionNames": ["Drug: Nifurtimox (Lampit, BAYA2502)_Test", "Drug: Nifurtimox (Lampit, BAYA2502)_Reference"]}], "interventions": [{"type": "DRUG", "name": "Nifurtimox (Lampit, BAYA2502)_Test", "description": "Orally intake of 1 \\*120mg new formulation tablet as test treatment", "armGroupLabels": ["Reference Treatment + Test Treatment", "Test Treatment + Reference Treatment"]}, {"type": "DRUG", "name": "Nifurtimox (Lampit, BAYA2502)_Reference", "description": "Orally intake of 1 \\*120mg current clinical formulation tablet as reference treatment", "armGroupLabels": ["Reference Treatment + Test Treatment", "Test Treatment + Reference Treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AUC of nifurtimox in plasma", "description": "AUC:area under the concentration versus time curve from zero to infinity after single (first) dose", "timeFrame": "Pre-dose (up to 30 minutes before study drug administration), and at 15 minutes, 30 minutes, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 15 hours post-dose"}, {"measure": "AUC(0-tlast) of nifurtimox in plasma", "description": "AUC(0-tlast): AUC from time 0 to the last data point \\> LLOQ(lower limit of quantitation)", "timeFrame": "Pre-dose (up to 30 minutes before study drug administration), and at 15 minutes, 30 minutes, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 15 hours post-dose"}, {"measure": "Cmax of nifurtimox in plasma", "description": "Cmax: Maximum observed drug concentration in measured matrix after single dose administration", "timeFrame": "Pre-dose (up to 30 minutes before study drug administration), and at 15 minutes, 30 minutes, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 15 hours post-dose"}], "secondaryOutcomes": [{"measure": "tmax of nifurtimox in plasma", "description": "tmax: time to reach Cmax", "timeFrame": "Pre-dose (up to 30 minutes before study drug administration), and at 15 minutes, 30 minutes, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 15 hours post-dose"}, {"measure": "t1/2 of nifurtimox in plasma", "description": "t1/2: Half-life associated with terminal slope", "timeFrame": "Pre-dose (up to 30 minutes before study drug administration), and at 15 minutes, 30 minutes, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 15 hours post-dose"}, {"measure": "AUCnorm of nifurtimox in plasma", "description": "AUCnorm: AUC divided by dose per body weight", "timeFrame": "Pre-dose (up to 30 minutes before study drug administration), and at 15 minutes, 30 minutes, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 15 hours post-dose"}, {"measure": "Cmax,norm of nifurtimox in plasma", "description": "Cmax,norm: Cmax divided by dose per body weight", "timeFrame": "Pre-dose (up to 30 minutes before study drug administration), and at 15 minutes, 30 minutes, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 15 hours post-dose"}, {"measure": "Number of participants with treatment emergent adverse events", "timeFrame": "Up to 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n- Male/female patient diagnosed with chronic Chagas' disease: Previous diagnosis of acute or chronic Chagas' disease by a health clinic prior to screening for the study. The diagnosis of chronic Chagas' disease may be made by clinical findings, supported by antibody titers if available. If there is a known history of acute disease, it is preferable to have documentation of parasites on the blood smear, if available.\n\n* Women and men of reproductive potential must agree to use adequate contraception when sexually active. This applies for the time period between signing of the informed consent form and 12 weeks after the last administration of study drug. The definition of adequate contraception will be based on the judgment of the investigator and on local requirements. Acceptable methods of contraception include, but are not limited to: (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based contraception. Subjects must agree to utilize two reliable and acceptable methods of contraception simultaneously.\n* Women of childbearing potential with confirmed last menstrual period by anamnesis and negative serum pregnancy test (beta-human chorionic gonadotropin \\[\u03b2hCG\\]) at screening and negative urine pregnancy test (\u03b2hCG) at pre-dose of each treatment.\n* Women of non-childbearing potential, such as surgically sterile women with either written documentation of surgical sterility or negative serum pregnancy test (\u03b2hCG) at screening and negative urine pregnancy test (\u03b2hCG) at pre-dose of each treatment.\n* Male subjects who agree not to act as sperm donors for 12 weeks after last administration of study drug.\n* Age: 18 to 45 years (inclusive) at screening.\n* Body mass index (BMI): \u226518 and \\<29.9 kg/m\u00b2.\n* At least 3 months since delivery or abortion, or 3 months since cessation of lactation before screening.\n* Ability to understand and follow study-related instructions.\n\nExclusion Criteria\n\n* Acute Chagas' disease. (During the acute phase, the parasite on a blood smear may be seen under a microscope. Different antibodies are present, depending on the course of the disease).\n* Known hypersensitivity to the study drug (active substance or excipients of the preparations)\n* Suspected or known porphyria.\n* Clinically significant allergies (e.g. allergies affecting the lower respiratory tract such as allergic asthma or allergies requiring therapy with systemic corticosteroids) within 1 year.\n* Clinically significant non-allergic drug reactions, or multiple severe drug allergies (e.g. adverse reactions in the form of bronchospasm, asthma, rhinitis or urticaria after taking non-steroidal anti-inflammatory drugs).\n* Unstable or uncontrolled medical condition such as hypertension or diabetes, decompensated heart failure, GI conditions that would interfere with the absorption of the study drug (e.g. GI ulceration, peptic ulceration, GI bleeding, gastroesophageal reflux, or other GI disease affecting gastroesophageal junction), conditions that could potentially have an impact on drug metabolism or elimination (renal, hepatic such as known hepatic or biliary abnormalities), or any clinically relevant active infections in the opinion of the investigator within 4 weeks before the screening visit, e.g. clinically relevant history or presence of significant respiratory (e.g. interstitial lung disease), hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, metabolic (e.g. diabetes), and dermatological or connective tissue disease.\n* Incompletely cured pre-existing diseases (except chronic Chagas' disease without active GI condition) for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study drugs will not be normal.\n* Febrile illness within 1 week before the first study drug administration.\n* Systolic blood pressure \\<100 or \\>140 mmHg (after resting in supine position for a minimum of 15 minutes).\n* Diastolic blood pressure \\<50 or \\>90 mmHg (after resting in supine position for a minimum of 15 minutes).\n* Heart rate \\<45\n* Positive pregnancy test.\n* Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV 1+2).\n* Positive urine drug screening.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "FP Clinical Pharma", "city": "Buenos Aires", "state": "Ciudad Auton. De Buenos Aires", "zip": "C1425BAB", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Click here to find results for studies related to Bayer Healthcare products.", "url": "https://clinicaltrials.bayer.com/"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M25306", "name": "Malnutrition", "relevance": "LOW"}, {"id": "M17107", "name": "Chagas Disease", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D009547", "term": "Nifurtimox"}], "ancestors": [{"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M12486", "name": "Nifurtimox", "asFound": "DSM-IV", "relevance": "HIGH"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01842854", "orgStudyIdInfo": {"id": "CEP-41-10"}, "secondaryIdInfos": [{"id": "Galectin-Chagas", "type": "REGISTRY", "domain": "CEP HSR 41-10"}], "organization": {"fullName": "Hospital Sao Rafael", "class": "OTHER"}, "briefTitle": "Galectin-3 as a Biomarker in Patients With Chagas Disease", "officialTitle": "Validation of Galectin-3 as a Biomarker for Determining Patients Prognosis With Chagas Disease"}, "statusModule": {"statusVerifiedDate": "2017-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-01"}, "primaryCompletionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-04-18", "studyFirstSubmitQcDate": "2013-04-25", "studyFirstPostDateStruct": {"date": "2013-04-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-11-27", "lastUpdatePostDateStruct": {"date": "2017-11-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Milena Botelho Pereira Soares", "investigatorTitle": "PhD", "investigatorAffiliation": "Hospital Sao Rafael"}, "leadSponsor": {"name": "Hospital Sao Rafael", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Galectin-3", "Chagas disease", "Biomarkers"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "CROSS_SECTIONAL"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "Plasma, Serum, Whole Blood"}, "enrollmentInfo": {"count": 60, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with Chagas disease diagnosis", "description": "Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Correlation of plasmatic levels of Galectin-3 with the percentage of heart fibrosis", "description": "Mensuration of heart fibrosis percentage with Magnetic Resonance Imaging", "timeFrame": "One year"}], "secondaryOutcomes": [{"measure": "Correlation of plasmatic levels of Galectin-3 with the functional capacity of the heart", "description": "Mensuration of the functional capacity with treadmill test", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of Galectin-3 with the serum levels of Pro-BNP.", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of Galectin-3 with the serum levels of TNF-alpha", "timeFrame": "One year"}, {"measure": "Correlation of plasmatic levels of Galectin-3 with the serum levels of IFN-gamma.", "timeFrame": "One year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Chagas Disease diagnosis confirmed by 2 different serologies\n* Diagnosis of indeterminate form or cardiac form, with and without ventricular dysfunction.\n\nExclusion Criteria:\n\n* Significant valve disease defined as aortic stenosis with a gradient of VE/Ao \\> 50 mmHg\n* Mitral stenosis with a valve area inferior than 1,5 cm2\n* Severe or moderate aortic and/or mitral regurgitation\n* Chronic use of immunosuppressive agents\n* Dialysis treatment of terminal renal failure\n* Fever on the last 48 hours or evidence of systemic infection in activity according to the definition of sepsis of the ACCP/SCCM (American College os Chest Physicians/Society of Critical Care Medicine)\n* Current abusive use of alcohol or illicit drugs (Based on the DSM IV)\n* Any other comorbidities that impact patient's survival within the next 2 years\n* Liver disease in activity\n* Continuous use of steroids as treatment for COPD\n* Hematologic, neoplastic or bone diseases\n* Homeostasis disturbances\n* Inflammatory diseases or chronic infectious diseases", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Tertiary Hospital", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Milena Botelho Pereira Soares, PhD", "affiliation": "Hospital S\u00e3o Rafael", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Ricardo Ribeiro dos Santos, MD, PhD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_DIRECTOR"}, {"name": "Ticiana Ferreira Larocca, MD, MSC", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "M\u00e1rcia Maria Noya Rabelo, MD, MSC", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Lu\u00eds Cl\u00e1udio Lemos Correia, MD, PhD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Bruno Solano de Freitas Souza, MD, MSC", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}, {"name": "Carolina Th\u00e9 Macedo, MD", "affiliation": "Hospital S\u00e3o Rafael", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Hospital S\u00e3o Rafael", "city": "Salvador", "state": "Bahia", "zip": "41253-190", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}]}, "referencesModule": {"references": [{"pmid": "27548475", "type": "DERIVED", "citation": "Noya-Rabelo MM, Larocca TF, Macedo CT, Torreao JA, Souza BS, Vasconcelos JF, Souza LE, Silva AM, Ribeiro Dos Santos R, Correia LC, Soares MB. Evaluation of Galectin-3 as a Novel Biomarker for Chagas Cardiomyopathy. Cardiology. 2017;136(1):33-39. doi: 10.1159/000447529. Epub 2016 Aug 23."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03378661", "orgStudyIdInfo": {"id": "DNDi-CH-E1224-003"}, "organization": {"fullName": "Drugs for Neglected Diseases", "class": "OTHER"}, "briefTitle": "BENDITA BEnznidazole New Doses Improved Treatment and Associations", "officialTitle": "Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease", "acronym": "BENDITA"}, "statusModule": {"statusVerifiedDate": "2017-12", "overallStatus": "UNKNOWN", "lastKnownStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-11-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-01-28", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2018-07-27", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2017-11-23", "studyFirstSubmitQcDate": "2017-12-14", "studyFirstPostDateStruct": {"date": "2017-12-20", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-12-14", "lastUpdatePostDateStruct": {"date": "2017-12-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Drugs for Neglected Diseases", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "conditionsModule": {"conditions": ["Chagas Disease"], "keywords": ["Chronic, Indeterminate"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Parallel Assignment", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "Double Dummy", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 210, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BZN STD Regimen", "type": "EXPERIMENTAL", "description": "Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 8 weeks.\n\nThree E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks.", "interventionNames": ["Drug: Benznidazole", "Drug: E1224 Placebo"]}, {"label": "BZN 300 mg - 4 wks", "type": "EXPERIMENTAL", "description": "Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks, followed by:\n\nBenznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.\n\nThree E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks.", "interventionNames": ["Drug: Benznidazole", "Drug: E1224 Placebo", "Drug: Benznidazole Placebo"]}, {"label": "BZN 300 mg - 2 wks", "type": "EXPERIMENTAL", "description": "Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 2 weeks, followed by:\n\nBenznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 6 weeks.\n\nThree E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks.", "interventionNames": ["Drug: Benznidazole", "Drug: E1224 Placebo", "Drug: Benznidazole Placebo"]}, {"label": "BZN 150 mg - 4 wks", "type": "EXPERIMENTAL", "description": "Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:\n\nBenznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.\n\nThree E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks.", "interventionNames": ["Drug: Benznidazole", "Drug: E1224 Placebo", "Drug: Benznidazole Placebo"]}, {"label": "BZN 150 mg - 4 wks / E1224 300 mg", "type": "EXPERIMENTAL", "description": "Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:\n\nBenznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.\n\nThree E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg).", "interventionNames": ["Drug: Benznidazole", "Drug: E1224", "Drug: Benznidazole Placebo"]}, {"label": "BZN 300 mg (weekly) 8 wks / E1224 300 mg", "type": "EXPERIMENTAL", "description": "Benznidazole (100 mg and 50 mg) tablets by mouth, once weekly for 8 weeks (total 8 days of intermittent treatment) and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in the other 6 days of the week for 8 weeks\n\nThree E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg).", "interventionNames": ["Drug: Benznidazole", "Drug: E1224", "Drug: Benznidazole Placebo"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Benznidazole Placebo (100 mg and 50mg) tablets by mouth, every 12 hours for 8 weeks.\n\nThree E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks.", "interventionNames": ["Drug: E1224 Placebo", "Drug: Benznidazole Placebo"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "description": "Benznidazole tablet", "armGroupLabels": ["BZN 150 mg - 4 wks", "BZN 150 mg - 4 wks / E1224 300 mg", "BZN 300 mg (weekly) 8 wks / E1224 300 mg", "BZN 300 mg - 2 wks", "BZN 300 mg - 4 wks", "BZN STD Regimen"], "otherNames": ["Abarax\u00ae", "N-benzil-2-nitro-1-imidazolacetamide)", "Lafepe Benznidazol", "ABALEA\u00ae"]}, {"type": "DRUG", "name": "E1224", "description": "E1224 capsules", "armGroupLabels": ["BZN 150 mg - 4 wks / E1224 300 mg", "BZN 300 mg (weekly) 8 wks / E1224 300 mg"], "otherNames": ["Fosravuconazole", "E1224 (prodrug for active ingredient Ravuconazole)"]}, {"type": "DRUG", "name": "E1224 Placebo", "description": "E1224 matched placebo capsules", "armGroupLabels": ["BZN 150 mg - 4 wks", "BZN 300 mg - 2 wks", "BZN 300 mg - 4 wks", "BZN STD Regimen", "Placebo"], "otherNames": ["Placebo (for E1224)"]}, {"type": "DRUG", "name": "Benznidazole Placebo", "description": "Benznidazole matched placebo tablets", "armGroupLabels": ["BZN 150 mg - 4 wks", "BZN 150 mg - 4 wks / E1224 300 mg", "BZN 300 mg (weekly) 8 wks / E1224 300 mg", "BZN 300 mg - 2 wks", "BZN 300 mg - 4 wks", "Placebo"], "otherNames": ["Placebo (for Benznidazole)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Parasitological response as determined by serial negative qualitative PCR results (3 negative PCR results, from 3 samples to be collected in the same day) at EOT and sustained parasitological clearance until 6 months follow-up.", "description": "To determine the efficacy of different dosing regimens of orally administered BZN and BZN/E1224 in individuals with chronic indeterminate CD, by determining the proportion of patients who convert from positive to negative in serial, qualitative PCR test results (3 negative PCR results) at end of treatment (EOT) and sustain parasitological clearance at 6 months of follow-up, in comparison to placebo.\n\nFor efficacy assessments, the EOT of each treatment arm will be defined in accordance to the duration of the treatment regimen. Sustained response will be assessed in all treatment arms using the same number of PCR samples (i.e., EOT; 12 weeks; 4 and 6 months).", "timeFrame": "From the end of the treatment period up to 6 months."}], "secondaryOutcomes": [{"measure": "Incidence of Adverse Events (AEs)", "description": "The safety consists the description of each serious adverse event and adverse event (preferred term) per treatment group and classified by system organ. EkG and Laboratory abnormalities will be considered as Adverse Events.", "timeFrame": "Through study completion, i.e up to 12 months."}, {"measure": "Severity of Adverse Events (AEs)", "description": "The safety consists the description of each serious adverse event and adverse event (preferred term) per treatment group and classified by system organ. EkG and Laboratory abnormalities will be considered as Adverse Events.", "timeFrame": "Through study completion, i.e up to 12 months."}, {"measure": "Incidence of Serious Adverse Events (SAEs) and/or adverse events leading to treatment discontinuation", "timeFrame": "Through study completion, i.e up to 12 months"}, {"measure": "Sustained parasitological clearance at 12 weeks and 12 months of follow-up", "description": "To assess the sustained parasitological response at week 12 and 12 months for each of the regimens, in comparison with placebo.\n\nTo determine the efficacy of the different dosing regimens in individuals with chronic indeterminate CD, by determining the proportion of patients who convert from positive to negative in serial, qualitative PCR test results (3 negative PCR results) at EOT, in comparison with placebo.", "timeFrame": "From the end of the treatment period up to 12 months."}, {"measure": "Parasite clearance as measured by qualitative PCR", "description": "To assess the time to parasite DNA clearance (below the Quantitative Polymerase Chain Reaction (qPCR) Limit of Detection (LOD) for each of the regimens.\n\nTo assess the time to sustained clearance of parasitemia for each of the regimens.", "timeFrame": "Weeks 1, 2, 3, 4, 6, 10, 12, and at 4, 6, and 12 months follow-up"}, {"measure": "Change in parasite load over time assessed as measured by quantitative PCR", "description": "To measure the reduction in parasite load at weeks 1, 2, 3, 4, 6, 10, 12 and at 4, 6 and 12 months follow-up, as measured by quantitative PCR.", "timeFrame": "Weeks 1, 2, 3, 4, 6, 10, 12, and at 4, 6, and 12 months follow-up."}, {"measure": "Serological response by conventional serology assessed at 12 months of follow up and non-conventional serology assessed at W12, 4, 6, and 12 months of follow up. (changes in titters over time)", "description": "To evaluate serological response by conventional serology at 12 months of follow up and non-conventional serology at week 12, 4, 6 and 12 months of follow up.", "timeFrame": "From the end of the treatment period up to 12 months."}], "otherOutcomes": [{"measure": "Area under the plasma concentration versus time curve (AUC) of ravuconazole and benznidazole", "description": "Characterization of population pharmacokinetic parameters of orally administered BZN and BZN/E1224", "timeFrame": "D0 (pre-dose), day 1 (post-dose), day 2, day 3, steady-state phase (week 2-10)"}, {"measure": "Peak Plasma Concentration (Cmax) of ravuconazole and benznidazole", "description": "To characterize the population pharmacokinetic parameters of orally administered BZN and BZN/E1224", "timeFrame": "D0 (pre-dose), day 1 (post-dose), day 2, day 3, steady-state phase (week 2-10)"}, {"measure": "Minimum Plasma Concentration (Cmin) of ravuconazole and benznidazole", "description": "To characterize the population pharmacokinetic parameters of orally administered BZN and BZN/E1224", "timeFrame": "D0 (pre-dose), day 1 (post-dose), day 2, day 3, steady-state phase (week 2-10)"}, {"measure": "Clearance of ravuconazole and benznidazole", "description": "To characterize the population pharmacokinetic parameters of orally administered BZN and BZN/E1224", "timeFrame": "D0 (pre-dose), day 1 (post-dose), day 2, day 3, steady-state phase (week 2-10)"}, {"measure": "Volume of Distribution of ravuconazole and benznidazole", "description": "To characterize the population pharmacokinetic parameters of orally administered BZN and BZN/E1224", "timeFrame": "D0 (pre-dose), day 1 (post-dose), day 2, day 3, steady-state phase (week 2-10)"}, {"measure": "Plasma Terminal Half-Life (t1/2) of ravuconazole and benznidazole", "description": "To characterize the population pharmacokinetic parameters of orally administered BZN and BZN/E1224", "timeFrame": "D0 (pre-dose), day 1 (post-dose), day 2, day 3, steady-state phase (week 2-10)"}]}, "eligibilityModule": {"eligibilityCriteria": "Screening criteria\n\n* Signed, written informed consent form\n* Age \\>18 to \\<50 years\n* Weight \\>50 kg to \\<80 kg\n* Diagnosis of T. cruzi infection by: Conventional serology (a minimum of two positive tests \\[Conventional ELISA, Recombinant Elisa and/or Indirect Immunofluorescence (IIF)\\])\n* Ability to comply with all protocol specified tests and visits and have a permanent address\n* Patients must be residents of areas free of vectorial transmission (Triatoma infestans). For this protocol, it will be accepted the status of Vectorial Transmission Interruption or Consolidation as per the definition of PAHO/WHO, or the Local Health Program.\n* No signs and/or symptoms of the chronic cardiac and/or digestive form of CD\n* No acute or chronic health conditions, that in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial drug (such as acute infections, history of HIV infection, liver and renal disease requiring treatment)\n* No formal contraindication to BZN (according to the Summary of Product Characteristics) and E1224 (according to the Investigator's Brochure) Note: The contraindications described for Benznidazole and E1224 are essentially hypersensitivity to the active ingredient or any excipient. In the case of hepatic or renal impairment or blood dyscrasia, the medication should only be administered under strict medical supervision. During all the treatment period, the blood count will be monitored, with special attention to leucocytes. Subjects will be indicated about the need of no alcohol intake.\n* No history of hypersensitivity, allergic, or serious adverse reactions to any of the \"azoles\" compound, and/or its components\n* No history of CD treatment with BZN or NFX at any time in the past\n* No history of systemic treatment with itraconazole, ketoconazole, posaconazole, isavuconazole, or allopurinol in the past\n* No history of alcohol abuse or any other drug addiction (as specified in the Study Manual of Operations)\n* No condition that prevents patient from taking oral medication\n* No concomitant or anticipated use of drugs that are either sensitive CYP3A4 substrates and/or extensively metabolized by CYP3A4 with a narrow therapeutic range (as per Appendix 2)\n* No medical history of Familial Short QT syndrome or concomitant therapy with medications that can shorten the QT interval (as per Appendix 2)\n* No family history of sudden death\n* No family history of sudden infant death syndrome\n\nInclusion criteria\n\nFollowing the screening period, patients must meet ALL of the following inclusion criteria to be eligible for randomization:\n\n* Confirmed diagnosis of T. cruzi infection by: Serial qualitative PCR (three samples collected over a single day, at least one of which must be positive) AND Conventional serology (a minimum of two positive tests must be positive \\[Conventional ELISA, Recombinant Elisa and/or IIF)\n* Women in reproductive age must have a negative serum pregnancy test at screening, must not be breastfeeding, and must use a double barrier method of contraception to avoid pregnancy throughout a clinical trial and for 3 months after completion of the trial, in such a manner that the risk of pregnancy is minimized especially during exposure to treatment. Women who are using oral, implanted, or injectable contraceptive hormones or mechanical products such as an intrauterine device with a hormonal component are required to use an additional barrier method of contraception for the time period specified.\n* Normal EKG (PR \u2264200 msec, QRS \\<120 msec, and QTc \u2265350 msec and \u2264450 msec interval durations in males and QTc \u2264470 msec in women) at screening.\n\nExclusion criteria\n\nThe presence of any of the following will exclude a patient from trial randomization:\n\n* Signs and/or symptoms of chronic cardiac and/or digestive form of CD\n* History of cardiomyopathy, heart failure, or ventricular arrhythmia.\n* History of digestive surgery or mega syndromes.\n* Any other acute or chronic health conditions that, in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial drug (such as acute infections, history of HIV infection, diabetes, uncontrolled systolic/diastolic blood pressure, liver, and renal disease requiring medical treatment).\n* Laboratory test values considered clinically significant or out of the allowable range at selection period as follows:\n* Total WBC must be within the normal range, with an acceptable margin of +/- 5% (3,800 - 10,500/mm3).\n* Platelets must be within the normal range up to 550,000/mm3\n* Total bilirubin must be within the normal range\n* Transaminases (ALT and AST) must be within the normal range, with an acceptable margin of 25% above the upper limit of normality (ULN), \\<1.25 x ULN.\n* Creatinine must be within an acceptable margin of 10% above the ULN, \\<1.10 x ULN.\n* Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (\\< 2.5 x ULN)\n* GGT must be within the normal range up to 2x ULN.\n* Fasting glucose must be within the normal range\n* Electrolytes (Ca, Mg, K) must be within the normal range\n* If the results of the blood tests (hematology and biochemistry) are out of the ranges defined above, but within the limits of CTCAE (version 4.03) Grade 1, and the laboratory finding is considered as non-clinically significant, a new sample can be collected for a retest. Only one retest will be allowed within the screening period.\n* If the result of retest is within the margins defined above, the Investigator will review the parameter(s) together with all other medical information available (medical history, clinical examinations, vital signs, etc.) and upon his/her medical judgment will decide if the patient is eligible or not for trial randomization.\n* Any condition that prevents the patient from taking oral medication\n* Patients with history of allergy (serious or not), allergic skin rash, asthma, intolerance, sensitivity or photosensitivity to any drug\n* Patients with any contra-indication (known hypersensitivity) to any nitroimidazoles, e.g. metronidazole.\n* Any concomitant use of allopurinol, antimicrobial, or anti-parasitic agents.\n* Any planned surgery likely to interfere with the trial conduction and/or treatment evaluation\n* Unlikely to co-operate with the trial\n* Any previous participation in any clinical trial for Chagas Disease treatment evaluation\n* Participation in another trial at the same time or within 3 months prior to selection (according to local regulations)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Faustino Torrico, PhD", "affiliation": "Plataforma de Atenci\u00f3n Integral de Pacientes con Enfermedad de Chagas. Cochabamba, Bolivia.", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Joaquim Gasc\u00f3n, PhD", "affiliation": "Centro de Salud Internacional, Hospital Cl\u00ednico de Barcelona CRESIB - Centre de Recerca en Salut Internacional de Barcelona Barcelona, Espa\u00f1a.", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Plataforma de Atenci\u00f3n Integral de Pacientes con Enfermedad de Chagas.", "city": "Sucre", "state": "Chuquisaca", "country": "Bolivia", "geoPoint": {"lat": -19.03332, "lon": -65.26274}}, {"facility": "Plataforma de Atenci\u00f3n Integral de Pacientes con Enfermedad de Chagas.", "city": "Cochabamba", "country": "Bolivia", "geoPoint": {"lat": -17.3895, "lon": -66.1568}}, {"facility": "Plataforma de Atenci\u00f3n Integral de Pacientes con Enfermedad de Chagas.", "city": "Tarija", "country": "Bolivia", "geoPoint": {"lat": -21.53549, "lon": -64.72956}}]}, "referencesModule": {"references": [{"pmid": "33836161", "type": "DERIVED", "citation": "Torrico F, Gascon J, Barreira F, Blum B, Almeida IC, Alonso-Vega C, Barboza T, Bilbe G, Correia E, Garcia W, Ortiz L, Parrado R, Ramirez JC, Ribeiro I, Strub-Wourgaft N, Vaillant M, Sosa-Estani S; BENDITA study group. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis. 2021 Aug;21(8):1129-1140. doi: 10.1016/S1473-3099(20)30844-6. Epub 2021 Apr 6. Erratum In: Lancet Infect Dis. 2021 Aug;21(8):e208. doi: 10.1016/S1473-3099(21)00419-9."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "annotationSection": {"annotationModule": {"unpostedAnnotation": {"unpostedResponsibleParty": "Drugs for Neglected Diseases", "unpostedEvents": [{"type": "RELEASE", "date": "2022-04-15"}, {"type": "RESET", "date": "2023-01-20"}]}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2022-04-15", "submissionInfos": [{"releaseDate": "2022-04-15", "resetDate": "2023-01-20"}]}}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01489228", "orgStudyIdInfo": {"id": "DNDi-CH-E1224-001"}, "organization": {"fullName": "Drugs for Neglected Diseases", "class": "OTHER"}, "briefTitle": "Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease", "officialTitle": "Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease"}, "statusModule": {"statusVerifiedDate": "2011-12", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-06"}, "primaryCompletionDateStruct": {"date": "2012-08", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2013-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2011-11-24", "studyFirstSubmitQcDate": "2011-12-07", "studyFirstPostDateStruct": {"date": "2011-12-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-12-19", "lastUpdatePostDateStruct": {"date": "2011-12-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Drugs for Neglected Diseases", "class": "OTHER"}, "collaborators": [{"name": "Eisai Co., Ltd.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "conditionsModule": {"conditions": ["Chronic Chagas Disease, Indeterminate"], "keywords": ["Chagas Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 230, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "High Dose E1224", "type": "EXPERIMENTAL", "description": "High Dose (HD - 8weeks) Group", "interventionNames": ["Drug: E1224"]}, {"label": "Low Dose E1224", "type": "EXPERIMENTAL", "description": "Low Dose (LD - 8 weeks) Group", "interventionNames": ["Drug: E1224"]}, {"label": "Short Dose E1224", "type": "EXPERIMENTAL", "description": "Short Dose (SD - 4 weeks) Group", "interventionNames": ["Drug: E1224"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo (8 weeks) Group", "interventionNames": ["Drug: Placebo"]}, {"label": "Benznidazol", "type": "ACTIVE_COMPARATOR", "description": "BZN (Laborat\u00f3rio do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days", "interventionNames": ["Drug: Benznidazole"]}], "interventions": [{"type": "DRUG", "name": "E1224", "description": "100 mg tablets", "armGroupLabels": ["High Dose E1224", "Low Dose E1224", "Short Dose E1224"], "otherNames": ["E1224 (prodrug for active ingredient Ravuconazole)"]}, {"type": "DRUG", "name": "Benznidazole", "description": "100mg tablets", "armGroupLabels": ["Benznidazol"], "otherNames": ["Benznidazole (N-benzil-2-nitro-1-imidazolacetamida)"]}, {"type": "DRUG", "name": "Placebo", "description": "tablets", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatment", "description": "To determine whether at least one of three dosing regimens of orally administered E1224 is more efficacious than placebo in individuals with chronic indeterminate CD, by determining the number of patients who convert from positive to negative in serial, qualitative PCR test results", "timeFrame": "Day 65 (end of treatment)"}], "secondaryOutcomes": [{"measure": "Consistently negative serial qualitative PCR as a measure of sustained parasitological eradication", "timeFrame": "4, 6 and 12 months follow-up"}, {"measure": "Qualitative PCR as a measure of parasite eradication", "timeFrame": "Day 8, 15, 36 , 65 and at 4, 6 and 12 months follow-up"}, {"measure": "Quantitative PCR as a measure of change in parasite load over time", "timeFrame": "Day 8, 15, 36, 65 and at 4, 6 and 12 months follow-up"}, {"measure": "Incidence of serological conversion to negative and changes in titers over time as measured by conventional and non-conventional serologies", "timeFrame": "Day 65 and at 4, 6 and 12 months after treatment"}, {"measure": "Changes in the levels of biomarkers over time: brain natriuretic peptide, troponin T, selected prothrombotic factors, lytic antibodies, apolipoprotein A1 and multiplex serodiagnostic assay", "timeFrame": "Day 36 , 65 and at 4, 6 and 12 months follow-up"}, {"measure": "Area under the plasma concentration versus time curve (AUC), Peak Plasma Concentration (Cmax), Minimum Plasma Concentration (Cmin), Clearance, Volume of Distribution , and Plasma Terminal Half-Life (t1/2) of ravuconazole and benznidazole", "description": "Samples for population pharmacokinetics parameters of ravuconazole and benznidazole will be collected at randomly selected time points on Days 1, 2 and 3.", "timeFrame": "Day 0 (pre-dose), Day 1 (after 1st dose), Day 2, Day 3, steady-state phase (D8-D50), at the end of treatment (D65) and at the 4 months follow-up visit"}, {"measure": "Incidence and severity of adverse events (clinical and laboratory)", "timeFrame": "Up to 12 months follow-up"}, {"measure": "Incidence of Serious Adverse Events and/or adverse events leading to treatment discontinuation", "timeFrame": "Up to 12 months follow-up"}, {"measure": "Early and late predictors of sustainable response to treatments", "timeFrame": "Up to 12 months follow-up"}, {"measure": "Correlation of pharmacokinetic parameters with parasitological response, changes in biomarkers and safety outcomes", "timeFrame": "Day 8, 15, 36, 65, and at 4, 6 months and 12 months follow-up"}]}, "eligibilityModule": {"eligibilityCriteria": "Screening Criteria:\n\n* Age \\>18 to \\< 50 years\n* Weight \\> 40 kg\n* Diagnosis of T. cruzi infection by conventional serology (a minimum of two out of three positive tests \\[enzyme linked immunosorbent assay (ELISA), indirect immunofluorescence (IIF), or hemagglutination inhibition (HAI)\\])\n* Signed, written informed consent form\n* No signs and/or symptoms of the chronic cardiac and/or digestive form of CD\n* No acute or chronic health conditions that may interfere with the efficacy and/or safety evaluation of the study drug\n* No formal contraindication to BZN and E1224\n* No known history of hypersensitivity, allergic, or serious adverse reactions to the study drugs\n* No history of CD treatment with BZN or NFX at any time in the past\n* No history of systemic treatment with itraconazole, ketoconazole, posaconazole, isavuconazole, or allopurinol in the past\n\nInclusion Criteria:\n\n* Confirmed diagnosis of T. cruzi infection by serial qualitative PCR AND Conventional serology\n* Women in reproductive age must have a negative serum pregnancy test at screening, must not be breastfeeding, and consistently use and/or have partner consistently use an adequate contraceptive method\n* Normal ECG at screening\n\nExclusion Criteria:\n\n* Abnormal laboratory test values at screening for the following parameters: total White Blood Cells (WBC) count, platelet count, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, or creatinine; or gamma-glutamyl transferase (GGT)\n* History of alcohol abuse or any other drug addiction (as specified in the Study Manual of Operations)\n* Any condition that prevents the patient from taking oral medication\n* Any concomitant use of antimicrobial or antiparasitic agents", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Fabiana P Alves, PhD", "role": "CONTACT", "phone": "+552122152941", "email": "falves@dndi.org"}], "overallOfficials": [{"name": "Isabela Ribeiro, MD", "affiliation": "Drugs for Neglected Diseases initiative", "role": "STUDY_DIRECTOR"}, {"name": "Faustino Torrico, PhD", "affiliation": "Universidad Mayor San Sim\u00f3n. Cochabamba, Bolivia.", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Joaquim Gasc\u00f3n, PhD", "affiliation": "CRESIB - Centre de Recerca en Salut Internacional de Barcelona, Spain.", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Plataforma de Atenci\u00f3n Integral a los Pacientes con Enfermidad de Chagas", "status": "RECRUITING", "city": "Cochabamba", "country": "Bolivia", "contacts": [{"name": "Faustino Torrico, PhD", "role": "CONTACT"}, {"name": "Cristina Alonso, MD", "role": "CONTACT"}, {"name": "Faustino Torrico, PhD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -17.3895, "lon": -66.1568}}, {"facility": "Plataforma de Atenci\u00f3n Integral a los Pacientes con Enfermidad de Chagas", "status": "RECRUITING", "city": "Tarija", "country": "Bolivia", "contacts": [{"name": "Lourdes Ortiz, MSc", "role": "CONTACT"}, {"name": "Lourdes Ortiz, MSc", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": -21.53549, "lon": -64.72956}}]}, "referencesModule": {"references": [{"pmid": "30509941", "type": "DERIVED", "citation": "Parrado R, Ramirez JC, de la Barra A, Alonso-Vega C, Juiz N, Ortiz L, Illanes D, Torrico F, Gascon J, Alves F, Flevaud L, Garcia L, Schijman AG, Ribeiro I. Usefulness of Serial Blood Sampling and PCR Replicates for Treatment Monitoring of Patients with Chronic Chagas Disease. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01191-18. doi: 10.1128/AAC.01191-18. Print 2019 Feb."}, {"pmid": "29352704", "type": "DERIVED", "citation": "Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, Almeida IC, Alves F, Strub-Wourgaft N, Ribeiro I; E1224 Study Group. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018 Apr;18(4):419-430. doi: 10.1016/S1473-3099(17)30538-8. Epub 2018 Jan 16."}], "seeAlsoLinks": [{"label": "Drugs for Neglected Diseases initiative", "url": "http://www.dndi.org"}]}}, "annotationSection": {"annotationModule": {"unpostedAnnotation": {"unpostedResponsibleParty": "Drugs for Neglected Diseases", "unpostedEvents": [{"type": "RELEASE", "date": "2022-04-15"}, {"type": "RESET", "date": "2023-01-18"}]}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2022-04-15", "submissionInfos": [{"releaseDate": "2022-04-15", "resetDate": "2023-01-18"}]}}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01539161", "orgStudyIdInfo": {"id": "Reveal Chagas"}, "organization": {"fullName": "Medtronic Cardiac Rhythm and Heart Failure", "class": "INDUSTRY"}, "briefTitle": "Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease", "officialTitle": "Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease"}, "statusModule": {"statusVerifiedDate": "2016-10", "overallStatus": "TERMINATED", "whyStopped": "Extremely low enrollment rate", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-07"}, "primaryCompletionDateStruct": {"date": "2015-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-02-09", "studyFirstSubmitQcDate": "2012-02-21", "studyFirstPostDateStruct": {"date": "2012-02-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-10-10", "lastUpdatePostDateStruct": {"date": "2016-10-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Medtronic Cardiac Rhythm and Heart Failure", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease", "Heart Diseases"], "keywords": ["Chagas Disease", "Chagasic", "Reveal XT", "Implantable Cardiac Monitor", "ICM"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 12, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Reveal XT plus SOC", "type": "EXPERIMENTAL", "description": "Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.", "interventionNames": ["Device: Implantable Cardiac Monitor"]}, {"label": "Standard of Care", "type": "ACTIVE_COMPARATOR", "description": "Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.", "interventionNames": ["Procedure: Standard of Care"]}], "interventions": [{"type": "DEVICE", "name": "Implantable Cardiac Monitor", "description": "9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.", "armGroupLabels": ["Reveal XT plus SOC"], "otherNames": ["9529 Reveal XT", "9539 Reveal XT Patient Assistant"]}, {"type": "PROCEDURE", "name": "Standard of Care", "description": "Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.", "armGroupLabels": ["Standard of Care"], "otherNames": ["SOC"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "To compare the time to the physician's decision to treat for electrical disorders (brady/tachyarrhythmias) between the two randomized groups.", "description": "The primary endpoint is time to the first decision to implant a device (IPG, CRT-P, ICD or CRT-D) or prescribe anti-arrhythmic drugs.", "timeFrame": "36 months"}], "secondaryOutcomes": [{"measure": "Summarize the recorded arrhythmic events stored within the ICM (bradyarrhythmia and tachyarrhythmia.", "description": "Compute summary statistics for arrhythmic events recorded during follow-up, whether or not related to symptoms, for all patients in the ICM arm, including the total number, distribution (e.g., minimum, maximum, median, quartiles, and standard deviation), number per patient year, number of patients having events and percentage of patients having events. Summary statistics for bradyarrhythmia and tachyarrhythmia events will also be computed separately.", "timeFrame": "36 months"}, {"measure": "Compute the time duration spent in arrhythmias for ICM patients.", "description": "Compute the total duration each ICM patient spends in, 1) atrial arrhythmias and 2) ventricular arrhythmias during the entire follow-up period, and their corresponding distribution (e.g., minimum, maximum, median, quartiles, standard deviation). Compute the average duration each patient spends in an, 1) atrial arrhythmia event, and 2) a ventricular arrhythmia event, and the corresponding distributions.", "timeFrame": "36 months"}, {"measure": "Compute the incidence of symptomatic arrhythmias in patients with an ICM", "description": "Compute the incidence rate of symptomatic arrhythmias in patients with an ICM, overall, and for bradyarrhythmias and tachyarrhythmias separately.", "timeFrame": "36 months"}, {"measure": "Compare the time to the physician's decision to treat with components of the composite primary endpoint between randomization arms.", "description": "Individually compare the time to the physicians' decision to treat with the following between the two randomization arms:\n\n* A device of any type (IPG, CRT-P, ICD or CRT-D)\n* A pacemaker (IPG)\n* Anti-arrhythmic drug therapy\n* A defibrillator (ICD or CRT-D) or prescribe anti-arrhythmic drug therapy", "timeFrame": "36 months"}, {"measure": "Compare the mortality rate between randomization arms.", "description": "Compare the mortality rate between randomization arms.", "timeFrame": "36 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have Chagas disease, confirmed by two serological tests.\n* Provide evidence through any of the following diagnosis methods: Rest ECG, 24 hour Holter monitoring, electrophysiological study, stress test or loop monitoring, at least one electrical disorder consistent with sinus bradycardia greater than 45 and lower than 60 bpm, sinus arrest not greater than 2.0 seconds, second degree atrial sinus block, intraventricular conduction disorders such as right branch, left branch or a bifascicular blockage type, first degree A-V blockage, or of type I second degree AV Block without associated bradycardia, atrial and/or ventricular arrhythmias that do NOT constitute an indication for pacemaker implant, ICD or mapping and radio frequency ablation.\n* Be asymptomatic or having minimal isolated unspecific symptoms not consistent with cardiac arrest, aborted sudden death, syncope, frequent and recurrent palpitations, cardiac failure, and lower extremity edema.\n* Have ejection fraction of left ventricle \\>35%\n* Be able to give his/her written informed consent.\n* Subject should be \\> 21 years old.\n* Be able to return for follow-up visits as required.\n\nExclusion Criteria:\n\n* Class I or II (according to AHA/HRS/ESC guidelines) indication for final implantation of pacemaker, ICD, or cardiac resynchronizer.\n* Exhibit extrinsic causes of sinus dysfunction or A-V blockage.\n* Exhibit infiltrative myocardial diseases such as tumors or associated valvular defects.\n* Suffer any concurrent disease that may limit the follow up or evaluation.\n* Suffer aftereffects of cerebral embolism.\n* Suffer ablation or isolation of pulmonary veins previous to their inclusion in the study.\n* Not being able or willing to comply with the follow-up schedule.\n* Have previous lesions of the spinal cord or aftereffects of skull trauma.\n* Have a record of epilepsy.\n* Receive pharmacological treatment for other diseases that may modify the autonomic function.\n* Have a record of myocardial infarction.\n* History of alcohol abuse or drug addiction.\n* History of emotional instability, unstable psychiatric disorders or are under treatment for such disorders.\n* Have previously implanted pacemakers, cardiodefibrillators or CRT systems.\n* Are included or intend to participate in another study of devices during the course of this study.\n* Have a clinical condition that may limit life expectancy to \\< 36 months.\n* Use of Antiarrhythmic drugs, except Beta Blockers", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Claudio Muratore, MD", "affiliation": "Medtronic", "role": "STUDY_CHAIR"}, {"name": "Diego Venagas, MD", "affiliation": "Colombia", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Jose Carlos Pachon Mateos, MD", "affiliation": "Brazil", "role": "STUDY_CHAIR"}, {"name": "Luis Medesani, MD", "affiliation": "Argentina - Hospital Interzonal Gernal de Agudos \"General Jos\u00e9 de San Martin\"", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hospital General de Agudos \"Juan Fernandez\"", "city": "Buenos Aires", "state": "Caba", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Hospital Interzonal General de Agudos \"General Jos\u00e9 de San Martin\"", "city": "La Plata", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"facility": "Fundacion Cardioinfantil", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Hospital Militar Central", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28", "removedCountries": ["Brazil"]}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}, {"id": "D006331", "term": "Heart Diseases"}], "ancestors": [{"id": "D002318", "term": "Cardiovascular Diseases"}, {"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01744405", "orgStudyIdInfo": {"id": "LACT-NIFURTIMOX"}, "organization": {"fullName": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}, "briefTitle": "Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease", "officialTitle": "Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease", "acronym": "LACTNFX"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-12"}, "primaryCompletionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-12-05", "studyFirstSubmitQcDate": "2012-12-05", "studyFirstPostDateStruct": {"date": "2012-12-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-03-17", "lastUpdatePostDateStruct": {"date": "2015-03-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Facundo Garcia-Bournissen", "investigatorTitle": "Associate Resesarcher", "investigatorAffiliation": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires"}, "leadSponsor": {"name": "Hospital de Ni\u00f1os R. Gutierrez de Buenos Aires", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease", "Lactation"], "keywords": ["Chagas disease", "lactation", "breastmilk", "postpartum period", "infants", "pediatric clinical pharmacology", "developmental clinical pharmacology", "parasitology", "trypanosoma cruzi", "nifurtimox"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "breastmilk; plasma"}, "enrollmentInfo": {"count": 12, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lactating Women with Chagas disease", "description": "Women with Chagas disease who fulfill clinical criteria for treatment with nifurtimox, and who are also lactating"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Nifurtimox concentration in breastmilk and in plasma", "description": "Randomly obtained breastmilk samples will be obtained to both evaluate the breastmilk / plasma concentration ratio of the drug, and to develop a population pharmacokinetics model of drug transfer into breastmilk, if possible.", "timeFrame": "at randomly selected, pre-specified, time points during the 30 days of treatment"}], "secondaryOutcomes": [{"measure": "Incidence of adverse drug reactions in women treated with nifurtimox during lactation", "description": "Women receiving treatment with nifurtimox while lactating, enrolled in the study will be followed according to current clinical guidelines, and monitored during the 30 days of treatment (as per Chagas disease treatment guidelines), and monthly for 3 months after treatment completion.", "timeFrame": "throughout the 30 days of treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Lactating women with Chagas disease, not treated before\n* Use of contraception\n\nExclusion Criteria:\n\n* History of allergy to nifurtimox or its excipients\n* Pregnancy\n* Significant heart involvement (due to Chagas disease)\n* Significant systemic diseases that could affect the interpretation of the results in the opinion of the principal investigator", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"], "studyPopulation": "Population of young women with Chagas disease referred to our center for evaluation and treatment", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Facundo Garcia Bournissen, MD PhD", "affiliation": "Buenos Aires Children\u00b4s Hospital Ricardo Gutierrez ; CONICET", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Parasitology and Chagas Service, Buenos Aires Children\u00b4s Hospital Ricardo Gutierrez", "city": "Buenos Aires", "zip": "1425", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}]}, "referencesModule": {"references": [{"pmid": "31415566", "type": "DERIVED", "citation": "Moroni S, Marson ME, Moscatelli G, Mastrantonio G, Bisio M, Gonzalez N, Ballering G, Altcheh J, Garcia-Bournissen F. Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease. PLoS Negl Trop Dis. 2019 Aug 15;13(8):e0007647. doi: 10.1371/journal.pntd.0007647. eCollection 2019 Aug."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M12486", "name": "Nifurtimox", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01755377", "orgStudyIdInfo": {"id": "BIOMARCHA"}, "organization": {"fullName": "Barcelona Centre for International Health Research", "class": "OTHER"}, "briefTitle": "New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease", "officialTitle": "Evolution of Serologic Biomarkers and Diastolic Function and Segmentary Contractility Determined by Echocardiography After Treatment in Chagas Diseases", "acronym": "BIOMARCHA"}, "statusModule": {"statusVerifiedDate": "2016-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-12"}, "primaryCompletionDateStruct": {"date": "2016-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-12-19", "studyFirstSubmitQcDate": "2012-12-19", "studyFirstPostDateStruct": {"date": "2012-12-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-08-19", "lastUpdatePostDateStruct": {"date": "2016-08-22", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Barcelona Centre for International Health Research", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "conditionsModule": {"conditions": ["Chagas Disease"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "Whole blood"}, "enrollmentInfo": {"count": 63, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "No Chagas Disease", "description": "Participants with no Chagas Disease will be evaluated as a Control Group"}, {"label": "Chagas Disease", "description": "Participants diagnosed with Chagas Disease will be followed-up as a Case Group", "interventionNames": ["Drug: Benznidazole"]}], "interventions": [{"type": "DRUG", "name": "Benznidazole", "armGroupLabels": ["Chagas Disease"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Biomarkers for prognosis, early diagnosis and effectiveness of treatment.", "description": "* Conventional polymerase chain reaction of T. cruzi in blood\n* Measurement of Brain natriuretic factor\n* Measurement of Prothrombotic factors\n* Measurement of antibodies against specific proteins of the trypomastigote of T. cruzi\n* Investigation of the phylogenetics of the parasite and the role of the lineages of T.cruzi in the clinical presentation and disease's progression", "timeFrame": "2 years"}], "secondaryOutcomes": [{"measure": "Cardiac function after antiparasitic treatment", "description": "- Correlation between biomarkers and alterations of the left ventricle diastolic function and segmentary contractility after antiparasitic treatment", "timeFrame": "2 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients from endemic areas (Latin America)\n* Older than 18 years old and younger than 50\n* With serological confirmation of Chagas Disease infection with two different techniques\n* Indeterminate or initial cardiac form\n* No previously treated for Chagas Disease\n\nExclusion Criteria:\n\n* Co-morbidity: previous cardiac disease from other aetiology (ischemic, alcoholic or hypertensive), active inflammatory or immunology diseases for another agent. Hepatic disfunction\n* Pregnancy or lactation", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"], "studyPopulation": "Migrants from Latin America visiting the Tropical Medicin Clinic", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Joaquim Gasc\u00f3n, PhD", "affiliation": "Barcelona Centre for International Health Research (CRESIB)", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "International Health Department, Hospital Clinic, Barcelona", "city": "Barcelona", "state": "Catalu\u00f1a", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}]}, "referencesModule": {"references": [{"pmid": "29351667", "type": "DERIVED", "citation": "Aldasoro E, Posada E, Requena-Mendez A, Calvo-Cano A, Serret N, Casellas A, Sanz S, Soy D, Pinazo MJ, Gascon J. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. J Antimicrob Chemother. 2018 Apr 1;73(4):1060-1067. doi: 10.1093/jac/dkx516."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-02-28"}, "conditionBrowseModule": {"meshes": [{"id": "D014355", "term": "Chagas Disease"}], "ancestors": [{"id": "D014352", "term": "Trypanosomiasis"}, {"id": "D056986", "term": "Euglenozoa Infections"}, {"id": "D011528", "term": "Protozoan Infections"}, {"id": "D010272", "term": "Parasitic Diseases"}, {"id": "D007239", "term": "Infections"}, {"id": "D000079426", "term": "Vector Borne Diseases"}], "browseLeaves": [{"id": "M17107", "name": "Chagas Disease", "asFound": "Chagas Disease", "relevance": "HIGH"}, {"id": "M17104", "name": "Trypanosomiasis", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M28673", "name": "Euglenozoa Infections", "relevance": "LOW"}, {"id": "M14388", "name": "Protozoan Infections", "relevance": "LOW"}, {"id": "M13185", "name": "Parasitic Diseases", "relevance": "LOW"}, {"id": "M2054", "name": "Vector Borne Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC01", "name": "Infections"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "C009999", "term": "Benzonidazole"}], "ancestors": [{"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D014344", "term": "Trypanocidal Agents"}, {"id": "D000981", "term": "Antiprotozoal Agents"}, {"id": "D000977", "term": "Antiparasitic Agents"}, {"id": "D000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M241352", "name": "Benzonidazole", "asFound": "Ventral Hernia Repair", "relevance": "HIGH"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}]]